Program #
Abstract Title
Last name
Disclosure Information
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Jose
Baselga
Dr. Baselga has disclosed that he has an
advisory board membership from Genentech.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Evandro
de Azambuja
Dr. de Azambuja has no relevant financial
relationships to disclose.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Peter
Dubsky
Dr. Dubsky has no relevant financial
relationships to disclose.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Christian
Fes
Mr. Fes has no relevant financial relationships
to disclose.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Jill
Fredickson
Ms. Fredickson has disclosed she is an
employee of Genentech.
First name
Gnant
Dr. Gnant has disclosed that he is a consultant
for Astra Zeneca, Novartis, and Accelsiors. He
also disclosed that he is a speaker for Amgen,
Novartis, GlaxoSmithKline, AstraZeneca, Roche,
Nanostring Technologies, Eisai, and Genomic
Health. and that he has contracts with Sanofiaventis, Novartis, Roche, GSK, Pfizer, and Smith
Medical.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Jerry Y
Hsu
Mr. Hsu has disclosed he is an employee of
Genentech.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Ray S
Lin
Mr. Lin has disclosed he is an employee of
Genentech.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Mafalda
Oliveira
Mafalda Oliveira has no relevant financial
relationships to disclose.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Hema
Parmar
Hema Parmar has disclosed she is an employee
of Genentech.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Michael
Piccard
Dr. Piccart has disclosed that she is board
member forPharma Mar and has an advisory
board membership from Genentech . She also
disclosed she is a consultant for Amgen,
Astellas, AstraZeneca, Bayer, Invivis, Lilly, MSD,
Novartis, Pfizer, Roche-Genentech, SanofiAventis, Symphogen, synthon, and Verastem
and receives research grants to Jules Bordet
done by most companies.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Kamal S
Saini
Kamal Saini has no relevant financial
relationships to disclose.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Cristina
Saura
Ms. Saura has no relevant financial
relationships to disclose.
Wilson
Mr. Wilson has disclosed he is an employee of
Genentech.
Beelen
Dr. Beelen has no relevant financial
relationships to disclose.
OT1-1-01
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Martine
OT1-1-01
OT1-1-02
LORELEI: A Phase II randomized, double-blind
study of neoadjuvant letrozole plus taselisib
(GDC-0032) versus letrozole plus placebo in
postmenopausal women with ER-positive/HER2negative, early stage breast cancer
Timothy R
PI3K-Akt-mTOR pathway analysis to obtain
further insight in the efficacy of everolimus in
combination with exemestane in metastatic, ERpositive breast cancer: A Dutch breast cancer
research group (BOOG) study
Karin
OT1-1-02
OT1-1-02
OT1-1-02
OT1-1-02
OT1-1-02
OT1-1-02
PI3K-Akt-mTOR pathway analysis to obtain
further insight in the efficacy of everolimus in
combination with exemestane in metastatic, ERpositive breast cancer: A Dutch breast cancer
research group (BOOG) study
PI3K-Akt-mTOR pathway analysis to obtain
further insight in the efficacy of everolimus in
combination with exemestane in metastatic, ERpositive breast cancer: A Dutch breast cancer
research group (BOOG) study
PI3K-Akt-mTOR pathway analysis to obtain
further insight in the efficacy of everolimus in
combination with exemestane in metastatic, ERpositive breast cancer: A Dutch breast cancer
research group (BOOG) study
PI3K-Akt-mTOR pathway analysis to obtain
further insight in the efficacy of everolimus in
combination with exemestane in metastatic, ERpositive breast cancer: A Dutch breast cancer
research group (BOOG) study
PI3K-Akt-mTOR pathway analysis to obtain
further insight in the efficacy of everolimus in
combination with exemestane in metastatic, ERpositive breast cancer: A Dutch breast cancer
research group (BOOG) study
PI3K-Akt-mTOR pathway analysis to obtain
further insight in the efficacy of everolimus in
combination with exemestane in metastatic, ERpositive breast cancer: A Dutch breast cancer
research group (BOOG) study
Epie
Boven
Dr. Boven has disclosed he received research
grants from Roche and Novartis.
Maurice
Jansen
Dr. Jansen has no relevant financial
relationships to disclose.
Jimenez
Dr. Jiminez has no relevant financial
relationships to disclose.
Connie
Dinja
Kruger
Sabine
Linn
Dr. Kruger has no relevant financial
relationships to disclose.
Dr. Linn has disclosed that he is an advisory
board member for Cergentis, Novartis, Roche,
and Sanofi. He also disclosed that he received
research support funding from Amgen,
AstraZeneca, Roche, and Sanofi.
Sleijfer
Dr. Sleijfer has no relevant financial
relationships to disclose.
Stefan
OT1-1-03
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified metastatic breast cancer (INES)
Valérie
OT1-1-03
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified metastatic breast cancer (INES)
Fabrice
Agrapart
Dr. Agrapart has disclosed she is an employee
of SERVIER.
André
Dr. André has disclosed that he is a consultant
for SERVIER.
OT1-1-03
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified metastatic breast cancer (INES)
Thomas
Bachelot
Mr. Bachelot has disclosed he is a consultant
for Servier.
OT1-1-03
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified metastatic breast cancer (INES)
Mario
Campone
Mr. Campone has disclosed that he is a
consultant for Servier.
OT1-1-03
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified metastatic breast cancer (INES)
Thibault
Chesnel
Dr. Chesnel has disclosed he is an employee of
SERVIER.
OT1-1-03
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified metastatic breast cancer (INES)
Frédéric
OT1-1-03
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified metastatic breast cancer (INES)
Marie-Jeanne
OT1-1-03
OT1-1-03
OT1-1-04
OT1-1-04
OT1-1-04
Phase Ib dose allocation study of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
receptor-positive and FGFR1 -amplified or nonamplified
metastatic
breast
cancer
(INES)
Phase
Ib dose
allocation
study
of oral
administration of lucitanib given in combination
with fulvestrant in patients with estrogen
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
Dubois
Mr. Dubois has disclosed he is an employee of
SERVIER.
Pierrat
Dr. Pierrat has disclosed she is an employee of
SERVIER.
Camille
Poirot
Chadi
Saba
Dr. Poirot has disclosed she is an employee of
SERVIER.
Dr. Saba has disclosed he is an employee of
SERVIER.
Judith
Balmaña
Ms. Balmaña has no relevant financial
relationships to disclose.
Peter
Fasching
Mr. Fasching has no relevant financial
relationships to disclose.
James
Ford
Mr. Ford has disclosed he receives research
support from Myriad and InVitae.
OT1-1-04
OT1-1-04
OT1-1-04
OT1-1-04
OT1-1-04
OT1-1-04
OT1-1-04
OT1-1-04
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
OlympiA, Neo-Olympia and OlympiAD:
Randomized phase III trials of olaparib in
patients (pts) with breast cancer (BC) and a
germline BRCA1/2 mutation (gBRCAm)
Garber
Ms. Garber has disclosed she receives research
funding from Myriad.
Geyer
Mr. Geyer has no relevant financial
relationships to disclose.
Kaufman
Bella Kaufman has no relevant financial
relationships to disclose.
Mann
Ms. Mann has disclosed she is an employee of
AstraZeneca and and owns stock in
AstraZeneca.
Mark
Robson
Mr. Robson has disclosed he is a consultant for
Biomarin. He also disclosed he has contracts
with AbbVie and AstraZeneca
Priyanka
Sharma
Dr. Sharma has no relevant financial
relationships to disclose.
Mary
Stuart
Ms. Stuart has disclosed she is an employee of
AstraZeneca and and owns stock in
AstraZeneca.
Andrew
Tutt
Mr. Tutt has no relevant financial relationships
to disclose.
Judy
Charles
Bella
Helen
OT1-1-05
OT1-1-05
OT1-1-05
OT1-1-05
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Antón
Dr. Antón has no relevant financial
relationships to disclose.
Begoña
Bermejo
Dr. Bermejo has no relevant financial
relationships to disclose.
Semir
Beslija
Semir Beslija has no relevant financial
relationships to disclose.
Carrasco
Dr. Carrasco has no relevant financial
relationships to disclose.
Antonio
Eva
OT1-1-05
OT1-1-05
OT1-1-05
OT1-1-05
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Chacón
Mr. Chacón has no relevant financial
relationships to disclose.
Juan
de la Haba
Dr. de la Haba has no relevant financial
relationships to disclose.
José
Escudero
Mr. Escudero has no relevant financial
relationships to disclose.
García-Saenz
Dr. García-Saenz has no relevant financial
relationships to disclose.
José Ignacio
José ángel
OT1-1-05
OT1-1-05
OT1-1-05
OT1-1-05
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Gil
Mr. Gil has no relevant financial relationships
to disclose.
Moshe
Inbar
Dr. Inbar has no relevant financial relationships
to disclose.
Dan
Jinga
Mr. Jinga has no relevant financial relationships
to disclose.
Kahan
Zsuzanna Kahan has no relevant financial
relationships to disclose.
Miguel
Zsuzanna
OT1-1-05
OT1-1-05
OT1-1-05
OT1-1-05
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Lang
Istvan Lang has no relevant financial
relationships to disclose.
Miguel
Martín
Mr. Martín has no relevant financial
relationships to disclose.
Serafín
Morales
Dr. Morales has no relevant financial
relationships to disclose.
Murillo
Ms. Murillo has no relevant financial
relationships to disclose.
Istvan
Laura
OT1-1-05
OT1-1-05
OT1-1-05
OT1-1-05
OT1-1-06
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
Phase III study of palbociclib in combination
with exemestane vs. capecitabine, in hormonal
receptor (HR) positive/HER2 negative
metastatic breast cancer (MBC) patients with
resistance to non-steroidal aromatase inhibitors
(NSAI): PEARL study (GEICAM/201302_CECOG/BC.1.3.006)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
Nisenbaum
Ms. Nisenbaum has no relevant financial
relationships to disclose.
Manuel
Ruiz-Borrego
Mr. Ruiz-Borrego has no relevant financial
relationships to disclose.
Günther
Steger
Mr. Steger has no relevant financial
relationships to disclose.
Christoph
Zielinski
Mr. Zielinksi has no relevant financial
relationships to disclose.
Silvia
Antolin
Ms. Antolin has no relevant financial
relationships to disclose.
Bella
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
Caballero
Ms. Caballero has no relevant financial
relationships to disclose.
Calvo
Dr. Calvo has no relevant financial relationships
to disclose.
Eva
Carrasco
Dr. Carrasco has disclosed that her husband is a
consultant and speaker for and has a contract
for (hematology drugs).
Jesus
Corral
Mr. Corral has no relevant financial
relationships to disclose.
Jose
Garcia-Saenz
Mr. Garcia-Saenz has no relevant financial
relationships to disclose.
Andres
Hernando
Andres Hernando has no relevant financial
relationships to disclose.
Sara
Lopez-Tarruella
Ms. Lopez-Tarruella has disclosed that she is a
consultant for Novartis Oncology.
Miguel
Martin
Mr. Martin has disclosed that he is a consultant
for and has contracts with Novartis.
Rosalia
Lourdes
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-06
OT1-1-07
OT1-1-07
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase I study of LDE225 in combination with
docetaxel in patients with triple negative (TN)
advanced breast cancer (ABC): GEICAM/2012-12
(EDALINE study)
A phase III study of abemaciclib (LY2835219)
combined with fulvestrant in women with
hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative
(HER2-) breast cancer (MONARCH 2)
A phase III study of abemaciclib (LY2835219)
combined with fulvestrant in women with
hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative
(HER2-) breast cancer (MONARCH 2)
Moreno
Mr. Moreno has no relevant financial
relationships to disclose.
Ocaña
Mr. Ocaña has no relevant financial
relationships to disclose.
Nuria
Ribelles
Nuria Ribelles has no relevant financial
relationships to disclose.
Federico
Rojo
Federico Rojo has no relevant financial
relationships to disclose.
Manuel
Ruiz-Borrego
Mr. Ruiz-Borrego has no relevant financial
relationships to disclose.
José
Trigo
Mr. Trigo has no relevant financial
relationships to disclose.
Edward
Chan
Dr. Chan has disclosed he is an employee of
and owns stock in Eli Lilly and Company.
Frenzel
Dr. Frenzel has disclosed he is an employee of
Eli Lilly and Company.
Fernando
Alberto
Martin
OT1-1-07
OT1-1-07
OT1-1-07
OT1-1-07
OT1-1-08
OT1-1-08
OT1-1-08
OT1-1-08
A phase III study of abemaciclib (LY2835219)
combined with fulvestrant in women with
hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative
(HER2-) breast cancer (MONARCH 2)
A phase III study of abemaciclib (LY2835219)
combined with fulvestrant in women with
hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative
(HER2-) breast cancer (MONARCH 2)
A phase III study of abemaciclib (LY2835219)
combined with fulvestrant in women with
hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative
(HER2-) breast cancer (MONARCH 2)
A phase III study of abemaciclib (LY2835219)
combined with fulvestrant in women with
hormone receptor positive (HR+), human
epidermal growth factor receptor 2 negative
(HER2-) breast cancer (MONARCH 2)
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Klise
Ms. Klise has disclosed he is an employee of
and owns stock in Eli Lilly and Company.
Llombart
Dr. Llombart has disclosed that he is a
consultant for Eli Lilly, Roche/Genentech,
Novartis, and Pfizer. He disclosed that he has
contracts with Eli Lilly, Pfizer, and EISAI.
Sledge
Dr. Sledge has no relevant financial
relationships to disclose.
Toi
Dr. Toi has no relevant financial relationships
to disclose.
Calfiano
Ms. Calfiano has no relevant financial
relationships to disclose.
Eileen
Connolly
Dr. Connolly has no relevant financial
relationships to disclose.
Katherine
Crew
Ms. Crew has no relevant financial
relationships to disclose.
Dawn
Hershman
Dr. Hershman has no relevant financial
relationships to disclose.
Suzanne
Antonio
George
Masakazu
Andrea
OT1-1-08
OT1-1-08
OT1-1-08
OT1-1-08
OT1-1-09
OT1-1-09
OT1-1-09
OT1-1-09
OT1-1-09
OT1-1-09
OT1-1-09
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Master regulator (MR)-directed therapy in
residual breast cancer patient derived
xenografts (PDXs)
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Hibshoosh
Dr. Hibshoosh has no relevant financial
relationships to disclose.
Kalinsky
Mr. Kalinsky has no relevant financial
relationships to disclose.
Maurer
Mr. Maurer has no relevant financial
relationships to disclose.
Mundi
Prabhjot Mundi has no relevant financial
relationships to disclose.
Califano
Ms. Califano has no relevant financial
relationships to disclose.
Dow-Chung
Chi
Dow-Chung Chi has no relevant financial
relationships to disclose.
Ellen
Chuang
Dr. Chuang has no relevant financial
relationships to disclose.
Katherine
Crew
Ms. Crew has no relevant financial
relationships to disclose.
Hershman
Dr. Hershman has no relevant financial
relationships to disclose.
Kalinsky
Mr. Kalinsky has no relevant financial
relationships to disclose.
Lee
Shing Lee has no relevant financial
relationships to disclose.
Hanina
Kevin
Matthew
Prabhjot
Andrea
Dawn
Kevin
Shing
OT1-1-09
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
Phase I/II trial of ruxolitinib in combination with
trastuzumab in metastatic HER2 positive breast
cancer
OT1-1-11
The B-YOND study: A phase II three-arm
randomized trial of the combination of
tamoxifen plus goserelin acetate with BYL719 or
buparlisib (BKM120) in premenopausal patients
with hormone receptor-positive/HER2-negative
locally advanced or metastatic breast cancer
Yen-Shen
OT1-1-11
The B-YOND study: A phase II three-arm
randomized trial of the combination of
tamoxifen plus goserelin acetate with BYL719 or
buparlisib (BKM120) in premenopausal patients
with hormone receptor-positive/HER2-negative
locally advanced or metastatic breast cancer
Yeon Hee
OT1-1-11
The B-YOND study: A phase II three-arm
randomized trial of the combination of
tamoxifen plus goserelin acetate with BYL719 or
buparlisib (BKM120) in premenopausal patients
with hormone receptor-positive/HER2-negative
locally advanced or metastatic breast cancer
Zhimin
OT1-1-09
OT1-1-09
OT1-1-09
Della
Matthew
Jose
Amy
Makower
Della Makower has no relevant financial
relationships to disclose.
Maurer
Mr. Maurer has no relevant financial
relationships to disclose.
Silva
Mr. Silva has no relevant financial relationships
to disclose.
Tiersten
Ms. Tiersten has no relevant financial
relationships to disclose.
Lu
Yen-Shen Lu has no relevant financial
relationships to disclose.
Park
Yeon Hee Park has no relevant financial
relationships to disclose.
Shao
Zhimin Shao has no relevant financial
relationships to disclose.
OT1-1-11
OT1-1-12
OT1-1-12
OT1-1-12
OT1-1-12
The B-YOND study: A phase II three-arm
randomized trial of the combination of
tamoxifen plus goserelin acetate with BYL719 or
buparlisib (BKM120) in premenopausal patients
with hormone receptor-positive/HER2-negative
locally advanced or metastatic breast cancer
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
Roberta
Joanne
Wolfgang
Young-Hyuck
Jennifer
Valenti
Ms. Valenti has disclosed she is a Novartis AG
employee in charge of the clinical study
conduction.
Blum
Ms. Blum has disclosed that she is on the
BioMarin BMN 673 Steering Committee and is
an investigator BioMarin BMN 673 phase 3
study.
Eiermann
Mr. Eiermann has disclosed he is on the
BioMarin BMN 673 Steering Committee and is
an investigator in BioMarin BMN 673 phase 3
and phase 2 studies.
Im
Dr. Im has disclosed that he is on the BioMarin
BMN 673 Steering Committee. He also
disclosed that he is an investigator in BioMarin
BMN 673 phase 3 study.
Litton
Dr. Litten has disclosed she is an investigator in
BioMarin phase 3 and phase 2 studies (BMN
673).
OT1-1-12
OT1-1-12
OT1-1-12
OT1-1-12
OT1-1-12
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
Lokker
Ms. Lokker has disclosed that she is a full-time
employee of BioMarin Pharmaceutical Inc and
that as a full-time employee of BioMarin
Pharmaceutical Inc., she receives stock
options.
Lounsbury
Ms. Loounsbury has disclosed that she is a fulltime employee of BioMarin Pharmaceutical Inc
and that as a full-time employee of BioMarin
Pharmaceutical Inc., she receives stock
options.
Martin
Mr. Martin has disclosed that he is on the
BioMarin BMN 673 Steering Committee. He
also disclosed that he is an Investigator in
BioMarin BMN 673 phase 3 and phase 2
studies.
Lida
Mina
Ms. Mina has disclosed that she is on the
BioMarin BMN 673 Steering Committee and is
an investigator in BioMarin phase 3 and phase
2 studies.
Henri
Roché
Nathalie
Debra
Miguel
OT1-1-12
OT1-1-12
OT1-1-12
OT1-1-13
OT1-1-13
OT1-1-13
OT1-1-13
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A phase 3, open-label, randomized, parallel, 2arm multi-center study of the oral PARP
inhibitor BMN 673 versus physician's choice in
germline BRCA mutation subjects with locally
advanced and/or metastatic breast cancer
(EMBRACA study)
A Phase 2, randomized, open-label, multicenter,
safety and efficacy study of oral lucitanib in
patients with metastatic breast cancer with
alterations in the FGF pathway
A Phase 2, randomized, open-label, multicenter,
safety and efficacy study of oral lucitanib in
patients with metastatic breast cancer with
alterations in the FGF pathway
A Phase 2, randomized, open-label, multicenter,
safety and efficacy study of oral lucitanib in
patients with metastatic breast cancer with
alterations in the FGF pathway
A Phase 2, randomized, open-label, multicenter,
safety and efficacy study of oral lucitanib in
patients with metastatic breast cancer with
alterations in the FGF pathway
Hope
Frances
Charlie
Maysa
Andrew
Carlos
Jason
Rugo
Dr. Rugo has disclosed that she is an
investigator in BioMarin phase 3 and phase 2
studies.
Visco
Frances Visco has no relevant financial
relationships to disclose.
Zhang
Mr. Zhang has disclosed he is a full-time
employee of BioMarin Pharmaceutical Inc and
that as an employee of BioMarin
Pharmaceutical Inc., he receives stock options.
Abu-Khalaf
Dr. Abu-Khalaf has disclosed he receives
research support (PI) from Novartis, Pfizer,
Merck, and Clovis.
Allen
Dr. Allen has disclosed he is an employee of
and has stock in Clovis Oncology.
Arteaga
Dr. Arteaga has disclosed he receives research
support from: Novartis, AstraZeneca, Puma
Biotechnology, U3-Daichi, and OSI-Astellas.
Litten
Dr. Litten has disclosed he is an employee of
and has stock in Clovis Oncology.
OT1-1-13
OT1-1-13
OT1-1-13
OT1-1-14
OT1-1-14
OT1-1-14
OT1-1-14
A Phase 2, randomized, open-label, multicenter,
safety and efficacy study of oral lucitanib in
patients with metastatic breast cancer with
alterations in the FGF pathway
A Phase 2, randomized, open-label, multicenter,
safety and efficacy study of oral lucitanib in
patients with metastatic breast cancer with
alterations in the FGF pathway
A Phase 2, randomized, open-label, multicenter,
safety and efficacy study of oral lucitanib in
patients with metastatic breast cancer with
alterations in the FGF pathway
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
Ingrid
Lajos
Mitch
Judith
Mayer
Dr. Mayer has disclosed that she receives
research support from Novartis.
Pusztai
Dr. Pusztai has disclosed he is on the Clovis
Oncology advisory board and received
honorarium.
Raponi
Dr. Raponi has disclosed he is an employee of
and has stock in Clovis Oncology.
Balmana
Ms. Balmana has disclosed that he is on the
BioMarin BMN 673 Steering Committee and is
an investigator for ABRAZO Study.
Susan
Domchek
Nathalie
Lokker
Debra
Lounsbury
Ms. Domchek has disclosed that she is a
consultant for BioMarin Pharmaceutical Inc.
(BMN 673 steering committee) and an
investigator - BioMarin ABRAZO phase 2 study.
Ms. Lokker has disclosed that she is a full-time
employee of BioMarin Pharmaceutical Inc and
that as a full-time employee of BioMarin
Pharmaceutical Inc., she receives stock
options.
Ms. Loounsbury has disclosed that she is a fulltime employee of BioMarin Pharmaceutical Inc
and that as a full-time employee of BioMarin
Pharmaceutical Inc., she receives stock
options.
OT1-1-14
OT1-1-14
OT1-1-14
OT1-1-14
OT1-1-15
OT1-1-15
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
A phase 2, 2-stage, 2-cohort study of the oral
PARP inhibitor BMN 673 in patients with
germline BRCA mutation and locally advanced
and/or metastatic breast cancer (ABRAZO
study)
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
Mark
Robson
Nicholas
Turner
Mr. Robson has disclosed he is a consultant for
Bayer (advisory board); BioMarin
Pharmaceutical (steering committee - ABRAZO
phase 2 study). He also disclosed that he is an
investigator on the BioMarin ABRAZO phase 2
study and has received other financial support
from AbbVie (institutional research funding);
Astra-Zeneca (travel).
Dr. Turner has disclosed he is a consultant for
BioMarin Pharmaceutical Inc (steering
committee). He has alos disclosed he is an
investigator on the BioMarin ABRAZO phase 2
study
Visco
Frances Visco has no relevant financial
relationships to disclose.
Zhang
Mr. Zhang has disclosed he is a full-time
employee of BioMarin Pharmaceutical Inc and
that as an employee of BioMarin
Pharmaceutical Inc., he receives stock options.
Ricardo
Alvarez
Dr. Alvarez has no relevant financial
relationships to disclose.
Gildy
Babiera
Dr. Babiera has no relevant financial
relationships to disclose.
Frances
Charlie
OT1-1-15
OT1-1-15
OT1-1-15
OT1-1-15
OT1-1-15
OT1-1-15
OT1-1-15
OT1-1-15
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
Chavez-MacGregor
Dr. Chavez-MacGregor has no relevant
financial relationships to disclose.
Culver
Dr. Culver has disclosed that he is an employee
of Novartis Pharmaceuticals Corporation.
Joe
Ensor
Dr. Ensor has no relevant financial relationships
to disclose.
Summer
Jackson
Summer Jackson has no relevant financial
relationships to disclose.
Kimberly
Koenig
Dr. Koenig has no relevant financial
relationships to disclose.
Savitri
Krishnamurty
Dr. Krishnamurty has no relevant financial
relationships to disclose.
Antony
Lucci
Dr. Lucci has no relevant financial relationships
to disclose.
James
Murray
Dr. Murray has no relevant financial
relationships to disclose.
Mariana
Kenneth
OT1-1-15
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
A phase II study of dovitinib as salvage therapy
in patients with stage IV inflammatory breast
cancer HER2-negative with local or distant
relapse
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Rebecca
OT1-1-15
OT1-1-15
OT1-1-15
OT1-1-15
OT1-1-15
Reuben
Dr. Reuben has no relevant financial
relationships to disclose.
Shi
Dr. Shi has disclosed that he is an employee of
Novartis Pharmaceuticals Corporation.
Naoto
Ueno
Dr. Ueno has no relevant financial relationships
to disclose.
Vicente
Valero
Dr. Valero has no relevant financial
relationships to disclose.
Gary
Whitman
Dr. Whitman has no relevant financial
relationships to disclose.
Wendy
Woodward
Dr. Woodward has no relevant financial
relationships to disclose.
Dent
Dr. Dent has no relevant financial relationships
to disclose.
James
Michael
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Seock-Ah
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Steven
Im
Dr. Im has no relevant financial relationships to
disclose.
Isakoff
Dr. Isakoff has no relevant financial
relationships to disclose.
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Sung-Bae
Kim
Dr. Kim has no relevant financial relationships
to disclose.
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Mafalda
Oliveira
Dr. Oliveira has no relevant financial
relationships to disclose.
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Premal
Patel
Dr. Patel has disclosed that he is an employee
of Genentech, Inc.
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Cristina
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Tiffany
OT1-1-16
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Vicente
OT1-1-16
OT1-2-01
OT1-2-01
A randomized, multicenter, phase II study of
ipatasertib (Ipat, GDC-0068), an inhibitor of Akt,
in combination with paclitaxel (Pac) as front-line
treatment for patients (pts) with metastatic
triple-negative breast cancer (TNBC)
Sreeni
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Richard
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Jennifer
Saura
Dr. Saura has no relevant financial relationships
to disclose.
Traina
Dr. Traina has no relevant financial
relationships to disclose.
Valero
Dr. Valero has no relevant financial
relationships to disclose.
Yalamanchili
Barth
Dr. Barth has no relevant financial relationships
to disclose.
Bean
Ms. Bean has no relevant financial
relationships to disclose.
OT1-2-01
OT1-2-01
OT1-2-01
OT1-2-01
OT1-2-01
OT1-2-01
OT1-2-02
OT1-2-02
OT1-2-02
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Circulating tumor DNA in plasma as a surrogate
for tumor biopsy to identify tumor genetic
alterations in patients with multi-focal
metastatic breast cancer
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Chamberlin
Dr. Chamberlin has no relevant financial
relationships to disclose.
Gemery
Dr. Gemery has no relevant financial
relationships to disclose.
Jiang
Gui
Dr. Gui has no relevant financial relationships
to disclose.
Jonathan
Marotti
Dr. Marotti has no relevant financial
relationships to disclose.
Todd
Miller
Dr. Miller has no relevant financial
relationships to disclose.
Kari
Rosenkranz
Dr. Rosenkranz has no relevant financial
relationships to disclose.
Mary
John
Christian
Dittrich
Michail
Ignatiadis
Mr. Dittrich has no relevant financial
relationships to disclose.
Dr. Ignatiadis has disclosed that the Treat CTC
trial is supported by an educational grant from
ROCHE and Janssen Diagnostics.
Janni
Mr. Janni has disclosed that he receives a
research grant from Janssen Diagnostics.
Wolfgang
OT1-2-02
OT1-2-02
OT1-2-02
OT1-2-02
OT1-2-02
OT1-2-02
OT1-2-02
OT1-2-02
OT1-2-03
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Anthony
Saskia
Dimitris
Kong
Mr. Kong has no relevant financial relationships
to disclose.
Litiere
Saskia Litiere has no relevant financial
relationships to disclose.
Mavroudis
Mr. Mavroudis has no relevant financial
relationships to disclose.
Carlo
Messina
Martine
Piccart
Jean-Yves
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Brigitte
Trastuzumab in HER2-negative early breast
cancer as adjuvant treatment for circulating
tumor cells (CTCs) (Treat CTC)
Christos
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Susanne
Carlo Messina has no relevant financial
relationships to disclose.
Dr. Piccart has disclosed that she is a
consultant for Amgen, Astellas, AstraZeneca,
Bayer, Eli Lilly, Invivis, MSD, Novartis, Pfizer,
Roche-Genentech, sanofi Aventis, Symphogen,
Synthon, Verastem. She also disclosed that she
is a board member for PharmaMar and
receives research grants to my Institute : most
companies.
Rack
Dr. Pierga has no relevant financial
relationships to disclose.
Dr. Rack has disclosed she receives speakers
honoraria (Novartis, Roche). She also disclosed
that she receives reasearch grant from
SanofiAventis, Novartis, Lilly, Janssen
Diagnostics.
Sotiriou
Dr. Sotiriou has no relevant financial
relationships to disclose.
Albrecht
Dr. Albrecht has no relevant financial
relationships to disclose.
Pierga
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-03
OT1-2-04
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Peter
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Tanja
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Thomas
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Carsten
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Bernadette
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Wolfgang
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Volkmar
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Carola
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Brigitte
The DETECT-study concept: Treatment based on
the phenotype of circulating tumor cells in HER2negative metastatic breast cancer
Fabienne
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
Bernard
Fasching
Mr. Fasching has no relevant financial
relationships to disclose.
Fehm
Tanja Fehm has no relevant financial
relationships to disclose.
Friedl
Mr. Friedl has no relevant financial
relationships to disclose.
Hagenbeck
Carsten Hagenbeck has no relevant financial
relationships to disclose.
Jaeger
Ms. Jaeger has no relevant financial
relationships to disclose.
Janni
Mr. Janni has disclosed that he receives salary
from Novartis, Roche, Teva, GSK, and Veridex.
Müller
Dr. Müller has no relevant financial
relationships to disclose.
Melcher
Ms. Melcher has no relevant financial
relationships to disclose.
Rack
Ms. Rack has disclosed that she receives salary
from Novartis, Roche, Teva, GSK, and Veridex.
Schochter
Dr. Schochter has no relevant financial
relationships to disclose.
Asselain
Dr. Asselain has no relevant financial
relationships to disclose.
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
OT1-2-04
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
TP53 mutants in circulating tumor DNA and
follow-up of BRCA1 mutation carriers: The
CirCA01 study
Berger
Frédérique Berger has no relevant financial
relationships to disclose.
Bidard
Dr. Bidard has disclosed that he is a consultant
for Jansen and has a contract with Roche.
Caron
Mr. Caron has no relevant financial
relationships to disclose.
Delaloge
Dr. Delaloge has no relevant financial
relationships to disclose.
Dugast
Ms. Dugast has no relevant financial
relationships to disclose.
Olivier
Lantz
Mr. Lantz has no relevant financial
relationships to disclose.
Christine
Lasset
Ms. Lasset has no relevant financial
relationships to disclose.
Catherine
Nogues
Ms. Nogues has no relevant financial
relationships to disclose.
Pierga
Dr. Pierga has disclosed that he is a consultant
for Roche and Janssen. He has also disclosed
that he has a contract with Roche.
Stern
Mr. Stern has no relevant financial
relationships to disclose.
Stoppa-Lyonnet
Ms. Stoppa-Lyonnet has no relevant financial
relationships to disclose.
Frederique
Francois-Clement
Olivier
Suzette
Catherine
Jean-Yves
Marc-Henri
Dominique
OT1-3-01
OT1-3-01
OT1-3-01
OT1-3-01
OT1-3-01
OT1-3-01
OT1-3-01
OT1-3-01
OT1-3-02
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Phase II study on radiofrequency ablation in
stage 0 and I breast cancer without extensive
intraductal components
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Imoto
Dr. Imoto has no relevant financial
relationships to disclose.
Ito
Dr. Ito has no relevant financial relationships to
disclose.
Morita
Dr. Morita has no relevant financial
relationships to disclose.
Nagamine
Dr. Nagamine has no relevant financial
relationships to disclose.
Tozaki
Dr. Tozaki has no relevant financial
relationships to disclose.
Hitoshi
Tsuda
Dr. Tsuda has no relevant financial
relationships to disclose.
Takayuki
Ueno
Dr. Ueno has no relevant financial relationships
to disclose.
Masayuki
Yoshida
Dr. Yoshida has no relevant financial
relationships to disclose.
Hanna
Bandos
Ms. Bandos has no relevant financial
relationships to disclose.
Shigeru
Shunichi
Satoshi
Shinji
Mitsuhiro
OT1-3-02
OT1-3-02
OT1-3-02
OT1-3-02
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Joseph
Costantino
Mr. Costantino has no relevant financial
relationships to disclose.
Walter
Curran, Jr
Mr. Curran has no relevant financial
relationships to disclose.
Patricia
Ganz
Dr. Ganz has no relevant financial relationships
to disclose.
Nilendu
Gupta
Nilendu Gupta has no relevant financial
relationships to disclose.
OT1-3-02
OT1-3-02
OT1-3-02
OT1-3-02
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Thomas
Julian
Mr. Julian has no relevant financial
relationships to disclose.
Atif
Khan
Dr. Khan has no relevant financial relationships
to disclose.
Eleftherios
Mamounas
Eleftherios Mamounas has no relevant
financial relationships to disclose.
Susan
McCloskey
Ms. McCloskey has no relevant financial
relationships to disclose.
OT1-3-02
OT1-3-02
OT1-3-02
OT1-3-02
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Paik
Soonmyung Paik has no relevant financial
relationships to disclose.
Simona
Shaitelman
Ms. Shaitelman has disclosed she is a MD
Anderson Physicians Network consultant and
received a grant from ELEKTA.
Mylin
Torres
Mylin Torres has no relevant financial
relationships to disclose.
Frank
Vicini
Mr. Vicini has no relevant financial
relationships to disclose.
Soonmyung
OT1-3-02
OT1-3-02
OT1-4-01
OT1-4-01
OT1-4-01
OT1-4-01
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
Will chest wall and regional nodal radiotherapy
post mastectomy or the addition of regional
nodal radiotherapy to breast radiotherapy post
lumpectomy reduce the rate of invasive cancer
events in patients with positive axillary nodes
who convert to ypN0 after neoadjuvant
chemotherapy? NSABP B-51/RTOG 1304 a
phase III trial
HIOB trial - Hypofractionated whole-breast
irradiation preceded by intraoperative
radiotherapy with electrons as anticipated
boost
HIOB trial - Hypofractionated whole-breast
irradiation preceded by intraoperative
radiotherapy with electrons as anticipated
boost
HIOB trial - Hypofractionated whole-breast
irradiation preceded by intraoperative
radiotherapy with electrons as anticipated
boost
HIOB trial - Hypofractionated whole-breast
irradiation preceded by intraoperative
radiotherapy with electrons as anticipated
boost
Julia
White
Ms. White has no relevant financial
relationships to disclose.
Norman
Wolmark
Mr. Wolmark has no relevant financial
relationships to disclose.
Gerd
Fastner
Dr. Fastner has no relevant financial
relationships to disclose.
Michael
Kopp
Dr. Kopp has no relevant financial relationships
to disclose.
Roland
Reitsamer
Dr. Reitsamer has no relevant financial
relationships to disclose.
Felix
Sedlmayer
Dr. Sedlmayer has no relevant financial
relationships to disclose.
OT2-1-01
OT2-1-01
OT2-1-01
OT2-1-01
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Barlow
Dr. Barlow has no relevant financial
relationships to disclose.
Julie
Gralow
Dr. Gralow has disclosed that she has contracts
with Novartis, Amgen, Genentech/Roche. She
also disclosed that she is on Steering
Committees for Roche, Novartis.
Daniel
Hayes
Dr. Hayes has no relevant financial
relationships to disclose.
Hicks
Dr. Hicks has no relevant financial relationships
to disclose.
William
James
OT2-1-01
OT2-1-01
OT2-1-01
OT2-1-01
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Hortobagyl
Dr. Hortobagyi has disclosed that he is a
consultant for Novartis.
Peter
Kuhn
Dr. Kuhn has disclosed that he is a shareholder
of Epic Sciences.
Danika
Lew
Danika Lew has no relevant financial
relationships to disclose.
Moore
Dr. Moore has no relevant financial
relationships to disclose.
Gabriel
Halle
OT2-1-01
OT2-1-01
OT2-1-01
OT2-1-02
OT2-1-02
OT2-1-02
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
Fulvestrant alone versus fulvestrant and
everolimus versus fulvestrant, everolimus and
anastrozole: A Phase III randomized, placebocontrolled trial in postmenopausal patients with
hormone-receptor-positive stage IV breast
cancer: SWOG-Clinical Trials Initiative (CTI)*
S1222
A phase 2 study of neoadjuvant goserelin and
letrozole for premenopausal women with
estrogen receptor positive HER2 negative stage
2 and 3 breast cancer
A phase 2 study of neoadjuvant goserelin and
letrozole for premenopausal women with
estrogen receptor positive HER2 negative stage
2 and 3 breast cancer
A phase 2 study of neoadjuvant goserelin and
letrozole for premenopausal women with
estrogen receptor positive HER2 negative stage
2 and 3 breast cancer
Schott
Dr. Schott has no relevant financial
relationships to disclose.
George
Somlo
Dr. Somlo has disclosed he is a consultant for
Genentech, Millenium, and Celgene. He also
disclosed he has contracts with Genentech and
Celgene and is on the Steering Committee for
Abbvie.
Debu
Tripathy
Matthew
Ellis
Dr. Tripathy has no relevant financial
relationships to disclose.
Dr. Ellis has disclosed he receives Ad hoc
consulting fee from Astra Zeneca and Novartis.
He also disclosed he has a contract with Astra
Zeneca.
Rodrigo
Goncalves
Dr. Goncalves has no relevant financial
relationships to disclose.
Hegg
Dr. Hegg has no relevant financial relationships
to disclose.
Anne
Roberto
OT2-1-02
OT2-1-03
OT2-1-03
OT2-1-03
OT2-1-03
OT2-1-03
OT2-1-03
OT2-1-03
A phase 2 study of neoadjuvant goserelin and
letrozole for premenopausal women with
estrogen receptor positive HER2 negative stage
2 and 3 breast cancer
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
Mattar
Dr. Mattar has no relevant financial
relationships to disclose.
Bellavance
Dr. Bellavance has no relevant financial
relationships to disclose.
Angela
Brodie
Dr. Brodie has no relevant financial
relationships to disclose.
Saranya
Chumsri
Dr. Chumsri has no relevant financial
relationships to disclose.
Martin
Edelman
Dr. Edelman has no relevant financial
relationships to disclose.
Steven
Feigenberg
Dr. Feigenberg has no relevant financial
relationships to disclose.
Susan
Kesmodel
Dr. Kesmodel has no relevant financial
relationships to disclose.
Jane
Lewis
Ms. Lewis has no relevant financial
relationships to disclose.
Andre
Emily
OT2-1-03
OT2-1-03
OT2-1-03
OT2-1-03
OT2-1-04
OT2-1-04
OT2-1-04
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
A pilot and phase II study of entinostat and
anastrozole/tamoxifen in women with triple
negative breast cancer (TNBC) to evaluate
biomarkers and surrogates for response
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Ordentlich
Dr. Ordentlich has disclosed that she works
with Syndax Pharmaceuticals, Inc.
Sabnis
Dr. Sabnis has no relevant financial
relationships to disclose.
Nancy
Tait
Ms. Tait has no relevant financial relationships
to disclose.
Katherine
Tkaczuk
Dr. Tkaczuk has no relevant financial
relationships to disclose.
Katherine
DeSchryver
Dr. DeSchryver has no relevant financial
relationships to disclose.
Ellis
Dr. Ellis has disclosed he receives less than
$5,000 for consulting. He also disclosed he
receives clinical trial funding from AstraZeneca.
Hahn
Dr. Hahn has no relevant financial relationships
to disclose.
Peter
Gauri
Matthew
Olwen
OT2-1-04
OT2-1-04
OT2-1-04
OT2-1-04
OT2-1-04
OT2-1-04
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Paul
Haluska
Dr. Haluska has no relevant financial
relationships to disclose.
Cliff
Hudis
Dr. Hudis has no relevant financial relationships
to disclose.
Hunt
Dr. Hunt has no relevant financial relationships
to disclose.
Leitch
Dr. Leitch has no relevant financial
relationships to disclose.
Ma
Dr. Ma has no relevant financial relationships
to disclose.
Sanati
Dr. Sanati has no relevant financial
relationships to disclose.
Kelly
A Marilyn
Cynthia
Souzan
OT2-1-04
OT2-1-04
OT2-1-04
OT2-1-04
OT2-1-04
OT2-1-05
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Alliance A011106: ALTernate approaches for
clinical stage II or III Estrogen Receptor positive
breast cancer NeoAdjuvant TrEatment
(ALTERNATE) in postmenopausal women: A
phase III study
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Vera
Suman
Dr. Suman has no relevant financial
relationships to disclose.
Gary
Unzeitig
Dr. Unzeitig has no relevant financial
relationships to disclose.
Watson
Dr. Watson has no relevant financial
relationships to disclose.
Winer
Dr. Winer has no relevant financial
relationships to disclose.
Zujewski
Dr. Zujewski has no relevant financial
relationships to disclose.
Berteloot
Mr. Berteloot has no relevant financial
relationships to disclose.
Mark
Eric
Jo Anne
Patrick
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Chantal
Blomme
Ms. Blomme has no relevant financial
relationships to disclose.
Olivier
Brouckaert
Mr. Brouckaert has no relevant financial
relationships to disclose.
Christiaens
Dr. Christiaens has no relevant financial
relationships to disclose.
Decloedt
Jan Decloedt has no relevant financial
relationships to disclose.
Dezentjé
Mr. Dezentjé has no relevant financial
relationships to disclose.
Dieudonné
Ms. Dieudonné has no relevant financial
relationships to disclose.
Marie-Rose
Jan
Vincent
Anne-Sophie
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Markus
Joerger
Mr. Joerger has no relevant financial
relationships to disclose.
Lynn
Jongen
Lynn Jongen has no relevant financial
relationships to disclose.
Lambrechts
Diether Lambrechts has no relevant financial
relationships to disclose.
Lintermans
Anneleen Lintermans has no relevant financial
relationships to disclose.
Neven
Dr. Neven has no relevant financial
relationships to disclose.
Timmerman
Dirk Timmerman has no relevant financial
relationships to disclose.
Diether
Anneleen
Patrick
Dirk
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-05
OT2-1-06
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
Prospective multicenter study evaluating the
effect of impaired tamoxifen metabolization on
efficacy in breast cancer patients receiving
tamoxifen in the neo-adjuvant or metastatic
setting - The CYPTAM-BRUT 2 trial
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
Kathleen
Van Asten
Ms. Van Asten has no relevant financial
relationships to disclose.
Ben
Van Calster
Mr. Van Calster has no relevant financial
relationships to disclose.
Verhoeven
Didier Verhoeven has no relevant financial
relationships to disclose.
Wildiers
Mr. Wildiers has no relevant financial
relationships to disclose.
Zaman
Khalil Zaman has no relevant financial
relationships to disclose.
Connolly
Roisin Connolly has disclosed that he receives
research funding from Genentech, Novartis,
and Puma Biotechnology.
Didier
Hans
Khalil
Roisin
OT2-1-06
OT2-1-06
OT2-1-06
OT2-1-06
OT2-1-06
OT2-1-06
OT2-1-06
OT2-1-06
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
Robert
Gray
Mr. Gray has disclosed as co-leader of the
ECOG-ACRIN statistical center, he is often PI on
subcontracts sending company funds to DFCI
for statistical support. Typically, the contracts
go company -> ECOG foundation -> FSTRF ->
DFCI, and the intermediate.
Min-Jung
Lee
Min-Jung Lee has no relevant financial
relationships to disclose.
Miller
Ms. Miller has no relevant financial
relationships to disclose.
Murray
Ms. Murray has no relevant financial
relationships to disclose.
Piekarz
Mr. Piekarz has no relevant financial
relationships to disclose.
Sparano
Dr. Sparano has no relevant financial
relationships to disclose.
Tevaarwerk
Dr. Tevaarwerk has no relevant financial
relationships to disclose.
Wagner
Lynne Wagner has no relevant financial
relationships to disclose.
Kathy
Judy
Richard
Joseph
Amye
Lynne
OT2-1-06
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
Fengmin
E2112: A randomized phase III trial of endocrine
therapy plus entinostat/placebo in patients with
hormone receptor-positive advanced breast
cancer
Jo Anne
OT2-1-07
A phase II study with orteronel as monotherapy
in patients with androgen receptor (AR)
expressing metastatic breast cancer (MBC)
Howard
Burris III
Dr. Burris has no relevant financial
relationships to disclose.
OT2-1-07
A phase II study with orteronel as monotherapy
in patients with androgen receptor (AR)
expressing metastatic breast cancer (MBC)
Suzanne
Jones
Dr. Jones has no relevant financial relationships
to disclose.
OT2-1-07
A phase II study with orteronel as monotherapy
in patients with androgen receptor (AR)
expressing metastatic breast cancer (MBC)
Andre
Kallab
Dr. Kallab has no relevant financial
relationships to disclose.
OT2-1-07
A phase II study with orteronel as monotherapy
in patients with androgen receptor (AR)
expressing metastatic breast cancer (MBC)
Nancy
Peacock
Dr. Peacock has no relevant financial
relationships to disclose.
OT2-1-07
A phase II study with orteronel as monotherapy
in patients with androgen receptor (AR)
expressing metastatic breast cancer (MBC)
Mythili
Shastry
Dr. Shastry has no relevant financial
relationships to disclose.
OT2-1-07
A phase II study with orteronel as monotherapy
in patients with androgen receptor (AR)
expressing metastatic breast cancer (MBC)
Denise
Yardley
Dr. Yardley has no relevant financial
relationships to disclose.
OT2-1-06
Zhao
Fengmin Zhao has no relevant financial
relationships to disclose.
Zujewski
Dr. Zujewski has no relevant financial
relationships to disclose.
OT2-1-07
OT2-1-08
OT2-1-08
OT2-1-08
OT2-1-08
OT2-1-08
OT2-1-10
OT2-1-10
A phase II study with orteronel as monotherapy
in patients with androgen receptor (AR)
expressing metastatic breast cancer (MBC)
A phase II open label study of everolimus in
combination with anti-estrogen therapy in
hormone receptor-positive HER2-negative
advanced breast cancer
A phase II open label study of everolimus in
combination with anti-estrogen therapy in
hormone receptor-positive HER2-negative
advanced breast cancer
A phase II open label study of everolimus in
combination with anti-estrogen therapy in
hormone receptor-positive HER2-negative
advanced breast cancer
A phase II open label study of everolimus in
combination with anti-estrogen therapy in
hormone receptor-positive HER2-negative
advanced breast cancer
A phase II open label study of everolimus in
combination with anti-estrogen therapy in
hormone receptor-positive HER2-negative
advanced breast cancer
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
Young
Dr. Young has no relevant financial
relationships to disclose.
Burris III
Dr. Burris has no relevant financial
relationships to disclose.
Laura
DeBusk
Dr. DeBusk has no relevant financial
relationships to disclose.
John
Hainsworth
Dr. Hainsworth has no relevant financial
relationships to disclose.
Mythili
Shastry
Dr. Shastry has no relevant financial
relationships to disclose.
Denise
Yardley
Dr. Yardley has no relevant financial
relationships to disclose.
Kate
Banks
Ms. Banks has disclosed that she has
ownership in Radius Health.
Marcie
Clarkin
Ms. Clarkin has disclosed that she has
ownership in Radius Health.
Robyn
Howard
OT2-1-10
OT2-1-10
OT2-1-10
OT2-1-10
OT2-1-10
OT2-1-10
OT2-1-10
OT2-1-10
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
David
Dr. David has disclosed that he is a consultant
for Radius Health.
de Vries
Dr. de Vries has disclosed that he has a
contract with Radius Health.
Janine
Doorduin
Dr. Doorduin has disclosed that he has a
contract with Radius Health.
Andor
Glaudemans
Dr. Glaudemans has disclosed that he has a
contract with Radius Health.
Alan
Harris
Ms. Clarkin has disclosed that she has
ownership in Radius Health.
Gary
Hattersley
Ms. Clarkin has disclosed that she has
ownership in Radius Health.
Michel
Koole
Dr. Koole has disclosed that he has ownership
in Radius Health.
Rich
Lyttle
Ms. Clarkin has disclosed that she has
ownership in Radius Health.
Frank
Erik
OT2-2-01
RAD1901, a novel tissue-selective estrogen
receptor degrader (SERD) demonstrates
estrogen receptor engagement in a phase 1
clinical study
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
OT2-2-01
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
Javier
OT2-1-10
OT2-2-01
OT2-2-01
OT2-2-01
Williams
Ms. Clarkin has disclosed that she has
ownership in Radius Health.
Barton
Dr. Barton has disclosed she is an employee of
and owns stock in Celgene Corporation.
Brufsky
Dr. Brufsky has disclosed he receives consulting
fees from Celgene Corporation.
Robert
Coleman
Dr. Coleman has no relevant financial
relationships to disclose.
Pierfranco
Conte
Dr. Conte has no relevant financial
relationships to disclose.
Cortes
Dr. Cortes has disclosed he receives consulting
fees from Celgene Corporation and Novartis.
He also disclosed that he receives speaker fees
for non-CME services from Roche, Celgene
Corporation, Novartis and Eisai.
Greg
Debora
Adam
OT2-2-01
OT2-2-01
OT2-2-01
OT2-2-01
OT2-2-01
OT2-2-01
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
Stefan
Nadia
Li
JulieAnn
Glück
Dr. Glück has disclosed that he receives
consulting fees from Agendia, Genomic Health,
Celgene Corporation, Eisai, Genentech, and
Dara. He also disclosed that he has contracted
research with Agendia, Genomic Health,
Celgene Corporation, Eisai, Genentech, and
Dara.
Harbeck
Dr. Harbeck has disclosed that she receives
consulting fees and fees for CME services from
Celgene Corporation.
Li
Li Li has disclosed he is an employee of and
owns stock in Celgene Corporation.
Miller
Ms. Miller has disclosed she is an employee of
and owns stock in Celgene Corporation.
Jean-Marc
Nabholtz
Joyce
O'Shaughnessy
Dr. Nabholtz has no relevant financial
relationships to disclose.
Dr. O'Shaughnessy has disclosed that he
receives consulting fees from Genentech,
Sanofi US, Boehringer Ingelheim Int GmbH,
BMS, Caris Diagnostics, Eisai, GSK, J&J, and
Roche.
OT2-2-01
OT2-2-01
OT2-2-02
OT2-2-02
OT2-2-02
OT2-2-02
OT2-2-02
OT2-2-02
OT2-2-03
OT2-2-03
OT2-2-03
OT2-2-03
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
tnAcity: A phase II/III trial of nab -paclitaxel (na P) plus either gemcitabine (Gem) or carboplatin
(Carbo) vs Gem/Carbo as first-line treatment for
patients with triple-negative metastatic breast
cancer (TNMBC)
Phase I/II clinical trial on the combination of
carboplatin, eribulin and E7449
Phase I/II clinical trial on the combination of
carboplatin, eribulin and E7449
Phase I/II clinical trial on the combination of
carboplatin, eribulin and E7449
Phase I/II clinical trial on the combination of
carboplatin, eribulin and E7449
Phase I/II clinical trial on the combination of
carboplatin, eribulin and E7449
Phase I/II clinical trial on the combination of
carboplatin, eribulin and E7449
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
On bahalf of the tnAcity Investigators have no
relevant financial relationships to disclose.
on bahalf of the tnAcity Investigators
Denise
Yardley
William
Gradishar
Kent
Hoskins
Virginia
Kaklamani
Ruth
o'Regan
James
Wade
Kari
Wisinski
Dr. Yardley has no relevant financial
relationships to disclose.
Dr. Gradishar has no relevant financial
relationships to disclose.
Dr. Hoskins has no relevant financial
relationships to disclose.
Dr. Kaklamani has disclosed that she is a
speaker for Eisai.
Dr. O'Regan has no relevant financial
relationships to disclose.
Dr. Wade has no relevant financial
relationships to disclose.
Dr. Wisinski has no relevant financial
relationships to disclose.
Antón
Dr. Antón has no relevant financial
relationships to disclose.
Blanco
Dr. Blanco has no relevant financial
relationships to disclose.
Calvo
Dr. Calvo has no relevant financial relationships
to disclose.
Cortés
Dr. Cortés has no relevant financial
relationships to disclose.
Antonio
Esperanza
Lourdes
Javier
OT2-2-03
OT2-2-03
OT2-2-03
OT2-2-03
OT2-2-03
OT2-2-03
OT2-2-03
OT2-2-04
OT2-2-04
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
MERIBEL study: Efficacy of eribulin in first line of
taxane-resistant patients with HER2 negative
metastatic breast cancer
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
Fernández
Dr. Fernández has no relevant financial
relationships to disclose.
Garau
Dr. Garau has no relevant financial
relationships to disclose.
García
Dr. García has no relevant financial
relationships to disclose.
Illarramendi
Dr. Illarramendi has no relevant financial
relationships to disclose.
Llombart
Dr. Llombart has no relevant financial
relationships to disclose.
María
Martínez
Dr. Martínez has no relevant financial
relationships to disclose.
Vanessa
Ortega
Dr. Ortega has no relevant financial
relationships to disclose.
Alvarez
Dr. Alvarez has no relevant financial
relationships to disclose.
Booser
Dr. Booser has no relevant financial
relationships to disclose.
Yolanda
Isabel
Mirta
José
Antonio
Ricardo
Daniel
OT2-2-04
OT2-2-04
OT2-2-04
OT2-2-04
OT2-2-04
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
Caudle
Dr. Caudle has no relevant financial
relationships to disclose.
Chavez-MacGregor
Dr. Chavez-MacGregor has no relevant
financial relationships to disclose.
David
Cox
Dr. Cox has disclosed that he is an employee of
Eisai Inc.
Joe
Ensor
Dr. Ensor has no relevant financial relationships
to disclose.
Gonzalez-Angulo
Dr. Gonzalez-Angulo has no relevant financial
relationships to disclose.
Abigail
Mariana
Ana
OT2-2-04
OT2-2-04
OT2-2-04
OT2-2-04
OT2-2-04
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
Ibrahim
Dr. Ibrahim has no relevant financial
relationships to disclose.
Koenig
Dr. Koenig has no relevant financial
relationships to disclose.
Savitri
Krishnamurthy
Dr. Krishnamurthy has no relevant financial
relationships to disclose.
Aurora
Madrigal
Aurora Madrigal has no relevant financial
relationships to disclose.
Murray
Dr. Murray has no relevant financial
relationships to disclose.
Nuhad
Kimberly
Lee
OT2-2-04
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
A randomized phase II neoadjuvant study of
sequential eribulin followed by FAC/FECregimen compared to sequential paclitaxel
followed by FAC/FEC-regimen in patients with
operable breast cancer not overexpressing HER2
OT2-2-05
Metronomic eribulin in metastatic breast cancer Pavani
OT2-2-04
OT2-2-04
OT2-2-04
OT2-2-04
Reuben
Dr. Reuben has no relevant financial
relationships to disclose.
Schwartz Gomez
Ms. Schwartz Gomez has no relevant financial
relationships to disclose.
Simona
Shaitelman
Dr. Shaitelman has no relevant financial
relationships to disclose.
Vicente
Valero
Dr. Valero has no relevant financial
relationships to disclose.
James
Jill
Gary
Whitman
Chalasani
Dr. Whitman has no relevant financial
relationships to disclose.
Dr. Chalasani has disclosed that Eisai provides
support for the trial discussed in the abstract.
Additional information is available upon
request.
OT2-2-05
Metronomic eribulin in metastatic breast cancer Vijayakrishna
Gadi
OT2-2-05
Metronomic eribulin in metastatic breast cancer Thomas
Kummet
OT2-2-05
Metronomic eribulin in metastatic breast cancer Hannah
Linden
OT2-2-05
Metronomic eribulin in metastatic breast cancer Thomas
Rado
OT2-2-05
Metronomic eribulin in metastatic breast cancer Livingston
Robert
OT2-2-05
Metronomic eribulin in metastatic breast cancer Jennifer
Specht
OT2-2-05
Metronomic eribulin in metastatic breast cancer
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Alison
Stopeck
Dr. Gadi has no relevant financial relationships
to disclose.
Dr. Kummet has no relevant financial
relationships to disclose.
Dr. Linden has disclosed that Eisai provides
support for the trial discussed in the abstract.
Additional information is available upon
request.
Dr. Rado has no relevant financial relationships
to disclose.
Dr. Livingston has no relevant financial
relationships to disclose.
Dr. Specht has no relevant financial
relationships to disclose.
Dr. Stopeck has no relevant financial
relationships to disclose.
Ricardo
Alvarez
Dr. Alvarez has no relevant financial
relationships to disclose.
Arun
Dr. Arun has no relevant financial relationships
to disclose.
Gilcrease
Dr. Gilcrease has no relevant financial
relationships to disclose.
OT2-2-06
OT2-2-06
OT2-2-06
Banu
Michael
OT2-2-06
OT2-2-06
OT2-2-06
OT2-2-06
OT2-2-06
OT2-2-06
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Nuhad
Jennifer
Stacy
Rashmi
William
Debasish
Ibrahim
Dr. Ibrahim has no relevant financial
relationships to disclose.
Litton
Dr. Litten has disclosed she receives
uncompensated research funding from
Biomarin, Novartis, and BMS.
Moulder
Dr. Moulder has no relevant financial
relationships to disclose.
Murthy
Dr. Murthy has no relevant financial
relationships to disclose.
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
Tripathy
Dr. Tripathy has no relevant financial
relationships to disclose.
OT2-2-06
OT2-2-06
OT2-2-07
OT2-2-07
OT2-2-07
OT2-2-07
OT2-2-07
OT2-2-07
OT2-2-07
OT2-2-07
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
Phase II single arm study of liposomal
doxorubicin (D), bevacizumab (A), and
temsirolimus (T) for treatment of triple negative
early breast cancer refractory to standard
neoadjuvant chemotherapy
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
Naoto
Ueno
Dr. Ueno has no relevant financial relationships
to disclose.
Vicente
Valero
Dr. Valero has no relevant financial
relationships to disclose.
Akinori
Hattori
Dr. Hattori has no relevant financial
relationships to disclose.
Akira
Hirano
Dr. Hirano has no relevant financial
relationships to disclose.
Inoue
Dr. Inoue has no relevant financial
relationships to disclose.
Jibiki
Dr. Jibiki has no relevant financial relationships
to disclose.
Kamimura
Dr. Kamimura has no relevant financial
relationships to disclose.
Kinoshita
Dr. Kinoshita has no relevant financial
relationships to disclose.
Miyamoto
Dr. Miyamoto has no relevant financial
relationships to disclose.
Naritaka
Dr. Naritaka has no relevant financial
relationships to disclose.
Hiroaki
Norie
Mari
Jun
Reiko
Yoshihiko
OT2-2-07
OT2-2-07
OT2-2-07
OT2-2-07
OT2-2-08
OT2-2-08
OT2-2-08
OT2-2-08
OT2-2-08
OT2-2-08
OT2-3-01
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A phase II study of S-1 (14 days' administration
followed by 7 days' rest) for metastatic breast
cancer
A Phase IIb study of ANG1005, a novel, brainpenetrant taxane derivative, in HER2+ breast
cancer patients with brain metastases
A Phase IIb study of ANG1005, a novel, brainpenetrant taxane derivative, in HER2+ breast
cancer patients with brain metastases
A Phase IIb study of ANG1005, a novel, brainpenetrant taxane derivative, in HER2+ breast
cancer patients with brain metastases
A Phase IIb study of ANG1005, a novel, brainpenetrant taxane derivative, in HER2+ breast
cancer patients with brain metastases
A Phase IIb study of ANG1005, a novel, brainpenetrant taxane derivative, in HER2+ breast
cancer patients with brain metastases
A Phase IIb study of ANG1005, a novel, brainpenetrant taxane derivative, in HER2+ breast
cancer patients with brain metastases
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
Ogura
Dr. Ogura has no relevant financial
relationships to disclose.
Okubo
Dr. Okubo has no relevant financial
relationships to disclose.
Sakaguchi
Dr. Sakaguchi has no relevant financial
relationships to disclose.
Shimizu
Dr. Shimizu has no relevant financial
relationships to disclose.
Burdusel
Ms. Burdusel has no relevant financial
relationships to disclose.
Jean-Paul
Castaigne
Dr. Castaigne has no relevant financial
relationships to disclose.
Dimitri
Fitsialos
Mr. Fitsialos has no relevant financial
relationships to disclose.
Sana
Ghani
Sana Ghani has no relevant financial
relationships to disclose.
Iordanova
Vihra Iordanova has no relevant financial
relationships to disclose.
Lawrence
Ms. Lawrence has no relevant financial
relationships to disclose.
Burris III
Dr. Burriss has disclosed that he has a contract
with Seattle Genetics, Inc.
Kaoru
Fumie
Shiho
Tadao
Veronica
Vihra
Betty
Howard
OT2-3-01
OT2-3-01
OT2-3-01
OT2-3-01
OT2-3-01
OT2-3-01
OT2-3-01
OT2-3-01
OT2-3-01
OT2-3-01
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
Andres
Forero
Ana
Kostic
Minetta
Liu
Mr. Forero has disclosed he is a speaker for
and has a contract with Seattle Genetics, Inc.
Ms. Kostic has disclosed that she receives
salary from and has ownership in Seattle
Genetics, Inc.
Dr. Liu has disclosed that she has contracts
with Seattle Genetics, Inc., Eisai, Celgene,
Veridex/Janssen, and ClearBridge Biomedics.
LoRusso
Ms. LoRusso has disclosed that she has
contracts with Seattle Genetics, Inc.
Miller
Ms. Miller has disclosed that she has a contract
with Seattle Genetics, Inc.
Patricia
Kathy
Monica
Mita
Shanu
Modi
Dr. Mita has disclosed that she has a contract
with Seattle Genetics, Inc.
Dr. Modi has disclosed that he has a contract
with Seattle Genetics, Inc., Genentech,
Novartis, and Synta Pharmaceuticals.
Lajos
Pusztai
Dr. Pusztai has disclosed that he has a contract
with Seattle Genetics, Inc.
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
Jennifer
SGN-LIV1A: A phase 1 trial evaluating a novel
antibody-drug conjugate in patients with LIV-1positive breast cancer
Django
Specht
Sussman
Ms. Specht has disclosed that she has contracts
with Seattle Genetics, Inc., Pfizer, Genentech,
Veridex, Celgene, Nektar, and GlaxoSmithKline.
Mr. Sussman has disclosed he receives salary
from and has ownership in Seattle Genetics,
Inc.
OT2-4-01
OT2-4-01
OT2-4-01
OT2-4-01
OT2-4-01
OT2-4-01
OT2-4-01
OT2-4-01
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
Bellavance
Dr. Bellavance has no relevant financial
relationships to disclose.
Campassi
Dr. Campassi has no relevant financial
relationships to disclose.
Steven
Feigenberg
Dr. Feigenberg has no relevant financial
relationships to disclose.
David
Hicks
Mr. Hicks has disclosed that he is employed by
A&G Pharmaceutical.
Susan
Kesmodel
Dr. Kesmodel has no relevant financial
relationships to disclose.
Elizabeth
Nichols
Dr. Nichols has no relevant financial
relationships to disclose.
Olson
Dr. Olson has no relevant financial
relationships to disclose.
Serrero
Dr. Serrero has disclosed that he receives
salary from and has ownership in A&G
Pharmaceutical.
Emily
Cristina
John
Ginette
OT2-4-01
OT2-4-01
OT2-4-02
OT2-4-02
OT2-4-02
OT2-4-02
OT2-4-02
OT2-4-02
OT2-4-02
OT2-4-02
OT2-4-02
OT2-5-01
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
A prospective study of glycoprotein 88 GP-88
blood test in healthy women with Gail model
risk <=1.66 undergoing screening for breast
cancer (BC) with mammography (MM)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Testing BRCA 1/2 mutation using next
generation sequencing (BRCANGS)
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
Katherine
Tkaczuk
Dr. Tkaczuk has disclosed she received a grant
Maryland Industry PArtnership (MIPS).
Binbin
Yue
Jong Rak
Choi
Jee Ye
Kim
Sanghwa
Kim
Seung Il
Kim
Hyung Seok
Park
Seho
Park
Seo Jin
Park
Jegyu
Ryu
Joo Hyuk
Sohn
Binbin Yue has disclosed he is employed by
A&G Pharmaceutical.
Dr. Choi has no relevant financial relationships
to disclose.
Dr. Kim has no relevant financial relationships
to disclose.
Dr. Kim has no relevant financial relationships
to disclose.
Dr. Kim has no relevant financial relationships
to disclose.
Dr. Park has no relevant financial relationships
to disclose.
Dr. Park has no relevant financial relationships
to disclose.
Dr. Park has no relevant financial relationships
to disclose.
Dr. Ryu has no relevant financial relationships
to disclose.
Dr. Sohn has no relevant financial relationships
to disclose.
Fehm
Dr. Fehm has no relevant financial relationships
to disclose.
Tanja
OT2-5-01
OT2-5-01
OT2-5-01
OT2-5-01
OT2-5-01
OT2-5-01
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
Julia
Kaiser
Dr. Kaiser has no relevant financial
relationships to disclose.
Elena
Laakmann
Dr. Laakmann has no relevant financial
relationships to disclose.
Loibl
Dr. Loibl has no relevant financial relationships
to disclose.
Möbus
Dr. Möbus has no relevant financial
relationships to disclose.
Müller
Dr. Müller has no relevant financial
relationships to disclose.
vonMinckwitz
Dr. vonMinckwitz has no relevant financial
relationships to disclose.
Sibylle
Volker
Volkmar
Gunter
OT2-5-01
OT2-5-02
OT2-5-02
OT2-5-02
OT2-5-02
OT3-1-01
Brain metastases in breast cancer network
Germany (BMBC, GBG 79): Multicentric, retroand prospective collection of patient data and
biomaterial from breast cancer patients with
brain metastases
A phase 2 randomized, double-blind, placebocontrolled trial of hormone therapy ± radium223 dichloride in HER2-negative hormone
receptor-positive breast cancer patients with
bone metastases
A phase 2 randomized, double-blind, placebocontrolled trial of hormone therapy ± radium223 dichloride in HER2-negative hormone
receptor-positive breast cancer patients with
bone metastases
A phase 2 randomized, double-blind, placebocontrolled trial of hormone therapy ± radium223 dichloride in HER2-negative hormone
receptor-positive breast cancer patients with
bone metastases
A phase 2 randomized, double-blind, placebocontrolled trial of hormone therapy ± radium223 dichloride in HER2-negative hormone
receptor-positive breast cancer patients with
bone metastases
A two-cohort, phase II, cardiac safety study of
pertuzumab, trastuzumab, and neoadjuvant
anthracycline-based chemotherapy in patients
with HER2-positive, locally advanced,
inflammatory, or early breast cancer
Isabell
Robert
Liping
Oana
Paola
Chau
Witzel
Dr. Witzel has no relevant financial
relationships to disclose.
Coleman
Dr. Coleman has disclosed that he receives
other financial funding for expert testimony
from Novartis.
Huang
Dr. Huang has disclosed that he is employed by
Bayer HealthCare.
Petrenciuc
Dr. Petrenciuc has disclosed that she is
employed by Bayer HealthCare.
Zaccarini
Dr. Zaccarini has disclosed she is employed by
Bayer SpA, Bayer HealthCare.
Dang
Dr. Dang has disclosed he receives research
funding from Roche/Genentech and
GlaxoSmithKine.
OT3-1-01
OT3-1-01
OT3-1-01
OT3-1-01
OT3-1-01
OT3-1-02
A two-cohort, phase II, cardiac safety study of
pertuzumab, trastuzumab, and neoadjuvant
anthracycline-based chemotherapy in patients
with HER2-positive, locally advanced,
inflammatory, or early breast cancer
A two-cohort, phase II, cardiac safety study of
pertuzumab, trastuzumab, and neoadjuvant
anthracycline-based chemotherapy in patients
with HER2-positive, locally advanced,
inflammatory, or early breast cancer
A two-cohort, phase II, cardiac safety study of
pertuzumab, trastuzumab, and neoadjuvant
anthracycline-based chemotherapy in patients
with HER2-positive, locally advanced,
inflammatory, or early breast cancer
A two-cohort, phase II, cardiac safety study of
pertuzumab, trastuzumab, and neoadjuvant
anthracycline-based chemotherapy in patients
with HER2-positive, locally advanced,
inflammatory, or early breast cancer
A two-cohort, phase II, cardiac safety study of
pertuzumab, trastuzumab, and neoadjuvant
anthracycline-based chemotherapy in patients
with HER2-positive, locally advanced,
inflammatory, or early breast cancer
A Phase 3 randomized, double-blind trial
comparing PF-05280014 + docetaxel and
carboplatin vs. trastuzumab + docetaxel and
carboplatin for neoadjuvant treatment of
+
operable HER2 breast cancer
Hannah
Douthwaite
Michael
Ewer
Sandra
Swain
Ms. Douthweite has disclosed that she is an
employee of Roche/Genentech.
Mr. Ewer has disclosed that he receives book
royalty for publication of "Cancer and the
Heart" second edition (2013). He also
disclosed that he is a member of DSMB for
Roche, consultant for GlaxoSmithKline and
AstraZeneca.
Dr. Swainhas disclosed she is an
uncompensated steering committee member
for Roche/Genentech. She also disclosed she
has a contract and receives travel
compensation from Roche/Genentech.
Tania
Szado
Ms. Szado has disclosed that she is an
employee of Roche/Genentech.
Waldron-Lynch
Ms. Waldron-Lynch has disclosed that she is an
employee of Roche/Genentech.
Abbas
Richat has disclosed that he receives salary and
has ownership in Pfizer Inc.
Maeve
Richat
OT3-1-02
OT3-1-02
OT3-1-02
OT3-1-02
OT3-1-02
OT3-1-03
A Phase 3 randomized, double-blind trial
comparing PF-05280014 + docetaxel and
carboplatin vs. trastuzumab + docetaxel and
carboplatin for neoadjuvant treatment of
operable HER2+ breast cancer
A Phase 3 randomized, double-blind trial
comparing PF-05280014 + docetaxel and
carboplatin vs. trastuzumab + docetaxel and
carboplatin for neoadjuvant treatment of
operable HER2+ breast cancer
A Phase 3 randomized, double-blind trial
comparing PF-05280014 + docetaxel and
carboplatin vs. trastuzumab + docetaxel and
carboplatin for neoadjuvant treatment of
operable HER2+ breast cancer
A Phase 3 randomized, double-blind trial
comparing PF-05280014 + docetaxel and
carboplatin vs. trastuzumab + docetaxel and
carboplatin for neoadjuvant treatment of
operable HER2+ breast cancer
A Phase 3 randomized, double-blind trial
comparing PF-05280014 + docetaxel and
carboplatin vs. trastuzumab + docetaxel and
carboplatin for neoadjuvant treatment of
operable HER2+ breast cancer
An open-label, multicentre, phase IIIb study
with intravenous administration of pertuzumab,
subcutaneous trastuzumab, and a taxane in
patients with HER2-positive metastatic breast
cancer (SAPPHIRE)
Jennifer
Coiro
Ms. Coiro has disclosed that she receives
funding from Pfizer Inc.
Fiona
Hilton
Ms. Hilton has disclosed that she receives
salary from and has ownership in Pfizer Inc.
Jacobs
Dr. Jacobs has disclosed that he receives salary
from and has ownership in Pfizer Inc..
Orazem
Mr. Orazem has disclosed that he receives
salary from and has ownership in Pfizer, Inc.
Charles
Zacharchuk
Mr. Zacharchuk has disclosed he receives
salary from and has ownership in Pfizer, Inc.
Jane
Beith
Ms. Beith has disclosed that she served on
advisory boards for Roche.
Ira
John
OT3-1-03
OT3-1-03
OT3-1-03
OT3-1-03
OT3-1-03
OT3-1-04
An open-label, multicentre, phase IIIb study
with intravenous administration of pertuzumab,
subcutaneous trastuzumab, and a taxane in
patients with HER2-positive metastatic breast
cancer (SAPPHIRE)
An open-label, multicentre, phase IIIb study
with intravenous administration of pertuzumab,
subcutaneous trastuzumab, and a taxane in
patients with HER2-positive metastatic breast
cancer (SAPPHIRE)
An open-label, multicentre, phase IIIb study
with intravenous administration of pertuzumab,
subcutaneous trastuzumab, and a taxane in
patients with HER2-positive metastatic breast
cancer (SAPPHIRE)
An open-label, multicentre, phase IIIb study
with intravenous administration of pertuzumab,
subcutaneous trastuzumab, and a taxane in
patients with HER2-positive metastatic breast
cancer (SAPPHIRE)
An open-label, multicentre, phase IIIb study
with intravenous administration of pertuzumab,
subcutaneous trastuzumab, and a taxane in
patients with HER2-positive metastatic breast
cancer (SAPPHIRE)
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
Richard
Ronelle
Andrew
Vita
Natasha
Hajime
De Boer
Mr. De Boer has disclosed that he served on
advisory boards for Roche.
Heath
Ms. Heath has disclosed that she is an
employee of Novotech, (Australia) Pty Limited
who is contracted to Roche Products Pty
Limited to support this research.
Redfern
Mr. Redfern has disclosed that he has served
on advisory boards for Roche.
Von Neumann-Cosel
Ms. Von Neumann-Cosel has disclosed she is
an employee of Roche Products, Pty. Limited.
Woodward
Dr. Woodward has disclosed she served on
advisory boards for Roche.
Abe
Dr. Abe has no relevant financial relationships
to disclose.
OT3-1-04
OT3-1-04
OT3-1-04
OT3-1-04
OT3-1-04
OT3-1-04
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
Shunji
Kamigaki
Dr. Kamigaki has no relevant financial
relationships to disclose.
Yoshifumi
Komoike
Dr. Komoike has no relevant financial
relationships to disclose.
Matsunami
Dr. Matsunami has no relevant financial
relationships to disclose.
Nakano
Dr. Nakano has no relevant financial
relationships to disclose.
Tezuka
Dr. Tezuka has no relevant financial
relationships to disclose.
Tsurutani
Dr. Tsurutani has no relevant financial
relationships to disclose.
Nobuki
Yoshiaki
Kenji
Junji
OT3-1-04
OT3-1-04
OT3-1-05
OT3-1-05
OT3-1-05
OT3-1-05
OT3-1-05
OT3-1-05
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
A phase 2 study of eribulin in combination with
pertuzumab and trastuzumab for advanced or
recurrent human epidermal growth factor
receptor 2 (HER2)-positive breast cancer (SONG02)
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Jun
Yamamura
Dr. Yamamura has no relevant financial
relationships to disclose.
Keiichi
Yamazaki
Dr. Yamazaki has no relevant financial
relationships to disclose.
Baselga
Dr. Baselga has disclosed that he is a
consultant for Novartis Pharmaceuticals.
Chandarlapaty
Dr. Chandarlapaty has no relevant financial
relationships to disclose.
Dickler
Dr. Dickler has disclosed that she receives
research funding from Novartis
Pharmaceuticals and Genentech.
Hudis
Dr. Hudis has no relevant financial relationships
to disclose.
Iasonos
Dr. Iasonos has no relevant financial
relationships to disclose.
Modi
Dr. Modi has disclosed that he receives
research funding with Novartis, Genentech,
Synta and Seattle Genetics
Jose
Sarat
Maura
Clifford
Alexia
Shanu
OT3-1-05
OT3-1-05
OT3-1-05
OT3-1-05
OT3-1-05
OT3-1-06
OT3-1-06
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
Phase I, open-label study evaluating the safety
and tolerability of LJM716, BYL719 and
trastuzumab in patients with metastatic HER2+
breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
Moynahan
Dr. Moynahan has no relevant financial
relationships to disclose.
Shah
Dr. Shah has no relevant financial relationships
to disclose.
Valentina
Sterlin
Ms. Sterlin has no relevant financial
relationships to disclose.
Gary
Ulaner
Dr. Ulaner has no relevant financial
relationships to disclose.
Zamora
Mr. Zamora has no relevant financial
relationships to disclose.
Dydo
Mr. Dydo has disclosed he is employed by
Astellas.
Gradishar
Dr. Gradishar has no relevant financial
relationships to disclose.
Mary Ellen
Payal
Stephen
Michael
William
OT3-1-06
OT3-1-06
OT3-1-06
OT3-1-06
OT3-1-06
OT3-1-06
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
Maggie
Liosatos
Ms. Liosatos has disclosed she is employed by
Astellas.
Amy
Peterson
Ms. Peterson has disclosed she is an employee
of Medivation.
Poondru
Srinivasu Poondru has disclosed he is
employed by Astellas.
Steinberg
Ms. Steinberrg has disclosed she is employed
by Astellas.
Trudeau
Ms. Trudeau has no relevant financial
relationships to disclose.
Westphal
Mr. Westphal has disclosed he is employed by
Astellas.
Srinivasu
Joyce
Maureen
Michael
OT3-1-06
OT3-1-06
OT3-1-07
OT3-1-07
OT3-1-07
OT3-1-07
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
A phase 2 single-arm study to evaluate the
clinical activity, safety and tolerability of
enzalutamide (ENZA) with trastuzumab in
patients with advanced human growth factor
receptor 2 (HER2)-positive breast cancer
MotHER: A US registry for women with breast
cancer who have received trastuzumab,
pertuzumab in combination with trastuzumab,
or trastuzumab emtansine (T-DM1) during
pregnancy or within 7 months prior to
conception
MotHER: A US registry for women with breast
cancer who have received trastuzumab,
pertuzumab in combination with trastuzumab,
or trastuzumab emtansine (T-DM1) during
pregnancy or within 7 months prior to
conception
MotHER: A US registry for women with breast
cancer who have received trastuzumab,
pertuzumab in combination with trastuzumab,
or trastuzumab emtansine (T-DM1) during
pregnancy or within 7 months prior to
conception
MotHER: A US registry for women with breast
cancer who have received trastuzumab,
pertuzumab in combination with trastuzumab,
or trastuzumab emtansine (T-DM1) during
pregnancy or within 7 months prior to
conception
Eric
Winer
Dr. Winer has no relevant financial
relationships to disclose.
Yun
Zhou
Yun Zhou has disclosed he is employed by
Astellas.
Elizabeth
Andrews
Ms. Andrews has disclosed that she is a
consultant for Genentech.
Brown
Ms. Brown has disclosed thatINC Research
conducts the MotHER registry for Genentech,
Inc.
Chow
Ms. Chow has disclosed she is an employee of
Genentech/Roche and has ownership in Roche.
Chu
Ms. Chu has disclosed she is an employee of
Genentech/Roche and has ownership in Roche.
Vikki
Cheryl
Laura
OT3-1-07
OT3-1-07
OT3-1-08
OT3-1-08
OT3-1-08
OT3-1-08
OT3-1-08
MotHER: A US registry for women with breast
cancer who have received trastuzumab,
pertuzumab in combination with trastuzumab,
or trastuzumab emtansine (T-DM1) during
pregnancy or within 7 months prior to
conception
MotHER: A US registry for women with breast
cancer who have received trastuzumab,
pertuzumab in combination with trastuzumab,
or trastuzumab emtansine (T-DM1) during
pregnancy or within 7 months prior to
conception
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
Richard
Miller
Mr. Miller has disclosed that he is a member of
Scientific Advisory Board and dysmorphologist
for MotHER Pregnancy Registry, for Ribavirin
Pregnancy Registry and Belimumab Pregnancy
Registry. Expert Witness for medical legal cases
concerning adverse outcomes during
pregnancy.
Caroline
Trudeau
Ms. Trudeau has disclosed she is an employee
of Genentech and has ownership in Roche.
Jose
Baselga
Dr. Baselga has no relevant financial
relationships to disclose.
Elena
Bernedo
Ms. Bernedo has disclosed that she is a Roche
employee.
Eva
Ciruelos
Ms. Ciruelos has no relevant financial
relationships to disclose.
Javier
Cortés
Dr. Cortés has no relevant financial
relationships to disclose.
de la Peña
Ms. de la Peña has no relevant financial
relationships to disclose.
Lorena
OT3-1-08
OT3-1-08
OT3-1-08
OT3-1-08
OT3-1-08
OT3-1-09
OT3-1-09
OT3-1-09
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
A phase II, randomized study of T-DM1 versus TDM1 plus short induction with docetaxel in first
line treatment for locally advanced or
metastatic HER2+ breast cancer (SOLTI-1203)
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
González
Xavier González has no relevant financial
relationships to disclose.
Llombart
Dr. Llombart has no relevant financial
relationships to disclose.
Susanne
Meya
Ms. Meya has disclosed that she is a Roche
employee.
Katya
Moreno
Ms. Moreno has disclosed that she is a Roche
employee.
Patricia
Villagrasa
Ms. Villagrasa has no relevant financial
relationships to disclose.
John
Berry
Dr. Berry has no relevant financial relationships
to disclose.
Guy
Clifton
Dr. Clifton has no relevant financial
relationships to disclose.
Julia
Greene
Dr. Greene has no relevant financial
relationships to disclose.
Xavier
Antonio
OT3-1-09
OT3-1-09
OT3-1-09
OT3-1-09
OT3-1-09
OT3-1-09
OT3-1-09
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Combination immunotherapy with trastuzumab
and the HER2 vaccine E75 (nelipepimut-S) in
high-risk HER2+ breast cancer patients to
prevent recurrence
Jarrod
Nuhad
Holmes
Dr. Holmes has no relevant financial
relationships to disclose.
Ibrahim
Dr. Ibrahim has no relevant financial
relationships to disclose.
Beth
Mittendorf
George
Peoples
Dr. Mittendorf has no relevant financial
relationships to disclose.
Dr. Peoples has disclosed that he has a patient
rights patent. He is a consultant to Galena
Biopharma and is Founder CRO, Cancer InCITe,
LLC.
Sathibalan
Ponniah
Dr. Ponniah has no relevant financial
relationships to disclose.
Erika
Schneble
Dr. Schneble has no relevant financial
relationships to disclose.
Trappey
Dr. Trappey has no relevant financial
relationships to disclose.
Alfred
OT3-1-10
OT3-1-10
OT3-1-10
OT3-1-10
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
Cortes
Dr. Cortes has disclosed he receives consulting
fees from Roche and Celgene.
Sara
Hurvitz
Ms. Hurvitz has disclosed that she has
contracted research/grants paid to institution
by Genentech/Roche.
Ian
Krop
Dr. Krop has disclosed that he has a contract
with Genentech.
Miller
Dr. Miller has no relevant financial
relationships to disclose.
Javier
Kathy
OT3-1-10
OT3-1-10
OT3-1-10
OT3-1-10
OT3-2-01
OT3-2-01
OT3-2-01
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
HERmione: A Phase 2, randomized, open label
trial comparing MM-302 plus trastuzumab with
physician's choice of chemotherapy plus
trastuzumab, in anthracycline naive HER2positive, locally advanced/metastatic breast
cancer, previously treated with pertuzumab and
trastuzumab emtansine (T-DM1)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
Kaveh
Debu
Sunil
Riahi
Kaveh Riahi has disclosed he is an employee of
and has ownership in Merrimack
Pharmaceuticals.
Tripathy
Dr. Tripathy has no relevant financial
relationships to disclose.
Verma
Dr. Verma has disclosed she is on Advisory
board/Honoraria: Novartis, Roche, Astra
Zeneca, Pfizer, Eisai, and GSK.
Denise
Yardley
Frederike
Bensch
Eline
Boon
Adrienne
Brouwers
Dr. Yardley has no relevant financial
relationships to disclose.
Frederike Bensch has no relevant financial
relationships to disclose.
Eline Boon has no relevant financial
relationships to disclose.
Adrienne Brouwers has no relevant financial
relationships to disclose.
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
OT3-2-01
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
IMPACT: IMaging PAtients for Cancer drug
selecTion - Metastatic breast cancer (MBC)
Lioe-Fee
Johan
Erik
Liesbeth
Sjoerd
Andor
Otto
Marc
Jim
Willemien
Carl
Wim
Carolien
Winette
Erik
Henk
Eric
Lioe-Fee de Geus-Oei has no relevant financial
relationships to disclose.
Mr. de Jong has no relevant financial
relationships to disclose.
de Jong
Mr. de Vries has no relevant financial
relationships to disclose.
de Vries
Liesbeth de Vries has no relevant financial
relationships to disclose.
de Vries
Sjoerd Elias has no relevant financial
relationships to disclose.
Elias
Andor Glaudemans has no relevant financial
relationships to disclose.
Glaudemans
Mr. Hoekstra has no relevant financial
relationships to disclose.
Hoekstra
Mr. Huisman has no relevant financial
relationships to disclose.
Huisman
Mr. Janssen has no relevant financial
relationships to disclose.
Janssen
Mr. Menke-van der Hoeven van Oordt has no
Menke-van der Hoeven van Oordt relevant financial relationships to disclose.
Mr. Moons has no relevant financial
relationships to disclose.
Moons
Wim Oyen has no relevant financial
relationships to disclose.
Oyen
Ms. Schröder has no relevant financial
relationships to disclose.
Schröder
Winette van de Graaf has no relevant financial
relationships to disclose.
van de Graaf
Mr. van Helden has no relevant financial
relationships to disclose.
van Helden
Henk Verheul has no relevant financial
relationships to disclose.
Verheul
Mr. Visser has no relevant financial
relationships to disclose.
Visser
de Geus-Oei
OT3-2-02
OT3-2-02
OT3-2-02
OT3-2-02
OT3-2-02
OT3-2-02
OT3-2-02
OT3-2-02
OT3-2-02
OT3-2-03
OT3-2-03
OT3-2-03
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
MINT I: Multi-Institutional Neo-adjuvant
Therapy, MammaPrint Project I
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Eli
Avisar
Peter
Blumencranz
Charles
Cox
Femke
de Snoo
William
Dooley
Ruben
Saez
Lisette
Stork-Sloots
Sarah
Untch
Robert
Wesolowski
Dr. Avisar has no relevant financial
relationships to disclose.
Dr. Blumencranz has no relevant financial
relationships to disclose.
Dr. Cox has no relevant financial relationships
to disclose.
Dr. de Snoo has disclosed he receives salary
from Agendia Inc.
Dr. Dooley has no relevant financial
relationships to disclose.
Dr. Saez has no relevant financial relationships
to disclose.
Ms. Stork-Sloots has disclosed she is an
employee of Agendia Inc.
Ms. Untch has disclosed she receives salary
from Agendia Inc.
Dr. Wesolowski has no relevant financial
relationships to disclose.
Oleg
Gluz
Nadia
Harbeck
Dr. Gluz has disclosed that he received
consulting fees from NanoString.
Prof. Dr. Harbeck has disclosed that she
received consulting fees for presentation and
advisory roles from NanoString Technologies.
She also disclosed that she is the PI of the
presented trial.
Hofmann
Mr. Hofmann has no relevant financial
relationships to disclose.
Daniel
OT3-2-03
OT3-2-03
OT3-2-03
OT3-2-03
OT3-2-03
OT3-2-03
OT3-2-03
OT3-2-03
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Janni
Dr. Janni has no relevant financial relationships
to disclose.
Kates
Dr. Kates has disclosed that his wife received
consulting fees for presentation and advisory
roles from NanoString Technologies.
Burkhard
Otremba
Dr. Otremba has no relevant financial
relationships to disclose.
Enrico
Pelz
Dr. Pelz has no relevant financial relationships
to disclose.
Christian
Schem
Dr. Schem has no relevant financial
relationships to disclose.
Christian
Schindlbeck
Dr. Schindlbeck has no relevant financial
relationships to disclose.
Karl
Sotlar
Prof. Sotlar has disclosed that he received
consulting fees from NanoString.
Hans
Tesch
Dr. Tesch has no relevant financial
relationships to disclose.
Wolfgang
Ronald
OT3-2-03
OT3-2-03
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
Prospective observational study of clinical
outcomes for the NanoString® technologies
Prosigna™ test by the West German Study
Group
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
Witzel
Dr. Witzel has no relevant financial
relationships to disclose.
Wuerstlein
Dr. Wuerstlein has disclosed she received
consulting fees for presentation and advisory
roles from NanoString Technologies.
Bahriye
Aktas
Dr. Aktas has no relevant financial relationships
to disclose.
Michael
Braun
Dr. Braun has no relevant financial
relationships to disclose.
Forstbauer
Dr. Forstbauer has no relevant financial
relationships to disclose.
Isabelle
Rachel
Helmut
Oleg
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
Nadia
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
Daniel
Harbeck
Dr. Gluz has disclosed that he received
consulting fees from Genomic Health, Inc. and
Roche.
Prof. Dr. Harbeck has disclosed that she
received consulting fees for presentation and
advisory roles from NanoString Technologies.
She also disclosed that she is the PI of the
presented trial.
Hofmann
Mr. Hofmann has no relevant financial
relationships to disclose.
Gluz
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-04
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
Kates
Dr. Kates has disclosed that his wife received
consulting fees from Roche, Celgene, Amgen,
and Genomic Health, Inc.
Kraemer
Dr. Kraemer has no relevant financial
relationships to disclose.
Sherko
Kuemmel
Dr. Kuemmel has no relevant financial
relationships to disclose.
Nicolai
Maass
Prof. Dr. Maass has no relevant financial
relationships to disclose.
Ulrike
Nitz
Prof. Dr. Nitz has disclosed that he received
consulting fees from Roche, Amgen, Celgene,
Genomic Health, Inc.
Benno
Nuding
Dr. Nuding has no relevant financial
relationships to disclose.
Mahdi
Rezai
Dr. Rezai has no relevant financial relationships
to disclose.
Claudia
Schumacher
Dr. Schumacher has no relevant financial
relationships to disclose.
Ronald
Stefan
OT3-2-04
OT3-2-04
OT3-2-04
OT3-2-05
OT3-2-05
OT3-2-05
OT3-2-05
OT3-2-05
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
ADAPT - Adjuvant Dynamic marker-Adjusted
Personalized Therapy trial optimizing risk
assessment and therapy response prediction in
early breast cancer
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
von Schumann
Ms. von Schumann has no relevant financial
relationships to disclose.
Warm
Dr. Warm has no relevant financial
relationships to disclose.
Rachel
Wuerstlein
Dr. Wuerstlein has no relevant financial
relationships to disclose.
Ricardo
Alvarez
Dr. Alvarez has no relevant financial
relationships to disclose.
Banu
Arun
Dr. Arun has no relevant financial relationships
to disclose.
Rosalind
Candelaria
Ms. Candelaria has no relevant financial
relationships to disclose.
Joe
Ensor
Dr. Ensor has no relevant financial relationships
to disclose.
Kelly
Hunt
Dr. Hunt has no relevant financial relationships
to disclose.
Raquel
Mathias
OT3-2-05
OT3-2-05
OT3-2-05
OT3-2-05
OT3-2-05
OT3-2-05
OT3-2-05
OT3-2-05
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Ibrahim
Dr. Ibrahim has no relevant financial
relationships to disclose.
Litton
Ms. Litton has no relevant financial
relationships to disclose.
Funda
Meric-Bernstam
Dr. Meric-Bernstam has no relevant financial
relationships to disclose.
Beth
Mittendorf
Dr. Mittendorf has no relevant financial
relationships to disclose.
Stacy
Moulder-Thompson
Dr. Moulder-Thompson has no relevant
financial relationships to disclose.
Rashmi
Murthy
Dr. Murthy has no relevant financial
relationships to disclose.
Helen
Piwnica-Worms
Ms. Piwnica-Worms has no relevant financial
relationships to disclose.
Fraser
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
Nuhad
Jennifer
OT3-2-05
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
Improving outcomes in triple-negative breast
cancer (TNBC) using molecular triaging and
diagnostic imaging to guide neoadjuvant
therapy
OT3-2-06
NEOPAL: A randomized phase II study
comparing RCB response to neoadjuvant
chemotherapy or letrozole-palbociclib in PAM50
defined postmenopausal luminal breast cancer Bernard
OT3-2-06
NEOPAL: A randomized phase II study
comparing RCB response to neoadjuvant
chemotherapy or letrozole-palbociclib in PAM50
defined postmenopausal luminal breast cancer Hervé
OT3-2-06
NEOPAL: A randomized phase II study
comparing RCB response to neoadjuvant
chemotherapy or letrozole-palbociclib in PAM50
defined postmenopausal luminal breast cancer Paul
OT3-2-05
OT3-2-05
OT3-2-05
Tripathy
Dr. Tripathy has no relevant financial
relationships to disclose.
Ueno
Dr. Ueno has no relevant financial relationships
to disclose.
Vicente
Valero
Dr. Valero has no relevant financial
relationships to disclose.
Wei
Yang
Wei Yang has no relevant financial
relationships to disclose.
Asselain
Dr. Asselain has no relevant financial
relationships to disclose.
Bonnefoi
Dr. Bonnefoi has no relevant financial
relationships to disclose.
Cottu
Dr. Cottu has no relevant financial relationships
to disclose.
Debu
Naoto
OT3-2-06
NEOPAL: A randomized phase II study
comparing RCB response to neoadjuvant
chemotherapy or letrozole-palbociclib in PAM50
defined postmenopausal luminal breast cancer Suzette
Delaloge
Dr. Delaloge has no relevant financial
relationships to disclose.
OT3-2-06
NEOPAL: A randomized phase II study
comparing RCB response to neoadjuvant
chemotherapy or letrozole-palbociclib in PAM50
defined postmenopausal luminal breast cancer François
Duhoux
Dr. Duhoux has no relevant financial
relationships to disclose.
OT3-2-06
NEOPAL: A randomized phase II study
comparing RCB response to neoadjuvant
chemotherapy or letrozole-palbociclib in PAM50
defined postmenopausal luminal breast cancer Jérçme
Lemonnier
Mr. Lemonnier has no relevant financial
relationships to disclose.
OT3-2-06
NEOPAL: A randomized phase II study
comparing RCB response to neoadjuvant
chemotherapy or letrozole-palbociclib in PAM50
defined postmenopausal luminal breast cancer Anne
Vincent Salomon
Dr. Vincent Salomon has no relevant financial
relationships to disclose.
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Albert
Cerussi
Dr. Cerussi has no relevant financial
relationships to disclose.
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Wen-Pin
Chen
Wen-Pin Chen has no relevant financial
relationships to disclose.
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Anais
Leproux
Dr. Leproux has no relevant financial
relationships to disclose.
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Christine
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Thomas
McLaren
Dr. McLaren has no relevant financial
relationships to disclose.
OSullivan
Dr. OSullivan has no relevant financial
relationships to disclose.
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Alice
Police
Dr. Police has no relevant financial
relationships to disclose.
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Min-Ying
Su
Dr. Su has no relevant financial relationships to
disclose.
OT3-2-07
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
Bruce
Tromberg
Dr. Tromberg has no relevant financial
relationships to disclose.
Wisner
Dr. Wisner has no relevant financial
relationships to disclose.
Soliman
Dr. Soliman has no relevant financial
relationships to disclose.
Stork
Ms. Stork-Sloots has disclosed she is an
employee of Agendia.
Untch
Ms. Untch has disclosed she is an employee of
Agendia Inc.
OT3-2-07
OT3-3-01
OT3-3-01
OT3-3-01
Predicting hormonal therapy response in breast
cancer using diffuse optical spectroscopic
imaging (DOSI): Ongoing clinical study
PROMIS: PRospective study Of MammaPrint in
breast cancer patients with an Intermediate
recurrence Score (PROMIS)
PROMIS: PRospective study Of MammaPrint in
breast cancer patients with an Intermediate
recurrence Score (PROMIS)
PROMIS: PRospective study Of MammaPrint in
breast cancer patients with an Intermediate
recurrence Score (PROMIS)
Dorota
Hatem
Lisette
Sarah
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
Allouache
Djelila Allouache has no relevant financial
relationships to disclose.
Blot
Mr. Blot has no relevant financial relationships
to disclose.
Franck
Bonnetain
Mr. Bonnetain has no relevant financial
relationships to disclose.
Emmanuelle
Bourbouloux
Mr. Bourbouloux has no relevant financial
relationships to disclose.
Etienne
Brain
Etienne Brain has no relevant financial
relationships to disclose.
Paul
Cottu
Dr. Cottu has no relevant financial relationships
to disclose.
Herve
Cure
Herve Cure has no relevant financial
relationships to disclose.
Coraline
Dubot
Ms. Dubot has no relevant financial
relationships to disclose.
Djelila
Emmanuel
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
OT3-3-02
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
Ferrero
Dr. Ferrero has no relevant financial
relationships to disclose.
Kirscher
Sylvie Kirscher has no relevant financial
relationships to disclose.
Magali
Lacroix-Triki
Magali Lacroix-Triki has no relevant financial
relationships to disclose.
Claudia
Lefeuvre
Ms. Lefeuvre has no relevant financial
relationships to disclose.
Emmanuelle
Malaurie
Emmanuelle Malaurie has no relevant financial
relationships to disclose.
Olivier
Mir
Mr. Mir has no relevant financial relationships
to disclose.
Christine
Orsini
Ms. Orsini has no relevant financial
relationships to disclose.
Hélène
Peyro-Saint-Paul
Ms. Peyro-Saint-Paul has disclosed that she is a
full time employee de QIAGEN Marseille SA.
Jean-Marc
Sylvie
OT3-3-02
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
ASTER 70s UNICANCER phase III trial: Can a
genomic prognosticator help tailoring adjuvant
systemic treatment for luminal breast
carcinoma in elderly women?
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Tomomi
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Haruhiko
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Fumikata
OT3-3-02
OT3-3-02
OT3-3-02
Rigal
Mr. Rigal has no relevant financial relationships
to disclose.
Rollot
Ms. Rollot has no relevant financial
relationships to disclose.
Gilles
Romieu
Dr. Romieu has no relevant financial
relationships to disclose.
Nicole
Tubiana-Mathieu
Ms. Tubiana-Mathieu has no relevant financial
relationships to disclose.
Fujisawa
Tomomii Fujisawa has no relevant financial
relationships to disclose.
Fukuda
Haruhiko Fukuda has no relevant financial
relationships to disclose.
Hara
Fumikata Hara has no relevant financial
relationships to disclose.
Olivier
Florence
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Kenichi
Inoue
Kenichi Inoue has no relevant financial
relationships to disclose.
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Hiroji
Iwata
Dr. Iwata has disclosed that he is a consultant
for Chugai Pharmaceutical.
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Takayuki
Kinoshita
Takayuki Kinoshita has no relevant financial
relationships to disclose.
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Norikazu
Masuda
Noryoichi Matsunuma has no relevant financial
relationships to disclose.
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Kenichi
Nakamura
Kenichi Nakamura has no relevant financial
relationships to disclose.
OT3-4-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
Taro
Shibata
Taro Shibata has no relevant financial
relationships to disclose.
OT3-4-01
OT3-5-01
OT3-5-01
OT3-5-01
OT3-5-01
OT3-5-01
OT3-5-01
OT3-5-01
A randomized controlled trial comparing
primary tumour resection plus systemic therapy
with systemic therapy alone in metastatic
breast cancer (JCOG1017 study; PRIM-BC)
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
Shien
Tadahiko Shien has no relevant financial
relationships to disclose.
Rebecca
Aft
Dr. Aft has no relevant financial relationships
to disclose.
Catherine
Appleton
Dr. Appleton has no relevant financial
relationships to disclose.
Amy
Cyr
Dr. Cyr has no relevant financial relationships
to disclose.
Timothy
Eberlein
Dr. Eberlein has no relevant financial
relationships to disclose.
Ademuyiwa
Foluso
Dr. Foluso has no relevant financial
relationships to disclose.
Feng
Gao
Dr. Gao has no relevant financial relationships
to disclose.
Gillanders
Dr. Gillanders has no relevant financial
relationships to disclose.
Tadahiko
William
OT3-5-01
OT3-5-01
OT3-5-01
OT3-6-01
OT3-6-01
OT3-6-01
OT3-6-01
OT3-6-01
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
A prospective, randomized trial of sentinel
lymph node biopsy versus no additional staging
in patients with T1-T2 invasive breast cancer
and negative axillary ultrasound
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
Margenthaler
Dr. Margenthaler has no relevant financial
relationships to disclose.
Tucker
Dr. Tucker has no relevant financial
relationships to disclose.
Imran
Zoberi
Dr. Zoberi has no relevant financial
relationships to disclose.
Nina
Bijker
Dr. Bijker has no relevant financial
relationships to disclose.
Eveline
Bleiker
Dr. Bleiker has no relevant financial
relationships to disclose.
Nicolas
Dif
Dr. Dif has no relevant financial relationships to
disclose.
Lotte
Elshof
Dr. Elshof has no relevant financial
relationships to disclose.
Claudette
Loo
Dr. Loo has no relevant financial relationships
to disclose.
Julie
Natalia
OT3-6-01
OT3-6-01
OT3-6-01
OT3-6-01
OT3-6-01
OT3-6-01
OT3-6-01
OT3-6-01
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
The LORD trial: A randomized, non-inferiority
trial, between active surveillance versus
standard treatment in patients with low risk
ductal carcinoma in situ
Pijnappel
Dr. Pijnappel has no relevant financial
relationships to disclose.
Rutgers
Dr. Rutgers has no relevant financial
relationships to disclose.
Victoria
Skinner
Ms. Skinner has no relevant financial
relationships to disclose.
Leen
Slaets
Dr. Slaets has no relevant financial
relationships to disclose.
Konstantinos
Tryfonidis
Dr. Tryfonidis has no relevant financial
relationships to disclose.
A
van Leeuwen-Stok
Dr. van Leeuwen-Stok has no relevant financial
relationships to disclose.
Gonneke
Warnars
Dr. Warnars has no relevant financial
relationships to disclose.
Jelle
Wesseling
Dr. Wesseling has no relevant financial
relationships to disclose.
Ruud
Emiel
P1-01-03
Mammographic breast density and magnetic
resonance (MR) imaging in women with
mammographically occult breast cancer
Mammographic breast density and magnetic
resonance (MR) imaging in women with
mammographically occult breast cancer
Mammographic breast density and magnetic
resonance (MR) imaging in women with
mammographically occult breast cancer
Mammographic breast density and magnetic
resonance (MR) imaging in women with
mammographically occult breast cancer
Mammographic breast density and magnetic
resonance (MR) imaging in women with
mammographically occult breast cancer
Mammographic breast density and magnetic
resonance (MR) imaging in women with
mammographically occult breast cancer
Value of breast MRI for preoperative axillary
assessment of breast cancer patients
Value of breast MRI for preoperative axillary
assessment of breast cancer patients
Value of breast MRI for preoperative axillary
assessment of breast cancer patients
Value of breast MRI for preoperative axillary
assessment of breast cancer patients
Value of breast MRI for preoperative axillary
assessment of breast cancer patients
P1-01-04
Evaluation of tumor response after neoadjuvant
chemotherapy in breast cancer patients:
Correlation between dynamic contrastenhanced MRI and pathologic tumor cellularity Joo Hee
P1-01-02
P1-01-02
P1-01-02
P1-01-02
P1-01-02
P1-01-02
P1-01-03
P1-01-03
P1-01-03
P1-01-03
Jessica
Jennifer
Chun
Linda
Freya
Billig
Dr. Billig has no relevant financial relationships
to disclose.
Gillman
Ms. Gillman has no relevant financial
relationships to disclose.
Jennifer
Chun Jennifer has no relevant financial
relationships to disclose.
Moy
Dr. Moy has no relevant financial relationships
to disclose.
Schnabel
Dr. Schnabel has no relevant financial
relationships to disclose.
Shira
Schwartz
Judy
Boughey
Sean
Dupont
Katrina
Glazebrook
Tina
Hieken
Tanya
Hoskin
Shira Schwartz has no relevant financial
relationships to disclose.
Dr. Boughey has no relevant financial
relationships to disclose.
Dr. Dupont has no relevant financial
relationships to disclose.
Ms. Glazebrook has no relevant financial
relationships to disclose.
Dr. Hieken has no relevant financial
relationships to disclose.
Ms. Hoskin has no relevant financial
relationships to disclose.
Cha
Dr. Cha has no relevant financial relationships
to disclose.
P1-01-04
Evaluation of tumor response after neoadjuvant
chemotherapy in breast cancer patients:
Correlation between dynamic contrastenhanced MRI and pathologic tumor cellularity Eun Young
Chae
Dr. Chae has no relevant financial relationships
to disclose.
P1-01-04
Evaluation of tumor response after neoadjuvant
chemotherapy in breast cancer patients:
Correlation between dynamic contrastenhanced MRI and pathologic tumor cellularity Woo Jung
Choi
Dr. Choi has no relevant financial relationships
to disclose.
P1-01-04
Evaluation of tumor response after neoadjuvant
chemotherapy in breast cancer patients:
Correlation between dynamic contrastenhanced MRI and pathologic tumor cellularity Hak Hee
Kim
Dr. Kim has no relevant financial relationships
to disclose.
P1-01-04
Evaluation of tumor response after neoadjuvant
chemotherapy in breast cancer patients:
Correlation between dynamic contrastenhanced MRI and pathologic tumor cellularity Won Kyung
Kim
Dr. Kim has no relevant financial relationships
to disclose.
P1-01-04
Evaluation of tumor response after neoadjuvant
chemotherapy in breast cancer patients:
Correlation between dynamic contrastenhanced MRI and pathologic tumor cellularity Hee Jung
Shin
Dr. Shin has no relevant financial relationships
to disclose.
P1-01-05
Effects of preoperative MRI on rate of ipsilateral
and contralateral recurrence of breast cancer
Amanda
Amin
Dr. Amin has no relevant financial relationships
to disclose.
P1-01-05
Effects of preoperative MRI on rate of ipsilateral
and contralateral recurrence of breast cancer
Kevin
Bethke
Dr. Bethke has no relevant financial
relationships to disclose.
P1-01-05
Effects of preoperative MRI on rate of ipsilateral
and contralateral recurrence of breast cancer
Nora
Hansen
Dr. Hansen has no relevant financial
relationships to disclose.
P1-01-05
Effects of preoperative MRI on rate of ipsilateral
and contralateral recurrence of breast cancer
Irene
P1-01-05
Effects of preoperative MRI on rate of ipsilateral
and contralateral recurrence of breast cancer
Seema
P1-01-05
Effects of preoperative MRI on rate of ipsilateral
and contralateral recurrence of breast cancer
Thomas
P1-01-06
Effects of preoperative MRI on rate of ipsilateral
and contralateral recurrence of breast cancer
Quantitative breast DCE-MRI risk biomarkers
and breast tumor immunohistochemistry
phenotypes: A preliminary assessment
Quantitative breast DCE-MRI risk biomarkers
and breast tumor immunohistochemistry
phenotypes: A preliminary assessment
Quantitative breast DCE-MRI risk biomarkers
and breast tumor immunohistochemistry
phenotypes: A preliminary assessment
Quantitative breast DCE-MRI risk biomarkers
and breast tumor immunohistochemistry
phenotypes: A preliminary assessment
Quantitative breast DCE-MRI risk biomarkers
and breast tumor immunohistochemistry
phenotypes: A preliminary assessment
Quantitative breast DCE-MRI risk biomarkers
and breast tumor immunohistochemistry
phenotypes: A preliminary assessment
P1-01-07
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
P1-01-05
P1-01-06
P1-01-06
P1-01-06
P1-01-06
P1-01-06
Helenowski
Dr. Helenowski has no relevant financial
relationships to disclose.
Khan
Dr. Khan has no relevant financial relationships
to disclose.
Kmiecik
Dr. Kmiecik has no relevant financial
relationships to disclose.
Zaveri
Shruti Zaveri has no relevant financial
relationships to disclose.
Gur
Dr. Gur has no relevant financial relationships
to disclose.
Rachel
Jankowitz
Dr. Jankowitz has no relevant financial
relationships to disclose.
Brenda
Kurland
Jules
Sumkin
Dr. Kurland has no relevant financial
relationships to disclose.
Dr. Sumkin has disclosed he is the PI for
Research Agreement between the University of
Pittsburgh and Hologic, Inc.
Wu
Dr. Wu has no relevant financial relationships
to disclose.
Zuley
Dr. Zuley has disclosed she is the PI on research
for tomosynthesis from Hologic, Inc.
Berg
Dr. Berg has disclosed that Gamma Medica and
General Electric Healthcare provides research
and equipment support to his Department.
Shruti
David
Shandong
Margarita
Wendie
P1-01-07
P1-01-07
P1-01-07
P1-01-07
P1-01-07
P1-01-07
P1-01-07
P1-01-08
P1-01-08
P1-01-08
P1-01-08
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
Quantitative assessment of early- and delayed
DCE-MRI background parenchymal
enhancement in breast cancer risk prediction
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
David
Rachel
Brenda
Gur
Dr. Gur has no relevant financial relationships
to disclose.
Jankowitz
Dr. Jankowitz has no relevant financial
relationships to disclose.
Kurland
Dr. Kurland has no relevant financial
relationships to disclose.
Robert
Nishikawa
Jules
Sumkin
Dr. Nishikawa has no relevant financial
relationships to disclose.
Dr. Sumkin has disclosed he is the PI for
Research Agreement between the University of
Pittsburgh and Hologic, Inc.
Shandong
Wu
Dr. Wu has no relevant financial relationships
to disclose.
Margarita
Zuley
Dr. Zuley has disclosed she is the PI on research
for tomosynthesis from Hologic, Inc.
Katherine
Crew
Dr. Crew has no relevant financial relationships
to disclose.
Guo
Xiaotao Guo has no relevant financial
relationships to disclose.
Ha
Dr. Ha has no relevant financial relationships to
disclose.
Hershman
Dr. Hershman has no relevant financial
relationships to disclose.
Xiaotao
Richard
Dawn
P1-01-08
P1-01-08
P1-01-08
P1-01-08
P1-01-08
P1-01-08
P1-01-09
P1-01-09
P1-01-09
P1-01-09
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Changes in breast density with mammography
and breast MRI among high-risk
postmenopausal women
Optimization of magnetic resonance imaging
predictive performance by breast cancer
subtypes for predicting response to
neoadjuvant chemotherapy
Optimization of magnetic resonance imaging
predictive performance by breast cancer
subtypes for predicting response to
neoadjuvant chemotherapy
Optimization of magnetic resonance imaging
predictive performance by breast cancer
subtypes for predicting response to
neoadjuvant chemotherapy
Optimization of magnetic resonance imaging
predictive performance by breast cancer
subtypes for predicting response to
neoadjuvant chemotherapy
Swathi
Susan
Mary Beth
Parijatham
Tong
Binsheng
Nola
Ella
John
Wen
Namburi
Dr. Namburi has no relevant financial
relationships to disclose.
Refice
Ms. Refice has no relevant financial
relationships to disclose.
Terry
Dr. Terry has no relevant financial relationships
to disclose.
Thomas
Dr. Thomas has no relevant financial
relationships to disclose.
Xiao
Tong Xiao has no relevant financial
relationships to disclose.
Zhao
Dr. Zhao has no relevant financial relationships
to disclose.
Hylton
Dr. Hylton has no relevant financial
relationships to disclose.
Jones
Dr. Jones has no relevant financial relationships
to disclose.
Kornak
Dr. Kornak has no relevant financial
relationships to disclose.
Li
Dr. Li has no relevant financial relationships to
disclose.
P1-01-09
P1-01-09
P1-01-09
P1-01-10
P1-01-10
P1-01-10
P1-01-10
P1-01-10
P1-01-10
P1-01-10
Optimization of magnetic resonance imaging
predictive performance by breast cancer
subtypes for predicting response to
neoadjuvant chemotherapy
Optimization of magnetic resonance imaging
predictive performance by breast cancer
subtypes for predicting response to
neoadjuvant chemotherapy
Optimization of magnetic resonance imaging
predictive performance by breast cancer
subtypes for predicting response to
neoadjuvant chemotherapy
A preoperative PET/MR imaging for diagnosing
malignant axillary lymph nodes in women
evaluated for breast cancer
A preoperative PET/MR imaging for diagnosing
malignant axillary lymph nodes in women
evaluated for breast cancer
A preoperative PET/MR imaging for diagnosing
malignant axillary lymph nodes in women
evaluated for breast cancer
A preoperative PET/MR imaging for diagnosing
malignant axillary lymph nodes in women
evaluated for breast cancer
A preoperative PET/MR imaging for diagnosing
malignant axillary lymph nodes in women
evaluated for breast cancer
A preoperative PET/MR imaging for diagnosing
malignant axillary lymph nodes in women
evaluated for breast cancer
A preoperative PET/MR imaging for diagnosing
malignant axillary lymph nodes in women
evaluated for breast cancer
Lo
Wei-Ching Lo has no relevant financial
relationships to disclose.
Newitt
Dr. Newitt has no relevant financial
relationships to disclose.
Wilmes
Dr. Wilmes has no relevant financial
relationships to disclose.
Cho
Dr. Cho has no relevant financial relationships
to disclose.
Jung Eun
Choi
Dr. Choi has no relevant financial relationships
to disclose.
Su Hwan
Kang
Dr. Kang has no relevant financial relationships
to disclose.
Eun-Jung
Kong
Dr. Kong has no relevant financial relationships
to disclose.
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Park
Dr. Park has no relevant financial relationships
to disclose.
Yeu
Dr. Yeu has no relevant financial relationships
to disclose.
Wei-Ching
David
Lisa
Ihn-Ho
Soo Jung
Jeong Yeong
Kyung Jun
P1-01-11
The impact of a critical look at the
consequences of preoperative MRI in breast
cancer patients
The impact of a critical look at the
consequences of preoperative MRI in breast
cancer patients
The impact of a critical look at the
consequences of preoperative MRI in breast
cancer patients
The impact of a critical look at the
consequences of preoperative MRI in breast
cancer patients
The impact of a critical look at the
consequences of preoperative MRI in breast
cancer patients
P1-01-12
Preoperative breast MRI does not affect survival
outcomes in T1-2 breast cancer patients who
underwent breast-conserving therapy
Jee Ye
P1-01-12
Preoperative breast MRI does not affect survival
outcomes in T1-2 breast cancer patients who
underwent breast-conserving therapy
Sanghwa
P1-01-12
Preoperative breast MRI does not affect survival
outcomes in T1-2 breast cancer patients who
underwent breast-conserving therapy
Seung il
P1-01-12
Preoperative breast MRI does not affect survival
outcomes in T1-2 breast cancer patients who
underwent breast-conserving therapy
Hyung Seok
P1-01-11
P1-01-11
P1-01-11
P1-01-11
Angel
Valerie
Fatima
Mehrzad
I Ching
Arnaout
Dr. Arnaout has no relevant financial
relationships to disclose.
Deslauriers
Dr. Deslauriers has no relevant financial
relationships to disclose.
Haggar
Dr. Haggar has no relevant financial
relationships to disclose.
Namazi
Dr. Namazi has no relevant financial
relationships to disclose.
Yeung
Dr. Yeung has no relevant financial
relationships to disclose.
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Park
Dr. Park has no relevant financial relationships
to disclose.
P1-01-12
P1-01-12
P1-01-13
P1-01-13
P1-01-13
P1-01-13
P1-01-13
P1-02-01
P1-02-01
Preoperative breast MRI does not affect survival
outcomes in T1-2 breast cancer patients who
underwent breast-conserving therapy
Seho
Preoperative breast MRI does not affect survival
outcomes in T1-2 breast cancer patients who
underwent breast-conserving therapy
Triple negative breast cancer targeting
paramagnetic nanoparticle for non-invasive
tumor imaging
Triple negative breast cancer targeting
paramagnetic nanoparticle for non-invasive
tumor imaging
Triple negative breast cancer targeting
paramagnetic nanoparticle for non-invasive
tumor imaging
Triple negative breast cancer targeting
paramagnetic nanoparticle for non-invasive
tumor imaging
Triple negative breast cancer targeting
paramagnetic nanoparticle for non-invasive
tumor imaging
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Jegyu
Meser
James
Branislava
Nadimpalli
Li
Yasufumi
Fakhrejahani
Park
Seho Park has no relevant financial
relationships to disclose.
Ryu
Dr. Ryu has no relevant financial relationships
to disclose.
Ali
Dr. Ali has no relevant financial relationships to
disclose.
Ewing
Dr. Ewing has no relevant financial
relationships to disclose.
Janic
Dr. Janic has no relevant financial relationships
to disclose.
Varma
Dr. Varma has no relevant financial
relationships to disclose.
Zhang
Dr. Zhang has no relevant financial
relationships to disclose.
Asao
Dr. Asao has disclosed he receives salary from
and has ownership in Canon Inc.
Elham
Fakhrejahani Elham has no relevant financial
relationships to disclose.
P1-02-01
P1-02-01
P1-02-01
P1-02-01
P1-02-01
P1-02-01
P1-02-01
P1-02-01
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Kanao
Shotaro Kanao has no relevant financial
relationships to disclose.
Kataoka
Masako Kataoka has no relevant financial
relationships to disclose.
Masahiro
Kawashima
Masahiro Kawashima has no relevant financial
relationships to disclose.
Tsuyoshi
Shiina
Dr. Shiina has no relevant financial
relationships to disclose.
Masahiro
Takada
Dr. Takada has no relevant financial
relationships to disclose.
Masakazu
Toi
Dr. Toi has no relevant financial relationships
to disclose.
Mariko
Tokiwa
Mariko Tokiwa has no relevant financial
relationships to disclose.
Masae
Torii
Masae Torii has no relevant financial
relationships to disclose.
Shotaro
Masako
P1-02-01
P1-02-02
P1-02-02
P1-02-02
P1-02-02
P1-02-02
P1-02-02
P1-02-02
P1-02-02
P1-02-03
P1-02-03
Evaluation of second-generation photoacoustic
mammography in detecting the breast cancer
vasculature and hypoxic status; a preliminary
study
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
analysis
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
analysis
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
analysis
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
analysis
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
analysis
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
analysis
Locoregional assessment by FDG PET/CT in
stage II/III breast cancer patients: A multivariate
analysis
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
or occult N3-disease in breast cancer patients
with PET/CT
Yamaga
Iku Yamaga has no relevant financial
relationships to disclose.
Bas
Koolen
Dr. Koolen has no relevant financial
relationships to disclose.
Emiel
Rutgers
Marcel
Stokkel
Dr. Rutgers has no relevant financial
relationships to disclose.
Dr. Stokkel has no relevant financial
relationships to disclose.
Teixeira
Dr. Teixeira has no relevant financial
relationships to disclose.
Valdés-Olmos
Dr. Valdés-Olmos has no relevant financial
relationships to disclose.
van der Noort
Dr. van der Noort has no relevant financial
relationships to disclose.
Vogel
Dr. Vogel has no relevant financial
relationships to disclose.
Iku
Suzana
Renato
Vincent
Wouter
Marie-Jeanne
Vrancken-Peeters
Paula
Elkhuizen
Dr. Vrancken-Peeters has no relevant financial
relationships to disclose.
Dr. Elkhuizen has no relevant financial
relationships to disclose.
Koolen
Dr. Koolen has no relevant financial
relationships to disclose.
Bas
P1-02-03
P1-02-03
P1-02-03
P1-02-03
P1-02-03
P1-02-03
P1-02-04
P1-02-04
P1-02-04
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
or occult N3-disease in breast cancer patients
with PET/CT
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
or occult N3-disease in breast cancer patients
with PET/CT
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
or occult N3-disease in breast cancer patients
with PET/CT
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
or occult N3-disease in breast cancer patients
with PET/CT
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
or occult N3-disease in breast cancer patients
with PET/CT
The effect on short-term progression free
survival of the detection of ≥4 FDG-avid nodes
or occult N3-disease in breast cancer patients
with PET/CT
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Rutgers
Dr. Rutgers has no relevant financial
relationships to disclose.
Stokkel
Dr. Stokkel has no relevant financial
relationships to disclose.
Suzana
Teixeira
Dr. Teixeira has no relevant financial
relationships to disclose.
Renato
Valdés-Olmos
Dr. Valdés-Olmos has no relevant financial
relationships to disclose.
Vincent
van der Noort
Dr. van der Noort has no relevant financial
relationships to disclose.
Marie-Jeanne
Vrancken-Peeters
Dr. Vrancken-Peeters has no relevant financial
relationships to disclose.
Amioka
Ai Amioka has no relevant financial
relationships to disclose.
Emi
Akiko Emi has no relevant financial
relationships to disclose.
Haruta
Rumi Haruta has no relevant financial
relationships to disclose.
Emiel
Marcel
Ai
Akiko
Rumi
P1-02-04
P1-02-04
P1-02-04
P1-02-04
P1-02-04
P1-02-04
P1-02-04
P1-02-05
P1-02-06
P1-02-06
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
Impact of perflubutane-enhanced
ultrasonography for evaluating malignancy
grade of breast cancer
An analysis of lesions diagnosed on screening
breast ultrasound in women with dense breasts:
Four years of data
Retrospective comparison of sensitivity and
positive predictive value (PPV) of contrast
enhanced spectral mammography (CESM) to
contrast enhanced breast MRI (BMRI) in 50
malignant breasts
Retrospective comparison of sensitivity and
positive predictive value (PPV) of contrast
enhanced spectral mammography (CESM) to
contrast enhanced breast MRI (BMRI) in 50
malignant breasts
Kadoya
Dr. Kadoya has no relevant financial
relationships to disclose.
Kajitani
Keiko Kajitani has no relevant financial
relationships to disclose.
Kataoka
Tsuyoshi Kataoka has no relevant financial
relationships to disclose.
Masumoto
Dr. Masumoto has no relevant financial
relationships to disclose.
Okada
Morihito Okada has no relevant financial
relationships to disclose.
Hideo
Shigematsu
Hideo Shigematsu has no relevant financial
relationships to disclose.
Noriko
Yoshimura
Noriko Yoshimura has no relevant financial
relationships to disclose.
Jean
Weigert
Dr. Weigert has disclosed he is a consultant for
and has a ownership in Tractus Inc.
Kristin
Brill
Dr. Brill has no relevant financial relationships
to disclose.
Germaine
Dr. Germaine has no relevant financial
relationships to disclose.
Takayuki
Keiko
Tsuyoshi
Norio
Morihito
Pauline
P1-02-06
P1-02-06
P1-02-06
P1-02-06
P1-02-07
P1-02-07
P1-02-07
P1-02-07
Retrospective comparison of sensitivity and
positive predictive value (PPV) of contrast
enhanced spectral mammography (CESM) to
contrast enhanced breast MRI (BMRI) in 50
malignant breasts
Retrospective comparison of sensitivity and
positive predictive value (PPV) of contrast
enhanced spectral mammography (CESM) to
contrast enhanced breast MRI (BMRI) in 50
malignant breasts
Retrospective comparison of sensitivity and
positive predictive value (PPV) of contrast
enhanced spectral mammography (CESM) to
contrast enhanced breast MRI (BMRI) in 50
malignant breasts
Retrospective comparison of sensitivity and
positive predictive value (PPV) of contrast
enhanced spectral mammography (CESM) to
contrast enhanced breast MRI (BMRI) in 50
malignant breasts
Contrast-enhanced ultrasound for evaluation of
therapeutic efficacy of radiofrequency ablation
for primary breast cancer
Contrast-enhanced ultrasound for evaluation of
therapeutic efficacy of radiofrequency ablation
for primary breast cancer
Contrast-enhanced ultrasound for evaluation of
therapeutic efficacy of radiofrequency ablation
for primary breast cancer
Contrast-enhanced ultrasound for evaluation of
therapeutic efficacy of radiofrequency ablation
for primary breast cancer
Karen
Hendershott
Dr. Hendershott has no relevant financial
relationships to disclose.
Luna
Li
Dr. Li has no relevant financial relationships to
disclose.
Liao
Dr. Liao has no relevant financial relationships
to disclose.
Tinney
Ms. Tinney has no relevant financial
relationships to disclose.
Ito
Toshikazu Ito has no relevant financial
relationships to disclose.
Masaaki
Izukura
Masaaki Izukura has no relevant financial
relationships to disclose.
Jyunji
Okayama
Jyunji Okayama has no relevant financial
relationships to disclose.
Kumiko
Uji
Kumiko Uji has no relevant financial
relationships to disclose.
Lydia
Elizabeth
Toshikazu
18
P1-02-08
P1-02-08
P1-02-08
P1-02-08
P1-02-08
P1-02-08
F-fluoro-2-deoxy-glucose positron emission
tomography/ computed tomography evaluation
shows the utility for predicting postoperative
outcomes on Luminal types breast cancer
patients
18
F-fluoro-2-deoxy-glucose positron emission
tomography/ computed tomography evaluation
shows the utility for predicting postoperative
outcomes on Luminal types breast cancer
patients
18
F-fluoro-2-deoxy-glucose positron emission
tomography/ computed tomography evaluation
shows the utility for predicting postoperative
outcomes on Luminal types breast cancer
patients
18
F-fluoro-2-deoxy-glucose positron emission
tomography/ computed tomography evaluation
shows the utility for predicting postoperative
outcomes on Luminal types breast cancer
patients
18
F-fluoro-2-deoxy-glucose positron emission
tomography/ computed tomography evaluation
shows the utility for predicting postoperative
outcomes on Luminal types breast cancer
patients
18
F-fluoro-2-deoxy-glucose positron emission
tomography/ computed tomography evaluation
shows the utility for predicting postoperative
outcomes on Luminal types breast cancer
patients
Kenjiro
Aogi
Dr. Aogi has no relevant financial relationships
to disclose.
Takayuki
Kadoya
Dr. Kadoya has no relevant financial
relationships to disclose.
Kiyoto
Dr. Kiyoto has no relevant financial
relationships to disclose.
Masumoto
Dr. Masumoto has no relevant financial
relationships to disclose.
Okada
Dr. Okada has no relevant financial
relationships to disclose.
Shigematsu
Dr. Shigematsu has no relevant financial
relationships to disclose.
Sachiko
Norio
Morihito
Hideo
18
P1-02-08
P1-02-09
P1-02-09
P1-02-09
P1-02-09
P1-02-10
P1-02-10
P1-02-10
P1-02-10
P1-02-10
F-fluoro-2-deoxy-glucose positron emission
tomography/ computed tomography evaluation
shows the utility for predicting postoperative
outcomes on Luminal types breast cancer
patients
Clinical studies of palpation imaging of the
breast on over 1000 patients
Clinical studies of palpation imaging of the
breast on over 1000 patients
Clinical studies of palpation imaging of the
breast on over 1000 patients
Clinical studies of palpation imaging of the
breast on over 1000 patients
Contrast enhanced spectral mammography
(CESM) is a new breast imaging contrast study:
A review of indications, protocol, interpretation
and pitfalls
Contrast enhanced spectral mammography
(CESM) is a new breast imaging contrast study:
A review of indications, protocol, interpretation
and pitfalls
Contrast enhanced spectral mammography
(CESM) is a new breast imaging contrast study:
A review of indications, protocol, interpretation
and pitfalls
Contrast enhanced spectral mammography
(CESM) is a new breast imaging contrast study:
A review of indications, protocol, interpretation
and pitfalls
Contrast enhanced spectral mammography
(CESM) is a new breast imaging contrast study:
A review of indications, protocol, interpretation
and pitfalls
Yoshifumi
Sugawara
Cary
Kaufman
Armen
Sarvazyan
Jae
Son
Eli
Yered
Dr. Sugawara has no relevant financial
relationships to disclose.
Dr. Kaufman has no relevant financial
relationships to disclose.
Dr. Sarvazyan has no relevant financial
relationships to disclose.
Dr. Son has no relevant financial relationships
to disclose.
Mr. Yered has no relevant financial
relationships to disclose.
Kristin
Brill
Dr. Brill has no relevant financial relationships
to disclose.
Pauline
Germaine
Dr. Germaine has no relevant financial
relationships to disclose.
Karen
Hendershott
Dr. Hendershott has no relevant financial
relationships to disclose.
Luna
Li
Dr. Li has no relevant financial relationships to
disclose.
Lydia
Liao
Dr. Liao has no relevant financial relationships
to disclose.
P1-02-10
P1-02-11
P1-02-11
P1-02-11
P1-02-11
P1-02-11
P1-02-11
P1-02-11
P1-02-11
Contrast enhanced spectral mammography
(CESM) is a new breast imaging contrast study:
A review of indications, protocol, interpretation
and pitfalls
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
Tinney
Ms. Tinney has no relevant financial
relationships to disclose.
Emi
Dr. Emi has no relevant financial relationships
to disclose.
Rumi
Haruta
Dr. Haruta has no relevant financial
relationships to disclose.
Takayuki
Kadoya
Dr. Kadoya has no relevant financial
relationships to disclose.
Keiko
Kajitani
Dr. Kajitani has no relevant financial
relationships to disclose.
Tsuyoshi
Kataoka
Noriko
Masumoto
Dr. Kataoka has no relevant financial
relationships to disclose.
Dr. Masumoto has no relevant financial
relationships to disclose.
Okada
Dr. Okada has no relevant financial
relationships to disclose.
Shigematsu
Dr. Shigematsu has no relevant financial
relationships to disclose.
Elizabeth
Akiko
Morihito
Hideo
P1-02-11
P1-02-12
P1-02-12
P1-02-12
P1-02-12
P1-02-12
P1-02-12
P1-02-12
P1-02-12
P1-02-12
P1-02-12
Role of FDG-PET/CT in prediction of
underestimation of invasive breast cancer in
cases of ductal carcinoma in situ diagnosed at
needle biopsy
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
High-resolution specimen-positron emission
mammography (s-PEM) indicates the spread of
cancer in breast-conserving surgery
Yoshimura
Dr. Yoshimura has no relevant financial
relationships to disclose.
Takanori
Ishida
Dr. Ishida has no relevant financial
relationships to disclose.
Masatoshi
Itoh
Dr. Itoh has no relevant financial relationships
to disclose.
Dan
Kyokutou
Dr. Kyokutou has no relevant financial
relationships to disclose.
Minoru
Miyashita
Dr. Miyashita has no relevant financial
relationships to disclose.
Mori
Dr. Mori has no relevant financial relationships
to disclose.
Ohuchi
Dr. Ohuchi has no relevant financial
relationships to disclose.
Suzuki
Dr. Suzuki has no relevant financial
relationships to disclose.
Tada
Dr. Tada has no relevant financial relationships
to disclose.
Watanabe
Dr. Watanabe has no relevant financial
relationships to disclose.
Watanabe
Dr. Watanabe has no relevant financial
relationships to disclose.
Noriko
Naoko
Noriaki
Akihiko
Hiroshi
Gou
Mika
P1-03-01
P1-03-01
P1-03-01
P1-03-01
P1-03-01
P1-03-01
P1-03-01
P1-03-01
P1-03-01
P1-03-01
P1-03-01
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Cardiac function in BRCA1/2 mutation carriers
with a history of breast cancer (BC) treated with
anthracyclines (anthra)
Barac
Dr. Barac has no relevant financial relationships
to disclose.
Herbolsheimer
Dr. Herbolsheimer has no relevant financial
relationships to disclose.
Isaacs
Dr. Isaacs has no relevant financial
relationships to disclose.
Lynce
Dr. Lynce has no relevant financial
relationships to disclose.
Mete
Dr. Mete has no relevant financial relationships
to disclose.
Madeline
Nardacci
Ms. Nardacci has no relevant financial
relationships to disclose.
Raquel
Nunes
Dr. Nunes has no relevant financial
relationships to disclose.
Karen
Smith
Dr. Smith has no relevant financial
relationships to disclose.
Swain
Dr. Swain has no relevant financial
relationships to disclose.
Warren
Dr. Warren has no relevant financial
relationships to disclose.
Wray
Ms. Wray has no relevant financial
relationships to disclose.
Ana
Pia
Claudine
Filipa
Mihriye
Sandra
Robert
Lynette
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
P1-03-02
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
Steven
Anderson
Lisa
Carey
Daniel
Carrizosa
Steven
Corso
Zeruesenay
Desta
James
Evans
David
Flockhart
Daniel
Hertz
Joseph
Ibrahim
William
Irvin, Jr
Howard
McLeod
Susan
Moore
Oludamilola
Olajide
Jeffrey
Peppercorn
Rachel
Raab
Peter
Rubin
Gary
Schwartz
Dr. Anderson has disclosed he is an employee
of Laboratory Corporation of America.
Dr. Carey has no relevant financial
relationships to disclose.
Dr. Carrizosa has no relevant financial
relationships to disclose.
Dr. Corso has no relevant financial
relationships to disclose.
Dr. Desta has no relevant financial
relationships to disclose.
Dr. Evans has no relevant financial
relationships to disclose.
Dr. Flockhart has no relevant financial
relationships to disclose.
Dr. Hertz has no relevant financial relationships
to disclose.
Dr. Ibrahim has no relevant financial
relationships to disclose.
Dr. Irvin has no relevant financial relationships
to disclose.
Dr. McLeod has no relevant financial
relationships to disclose.
Dr. Moore has no relevant financial
relationships to disclose.
Dr. Olajide has no relevant financial
relationships to disclose.
Dr. Peppercorn has no relevant financial
relationships to disclose.
Dr. Raab has no relevant financial relationships
to disclose.
Dr. Rubin has no relevant financial
relationships to disclose.
Dr. Schwartz has no relevant financial
relationships to disclose.
P1-03-02
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
CYP2D6 intermediate metabolizers includes
patient groups with distinct metabolic activity
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
Lisa
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
Sami
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
Mike
Janicek
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
Lucy
Langer
Dr. Janicek has no relevant financial
relationships to disclose.
Ms. Lüftner has disclosed that he is a
consultant for Myriad Genetic Laboratories,
Inc., Ambry, and Genentech. He also disclosed
he is a speaker for Myriad Genetic
Laboratories, Inc. and Ambry.
Leininger
Ms. Leininger has disclosed that she is a
consultant for Myriad Genetic Laboratories,
Inc. She also disclosed that she has ownership
in Myriad Genetic Laboratories, Inc.
Rodriguez
Dr. Rodriguez has no relevant financial
relationships to disclose.
Saam
Dr. Saam has disclosed she is an employee of
Myriad Genetic Laboratories, Inc.
Sandbach
Dr. Sandbach has no relevant financial
relationships to disclose.
P1-03-02
P1-03-02
Clark
Dr. Snavely has no relevant financial
relationships to disclose.
Dr. Walko has no relevant financial
relationships to disclose.
Dr. Weck has no relevant financial relationships
to disclose.
Ms. Clark has disclosed she receives speaker
and consulting fees from Myriad Genetic
Laboratories, Inc.
Diab
Dr. Diab has no relevant financial relationships
to disclose.
Anna
Snavely
Christine
Walko
Karen
Weck
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
Anna
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
Patricia
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
Jennifer
P1-03-03
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
John
P1-03-03
P1-03-04
P1-03-04
P1-03-04
P1-03-04
P1-03-05
P1-03-05
P1-03-05
Experience in the community oncology practice
with a 25-gene hereditary cancer panel
The impact of Angelina Jolie (AJ)'s story on
genetic referral and testing at an academic
cancer centre
The impact of Angelina Jolie (AJ)'s story on
genetic referral and testing at an academic
cancer centre
The impact of Angelina Jolie (AJ)'s story on
genetic referral and testing at an academic
cancer centre
The impact of Angelina Jolie (AJ)'s story on
genetic referral and testing at an academic
cancer centre
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
Ellen
Andrea
Paul
Smith
Dr. Smith has no relevant financial
relationships to disclose.
Eisen
Dr. Eisen has no relevant financial relationships
to disclose.
Hewitt
Mr. Hewitt has no relevant financial
relationships to disclose.
Jacques
Raphael
Sunil
Verma
Dr. Raphael has no relevant financial
relationships to disclose.
Dr. Verma has disclosed she receives salary
from Pfizer, Novartis, Roche/Genentech,
Amgen, Astra Zeneca, and Boehringer
Ingelheim. She is a consultant for
Roche/Genentech, Amgen, Novartis, Astra
Zeneca, Lilly, and Eisai. She also disclosed she is
a speaker for Novartis and has contracts with
Sanofi Aventis.
Annouschka
Laenen
Annouschka Laenen has no relevant financial
relationships to disclose.
Diether
Lambrechts
Diether Lambrechts has no relevant financial
relationships to disclose.
Anneleen
Lintermans
Anneleen Lintermans has no relevant financial
relationships to disclose.
P1-03-05
P1-03-05
P1-03-05
P1-03-05
P1-03-05
P1-03-06
P1-03-06
P1-03-06
P1-03-06
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
Genetic variant in the OPG gene is associated
with aromatase inhibitor-related
musculoskeletal toxicity in breast cancer
patients
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
Neven
Dr. Neven has no relevant financial
relationships to disclose.
Van Asten
Ms. Van Asten has no relevant financial
relationships to disclose.
Thomas
Van Brussel
Mr. Van Brussel has no relevant financial
relationships to disclose.
Dirk
Vanderschueren
Mr. Vanderschueren has no relevant financial
relationships to disclose.
Verhaeghe
Johan Verhaeghe has no relevant financial
relationships to disclose.
Abbas
Dr. Abbas has no relevant financial
relationships to disclose.
Deborah
Armstrong
Dr. Armstrong has no relevant financial
relationships to disclose.
Hussein
Assi
Dr. Assi has no relevant financial relationships
to disclose.
Yannick
Bidet
Dr. Bidet has no relevant financial relationships
to disclose.
Patrick
Kathleen
Johan
Jaber
P1-03-06
P1-03-06
P1-03-06
P1-03-06
P1-03-06
P1-03-06
P1-03-06
P1-03-06
P1-03-06
P1-03-06
P1-03-06
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
Bignon
Dr. Bignon has no relevant financial
relationships to disclose.
Charara
Dr. Charara has no relevant financial
relationships to disclose.
Decousous
Ms. Decousous has no relevant financial
relationships to disclose.
El Saghir
Dr. El Saghir has no relevant financial
relationships to disclose.
Farhat
Dr. Farhat has no relevant financial
relationships to disclose.
Sara
Jaber
Dr. Jaber has no relevant financial relationships
to disclose.
Faek
Jamali
Dr. Jamali has no relevant financial
relationships to disclose.
Katia
Khoury
Dr. Khoury has no relevant financial
relationships to disclose.
Salem
Dr. Salem has no relevant financial
relationships to disclose.
Seoud
Dr. Seoud has no relevant financial
relationships to disclose.
Shamseddine
Dr. Shamseddine has no relevant financial
relationships to disclose.
Yves-Jean
Raghid
Stephanie
Nagi
Rania
Ziad
Muhieddine
Ali
P1-03-06
P1-03-06
P1-03-06
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
P1-03-08
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
BRCA1 and BRCA2 mutations in ethnic Lebanese
Arab high risk women for hereditary breast
cancer
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Arafat
Nancy
Tfayli
Dr. Tfayli has no relevant financial relationships
to disclose.
Uhrhammer
Dr. Uhrhammer has no relevant financial
relationships to disclose.
Nathalie
Zgheib
Konstantinos
Agiannitopoulos
Angela
Apessos
Nikolaos
Bredakis
Stylianos
Kakolyris
Antonios
Keramopoulos
Georgios
Kesisis
Christos
Markopoulos
Vassiliki
Metaxa-Mariatou
Georgios
Nasioulas
Ioannis
Natsiopoulos
Eirini
Papadopoulou
Konstantinos
Papazisis
Dr. Zgheib has no relevant financial
relationships to disclose.
Konstantinos Agiannitopoulos has no relevant
financial relationships to disclose.
Ms. Apessos has no relevant financial
relationships to disclose.
Mr. Bredakis has no relevant financial
relationships to disclose.
Stylianos Kakolyris has no relevant financial
relationships to disclose.
Mr. Keramopoulos has no relevant financial
relationships to disclose.
Georgios Kesisis has no relevant financial
relationships to disclose.
Mr. Markopoulos has no relevant financial
relationships to disclose.
Vassiliki Metaxa-Mariatou has no relevant
financial relationships to disclose.
Georgios Nasioulas has no relevant financial
relationships to disclose.
Ioannis Natsiopoulos has no relevant financial
relationships to disclose.
Eirini Papadopoulou has no relevant financial
relationships to disclose.
Mr. Papazisis has no relevant financial
relationships to disclose.
P1-03-08
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
Different genomic rearrangements account for
17% of BRCA1/2 mutations in Greece
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Mabel
Bohorquez
Ms. Bohorquez has no relevant financial
relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Luis
Carvajal-Carmona
Dr. Carvajal-Carmona has no relevant financial
relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Jorge
Castro
Mr. Castro has no relevant financial
relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia
COLOMBUS Consortium
COLOMBUS Consortium has no relevant
financial relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Magdalena
Echeverry
Dr. Echeverry has no relevant financial
relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Gilbert
Mateus
Mr. Mateus has no relevant financial
relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Justo
Olaya
Justo Olaya has no relevant financial
relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Rodrigo
Prieto
Mr. Prieto has no relevant financial
relationships to disclose.
P1-03-08
P1-03-08
P1-03-08
P1-03-08
Nikolaos
Touroutoglou
Aristeidis
Tsiftsoglou
Maria
Vasilaki-Antonatou
Vasileios
Venizelos
Grigorios
Xepapadakis
Mr. Touroutoglou has no relevant financial
relationships to disclose.
Aristeidis Tsiftsoglou has no relevant financial
relationships to disclose.
Ms. Vasilaki-Antonatou has no relevant
financial relationships to disclose.
Vasileios Venizelos has no relevant financial
relationships to disclose.
Grigorios Xepapadakis has no relevant financial
relationships to disclose.
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Carolina
P1-03-09
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia Anna Marie
P1-03-09
P1-04-02
P1-04-02
P1-04-02
P1-04-02
P1-04-02
P1-04-03
P1-04-03
P1-04-03
Identification of BRCA1 and BRCA2 founder
mutations in population isolates from Colombia
Exome sequencing identified emergence of
HER2 kinase domain mutations in trastuzumabresistant breast cancer
Exome sequencing identified emergence of
HER2 kinase domain mutations in trastuzumabresistant breast cancer
Exome sequencing identified emergence of
HER2 kinase domain mutations in trastuzumabresistant breast cancer
Exome sequencing identified emergence of
HER2 kinase domain mutations in trastuzumabresistant breast cancer
Exome sequencing identified emergence of
HER2 kinase domain mutations in trastuzumabresistant breast cancer
Prognostic and predictive implications of
monosomy 17 in curable HER2-amplified breast
cancer
Prognostic and predictive implications of
monosomy 17 in curable HER2-amplified breast
cancer
Prognostic and predictive implications of
monosomy 17 in curable HER2-amplified breast
cancer
Ramirez
Ms. Ramirez has no relevant financial
relationships to disclose.
Tuazon
Ms. Tuazon has no relevant financial
relationships to disclose.
Velez
Mr. Velez has no relevant financial
relationships to disclose.
Jiang
Dr. Jiang has no relevant financial relationships
to disclose.
Shao
Dr. Shao has no relevant financial relationships
to disclose.
Yu-Jie
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Ke-Da
Yu
Dr. Yu has no relevant financial relationships to
disclose.
Wen-Jia
Zuo
Dr. Zuo has no relevant financial relationships
to disclose.
Dure
Dr. Dure has no relevant financial relationships
to disclose.
Alejandro
Yizhou
Zhi-Ming
Dana
Clifford
Hudis
Heather
McArthur
Dr. Hudis has no relevant financial relationships
to disclose.
Dr. McArthur has disclosed that she is a
consultant for Celgene and receives research
funds from Bristol-Myers Squibb.
P1-04-03
P1-04-03
P1-04-04
P1-04-04
P1-04-04
P1-04-04
P1-04-05
P1-04-05
P1-04-05
P1-04-05
Prognostic and predictive implications of
monosomy 17 in curable HER2-amplified breast
cancer
Prognostic and predictive implications of
monosomy 17 in curable HER2-amplified breast
cancer
Activating HER2 mutations promote
oncogenesis and resistance to HER2-targeted
therapies in breast cancer
Activating HER2 mutations promote
oncogenesis and resistance to HER2-targeted
therapies in breast cancer
Activating HER2 mutations promote
oncogenesis and resistance to HER2-targeted
therapies in breast cancer
Activating HER2 mutations promote
oncogenesis and resistance to HER2-targeted
therapies in breast cancer
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
David
Yong
Yi-Zhou
Zhi-Ming
Ke-Da
Wen-Jia
Jonas
Anna
Rikard
Thomas
Page
Dr. Page has no relevant financial relationships
to disclose.
Wen
Dr. Wen has no relevant financial relationships
to disclose.
Jiang
Dr. Jiang has no relevant financial relationships
to disclose.
Shao
Dr. Shao has no relevant financial relationships
to disclose.
Yu
Dr. Yu has no relevant financial relationships to
disclose.
Zuo
Dr. Zuo has no relevant financial relationships
to disclose.
Bergh
Prof. Bergh has disclosed that the research
group of Prof. Jonas Bergh has received
external funding from Amgen, Bayer, Merck,
Pfizer Roche and Sanofi-Aventis for
Clinical/Molecular marker studies to Karolinska
university hospital and Karoinska institutet.
Danielsson
Dr. Danielsson has no relevant financial
relationships to disclose.
Erlandsson
Dr. Erlandsson has no relevant financial
relationships to disclose.
Hatschek
Dr. Hatschek has no relevant financial
relationships to disclose.
P1-04-05
P1-04-05
P1-04-05
P1-04-05
P1-04-05
P1-04-05
P1-04-05
P1-04-06
P1-04-06
P1-04-06
P1-04-06
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Heterogeneity and clonal evolution revealed by
exome sequencing of primary breast cancers
with paired metastatic lesions
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Hedenfalk
Ms. Hedenfalk has no relevant financial
relationships to disclose.
Karlsson
Dr. Karlsson has no relevant financial
relationships to disclose.
Kimbung
Siker Kimbung has no relevant financial
relationships to disclose.
Kjällquist
Dr. Kjällquist has no relevant financial
relationships to disclose.
Lindström
Dr. Lindström has no relevant financial
relationships to disclose.
Sten
Linnarsson
Sten Linnarsson has no relevant financial
relationships to disclose.
Nicholas
Tobin
Dr. Tobin has no relevant financial
relationships to disclose.
Karl-Friedrich
Bürrig
Dr. Bürrig has no relevant financial
relationships to disclose.
Buchmann
Dr. Buchmann has no relevant financial
relationships to disclose.
Dittmer
Dr. Dittmer has no relevant financial
relationships to disclose.
Hanf
Dr. Hanf has no relevant financial relationships
to disclose.
Ingrid
Eva
Siker
Una
Linda
Joerg
Juergen
Volker
P1-04-06
P1-04-06
P1-04-06
P1-04-06
P1-04-06
P1-04-06
P1-04-06
P1-04-06
P1-04-06
P1-04-06
P1-05-01
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Prevalence of PIK3CA mutations in tumor tissue
of a consecutive cohort of breast cancer
patients (n=700)
Optimized mixed micellar nanoparticle as
carrier improves therapeutic effect of PLK1
siRNA for breast cancer
John
Dr. John has no relevant financial relationships
to disclose.
Kantelhardt
Dr. Kantelhardt has no relevant financial
relationships to disclose.
Lantzsch
Dr. Lantzsch has no relevant financial
relationships to disclose.
Peschel
Dr. Peschel has no relevant financial
relationships to disclose.
Reinhardt
Ms. Reinhardt has no relevant financial
relationships to disclose.
Christoph
Thomssen
Dr. Thomssen has no relevant financial
relationships to disclose.
Christoph
Uleer
Dr. Uleer has no relevant financial relationships
to disclose.
Martina
Vetter
Dr. Vetter has no relevant financial
relationships to disclose.
Wegener
Dr. Wegener has no relevant financial
relationships to disclose.
Weigert
Dr. Weigelt has no relevant financial
relationships to disclose.
Liang
Dr. Liang has no relevant financial relationships
to disclose.
Jutta
Eva
Tilmann
Susanne
Kristin
Silke
Edith
Shi
P1-05-01
Optimized mixed micellar nanoparticle as
carrier improves therapeutic effect of PLK1
siRNA for breast cancer
Optimized mixed micellar nanoparticle as
carrier improves therapeutic effect of PLK1
siRNA for breast cancer
Optimized mixed micellar nanoparticle as
carrier improves therapeutic effect of PLK1
siRNA for breast cancer
P1-06-01
Histone deacetylase HDAC7 is a putative
therapeutic target in invasive lobular carcinoma Steffi
P1-05-01
P1-05-01
P1-06-01
P1-06-02
P1-06-02
P1-06-02
P1-06-02
P1-06-02
P1-06-02
Histone deacetylase HDAC7 is a putative
therapeutic target in invasive lobular carcinoma
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Song
Dr. Song has no relevant financial relationships
to disclose.
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Yang
Dr. Yang has no relevant financial relationships
to disclose.
Oesterreich
Dr. Oesterreich has no relevant financial
relationships to disclose.
Sikora
Dr. Sikora has no relevant financial
relationships to disclose.
Dae-Gyun
Ahn
Dae-Gyun Ahn has no relevant financial
relationships to disclose.
Krysta
Coyle
Ms. Coyle has no relevant financial
relationships to disclose.
Carman
Giacomantonio
Carman Giacomantonio has no relevant
financial relationships to disclose.
Lee
Mr. Lee has no relevant financial relationships
to disclose.
Marcato
Paola Marcato has no relevant financial
relationships to disclose.
Pan
Luzhe Pan has no relevant financial
relationships to disclose.
Erwei
Jun
Xianzhu
Matthew
Patrick
Paola
Luzhe
P1-06-02
P1-06-02
P1-06-03
P1-06-03
P1-06-03
P1-06-03
P1-06-03
P1-06-04
P1-06-04
P1-06-04
P1-06-04
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Identifying hypermethylated tumor suppressor
genes in breast cancer with an in vivo total
genome knockdown screen
Maintenance of a lean phenotype is associated
with increased ERβ expression and ERβ gene
intron methylation in murine MMTVneu luminal
mammary cancer
Maintenance of a lean phenotype is associated
with increased ERβ expression and ERβ gene
intron methylation in murine MMTVneu luminal
mammary cancer
Maintenance of a lean phenotype is associated
with increased ERβ expression and ERβ gene
intron methylation in murine MMTVneu luminal
mammary cancer
Maintenance of a lean phenotype is associated
with increased ERβ expression and ERβ gene
intron methylation in murine MMTVneu luminal
mammary cancer
Maintenance of a lean phenotype is associated
with increased ERβ expression and ERβ gene
intron methylation in murine MMTVneu luminal
mammary cancer
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Sultan
Mr. Sultan has no relevant financial
relationships to disclose.
Margaret
Thomas
Ms. Thomas has no relevant financial
relationships to disclose.
Laura
Bowers
Dr. Bowers has no relevant financial
relationships to disclose.
Dunlap
Dr. Dunlap has no relevant financial
relationships to disclose.
Ford
Dr. Ford has no relevant financial relationships
to disclose.
Hursting
Dr. Hursting has no relevant financial
relationships to disclose.
Mohammad
Sarah
Nikki
Stephen
Emily
Rossi
Mei Wei
Chen
Cindy
Collins
Matthew
Eaton
Christian
Fritz
Ms. Rossi has no relevant financial
relationships to disclose.
Mei Wei Chen has no relevant financial
relationships to disclose.
Ms. Collins has no relevant financial
relationships to disclose.
Mr. Eaton has no relevant financial
relationships to disclose.
Mr. Fritz has no relevant financial relationships
to disclose.
P1-06-04
P1-06-04
P1-06-04
P1-06-04
P1-06-04
P1-06-05
P1-06-05
P1-06-05
P1-06-05
P1-06-05
P1-06-05
P1-06-05
P1-06-06
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
Super-enhancer analysis defines breast cancer
subtype and identifies tumor dependencies
DNA methylation-based classification are mostly
concordant with intrinsic subtypes of breast
cancer
DNA methylation-based classification are mostly
concordant with intrinsic subtypes of breast
cancer
DNA methylation-based classification are mostly
concordant with intrinsic subtypes of breast
cancer
DNA methylation-based classification are mostly
concordant with intrinsic subtypes of breast
cancer
DNA methylation-based classification are mostly
concordant with intrinsic subtypes of breast
cancer
DNA methylation-based classification are mostly
concordant with intrinsic subtypes of breast
cancer
DNA methylation-based classification are mostly
concordant with intrinsic subtypes of breast
cancer
Meta-analysis reveal novel mechanism of
bisphenol A effect on mammary gland
Matthew
Guenther
Jakob
Loven
Eric
Olson
David
Orlando
Sneha
Solanki
Mr. Guenther has disclosed that all authors are
employed by Syros Pharmaceuticals.
Mr. Loven has no relevant financial
relationships to disclose.
Mr. Olson has no relevant financial
relationships to disclose.
Mr. Orlando has no relevant financial
relationships to disclose.
Sneha Solanki has no relevant financial
relationships to disclose.
Junji
Itou
Dr. Itou has no relevant financial relationships
to disclose.
Fengling
Pu
Dr. Pu has no relevant financial relationships to
disclose.
Saji
Dr. Saji has no relevant financial relationships
to disclose.
Sato
Dr. Sato has no relevant financial relationships
to disclose.
Tanaka
Sunao Tanaka has no relevant financial
relationships to disclose.
Toi
Dr. Toi has no relevant financial relationships
to disclose.
Shigehira
Fumiaki
Sunao
Masakazu
Natsue
Uehiro
Abhik
Bandyopadhyay
Dr. Uehiro has no relevant financial
relationships to disclose.
Abhik Bandyopadhyay has no relevant financial
relationships to disclose.
P1-06-06
P1-06-06
P1-06-06
P1-06-06
P1-06-06
P1-07-01
P1-07-01
P1-07-01
P1-07-01
P1-07-01
P1-07-01
P1-07-01
P1-07-01
P1-07-01
P1-07-01
P1-07-02
Meta-analysis reveal novel mechanism of
bisphenol A effect on mammary gland
Meta-analysis reveal novel mechanism of
bisphenol A effect on mammary gland
Meta-analysis reveal novel mechanism of
bisphenol A effect on mammary gland
Meta-analysis reveal novel mechanism of
bisphenol A effect on mammary gland
Meta-analysis reveal novel mechanism of
bisphenol A effect on mammary gland
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Modeling breast cancer dormancy and reemergence
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Qiaoxiang
Dong
Hui
Gao
Xiang
Gu
LuZhe
Sun
Danhan
Wang
Amanda
Clark
Linda
Griffith
Douglas
Lauffenburger
Venkateswaran
Pillai
Donna
Stolz
Donald
Taylor
Raman
Venkataramanan
Alan
Wells
Sarah
Wheeler
Carissa
Young
Qiaoxiang Dong has no relevant financial
relationships to disclose.
Hui Gao has no relevant financial relationships
to disclose.
Xiang Gu has no relevant financial relationships
to disclose.
LuZhe Sun has no relevant financial
relationships to disclose.
Danhan Wang has no relevant financial
relationships to disclose.
Dr. Clark has no relevant financial relationships
to disclose.
Dr. Griffith has disclosed that he is a Patent
Holder on LiverChip.
Dr. Lauffenburger has no relevant financial
relationships to disclose.
Dr. Pillai has no relevant financial relationships
to disclose.
Dr. Stolz has no relevant financial relationships
to disclose.
Dr. Taylor has no relevant financial
relationships to disclose.
Dr. Venkataramanan has no relevant financial
relationships to disclose.
Dr. Wells has disclosed that he is a patent
holder on LiverChip.
Dr. Wheeler has no relevant financial
relationships to disclose.
Dr. Young has no relevant financial
relationships to disclose.
Bell
Dr. Bell has no relevant financial relationships
to disclose.
George
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Bhasin
Dr. Bhasin has no relevant financial
relationships to disclose.
Campagne
Antoine Campagne has no relevant financial
relationships to disclose.
Cuiffo
Dr. Cuiffo has no relevant financial
relationships to disclose.
Hanson
Dr. Hanson has no relevant financial
relationships to disclose.
Hematti
Dr. Hematti has no relevant financial
relationships to disclose.
Antoine
Karnoub
Dr. Karnoub has no relevant financial
relationships to disclose.
Antonio
Lembo
Dr. Lembo has no relevant financial
relationships to disclose.
Evan
Lien
Mr. Lien has no relevant financial relationships
to disclose.
Mariani
Dr. Mariani has no relevant financial
relationships to disclose.
Marusyk
Dr. Marusyk has no relevant financial
relationships to disclose.
Orso
Dr. Orso has no relevant financial relationships
to disclose.
Manoj
Antoine
Benjamin
Summer
Peiman
Odette
Andriy
Francesca
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-02
P1-07-03
P1-07-03
P1-07-03
P1-07-03
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Mesenchymal stem cell regulated microRNAs
converge on the speech gene FOXP2 and
regulate breast cancer metastasis
Dual inhibition of IGF1R and insulin receptor in
estrogen receptor positive and triple negative
breast cancer and monitoring blockade of
metastasis using novel MRI
Dual inhibition of IGF1R and insulin receptor in
estrogen receptor positive and triple negative
breast cancer and monitoring blockade of
metastasis using novel MRI
Dual inhibition of IGF1R and insulin receptor in
estrogen receptor positive and triple negative
breast cancer and monitoring blockade of
metastasis using novel MRI
Dual inhibition of IGF1R and insulin receptor in
estrogen receptor positive and triple negative
breast cancer and monitoring blockade of
metastasis using novel MRI
Kornelia
Monica
Daniela
Anne
Stefano
Michael
Naoharu
Deepali
Joseph
Polyak
Dr. Polyak has no relevant financial
relationships to disclose.
Raimo
Ms. Raimo has no relevant financial
relationships to disclose.
Taverna
Dr. Taverna has no relevant financial
relationships to disclose.
Vincent-Salomon
Dr. Vincent-Salomon has no relevant financial
relationships to disclose.
Volinia
Dr. Volinia has no relevant financial
relationships to disclose.
Garwood
Dr. Garwood has no relevant financial
relationships to disclose.
Kobayashi
Dr. Kobayashi has no relevant financial
relationships to disclose.
Sachdev
Dr. Sachdev has no relevant financial
relationships to disclose.
Weber
Mr. Weber has no relevant financial
relationships to disclose.
P1-07-03
P1-07-05
P1-07-05
P1-07-05
P1-07-05
Dual inhibition of IGF1R and insulin receptor in
estrogen receptor positive and triple negative
breast cancer and monitoring blockade of
metastasis using novel MRI
Joel
Triple negative breast cancer metastases:
Protein signal transduction networks within the
tumor-stromal microenvironment complement
genomic analysis and stratify local versus
distant metastasis
John
Triple negative breast cancer metastases:
Protein signal transduction networks within the
tumor-stromal microenvironment complement
genomic analysis and stratify local versus
distant metastasis
David
Triple negative breast cancer metastases:
Protein signal transduction networks within the
tumor-stromal microenvironment complement
genomic analysis and stratify local versus
distant metastasis
Virginia
Triple negative breast cancer metastases:
Protein signal transduction networks within the
tumor-stromal microenvironment complement
genomic analysis and stratify local versus
distant metastasis
Maren
Winer
Mr. Winer has no relevant financial
relationships to disclose.
Carpten
Dr. Carpten has disclosed he receives salary
from TGen.
Espina
Dr. Craig has disclosed he receives salary from
TGen.
Dr. Espina has disclosed she receives royalties
from Theranostics Health and Ceres
Nanoscience. She also disclosed that she has
Patents: 8,497,137: Smart hydrogel particles
for biomarker harvesting; 8, 460,859 B2: Tissue
preservation and fixation method; 8,628,931
mTOR pathway theranostic. She has contracts
with National Institutes of Health, Department
of Defense Breast Cancer Research Program,
Susan G. Komen, Baylor Sammons Cancer
Center and owns Theranostics Health stock
options.
Levin
Maren Levin has no relevant financial
relationships to disclose.
Craig
P1-07-05
P1-07-05
P1-07-05
P1-07-06
P1-07-06
P1-07-06
Triple negative breast cancer metastases:
Protein signal transduction networks within the
tumor-stromal microenvironment complement
genomic analysis and stratify local versus
distant metastasis
Triple negative breast cancer metastases:
Protein signal transduction networks within the
tumor-stromal microenvironment complement
genomic analysis and stratify local versus
distant metastasis
Triple negative breast cancer metastases:
Protein signal transduction networks within the
tumor-stromal microenvironment complement
genomic analysis and stratify local versus
distant metastasis
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Liotta
Dr. Liotta has disclosed that he receives
royalties from Theranostics Health and
National Institutes of Health. 8,497,137: Smart
hydrogel particles for biomarker harvesting; 8,
460,859 B2: Tissue preservation and fixation
method; 8,628,931 mTOR pathway
theranostic. He is a consultant for Theranostics
Health and has contracts with National
Institutes of Health, Department of Defense
Breast Cancer Research Program, Susan G.
Komen, Baylor Sammons Cancer Center. He
also has ownership in Theranostics Health and
Ceres Nanoscience.
Joyce
O'Shaughnessy
Dr. O'Shaughnessy has disclosed she receives
salary from US Oncology.
Daniel
Von Hoff
Dr. Von Hoff has disclosed he receives salary
from and has a contract with TGen.
Arora
Dr. Arora has no relevant financial relationships
to disclose.
Creighton
Dr. Creighton has no relevant financial
relationships to disclose.
Donti
Dr. Donti has no relevant financial relationships
to disclose.
Lance
Kavisha
Chad
Taraka
P1-07-06
P1-07-06
P1-07-06
P1-07-06
P1-07-06
P1-07-06
P1-07-07
P1-07-07
P1-07-07
P1-07-07
P1-07-07
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Activation of oncogenic pathways by
mitochondrial reprogramming in triple negative
breast cancer
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Kaipparettu
Dr. Kaipparettu has no relevant financial
relationships to disclose.
Lewis
Dr. Lewis has no relevant financial relationships
to disclose.
Park
Dr. Park has no relevant financial relationships
to disclose.
Sreekumar
Dr. Sreekumar has no relevant financial
relationships to disclose.
Vithayathil
Sajna Vithayathil has no relevant financial
relationships to disclose.
Lee-Jun
Wong
Dr. Wong has no relevant financial
relationships to disclose.
Xi-Xi
Cao
Xi-Xi Cao has no relevant financial relationships
to disclose.
Eric
Chang
Mr. Chang has no relevant financial
relationships to disclose.
Contreras
Dr. Contreras has no relevant financial
relationships to disclose.
Edwards
Mr. Edwards has no relevant financial
relationships to disclose.
Hilsenbeck
Dr. Hilsenbeck has no relevant financial
relationships to disclose.
Benny
Michael
Jun Hyoung
Arun
Sajna
Alejandro
Dean
Susan
P1-07-07
P1-07-07
P1-07-07
P1-07-07
P1-07-07
P1-07-07
P1-07-08
P1-07-08
P1-07-08
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
Recurrent ESR1-CCDC170 rearrangements in an
aggressive subset of estrogen-receptor positive
breast cancers
TP53 alteration in morphologically benign
breast tissue in patients with ER/PR negative
high grade breast carcinomas: Marker for early
detection of high risk patients for high grade
carcinomas?
TP53 alteration in morphologically benign
breast tissue in patients with ER/PR negative
high grade breast carcinomas: Marker for early
detection of high risk patients for high grade
carcinomas?
TP53 alteration in morphologically benign
breast tissue in patients with ER/PR negative
high grade breast carcinomas: Marker for early
detection of high risk patients for high grade
carcinomas?
Jin-Ah
Rachel
Ying
Jamunarani
Xian
Xiao-Song
David
Todd
Paul
Kim
Jin-Ah Kim has no relevant financial
relationships to disclose.
Schiff
Dr. Schiff has no relevant financial relationships
to disclose.
Tan
Ying Tan has no relevant financial relationships
to disclose.
Veeraraghavan
Jamunarani Veeraraghavan has no relevant
financial relationships to disclose.
Wang
Xian Wang has no relevant financial
relationships to disclose.
Wang
Xiao-Song Wang has no relevant financial
relationships to disclose.
Hicks
Mr. Hicks has no relevant financial
relationships to disclose.
Laughlin
Mr. Laughlin has no relevant financial
relationships to disclose.
Rothberg
Mr. Rothberg has no relevant financial
relationships to disclose.
P1-07-08
P1-07-08
P1-07-08
P1-07-09
P1-07-09
TP53 alteration in morphologically benign
breast tissue in patients with ER/PR negative
high grade breast carcinomas: Marker for early
detection of high risk patients for high grade
carcinomas?
TP53 alteration in morphologically benign
breast tissue in patients with ER/PR negative
high grade breast carcinomas: Marker for early
detection of high risk patients for high grade
carcinomas?
TP53 alteration in morphologically benign
breast tissue in patients with ER/PR negative
high grade breast carcinomas: Marker for early
detection of high risk patients for high grade
carcinomas?
SMAD nuclear staining patterns in inflammatory
breast cancer suggest non-canonical TGFβsignalling establishing collective, sheet-like
invasion SMAD nuclear staining patterns in
inflammatory breast cancer suggest noncanonical TGFβ-signalling establishing collective,
sheet-like invasion
SMAD nuclear staining patterns in inflammatory
breast cancer suggest non-canonical TGFβsignalling establishing collective, sheet-like
invasion SMAD nuclear staining patterns in
inflammatory breast cancer suggest noncanonical TGFβ-signalling establishing collective,
sheet-like invasion
Kristin
Skinner
Ms. Skinner has no relevant financial
relationships to disclose.
Moritz
Stolla
Moritz Stolla has no relevant financial
relationships to disclose.
Wang
Xi Wang has no relevant financial relationships
to disclose.
Luc
Dirix
Dr. Dirix has no relevant financial relationships
to disclose.
Melike
Marsan
Melike Marsan has no relevant financial
relationships to disclose.
Xi
P1-07-09
P1-07-09
P1-07-09
P1-07-09
SMAD nuclear staining patterns in inflammatory
breast cancer suggest non-canonical TGFβsignalling establishing collective, sheet-like
invasion SMAD nuclear staining patterns in
inflammatory breast cancer suggest noncanonical TGFβ-signalling establishing collective,
sheet-like invasion
SMAD nuclear staining patterns in inflammatory
breast cancer suggest non-canonical TGFβsignalling establishing collective, sheet-like
invasion SMAD nuclear staining patterns in
inflammatory breast cancer suggest noncanonical TGFβ-signalling establishing collective,
sheet-like invasion
SMAD nuclear staining patterns in inflammatory
breast cancer suggest non-canonical TGFβsignalling establishing collective, sheet-like
invasion SMAD nuclear staining patterns in
inflammatory breast cancer suggest noncanonical TGFβ-signalling establishing collective,
sheet-like invasion
SMAD nuclear staining patterns in inflammatory
breast cancer suggest non-canonical TGFβsignalling establishing collective, sheet-like
invasion SMAD nuclear staining patterns in
inflammatory breast cancer suggest noncanonical TGFβ-signalling establishing collective,
sheet-like invasion
Neven
Dr. Neven has no relevant financial
relationships to disclose.
Gert
Van den Eynden
Gert Van den Eynden has no relevant financial
relationships to disclose.
Steven
Van Laere
Mr. Van Laere has no relevant financial
relationships to disclose.
Vergote
Ignace Vergote has no relevant financial
relationships to disclose.
Patrick
Ignace
P1-07-09
SMAD nuclear staining patterns in inflammatory
breast cancer suggest non-canonical TGFβsignalling establishing collective, sheet-like
invasion SMAD nuclear staining patterns in
inflammatory breast cancer suggest noncanonical TGFβ-signalling establishing collective,
sheet-like invasion
Peter
Vermeulen
Dr. Vermeulen has no relevant financial
relationships to disclose.
P1-07-10
Immunohistochemical (IHC) marker discordance
between primary breast cancer biopsy and
recurrent cancer: Would IHC testing of the
surgical breast or lymph node have altered
treatment?
Michele
Gage
Dr. Gage has no relevant financial relationships
to disclose.
Rubie
Jackson
Dr. Jackson has no relevant financial
relationships to disclose.
Charles
Mylander
Dr. Mylander has no relevant financial
relationships to disclose.
Rosman
Dr. Rosman has no relevant financial
relationships to disclose.
Tafra
Dr. Tafra has no relevant financial relationships
to disclose.
P1-07-10
P1-07-10
P1-07-10
P1-07-10
Immunohistochemical (IHC) marker discordance
between primary breast cancer biopsy and
recurrent cancer: Would IHC testing of the
surgical breast or lymph node have altered
treatment?
Immunohistochemical (IHC) marker discordance
between primary breast cancer biopsy and
recurrent cancer: Would IHC testing of the
surgical breast or lymph node have altered
treatment?
Immunohistochemical (IHC) marker discordance
between primary breast cancer biopsy and
recurrent cancer: Would IHC testing of the
surgical breast or lymph node have altered
treatment?
Immunohistochemical (IHC) marker discordance
between primary breast cancer biopsy and
recurrent cancer: Would IHC testing of the
surgical breast or lymph node have altered
treatment?
Martin
Lorraine
P1-07-10
P1-07-11
P1-07-11
P1-07-11
P1-07-11
P1-07-11
P1-07-12
P1-07-12
P1-07-12
P1-07-12
P1-07-12
P1-07-12
Immunohistochemical (IHC) marker discordance
between primary breast cancer biopsy and
recurrent cancer: Would IHC testing of the
surgical breast or lymph node have altered
treatment?
Promotion of lymphangiogenesis by postpartum
breast tumor cells
Promotion of lymphangiogenesis by postpartum
breast tumor cells
Promotion of lymphangiogenesis by postpartum
breast tumor cells
Promotion of lymphangiogenesis by postpartum
breast tumor cells
Promotion of lymphangiogenesis by postpartum
breast tumor cells
Defining the role of the kynurenine pathway in
mediating anoikis resistance in triple negative
breast cancer
Defining the role of the kynurenine pathway in
mediating anoikis resistance in triple negative
breast cancer
Defining the role of the kynurenine pathway in
mediating anoikis resistance in triple negative
breast cancer
Defining the role of the kynurenine pathway in
mediating anoikis resistance in triple negative
breast cancer
Defining the role of the kynurenine pathway in
mediating anoikis resistance in triple negative
breast cancer
Defining the role of the kynurenine pathway in
mediating anoikis resistance in triple negative
breast cancer
Crystal
Tran
Sarah
Black
Virginia
Borges
Bernard
Futscher
Traci
Lyons
Pepper
Schedin
Ms. Tran has no relevant financial relationships
to disclose.
Ms. Black has no relevant financial
relationships to disclose.
Dr. Borges has no relevant financial
relationships to disclose.
Dr. Futscher has no relevant financial
relationships to disclose.
Dr. Lyons has no relevant financial
relationships to disclose.
Dr. Schedin has no relevant financial
relationships to disclose.
Nicholas
D'Amato
Dr. D'Amato has no relevant financial
relationships to disclose.
Michael
Gordon
Dr. Gordon has no relevant financial
relationships to disclose.
Kirk
Hansen
Dr. Hansen has no relevant financial
relationships to disclose.
Nemkov
Mr. Nemkov has no relevant financial
relationships to disclose.
Richer
Dr. Richer has no relevant financial
relationships to disclose.
Rogers
Mr. Rogers has no relevant financial
relationships to disclose.
Travis
Jennifer
Thomas
P1-07-13
P1-07-13
P1-07-13
P1-07-13
P1-07-13
P1-07-13
P1-07-15
P1-07-15
P1-07-15
P1-07-15
P1-07-15
P1-07-15
P1-07-15
P1-07-15
P1-07-15
P1-07-15
Extramedullary hematopoiesis aids initiation of
cancer metastasis
Extramedullary hematopoiesis aids initiation of
cancer metastasis
Extramedullary hematopoiesis aids initiation of
cancer metastasis
Extramedullary hematopoiesis aids initiation of
cancer metastasis
Extramedullary hematopoiesis aids initiation of
cancer metastasis
Extramedullary hematopoiesis aids initiation of
cancer metastasis
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
P40 suppresses breast cancer metastasis by
inducing epigenetic silence of FZD10
Mauro
Ferrari
Megumi
Kai
Yan Ting
Liu
Yuki
Saito
Tomonori
Tanei
Kenji
Yokoi
Chang
Gong
Bodu
Liu
Qiang
Liu
Xiao-Bin
Lv
Yan
Nie
Shaohua
Qu
Erwei
Song
Fengxi
Su
Weige
Tan
Herui
Yao
Dr. Ferrari has no relevant financial
relationships to disclose.
Dr. Kai has no relevant financial relationships
to disclose.
Yan Ting Liu has no relevant financial
relationships to disclose.
Yuki Saito has no relevant financial
relationships to disclose.
Dr. Tanei has no relevant financial relationships
to disclose.
Dr. Yokoi has no relevant financial relationships
to disclose.
Chang Gong has no relevant financial
relationships to disclose.
Bodu Liu has no relevant financial relationships
to disclose.
Qiang Liu has no relevant financial
relationships to disclose.
Xiao-Bin Lv has no relevant financial
relationships to disclose.
Dr. Nie has no relevant financial relationships
to disclose.
Shaohua Qu has no relevant financial
relationships to disclose.
Dr. Song has no relevant financial relationships
to disclose.
Fengxi Su has no relevant financial
relationships to disclose.
Weige Tan has no relevant financial
relationships to disclose.
Herui Yao has no relevant financial
relationships to disclose.
P1-07-16
P1-07-16
P1-07-16
P1-07-16
P1-07-16
P1-07-16
P1-07-16
P1-07-17
P1-07-17
P1-07-17
P1-07-17
Galectin-7 increases resistance of breast cancer
cells to drug-induced apoptosis and promotes
tumor escape by killing T cells
Galectin-7 increases resistance of breast cancer
cells to drug-induced apoptosis and promotes
tumor escape by killing T cells
Galectin-7 increases resistance of breast cancer
cells to drug-induced apoptosis and promotes
tumor escape by killing T cells
Galectin-7 increases resistance of breast cancer
cells to drug-induced apoptosis and promotes
tumor escape by killing T cells
Galectin-7 increases resistance of breast cancer
cells to drug-induced apoptosis and promotes
tumor escape by killing T cells
Galectin-7 increases resistance of breast cancer
cells to drug-induced apoptosis and promotes
tumor escape by killing T cells
Galectin-7 increases resistance of breast cancer
cells to drug-induced apoptosis and promotes
tumor escape by killing T cells
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Doucet
Dr. Doucet has no relevant financial
relationships to disclose.
Gaboury
Dr. Gaboury has no relevant financial
relationships to disclose.
Gagné
Mr. Gagné has no relevant financial
relationships to disclose.
Grosset
Ms. Grosset has no relevant financial
relationships to disclose.
Labrie
Ms. Labrie has no relevant financial
relationships to disclose.
Yves
St-Pierre
Dr. St-Pierre has no relevant financial
relationships to disclose.
Maria-Claudia
Vladoiu
Ms. Vladoiu has no relevant financial
relationships to disclose.
Melanie
Kürschner
Ms. Kürschner has no relevant financial
relationships to disclose.
Labitzky
Ms. Labitzky has no relevant financial
relationships to disclose.
Müller
Dr. Müller has no relevant financial
relationships to disclose.
Milde-Langosch
Dr. Milde-Langosch has no relevant financial
relationships to disclose.
Nicolas
Louis
Donald
Andrée-Anne
Marilyne
Vera
Volkmar
Karin
P1-07-17
P1-07-17
P1-07-17
P1-07-17
P1-07-18
P1-07-18
P1-07-18
P1-07-19
P1-07-19
P1-07-19
P1-07-19
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Transcription factor Fra-1 modulates the
adhesive properties of breast cancer cells
contributing to a metastatic phenotype
Loss of Rab1B promotes triple-negative breast
cancer metastasis by activating TGF-β/Smad
signaling
Loss of Rab1B promotes triple-negative breast
cancer metastasis by activating TGF-β/Smad
signaling
Loss of Rab1B promotes triple-negative breast
cancer metastasis by activating TGF-β/Smad
signaling
Effects of JAK pathway inhibition in pre-clinical
models of breast cancer bone marrow
metastases
Effects of JAK pathway inhibition in pre-clinical
models of breast cancer bone marrow
metastases
Effects of JAK pathway inhibition in pre-clinical
models of breast cancer bone marrow
metastases
Effects of JAK pathway inhibition in pre-clinical
models of breast cancer bone marrow
metastases
Oliveira-Ferrer
Ms. Oliveira-Ferrer has no relevant financial
relationships to disclose.
Schröder
Ms. Schröder has no relevant financial
relationships to disclose.
Schumacher
Dr. Schumacher has no relevant financial
relationships to disclose.
Wicklein
Mr. Wicklein has no relevant financial
relationships to disclose.
Jiang
HongLin Jiang has no relevant financial
relationships to disclose.
Wei
Jin
Wei Jin has no relevant financial relationships
to disclose.
Hefen
Sun
Hefen Sun has no relevant financial
relationships to disclose.
Alessia
Bottos
Ms. Bottos has no relevant financial
relationships to disclose.
Gill
Mr. Gill has no relevant financial relationships
to disclose.
Leticia
Christine
Udo
Daniel
HongLin
Jason
Nancy
Hynes
Thomas
Radimerski
Ms. Hynes has no relevant financial
relationships to disclose.
Mr. Radimerski has disclosed that she is an
employee of Novartis Pharma AG and owns
employee stocks in Novartis Pharma AG.
P1-07-19
P1-07-19
P1-07-20
P1-07-20
P1-07-20
P1-07-20
P1-07-20
P1-07-20
P1-07-20
P1-07-20
P1-07-20
P1-07-21
P1-07-21
P1-07-21
Effects of JAK pathway inhibition in pre-clinical
models of breast cancer bone marrow
metastases
Effects of JAK pathway inhibition in pre-clinical
models of breast cancer bone marrow
metastases
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
Melatonin's inhibitory effect on breast cancer
metastasis mediated by ROCK-1
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
Alexandar
Tzankov
Mr. Tzankov has no relevant financial
relationships to disclose.
Aleksandra
Wodnar-Filipowicz
Ali
Arbab
Thaiz
Borin
Verena
Coimbra
Vanessa
Fabri
Lívia
Ferreira
Gustavo
Martins
Larissa
Maschio
Marina
Moschetta
Debora
Zuccari
Aleksandra Wodnar-Filipowicz has no relevant
financial relationships to disclose.
Dr. Arbab has no relevant financial
relationships to disclose.
Dr. Borin has no relevant financial relationships
to disclose.
Verena Coimbra has no relevant financial
relationships to disclose.
Ms. Fabri has no relevant financial
relationships to disclose.
Lívia Ferreira has no relevant financial
relationships to disclose.
Mr. Martins has no relevant financial
relationships to disclose.
Ms. Maschio has no relevant financial
relationships to disclose.
Ms. Moschetta has no relevant financial
relationships to disclose.
Dr. Zuccari has no relevant financial
relationships to disclose.
Karius
Tosca Karius has no relevant financial
relationships to disclose.
Müller
Dr. Müller has no relevant financial
relationships to disclose.
Milde-Langosch
Dr. Milde-Langosch has no relevant financial
relationships to disclose.
Tosca
Volkmar
Karin
P1-07-21
P1-07-21
P1-07-21
P1-07-21
P1-07-21
P1-07-22
P1-07-22
P1-07-22
P1-07-22
P1-07-22
P1-07-22
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
N-glycosylation changes in tumour cells are
associated with vascular invasion and
metastasis in breast cancer patients
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Oliveira-Ferrer
Dr. Oliveira-Ferrer has no relevant financial
relationships to disclose.
Schütze
Mr. Schütze has no relevant financial
relationships to disclose.
Schumacher
Dr. Schumacher has no relevant financial
relationships to disclose.
Wikman
Dr. Wikman has no relevant financial
relationships to disclose.
Witzel
Dr. Witzel has no relevant financial
relationships to disclose.
Brianna
Bennett
Ms. Bennett has no relevant financial
relationships to disclose.
Hailey
Campbell
Ms. Campbell has no relevant financial
relationships to disclose.
Melissa
Davis
Dr. Davis has no relevant financial relationships
to disclose.
Hire
Dr. Hire has no relevant financial relationships
to disclose.
Howerth
Dr. Howerth has no relevant financial
relationships to disclose.
Lou
Mr. Lou has no relevant financial relationships
to disclose.
Leticia
Dina
Udo
Harriet
Isabell
Rupali
Elizabeth
Michael
P1-07-22
P1-07-22
P1-07-22
P1-07-23
P1-07-23
P1-07-23
P1-07-23
P1-07-23
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Investigating the role of Duffy antigen receptor
for chemokines (DARC) isoforms in breast
cancer metastasis
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Monteil
Dr. Monteil has no relevant financial
relationships to disclose.
Mumin
Kauthar Mumin has no relevant financial
relationships to disclose.
Andrea
Walens
Ms. Walens has no relevant financial
relationships to disclose.
Stephen
Anthony
Dr. Anthony has disclosed that he is a
consultant for Paradigm.
Bryant
Dunetz
Mr. Dunetz has no relevant financial
relationships to disclose.
Mohammad
Jahanzeb
Lance
Liotta
Dr. Jahanzeb has no relevant financial
relationships to disclose.
Dr. Liotta has disclosed that he receives
royalties from NIH and George Mason
University and has ownership in Theranostics
Health and Ceres.
Donald
Northfelt
Dr. Northfelt has no relevant financial
relationships to disclose.
Michele
Kauthar
P1-07-23
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Emanuel
P1-07-23
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
Pathway activation mapping of metastatic
breast cancer identifies potential organ-specific
signatures: Implications for patient stratification
to targeted treatment
P1-07-24
Modeling breast cancer metastasis in the mouse
via measurement of circulating tumor cells
Martin
P1-07-24
Modeling breast cancer metastasis in the mouse
via measurement of circulating tumor cells
Sean
P1-07-23
P1-07-23
P1-07-23
P1-07-23
Mariaelena
K
Nicholas
Linda
Julia
Pierobon
Dr. Petricoin has disclosed that he receives
royalties from and has a patent with George
Mason University. He has also disclosed that
he is a consultant for Perthera, Inc;
Theranostics Health and has ownership in
Perthera, Inc; Theranostics Health; Ceres.
Dr. Pierobon has disclosed that she receives
salary from Side-out Foundation; has a patent
with George Mason University; is a consultant
for Perthera, Inc and has ownership in
Theranostics Health.
Reeder
K Reeder has disclosed that he receives salary
from Side-out Foundation.
Robert
Dr. Robert has no relevant financial
relationships to disclose.
Vocila
Ms. Vocila has no relevant financial
relationships to disclose.
Wulfkuhle
Dr. Wulfkuhle has disclosed she has ownership
in Theranostics Health.
Chang
Mr. Chang has no relevant financial
relationships to disclose.
Egan
Mr. Egan has no relevant financial relationships
to disclose.
Petricoin
P1-07-24
Modeling breast cancer metastasis in the mouse
via measurement of circulating tumor cells
Jennifer
Gorman
Ms. Gorman has no relevant financial
relationships to disclose.
P1-07-24
Modeling breast cancer metastasis in the mouse
via measurement of circulating tumor cells
Michael
Parsons
Mr. Parsons has no relevant financial
relationships to disclose.
P1-07-24
Modeling breast cancer metastasis in the mouse
via measurement of circulating tumor cells
Jim
Woodgett
Mr. Woodgett has no relevant financial
relationships to disclose.
P1-07-24
Modeling breast cancer metastasis in the mouse
via measurement of circulating tumor cells
Eldad
Zacksenhaus
Eldad Zacksenhaus has no relevant financial
relationships to disclose.
P1-07-25
SSA, a novel sulindac sulfide derivative, inhibits
tumor cell growth and invasion in breast cancer Hong
Chang
Dr. Chang has no relevant financial
relationships to disclose.
P1-07-25
SSA, a novel sulindac sulfide derivative, inhibits
tumor cell growth and invasion in breast cancer Xiangling
Feng
Dr. Feng has no relevant financial relationships
to disclose.
P1-07-25
SSA, a novel sulindac sulfide derivative, inhibits
tumor cell growth and invasion in breast cancer Ruixia
Ma
Ruixia Ma has no relevant financial
relationships to disclose.
P1-07-25
SSA, a novel sulindac sulfide derivative, inhibits
tumor cell growth and invasion in breast cancer Gary
Piazza
Dr. Piazza has no relevant financial
relationships to disclose.
P1-07-25
SSA, a novel sulindac sulfide derivative, inhibits
tumor cell growth and invasion in breast cancer Yaguang
Xi
Dr. Xi has no relevant financial relationships to
disclose.
P1-07-25
SSA, a novel sulindac sulfide derivative, inhibits
tumor cell growth and invasion in breast cancer Bin
Yi
Dr. Yi has no relevant financial relationships to
disclose.
P1-07-25
SSA, a novel sulindac sulfide derivative, inhibits
tumor cell growth and invasion in breast cancer Xiaoguo
Zhang
Xiaoguo Zhang has no relevant financial
relationships to disclose.
P1-07-26
P1-07-26
P1-07-26
P1-07-26
P1-07-26
P1-07-26
P1-07-26
P1-07-27
P1-07-27
P1-07-27
P1-07-27
Global analysis of the transcriptome in matched
primary and metastatic tumours defines ER
specific gene alterations
Global analysis of the transcriptome in matched
primary and metastatic tumours defines ER
specific gene alterations
Global analysis of the transcriptome in matched
primary and metastatic tumours defines ER
specific gene alterations
Global analysis of the transcriptome in matched
primary and metastatic tumours defines ER
specific gene alterations
Global analysis of the transcriptome in matched
primary and metastatic tumours defines ER
specific gene alterations
Global analysis of the transcriptome in matched
primary and metastatic tumours defines ER
specific gene alterations
Global analysis of the transcriptome in matched
primary and metastatic tumours defines ER
specific gene alterations
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Buckley
Dr. Buckley has no relevant financial
relationships to disclose.
Fagan
Dr. Fagan has no relevant financial
relationships to disclose.
Farrell
Dr. Farrell has no relevant financial
relationships to disclose.
Hill
Dr. Hill has no relevant financial relationships
to disclose.
McBryan
Dr. McBryan has no relevant financial
relationships to disclose.
Damir
Vareslija
Dr. Vareslija has no relevant financial
relationships to disclose.
Leonie
Young
Dr. Young has no relevant financial
relationships to disclose.
Laura
Annaratone
Ms. Annaratone has no relevant financial
relationships to disclose.
Balmativola
Mr. Balmativola has no relevant financial
relationships to disclose.
Bolla
Ms. Bolla has no relevant financial
relationships to disclose.
Brancaccio
Ms. Brancaccio has no relevant financial
relationships to disclose.
Patrick
Ailis
Michael
Arnold
Jean
Davide
Stefania
Mara
P1-07-27
P1-07-27
P1-07-27
P1-07-27
P1-07-27
P1-07-27
P1-07-27
P1-07-27
P1-07-28
P1-07-28
P1-07-28
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Neutrophil elastase modulates breast cancer
progression by fostering collective cell
detachment and tumor emboli dissemination
Expression of S100A14 promotes cancer cell
invasion and metastasis and is associated with
poor prognosis in breast cancer
Expression of S100A14 promotes cancer cell
invasion and metastasis and is associated with
poor prognosis in breast cancer
Expression of S100A14 promotes cancer cell
invasion and metastasis and is associated with
poor prognosis in breast cancer
Defilippi
Paola Defilippi has no relevant financial
relationships to disclose.
Fusella
Federica Fusella has no relevant financial
relationships to disclose.
Grasso
Ms. Grasso has no relevant financial
relationships to disclose.
Macrì
Luigia Macrì has no relevant financial
relationships to disclose.
Marchio
Ms. Marchio has no relevant financial
relationships to disclose.
Isabella
Russo
Ms. Russo has no relevant financial
relationships to disclose.
Anna
Sapino
Ms. Sapino has no relevant financial
relationships to disclose.
Maria Stella
Scalzo
Ms. Scalzo has no relevant financial
relationships to disclose.
Nakajima
Dr. Nakajima has no relevant financial
relationships to disclose.
Oishi
Dr. Oishi has no relevant financial relationships
to disclose.
Sugino
Dr. Sugino has no relevant financial
relationships to disclose.
Paola
Federica
Silvia
Luigia
Caterina
Takashi
Takuma
Takashi
P1-07-29
Expression of S100A14 promotes cancer cell
invasion and metastasis and is associated with
poor prognosis in breast cancer
The role of cytoplasmic polyadenylation
element binding protein-2 in breast cancer
The role of cytoplasmic polyadenylation
element binding protein-2 in breast cancer
The role of cytoplasmic polyadenylation
element binding protein-2 in breast cancer
P1-07-30
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
Rohit
P1-07-30
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
Omid
Gholamalamdari
Omid Gholamalamdari has no relevant
financial relationships to disclose.
P1-07-30
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
Tor
Jensen
Dr. Jensen has disclosed that he is a consultant
for Oracle Biosciences.
P1-07-30
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
Bomy
Kim
Bomy Kim has no relevant financial
relationships to disclose.
P1-07-30
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
K
Prasanth
Dr. Prasanth has no relevant financial
relationships to disclose.
P1-07-28
P1-07-29
P1-07-29
Mizuko
Tanaka
Asma
Hasan
Peeyush
Lala
Mousumi
Majumder
Dr. Tanaka has no relevant financial
relationships to disclose.
Asma Hasan has no relevant financial
relationships to disclose.
Peeyush Lala has no relevant financial
relationships to disclose.
Mousumi Majumder has no relevant financial
relationships to disclose.
Bhargava
Dr. Bhargava has no relevant financial
relationships to disclose.
P1-07-30
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
Partha
P1-07-30
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
Tania
P1-07-30
P1-07-31
P1-07-31
P1-07-31
P1-07-31
P1-07-31
P1-07-31
P1-07-31
P1-07-31
P1-07-32
FOXC1/FOXA1 transcriptional balance in breast
cancer: From acquisition of mesenchymal and
stem cell traits to occult lymph node
independent breast cancer metastasis
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Role of astrocyte in the triple-negative breast
cancer brain metastatic growth
Activated thrombin activatable fibrinolysis
inhibitor is a novel anti-metastatic factor in
breast cancer
Ray
Dr. Ray has disclosed that she is a named
inventor, patents related to FOXC1. She also
disclosed that she is on the Scientific Advisory
Board for Oracle Biosciences and has Stock
Ownership in Oracle Biosciences.
Ray
Dr. Ray has disclosed that she receives salary
from and has stock ownership in Oracle
Biosciences.
Connie
Tsai
Stephanie
Cossette
Michael
Dwinell
Jill
Gershan
David
Harder
Ramani
Ramchandran
Kevin
Rarick
Ling
Wang
Ling
Zhong
Dr. Tsai has no relevant financial relationships
to disclose.
Dr. Cossette has no relevant financial
relationships to disclose.
Dr. Dwinell has no relevant financial
relationships to disclose.
Dr. Gershan has no relevant financial
relationships to disclose.
Dr. Harder has no relevant financial
relationships to disclose.
Dr. Ramchandran has no relevant financial
relationships to disclose.
Dr. Rarick has no relevant financial
relationships to disclose.
Dr. Wang has no relevant financial
relationships to disclose.
Dr. Zhong has no relevant financial
relationships to disclose.
Bazzi
Zainab Bazzi has no relevant financial
relationships to disclose.
Zainab
P1-07-33
Activated thrombin activatable fibrinolysis
inhibitor is a novel anti-metastatic factor in
breast cancer
Activated thrombin activatable fibrinolysis
inhibitor is a novel anti-metastatic factor in
breast cancer
Activated thrombin activatable fibrinolysis
inhibitor is a novel anti-metastatic factor in
breast cancer
Activated thrombin activatable fibrinolysis
inhibitor is a novel anti-metastatic factor in
breast cancer
CIP4 promotes triple-negative breast cancer
metastasis and is associated with poor
prognosis
CIP4 promotes triple-negative breast cancer
metastasis and is associated with poor
prognosis
CIP4 promotes triple-negative breast cancer
metastasis and is associated with poor
prognosis
CIP4 promotes triple-negative breast cancer
metastasis and is associated with poor
prognosis
P1-07-34
A breast angiosarcoma treated by bilateral
mastectomy in a patient who had undergone to
arm amputation for Stewart Treves syndrome
following breast conserving surgery: Case report Serdar
P1-07-34
A breast angiosarcoma treated by bilateral
mastectomy in a patient who had undergone to
arm amputation for Stewart Treves syndrome
following breast conserving surgery: Case report Atilla
P1-07-32
P1-07-32
P1-07-32
P1-07-32
P1-07-33
P1-07-33
P1-07-33
Boffa
Mr. Boffa has no relevant financial
relationships to disclose.
Cavallo-Medved
Ms. Cavallo-Medved has no relevant financial
relationships to disclose.
Porter
Ms. Porter has no relevant financial
relationships to disclose.
Rudy
Ms. Rudy has no relevant financial
relationships to disclose.
Cerquiera
Dr. Cerquiera has no relevant financial
relationships to disclose.
Andrew
Craig
Dr. Craig has no relevant financial relationships
to disclose.
Eduardo
Reis
Dr. Reis has no relevant financial relationships
to disclose.
Fernando
Soares
Dr. Soares has no relevant financial
relationships to disclose.
Altunay
Dr. Altunay has no relevant financial
relationships to disclose.
Celik
Dr. Celik has no relevant financial relationships
to disclose.
Michael
Dora
Lisa
Deborah
Otto
P1-07-34
A breast angiosarcoma treated by bilateral
mastectomy in a patient who had undergone to
arm amputation for Stewart Treves syndrome
following breast conserving surgery: Case report Emel
Gokmen
Dr. Gokmen has no relevant financial
relationships to disclose.
P1-07-34
A breast angiosarcoma treated by bilateral
mastectomy in a patient who had undergone to
arm amputation for Stewart Treves syndrome
following breast conserving surgery: Case report Osman Bilgin
Gulcicek
Dr. Gulcicek has no relevant financial
relationships to disclose.
P1-07-34
A breast angiosarcoma treated by bilateral
mastectomy in a patient who had undergone to
arm amputation for Stewart Treves syndrome
following breast conserving surgery: Case report Esat
Namal
Dr. Namal has no relevant financial
relationships to disclose.
P1-07-34
A breast angiosarcoma treated by bilateral
mastectomy in a patient who had undergone to
arm amputation for Stewart Treves syndrome
following breast conserving surgery: Case report Ozgul
Pamukcu
Dr. Pamukcu has no relevant financial
relationships to disclose.
Tokocin
Dr. Tokocin has no relevant financial
relationships to disclose.
Ganju
Ramesh Ganju has no relevant financial
relationships to disclose.
Nasser
Mohd Nasser has no relevant financial
relationships to disclose.
Powell
Ms. Powell has no relevant financial
relationships to disclose.
P1-07-34
P1-07-35
P1-07-35
P1-07-35
A breast angiosarcoma treated by bilateral
mastectomy in a patient who had undergone to
arm amputation for Stewart Treves syndrome
following breast conserving surgery: Case report
Fatty acid binding protein 5 promotes
metastatic potential of triple negative breast
cancer
Fatty acid binding protein 5 promotes
metastatic potential of triple negative breast
cancer
Fatty acid binding protein 5 promotes
metastatic potential of triple negative breast
cancer
Merve
Ramesh
Mohd
Catherine
P1-07-35
Fatty acid binding protein 5 promotes
metastatic potential of triple negative breast
cancer
Fatty acid binding protein 5 promotes
metastatic potential of triple negative breast
cancer
Fatty acid binding protein 5 promotes
metastatic potential of triple negative breast
cancer
P1-08-01
Signaling consequences and rational therapeutic
combinations with glutaminase inhibitor, CB839, in basal breast cancer
Jennifer
P1-07-35
P1-07-35
Konstantin
Jacob
Xiaoli
P1-08-01
Signaling consequences and rational therapeutic
combinations with glutaminase inhibitor, CB839, in basal breast cancer
Mills
Signaling consequences and rational therapeutic
combinations with glutaminase inhibitor, CB839, in basal breast cancer
Zhenlin
P1-08-02
Metformin blocks de novo synthesis of
cholesterol in triple negative breast cancer cells Steve
P1-08-01
Shilo
Dr. Shilo has no relevant financial relationships
to disclose.
Wochna
Mr. Wochna has no relevant financial
relationships to disclose.
Gordon
Xiaoli Zhang has no relevant financial
relationships to disclose.
Dr. Dennison has disclosed that she received
sponsorship from Calithera Biosciences to
attend this conference and a previous
conference (Keystone Symposium, Metabolism
and Cancer, 2014). Conference expenses were
paid.
Dr. Mills has disclosed that he is a consultant
for AstraZeneca, Blend, Critical Outcome
Technologies, HanAl Bio Korea, Nuevolution,
Pfizer, Provista Diagnostics, Roche, Signalchem
Lifesciences, Symphogen, and Tau
Therapeutics. He also disclosed that he has
contracts with Adelson Medical Research
Foundation, AstraZeneca, Critical Outcomes
Technology, and GSK and has ownership in
Catena Pharmaceuticals, PTV Ventures, and
Spindle Top Ventures.
Ju
Dr. Ju has no relevant financial relationships to
disclose.
Anderson
Dr. Anderson has no relevant financial
relationships to disclose.
Zhang
Dennison
P1-08-02
Metformin blocks de novo synthesis of
cholesterol in triple negative breast cancer cells Susan
P1-08-02
Metformin blocks de novo synthesis of
cholesterol in triple negative breast cancer cells Zeying
P1-08-02
Metformin blocks de novo synthesis of
cholesterol in triple negative breast cancer cells Jennifer
P1-08-02
Metformin blocks de novo synthesis of
cholesterol in triple negative breast cancer cells Ann
P1-08-02
P1-08-03
P1-08-03
P1-08-03
P1-08-03
P1-08-04
P1-08-04
P1-08-04
Metformin blocks de novo synthesis of
cholesterol in triple negative breast cancer cells
Targeting lactate metabolism as a novel
therapeutic target in platinum-resistant triple
negative breast cancer (TNBC)
Targeting lactate metabolism as a novel
therapeutic target in platinum-resistant triple
negative breast cancer (TNBC)
Targeting lactate metabolism as a novel
therapeutic target in platinum-resistant triple
negative breast cancer (TNBC)
Targeting lactate metabolism as a novel
therapeutic target in platinum-resistant triple
negative breast cancer (TNBC)
Metabolic state of reprogrammed breast cancer
stem cells
Metabolic state of reprogrammed breast cancer
stem cells
Metabolic state of reprogrammed breast cancer
stem cells
Edgerton
Ms. Edgerton has no relevant financial
relationships to disclose.
Fan
Zeying Fan has no relevant financial
relationships to disclose.
Richer
Dr. Richer has no relevant financial
relationships to disclose.
Thor
Dr. Thor has no relevant financial relationships
to disclose.
Wahdan-Alaswad
Dr. Wahdan-Alaswad has no relevant financial
relationships to disclose.
Narumi
Harada
Dr. Harada has no relevant financial
relationships to disclose.
Laura M
Kenny
Dr. Kenny has no relevant financial
relationships to disclose.
Vidhya
Varghese
Vidhya Varghese has no relevant financial
relationships to disclose.
Reema
Lingmin
Xie
Yazeed
Alhiyari
Patricia
Frohnen
Chann
Lagadec
Lingmin Xie has no relevant financial
relationships to disclose.
Yazeed Alhiyari has no relevant financial
relationships to disclose.
Ms. Frohnen has no relevant financial
relationships to disclose.
Dr. Lagadec has no relevant financial
relationships to disclose.
P1-08-04
P1-08-04
P1-08-05
P1-08-05
P1-08-05
P1-08-05
P1-08-05
P1-08-05
P1-08-06
P1-08-06
P1-08-07
P1-08-07
P1-08-07
Metabolic state of reprogrammed breast cancer
stem cells
Metabolic state of reprogrammed breast cancer
stem cells
An association between obesity and more
aggressive breast cancer subtype
An association between obesity and more
aggressive breast cancer subtype
An association between obesity and more
aggressive breast cancer subtype
An association between obesity and more
aggressive breast cancer subtype
An association between obesity and more
aggressive breast cancer subtype
An association between obesity and more
aggressive breast cancer subtype
The role of nitric oxide synthase uncoupling in
breast tumor cell maintenance
The role of nitric oxide synthase uncoupling in
breast tumor cell maintenance
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
Frank
Pajonk
Erina
Vlashi
Angela
Brodie
Saranya
Chumsri
Olga
Goloubeva
Candace
Mainor
Paula
Rosenblatt
Gauri
Sabnis
Ross
Mikkelsen
Christopher
Rabender
Dr. Pajonk has no relevant financial
relationships to disclose.
Dr. Vlashi has no relevant financial
relationships to disclose.
Dr. Brodie has no relevant financial
relationships to disclose.
Dr. Chumsri has no relevant financial
relationships to disclose.
Dr. Goloubeva has no relevant financial
relationships to disclose.
Dr. Mainor has no relevant financial
relationships to disclose.
Dr. Rosenblatt has no relevant financial
relationships to disclose.
Dr. Sabnis has no relevant financial
relationships to disclose.
Dr. Mikkelsen has no relevant financial
relationships to disclose.
Dr. Rabender has no relevant financial
relationships to disclose.
Mark
Bennett
Dr. Bennett has disclosed he receives salary
and owns stock.
Ethan
Emberley
Dr. Emberley has disclosed he receives salary
and owns stock.
Mathew
Gross
Mr. Gross has disclosed she receives salary and
owns stock.
P1-08-07
P1-08-07
P1-08-07
P1-08-07
P1-08-07
P1-08-07
P1-08-07
P1-08-07
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
Janes
Ms. Janes has disclosed she receives salary and
owns stock.
Lewis
Dr. Lewis has disclosed he receives salary and
owns stock.
Andy
MacKinnon
Dr. MacKinnon has disclosed he receives salary
and owns stock.
Alison
Pan
Ms. Pan has disclosed she receives salary and
owns stock.
Francesco
Parlati
Dr. Parlati has disclosed he receives salary and
owns stock.
Mirna
Rodriguez
Ms. Rodriguez has disclosed she receives salary
and owns stock.
Peter
Shwonek
Mr. Shwonek has disclosed he receives salary
and owns stock.
Taotao
Wang
Mr. Wang has disclosed he receives salary and
owns stock.
Julie
Evan
P1-08-07
P1-08-07
P1-08-08
P1-08-08
P1-08-08
P1-08-08
P1-08-08
P1-08-08
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
A novel pharmacodynamic assay to measure
glutaminase inhibition following oral
administration of CB-839 in triple negative
breast cancer biopsies
Reduction of HER2-associated lipogenic
phenotype by docosahexaenoic acid (DHA)
induces apoptosis in breast tumor cells
harboring HER2 overexpression
Reduction of HER2-associated lipogenic
phenotype by docosahexaenoic acid (DHA)
induces apoptosis in breast tumor cells
harboring HER2 overexpression
Reduction of HER2-associated lipogenic
phenotype by docosahexaenoic acid (DHA)
induces apoptosis in breast tumor cells
harboring HER2 overexpression
Reduction of HER2-associated lipogenic
phenotype by docosahexaenoic acid (DHA)
induces apoptosis in breast tumor cells
harboring HER2 overexpression
Reduction of HER2-associated lipogenic
phenotype by docosahexaenoic acid (DHA)
induces apoptosis in breast tumor cells
harboring HER2 overexpression
Reduction of HER2-associated lipogenic
phenotype by docosahexaenoic acid (DHA)
induces apoptosis in breast tumor cells
harboring HER2 overexpression
Jinfu
Yang
Dr. Yang has disclosed he owns stock.
Frances
Zhao
Mr. Zhao has disclosed he owns stock.
Maria
Brentani
Prof. Brentani has no relevant financial
relationships to disclose.
William
Festuccia
Prof. Festuccia has no relevant financial
relationships to disclose.
Graziela
Ravacci
Dr. Ravacci has no relevant financial
relationships to disclose.
Tharcisio
Tortelli
Dr. Tortelli has no relevant financial
relationships to disclose.
Angela
Waitzberg
Prof. Waitzberg has no relevant financial
relationships to disclose.
Dan
Waitzberg
Prof. Waitzberg has no relevant financial
relationships to disclose.
P1-09-01
P1-09-01
P1-09-01
P1-09-01
P1-09-01
P1-09-01
P1-09-02
P1-09-02
P1-09-02
P1-09-03
Beyond fatigue - The impact of breast cancer
treatment on body composition and energy
expenditure
Beyond fatigue - The impact of breast cancer
treatment on body composition and energy
expenditure
Beyond fatigue - The impact of breast cancer
treatment on body composition and energy
expenditure
Beyond fatigue - The impact of breast cancer
treatment on body composition and energy
expenditure
Beyond fatigue - The impact of breast cancer
treatment on body composition and energy
expenditure
Beyond fatigue - The impact of breast cancer
treatment on body composition and energy
expenditure
BMI and metabolic factors in long-term breast
cancer survivors: Changes from diagnosis and
comparison to non-breast cancer controls
BMI and metabolic factors in long-term breast
cancer survivors: Changes from diagnosis and
comparison to non-breast cancer controls
BMI and metabolic factors in long-term breast
cancer survivors: Changes from diagnosis and
comparison to non-breast cancer controls
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Althouse
Ms. Althouse has no relevant financial
relationships to disclose.
Han
Ms. Han has no relevant financial relationships
to disclose.
Miller
Ms. Miller has no relevant financial
relationships to disclose.
Sledge
Mr. Sledge has no relevant financial
relationships to disclose.
Sollars
Ms. Sollars has no relevant financial
relationships to disclose.
Stephen
Ventura
Mr. Ventura has no relevant financial
relationships to disclose.
Marguerite
Ennis
Dr. Ennis has no relevant financial relationships
to disclose.
Pamela
Goodwin
Dr. Goodwin has no relevant financial
relationships to disclose.
Lohmann
Dr. Lohmann has no relevant financial
relationships to disclose.
Berger
Dr. Berger has no relevant financial
relationships to disclose.
Sandra
Linda
Kathy
Jeffrey
Jessica
Ana Elisa
Michael
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-03
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Knopp
Dr. Knopp has no relevant financial
relationships to disclose.
Layman
Dr. Layman has no relevant financial
relationships to disclose.
Joanne
Lester
Dr. Lester has no relevant financial
relationships to disclose.
Amanda
Logan
Ms. Logan has no relevant financial
relationships to disclose.
Charles
Loprinzi
Dr. Loprinzi has no relevant financial
relationships to disclose.
Maryam
Lustberg
Dr. Lustberg has no relevant financial
relationships to disclose.
Erin
Macrae
Dr. Macrae has no relevant financial
relationships to disclose.
Ewa
Mrozek
Dr. Mrozek has no relevant financial
relationships to disclose.
Michael
Rachel
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-03
P1-09-04
P1-09-04
P1-09-04
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Prevention of aromatase Inhibitor (AI)-induced
joint symptoms with omega-3 fatty acid
supplementation: A randomized placebocontrolled pilot study
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Orchard
Dr. Orchard has no relevant financial
relationships to disclose.
Pan
Dr. Pan has no relevant financial relationships
to disclose.
Bhuvaneswari
Ramaswamy
Dr. Ramaswamy has no relevant financial
relationships to disclose.
Raquel
Reinbolt
Dr. Reinbolt has no relevant financial
relationships to disclose.
Charles
Shapiro
Dr. Shapiro has no relevant financial
relationships to disclose.
Robert
Wesolowski
Dr. Wesolowski has no relevant financial
relationships to disclose.
Tonya
Xueliang
Lisa
Yee
Ajit
Chaudhari
Rachel
Layman
Charles
Loprinzi
Dr. Yee has no relevant financial relationships
to disclose.
Dr. Chaudhari has no relevant financial
relationships to disclose.
Dr. Layman has no relevant financial
relationships to disclose.
Dr. Loprinzi has no relevant financial
relationships to disclose.
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-04
P1-09-05
P1-09-05
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Longitudinal evaluation of taxane-induced
neuropathy in early stage breast cancer
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
Maryam
Lustberg
Erin
Macrae
Scott
Monfort
Ewa
Mrozek
Xueliang
Pan
Robyn
Patrick
Bhuvaneswari
Ramaswamy
Raquel
Reinbolt
Charles
Shapiro
Janani
Singaravelu
Robert
Wesolowski
Marc
Botteman
Dr. Lustberg has no relevant financial
relationships to disclose.
Dr. Macrae has no relevant financial
relationships to disclose.
Mr. Monfort has no relevant financial
relationships to disclose.
Dr. Mrozek has no relevant financial
relationships to disclose.
Dr. Pan has no relevant financial relationships
to disclose.
Robyn Patrick has no relevant financial
relationships to disclose.
Dr. Ramaswamy has no relevant financial
relationships to disclose.
Dr. Reinbolt has no relevant financial
relationships to disclose.
Dr. Shapiro has no relevant financial
relationships to disclose.
Janani Singaravelu has no relevant financial
relationships to disclose.
Dr. Wesolowski has no relevant financial
relationships to disclose.
Mr. Botteman has disclosed he is an employee
of Pharmerit, which received funding from
Celgene for this research. He also disclosed
that he is a shareholder of Pharmerit, which
received funding from Celgene for this
research.
William
Gradishar
Dr. Gradishar has no relevant financial
relationships to disclose.
P1-09-05
P1-09-05
P1-09-05
P1-09-05
P1-09-05
P1-09-05
P1-09-06
P1-09-06
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
Quality of life (QOL) impact of nanoparticle
albumin-bound paclitaxel (nab -P) vs.
conventional solvent-based paclitaxel (sb-P) in
metastatic breast cancer
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
Xiang
Ji
Bellinda
King-Kallimanis
Xiang Ji has disclosed that he is an employee of
Pharmerit International, which received
funding from Celgene for this research.
Dr. King-Kallimanis has disclosed that she is an
employee of Pharmerit International, which
received funding from Celgene for this
research.
Ko
Ms. Ko has disclosed She is an employee of
Celgene.
Lin
Dr. Lin has disclosed that he is an employee of
Pharmerit International, which received
funding from Celgene for this research.
Sotirios
Stergiopoulos
Dr. Stergiopoulos has disclosed he is an
employee of Celgene.
Scott
Whiting
Mr. Whiting has disclosed he is an employee
and owns stock of Celgene.
Giuliano
Bedoschi
Dr. Bedoschi has no relevant financial
relationships to disclose.
Tessa
Cigler
Dr. Cigler has no relevant financial
relationships to disclose.
Amy
Fang-Ju
P1-09-06
P1-09-06
P1-09-06
P1-09-06
P1-09-06
P1-09-06
P1-09-06
P1-09-06
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
Dickler
Dr. Dickler has no relevant financial
relationships to disclose.
Goldfarb
Dr. Goldfarb has no relevant financial
relationships to disclose.
Sumanta
Goswami
Dr. Goswami has no relevant financial
relationships to disclose.
Eli
Grunblatt
Mr. Grunblatt has no relevant financial
relationships to disclose.
Clifford
Hudis
Dr. Hudis has no relevant financial relationships
to disclose.
Fred
Moy
Dr. Moy has no relevant financial relationships
to disclose.
Kutluk
Oktay
Dr. Oktay has no relevant financial
relationships to disclose.
Fernanda
Pacheco
Dr. Pacheco has no relevant financial
relationships to disclose.
Maura
Shari
P1-09-06
P1-09-06
P1-09-06
P1-09-06
P1-09-07
P1-09-07
P1-09-07
P1-09-07
P1-09-07
P1-09-07
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
A prospective longitudinal study of the impact
of breast cancer treatment with adjuvant
chemotherapy or tamoxifen alone on ovarian
reserve
Patient centered support in the survivorship
care transition: Outcomes from the patientowned survivorship care plan intervention
Patient centered support in the survivorship
care transition: Outcomes from the patientowned survivorship care plan intervention
Patient centered support in the survivorship
care transition: Outcomes from the patientowned survivorship care plan intervention
Patient centered support in the survivorship
care transition: Outcomes from the patientowned survivorship care plan intervention
Patient centered support in the survivorship
care transition: Outcomes from the patientowned survivorship care plan intervention
Patient centered support in the survivorship
care transition: Outcomes from the patientowned survivorship care plan intervention
Patil
Dr. Patil has no relevant financial relationships
to disclose.
Quistorff
Ms. Quistorff has no relevant financial
relationships to disclose.
Mark
Robson
Dr. Robson has no relevant financial
relationships to disclose.
Robert
Stobezki
Mr. Stobezki has no relevant financial
relationships to disclose.
Azuero
Casey Azuero has no relevant financial
relationships to disclose.
Bae
Dr. Bae has no relevant financial relationships
to disclose.
Demark-Wahnefried
Dr. Demark-Wahnefried has no relevant
financial relationships to disclose.
Huang
Chao-Hui Huang has no relevant financial
relationships to disclose.
Kvale
Dr. Kvale has no relevant financial relationships
to disclose.
Meneses
Dr. Meneses has no relevant financial
relationships to disclose.
Sujata
Jessica
Casey
Sejong
Wendy
Chao-Hui
Elizabeth
Karen
Patient centered support in the survivorship
care transition: Outcomes from the patientowned survivorship care plan intervention
Risk factors for lymphedema are dependent on
level of axillary surgery
Risk factors for lymphedema are dependent on
level of axillary surgery
Risk factors for lymphedema are dependent on
level of axillary surgery
Risk factors for lymphedema are dependent on
level of axillary surgery
Risk factors for lymphedema are dependent on
level of axillary surgery
Risk factors for lymphedema are dependent on
level of axillary surgery
Risk factors for lymphedema are dependent on
level of axillary surgery
Yee
Dr. Ritchie has no relevant financial
relationships to disclose.
Dr. Beith has no relevant financial relationships
to disclose.
Mr. French has no relevant financial
relationships to disclose.
Ms. Kastania has no relevant financial
relationships to disclose.
Dr. Kilbreath has no relevant financial
relationships to disclose.
Ms. Koelmeyer has no relevant financial
relationships to disclose.
Dr. Refshauge has no relevant financial
relationships to disclose.
Mr. Ung has no relevant financial relationships
to disclose.
Dr. Ward has disclosed she has consulted for
ImpediMed Ltd. Impedimed Ltd has had no
involvement in the conception and execution
of this study or interpretation of the findings.
Ms. Yee has no relevant financial relationships
to disclose.
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Dale
Bailey
Dr. Bailey has no relevant financial
relationships to disclose.
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Elizabeth
Bailey
Ms. Bailey has no relevant financial
relationships to disclose.
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Jane
Beith
Dr. Beith has no relevant financial relationships
to disclose.
P1-09-07
P1-09-08
P1-09-08
P1-09-08
P1-09-08
P1-09-08
P1-09-08
P1-09-08
Christine
Ritchie
Jane
Beith
James
French
Katrina
Kastania
Sharon
Kilbreath
Louise
Koelmeyer
Kathryn
Refshauge
Owen
Ung
P1-09-08
Risk factors for lymphedema are dependent on
level of axillary surgery
Leigh
Risk factors for lymphedema are dependent on
level of axillary surgery
Jasmine
P1-09-08
Ward
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Deborah
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Elizabeth
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Sharon
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Kathryn
P1-09-09
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema Geoff
P1-09-09
P1-09-10
P1-09-10
P1-09-10
P1-09-10
P1-09-11
P1-09-11
Determination of the first evidence-based
diagnosis of secondary upper limb lymphedema
Impact of radiation on cardiovascular outcomes
in breast cancer patients
Impact of radiation on cardiovascular outcomes
in breast cancer patients
Impact of radiation on cardiovascular outcomes
in breast cancer patients
Impact of radiation on cardiovascular outcomes
in breast cancer patients
Objective markers of fatigue in women
undergoing adjuvant chemotherapy for breast
cancer
Objective markers of fatigue in women
undergoing adjuvant chemotherapy for breast
cancer
Black
Dr. Black has no relevant financial relationships
to disclose.
Dylke
Dr. Dylke has no relevant financial relationships
to disclose.
Kilbreath
Dr. Kilbreath has no relevant financial
relationships to disclose.
Refshauge
Dr. Refshauge has no relevant financial
relationships to disclose.
Leigh
Ward
Janice
Lyons
Angel
Qin
Paula
Silverman
Cheryl
Thompson
Mr. Schembri has no relevant financial
relationships to disclose.
Dr. Ward has disclosed she has consulted for
ImpediMed Ltd. Impedimed Ltd has had no
involvement in the conception and execution
of this study or interpretation of the findings.
Dr. Lyons has no relevant financial
relationships to disclose.
Dr. Qin has no relevant financial relationships
to disclose.
Dr. Silverman has no relevant financial
relationships to disclose.
Dr. Thompson has no relevant financial
relationships to disclose.
Behrendt
Dr. Behrendt has no relevant financial
relationships to disclose.
Frankel
Mr. Frankel has no relevant financial
relationships to disclose.
Carolyn
Paul
Schembri
P1-09-11
P1-09-11
P1-09-11
P1-09-12
P1-09-12
P1-09-12
P1-09-12
P1-09-12
Objective markers of fatigue in women
undergoing adjuvant chemotherapy for breast
cancer
Objective markers of fatigue in women
undergoing adjuvant chemotherapy for breast
cancer
Objective markers of fatigue in women
undergoing adjuvant chemotherapy for breast
cancer
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Mortimer
Dr. Mortimer has no relevant financial
relationships to disclose.
Patel
Sunita Patel has no relevant financial
relationships to disclose.
Waliany
Ms. Waliany has no relevant financial
relationships to disclose.
Abraham
Dr. Abraham has no relevant financial
relationships to disclose.
Daniel
Bonner
Mr. Bonner has no relevant financial
relationships to disclose.
Diana
Gilleland
Ms. Gilleland has no relevant financial
relationships to disclose.
Gerald
Hobbs
Dr. Hobbs has no relevant financial
relationships to disclose.
Kurian
Dr. Kurian has no relevant financial
relationships to disclose.
Joanne
Sunita
Sarah
Jame
Sobha
P1-09-12
P1-09-12
P1-09-12
P1-09-13
P1-09-13
P1-09-13
P1-09-13
P1-09-13
P1-09-13
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Effect of a 12-week supervised physical activity
and healthy eating program on body weight,
functional capacity and serum biomarkers in
survivors of triple-negative breast cancer: A
randomized, controlled trial
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Anne
Swisher
Dr. Swisher has no relevant financial
relationships to disclose.
Linda
Vona-Davis
Dr. Vona-Davis has no relevant financial
relationships to disclose.
Yanosik
Ms. Yanosik has no relevant financial
relationships to disclose.
Chantal
Ferguson
Chantal Ferguson has no relevant financial
relationships to disclose.
Nora
Horick
Ms. Horick has no relevant financial
relationships to disclose.
Lauren
Jammallo
Ms. Jammallo has no relevant financial
relationships to disclose.
Miller
Ms. Miller has no relevant financial
relationships to disclose.
O'Toole
Jean O'Toole has no relevant financial
relationships to disclose.
Skolny
Ms. Skolny has no relevant financial
relationships to disclose.
Mary Anne
Cynthia
Jean
Melissa
P1-09-13
P1-09-13
P1-09-13
P1-09-14
P1-09-14
P1-09-14
P1-09-14
P1-09-14
P1-09-14
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Risk of breast cancer related lymphedema after
treatment with taxane-based chemotherapy: A
prospective cohort study
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Specht
Dr. Specht has no relevant financial
relationships to disclose.
Swaroop
Meyha Swaroop has no relevant financial
relationships to disclose.
Alphonse
Taghian
Dr. Taghian has no relevant financial
relationships to disclose.
Alok
Dwivedi
Dr. Dwivedi has no relevant financial
relationships to disclose.
Rosalinda
Heydarian
Ms. Heydarian has no relevant financial
relationships to disclose.
Indika
Mallawaarachchi
Indika Mallawaarachchi has no relevant
financial relationships to disclose.
Zeina
Nahleh
Dr. Nahleh has no relevant financial
relationships to disclose.
Azadeh
Nasrazadani
Azadeh Nasrazadani has no relevant financial
relationships to disclose.
Ochoa
Ms. Ochoa has no relevant financial
relationships to disclose.
Michelle
Meyha
Cecilia
P1-09-14
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
Improved outcome of breast cancer survivors
participating in a multidisciplinary cancer
survivorship program at Texas Tech University
Health Sciences in El Paso, TX
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Kevin
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Mark
Burkard
Dr. Burkard has no relevant financial
relationships to disclose.
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge SarahMaria
Donohue
Ms. Donohue has no relevant financial
relationships to disclose.
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Mindy
Gribble
Ms. Gribble has no relevant financial
relationships to disclose.
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Willam
Hocking
Dr. Hocking has no relevant financial
relationships to disclose.
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Mary
Sesto
Dr. Sesto has no relevant financial relationships
to disclose.
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Wenjun
Sun
Wenjun Sun has no relevant financial
relationships to disclose.
P1-09-14
P1-09-14
Rebecca
Edward
Luis
Pasillas
Dr. Pasillas has no relevant financial
relationships to disclose.
Saltzstein
Dr. Saltzstein has no relevant financial
relationships to disclose.
Sanchez
Mr. Sanchez has no relevant financial
relationships to disclose.
Buhr
Dr. Buhr has no relevant financial relationships
to disclose.
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Abigail
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Amye
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Douglas
P1-09-15
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge Kari
P1-09-15
P1-09-16
P1-09-16
P1-09-16
P1-09-16
P1-09-16
P1-09-17
P1-09-17
Randomized clinical trial assessing the impact of
survivorship care plans on survivor knowledge
Exercise and the influence of endocrine therapy
on cardiac and metabolic outcomes in breast
cancer survivors
Exercise and the influence of endocrine therapy
on cardiac and metabolic outcomes in breast
cancer survivors
Exercise and the influence of endocrine therapy
on cardiac and metabolic outcomes in breast
cancer survivors
Exercise and the influence of endocrine therapy
on cardiac and metabolic outcomes in breast
cancer survivors
Exercise and the influence of endocrine therapy
on cardiac and metabolic outcomes in breast
cancer survivors
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Terhaar
Ms. Terhaar has no relevant financial
relationships to disclose.
Tevaarwerk
Dr. Tevaarwerk has no relevant financial
relationships to disclose.
Wiegman
Dr. Wiegman has no relevant financial
relationships to disclose.
Wisinski
Dr. Wisinski has no relevant financial
relationships to disclose.
Zeal
Jamie Zeal has no relevant financial
relationships to disclose.
Lyndsey
Harris
Dr. Harris has no relevant financial
relationships to disclose.
Karl
Insogna
Dr. Insogna has no relevant financial
relationships to disclose.
Sangchoon
Jeon
Dr. Jeon has no relevant financial relationships
to disclose.
Knobf
Dr. Knobf has no relevant financial
relationships to disclose.
Jamie
M Tish
Barbara
Smith
Germaine
Agollah
Melissa
Aldrich
Dr. Smith has no relevant financial
relationships to disclose.
Germaine Agollah has no relevant financial
relationships to disclose.
Ms. Aldrich has no relevant financial
relationships to disclose.
P1-09-18
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Is there a genetic predisposition for cancerrelated lymphedema?
Perceptions and gaps of women living with
advanced breast cancer: Results from the
'Count Us, Know Us, Join Us' online survey in
Latin America
P1-09-19
Patient's views of follow-up after treatment for
breast cancer. A comparison of two approaches Dimitri
P1-09-19
Patient's views of follow-up after treatment for
breast cancer. A comparison of two approaches Samantha
P1-09-17
P1-09-17
P1-09-17
P1-09-17
P1-09-17
P1-09-17
P1-09-17
P1-09-17
P1-09-17
P1-09-19
P1-09-20
Chinmay
Darne
Caroline
Fife
Manuel
Gonzalez-Garay
Renie
Guilliod
Philip
King
Erik
Maus
John
Rasmussen
Eva
Sevick-Muraca
I-Chih
Tan
Chinmay Darne has no relevant financial
relationships to disclose.
Ms. Fife has no relevant financial relationships
to disclose.
Mr. Gonzalez-Garay has no relevant financial
relationships to disclose.
Renie Guilliod has no relevant financial
relationships to disclose.
Mr. King has no relevant financial relationships
to disclose.
Mr. Maus has no relevant financial
relationships to disclose.
Mr. Rasmussen has no relevant financial
relationships to disclose.
Ms. Sevick-Muraca has no relevant financial
relationships to disclose.
I-Chih Tan has no relevant financial
relationships to disclose.
Caleffi
Dr. Caleffi has no relevant financial
relationships to disclose.
Hadjiminas
Dimitri Hadjiminas has no relevant financial
relationships to disclose.
Muktar
Ms. Muktar has no relevant financial
relationships to disclose.
Thiruchelvam
Mr. Thiruchelvam has no relevant financial
relationships to disclose.
Bea
Dr. Bea has no relevant financial relationships
to disclose.
Maira
Patient's views of follow-up after treatment for
breast cancer. A comparison of two approaches Paul
Evaluating alcohol and tobacco use in an
ethnically diverse sample of breast cancer
patients: Implications for survivorship
Vivian
P1-09-20
P1-09-20
P1-09-20
P1-09-21
P1-09-21
P1-09-21
P1-09-21
P1-09-22
P1-09-22
P1-09-22
P1-09-22
Evaluating alcohol and tobacco use in an
ethnically diverse sample of breast cancer
patients: Implications for survivorship
Evaluating alcohol and tobacco use in an
ethnically diverse sample of breast cancer
patients: Implications for survivorship
Evaluating alcohol and tobacco use in an
ethnically diverse sample of breast cancer
patients: Implications for survivorship
Metabolic syndrome is prevalent in women with
newly diagnosed breast cancer
Metabolic syndrome is prevalent in women with
newly diagnosed breast cancer
Metabolic syndrome is prevalent in women with
newly diagnosed breast cancer
Metabolic syndrome is prevalent in women with
newly diagnosed breast cancer
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Dana
Joan
Burshell
Dana Burshell has no relevant financial
relationships to disclose.
Cunningham
Dr. Cunningham has no relevant financial
relationships to disclose.
Marvella
Ford
Carolyn
Behrendt
Joanne
Mortimer
Robin
Smith
Louise
Wong
Dr. Ford has no relevant financial relationships
to disclose.
Dr. Behrendt has no relevant financial
relationships to disclose.
Dr. Mortimer has no relevant financial
relationships to disclose.
Robin Smith has no relevant financial
relationships to disclose.
Ms. Wong has no relevant financial
relationships to disclose.
Sarah
Arvey
Dr. Arvey has no relevant financial
relationships to disclose.
Leo
Castillo
Mr. Castillo has no relevant financial
relationships to disclose.
Kip
Gallion
Kip Gallion has no relevant financial
relationships to disclose.
Muñoz
Mr. Muñoz has no relevant financial
relationships to disclose.
Edgar
P1-09-22
P1-09-22
P1-09-22
P1-09-22
P1-09-23
P1-09-23
P1-09-23
P1-09-23
P1-09-23
P1-09-23
P1-09-24
P1-09-24
P1-09-24
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Improving quality of life among Latino breast
cancer survivors: A national randomized control
trial of patient navigators using LIVESTRONG's
Cancer Navigation Center
Symptoms, desire for help, and quality of life
among recent breast cancer survivors
Symptoms, desire for help, and quality of life
among recent breast cancer survivors
Symptoms, desire for help, and quality of life
among recent breast cancer survivors
Symptoms, desire for help, and quality of life
among recent breast cancer survivors
Symptoms, desire for help, and quality of life
among recent breast cancer survivors
Symptoms, desire for help, and quality of life
among recent breast cancer survivors
Oral health-related quality of life in women with
early stage breast cancer
Oral health-related quality of life in women with
early stage breast cancer
Oral health-related quality of life in women with
early stage breast cancer
Penedo
Dr. Penedo has no relevant financial
relationships to disclose.
Perez
Arely Perez has no relevant financial
relationships to disclose.
Amelie
Ramirez
Dr. Ramirez has no relevant financial
relationships to disclose.
Sandra
San Miguel
Angela
DeMichele
Karen
Glanz
Linda
Jacobs
Steven
Palmer
SarahLena
Panzer
Marilyn
Schapira
Thomas
Braun
William
Giannobile
Marita
Inglehart
Frank
Arely
Ms. San Miguel has no relevant financial
relationships to disclose.
Dr. DeMichele has no relevant financial
relationships to disclose.
Dr. Glanz has no relevant financial relationships
to disclose.
Dr. Jacobs has no relevant financial
relationships to disclose.
Dr. Palmer has no relevant financial
relationships to disclose.
Ms. Panzer has no relevant financial
relationships to disclose.
Dr. Schapira has no relevant financial
relationships to disclose.
Dr. Braun has no relevant financial
relationships to disclose.
Dr. Giannobile has no relevant financial
relationships to disclose.
Dr. Inglehart has no relevant financial
relationships to disclose.
P1-09-24
P1-09-24
P1-09-25
P1-09-25
P1-09-25
P1-09-25
P1-09-25
P1-09-26
P1-09-26
P1-09-26
P1-09-27
P1-09-27
Oral health-related quality of life in women with
early stage breast cancer
Oral health-related quality of life in women with
early stage breast cancer
Determinants of weight gain after breast cancer
diagnosis: Results from the prospective
SU.VI.MAX cohort
Determinants of weight gain after breast cancer
diagnosis: Results from the prospective
SU.VI.MAX cohort
Determinants of weight gain after breast cancer
diagnosis: Results from the prospective
SU.VI.MAX cohort
Determinants of weight gain after breast cancer
diagnosis: Results from the prospective
SU.VI.MAX cohort
Determinants of weight gain after breast cancer
diagnosis: Results from the prospective
SU.VI.MAX cohort
Surgery for breast cancer in the elderly is
associated with better outcomes
Surgery for breast cancer in the elderly is
associated with better outcomes
Surgery for breast cancer in the elderly is
associated with better outcomes
High serum levels of 25-hydroxyvitamin D are
associated with better quality-of-life, and lower
levels of perceived stress, depression, and
fatigue among breast cancer survivors
High serum levels of 25-hydroxyvitamin D are
associated with better quality-of-life, and lower
levels of perceived stress, depression, and
fatigue among breast cancer survivors
Linda
Taichman
Catherine
Van Poznak
Dr. Taichman has no relevant financial
relationships to disclose.
Dr. Van Poznak has no relevant financial
relationships to disclose.
Pilar
Galan
Dr. Galan has no relevant financial
relationships to disclose.
Serge
Hercberg
Dr. Hercberg has no relevant financial
relationships to disclose.
Fabien
Szabo
Dr. Szabo has no relevant financial
relationships to disclose.
Mathilde
Touvier
Dr. Touvier has no relevant financial
relationships to disclose.
Laurent
Zelek
Pam
Chaichanavichkij
Yasmin
Jauhari
Richard
Sainsbury
Dr. Zelek has no relevant financial relationships
to disclose.
Ms. Chaichanavichkij has no relevant financial
relationships to disclose.
Yasmin Jauhari has no relevant financial
relationships to disclose.
Dr. Sainsbury has no relevant financial
relationships to disclose.
Christine
Ambrosone
Dr. Ambrosone has no relevant financial
relationships to disclose.
Hong
Dr. Hong has no relevant financial relationships
to disclose.
Chi-Chen
P1-09-27
High serum levels of 25-hydroxyvitamin D are
associated with better quality-of-life, and lower
levels of perceived stress, depression, and
fatigue among breast cancer survivors
Shicha
High serum levels of 25-hydroxyvitamin D are
associated with better quality-of-life, and lower
levels of perceived stress, depression, and
fatigue among breast cancer survivors
Song
High serum levels of 25-hydroxyvitamin D are
associated with better quality-of-life, and lower
levels of perceived stress, depression, and
fatigue among breast cancer survivors
Yali
P1-09-28
What is a healthful diet? - Cancer survivors'
interpretations of their own dietary recall data
P1-09-28
What is a healthful diet? - Cancer survivors'
interpretations of their own dietary recall data
Laura
Caulfield
Dr. Caulfield has no relevant financial
relationships to disclose.
P1-09-28
What is a healthful diet? - Cancer survivors'
interpretations of their own dietary recall data
Kisha
Coa
Ms. Coa has no relevant financial relationships
to disclose.
P1-09-28
What is a healthful diet? - Cancer survivors'
interpretations of their own dietary recall data
Susan
Hannum
Dr. Hannum has no relevant financial
relationships to disclose.
P1-09-28
What is a healthful diet? - Cancer survivors'
interpretations of their own dietary recall data
Klassen
Dr. Klassen has no relevant financial
relationships to disclose.
P1-09-27
P1-09-27
P1-09-28
P1-09-29
P1-09-29
What is a healthful diet? - Cancer survivors'
interpretations of their own dietary recall data
A new model of care for breast cancer
survivorship
A new model of care for breast cancer
survivorship
Michelle
Ann
Kumar
Dr. Kumar has no relevant financial
relationships to disclose.
Yao
Dr. Yao has no relevant financial relationships
to disclose.
Zhang
Yali Zhang has no relevant financial
relationships to disclose.
Brosbe
Ms. Brosbe has no relevant financial
relationships to disclose.
Katherine
Smith
Gail
Larocque
Carrie
Liska
Dr. Smith has no relevant financial
relationships to disclose.
Ms. Larocque has no relevant financial
relationships to disclose.
Ms. Liska has no relevant financial relationships
to disclose.
P1-09-29
P1-09-29
P1-09-29
P1-09-30
P1-09-30
P1-09-30
P1-09-30
P1-09-30
P1-09-30
P1-09-30
A new model of care for breast cancer
survivorship
A new model of care for breast cancer
survivorship
A new model of care for breast cancer
survivorship
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Robin
Morash
Moira
Rushton
Roanne
Segal
Robin Morash has no relevant financial
relationships to disclose.
Dr. Rushton has no relevant financial
relationships to disclose.
Dr. Segal has no relevant financial relationships
to disclose.
Martha
Belury
Dr. Belury has no relevant financial
relationships to disclose.
Jackson
Dr. Jackson has no relevant financial
relationships to disclose.
Lester
Dr. Lester has no relevant financial
relationships to disclose.
Logan
Ms. Logan has no relevant financial
relationships to disclose.
Lustberg
Dr. Lustberg has no relevant financial
relationships to disclose.
Orchard
Dr. Orchard has no relevant financial
relationships to disclose.
Pan
Dr. Pan has no relevant financial relationships
to disclose.
Rebecca
Joanne
Amanda
Maryam
Tonya
Xueliang
P1-09-30
P1-09-30
P1-09-31
P1-09-31
P1-09-31
P1-09-32
P1-09-32
P1-09-32
P1-09-32
P1-09-32
P1-09-32
P1-09-33
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Relationship of dietary and red blood cell
polyunsaturated fatty acids to inflammatory
markers in breast cancer survivors taking
aromatase inhibitors
Crowdsourcing the collateral damage from
breast cancer treatment
Crowdsourcing the collateral damage from
breast cancer treatment
Crowdsourcing the collateral damage from
breast cancer treatment
A novel candidate for chemotherapy induced
alopecia (CIA) through local modulation of
apoptosis and inflammation
A novel candidate for chemotherapy induced
alopecia (CIA) through local modulation of
apoptosis and inflammation
A novel candidate for chemotherapy induced
alopecia (CIA) through local modulation of
apoptosis and inflammation
A novel candidate for chemotherapy induced
alopecia (CIA) through local modulation of
apoptosis and inflammation
A novel candidate for chemotherapy induced
alopecia (CIA) through local modulation of
apoptosis and inflammation
A novel candidate for chemotherapy induced
alopecia (CIA) through local modulation of
apoptosis and inflammation
Weight loss and bone health in postmenopausal
breast cancer survivors
Charles
Shapiro
Dr. Shapiro has no relevant financial
relationships to disclose.
Lisa
Yee
Christine
Fischetti
Susan
Love
Amaka
Obidegwu
Dr. Yee has no relevant financial relationships
to disclose.
Ms. Fischetti has no relevant financial
relationships to disclose.
Dr. Love has no relevant financial relationships
to disclose.
Amaka Obidegwu has no relevant financial
relationships to disclose.
Cauwenbergh
Dr. Cauwenbergh has disclosed that he is a
partner at Legacy Healthcare.
Harti
Saad Harti has disclosed that he is CEO and
founder of Legacy Healthcare.
Kondo
Reiko Kondo has disclosed that he is an
employee of Legacy Healthcare.
JiaWei
Liu
Dr. Liu has disclosed that he is VP R&D at
Legacy Healthcare.
Angelo
Mello
Mr. Mello has disclosed that he is an employee
at Legacy Healthcare.
Shiiba
Tadafumi
Graham
Colditz
Geert
Saad
Reiko
Ms. Tadafumi has disclosed she is an employee
at Legacy Healthcare.
Dr. Colditz has no relevant financial
relationships to disclose.
P1-09-33
Weight loss and bone health in postmenopausal
breast cancer survivors
Weight loss and bone health in postmenopausal
breast cancer survivors
Weight loss and bone health in postmenopausal
breast cancer survivors
Weight loss and bone health in postmenopausal
breast cancer survivors
Weight loss and bone health in postmenopausal
breast cancer survivors
Weight loss and bone health in postmenopausal
breast cancer survivors
Weight loss and bone health in postmenopausal
breast cancer survivors
P1-10-01
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study Angel
P1-10-01
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study Christina
P1-10-01
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study Mark
P1-10-01
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study Susan
P1-10-01
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study Dean
P1-09-33
P1-09-33
P1-09-33
P1-09-33
P1-09-33
P1-09-33
Patricia
Ganz
Sonya
Izadi
Jingxia
Liu
Anna
Schwartz
Adetunji
Toriola
Kathleen
Wolin
Lin
Yang
Dr. Ganz has no relevant financial relationships
to disclose.
Ms. Izadi has no relevant financial relationships
to disclose.
Dr. Liu has no relevant financial relationships to
disclose.
Dr. Schwartz has no relevant financial
relationships to disclose.
Dr. Toriola has no relevant financial
relationships to disclose.
Ms. Wolin has no relevant financial
relationships to disclose.
Dr. Yang has no relevant financial relationships
to disclose.
Arnaout
Dr. Arnaout has no relevant financial
relationships to disclose.
Catley
Dr. Catley has no relevant financial
relationships to disclose.
Clemons
Dr. Clemons has no relevant financial
relationships to disclose.
Dent
Dr. Dent has no relevant financial relationships
to disclose.
Fergusson
Dr. Fergusson has no relevant financial
relationships to disclose.
P1-10-01
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study Ian
P1-10-01
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study Demetrios
P1-10-01
P1-10-02
P1-10-02
P1-10-02
P1-10-02
P1-10-02
P1-10-02
P1-10-02
Are physicians 'choosing wisely' when imaging
for distant metastases in women with early
stage (1 or 2) breast cancer? A population study
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Graham
Dr. Graham has no relevant financial
relationships to disclose.
Simos
Dr. Simos has no relevant financial
relationships to disclose.
vanWalraven
Dr. vanWalraven has no relevant financial
relationships to disclose.
Blitzblau
Dr. Blitzblau has no relevant financial
relationships to disclose.
Rachel
Greenup
Dr. Greenup has no relevant financial
relationships to disclose.
Janet
Horton
Dr. Horton has no relevant financial
relationships to disclose.
Kevin
Houck
Mr. Houck has no relevant financial
relationships to disclose.
Howie
Dr. Howie has no relevant financial
relationships to disclose.
Hwang
Dr. Hwang has disclosed that she is on a
Genomic Health Advisory Board.
Mackey
Dr. Mackey has no relevant financial
relationships to disclose.
Carl
Rachel
Lynn
E Shelley
Aimee
P1-10-02
P1-10-02
P1-10-02
P1-10-02
P1-10-02
P1-10-02
P1-10-03
P1-10-03
P1-10-03
P1-10-03
P1-10-04
P1-10-04
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
Adjuvant radiation after lumpectomy: A cost
comparison of treatment patterns in 43,247
women from the National Cancer Data Base
NSABP B-43 is unlikely to produce a costeffective treatment strategy for HER2+ DCIS
NSABP B-43 is unlikely to produce a costeffective treatment strategy for HER2+ DCIS
NSABP B-43 is unlikely to produce a costeffective treatment strategy for HER2+ DCIS
NSABP B-43 is unlikely to produce a costeffective treatment strategy for HER2+ DCIS
Post-operative imaging after atypical ductal
hyperplasia excision: The findings and costs
Post-operative imaging after atypical ductal
hyperplasia excision: The findings and costs
Manisha
Palta
Jeffrey
Peppercorn
Dr. Palta has no relevant financial relationships
to disclose.
Dr. Peppercorn has disclosed that he is a
consultant for Genentech and Novartis. He
also disclosed that his spouse is an employee
of and has ownership in Glaxosmith Kline.
Randy
Scheri
Dr. Scheri has no relevant financial
relationships to disclose.
Barbara
Smith
Dr. Smith has no relevant financial
relationships to disclose.
Julie
Sosa
Dr. Sosa has no relevant financial relationships
to disclose.
Alphonse
Taghian
Michael
Alvarado
Mitchell
Hayes
Elissa
Ozanne
Rajni
Sethi
Gerard
Abood
Adrienne
Cobb
Dr. Taghian has no relevant financial
relationships to disclose.
Dr. Alvarado has disclosed he is a consultant
forGenentech. He is on the Advisory Board for
clinical trial - neoadjuvant Pertuzumab for early
stage breast cancer.
Mr. Hayes has no relevant financial
relationships to disclose.
Dr. Ozanne has no relevant financial
relationships to disclose.
Dr. Sethi has no relevant financial relationships
to disclose.
Dr. Abood has no relevant financial
relationships to disclose.
Dr. Cobb has no relevant financial relationships
to disclose.
P1-10-04
Post-operative imaging after atypical ductal
hyperplasia excision: The findings and costs
Post-operative imaging after atypical ductal
hyperplasia excision: The findings and costs
Post-operative imaging after atypical ductal
hyperplasia excision: The findings and costs
P1-10-05
A cost utility analysis from a Chinese health care
perspective of Nab-paclitaxel or docetaxel, both
as alternatives to solvent-based paclitaxel in
metastatic breast cancer (MBC)
George
Dranitsaris
Dr. Dranitsaris has disclosed that he is a
consultant for and has contracts with Celgene.
P1-10-05
A cost utility analysis from a Chinese health care
perspective of Nab-paclitaxel or docetaxel, both
as alternatives to solvent-based paclitaxel in
metastatic breast cancer (MBC)
Satyn
Kaura
Satyn Kaura has disclosed he receives salary
from Celgene.
P1-10-05
A cost utility analysis from a Chinese health care
perspective of Nab-paclitaxel or docetaxel, both
as alternatives to solvent-based paclitaxel in
metastatic breast cancer (MBC)
Jennifer
King
Ms. King has disclosed she receives salary from
Celgene.
P1-10-05
A cost utility analysis from a Chinese health care
perspective of Nab-paclitaxel or docetaxel, both
as alternatives to solvent-based paclitaxel in
metastatic breast cancer (MBC)
Zhai
Qing
Zhai Qing has no relevant financial
relationships to disclose.
P1-10-05
A cost utility analysis from a Chinese health care
perspective of Nab-paclitaxel or docetaxel, both
as alternatives to solvent-based paclitaxel in
metastatic breast cancer (MBC)
Bo
Yu
Bo Yu has disclosed he is a consultant for
Celgene.
P1-10-04
P1-10-04
Constantine
Godellas
Claudia
Perez
Jennifer
Plichta
Dr. Godellas has no relevant financial
relationships to disclose.
Dr. Perez has no relevant financial relationships
to disclose.
Dr. Plichta has no relevant financial
relationships to disclose.
P1-10-05
P1-10-06
P1-10-06
P1-10-06
P1-10-06
A cost utility analysis from a Chinese health care
perspective of Nab-paclitaxel or docetaxel, both
as alternatives to solvent-based paclitaxel in
metastatic breast cancer (MBC)
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Adams
Daniela
Martin
Jörg
Ursula
Zhang
Adams Zhang has disclosed he receives salary
from Celgene.
Bertschi
Ms. Bertschi has no relevant financial
relationships to disclose.
Bigler
Dr. Bigler has no relevant financial
relationships to disclose.
Brechbühl
Jörg Brechbühl has no relevant financial
relationships to disclose.
Hasler-Strub
Dr. Hasler-Strub has no relevant financial
relationships to disclose.
P1-10-06
P1-10-06
P1-10-06
P1-10-06
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Müller
Dr. Müller has no relevant financial
relationships to disclose.
Klazien
Matter-Walstra
Dr. Matter-Walstra has no relevant financial
relationships to disclose.
Christoph
Rochlitz
Dr. Rochlitz has no relevant financial
relationships to disclose.
Schwenkglenks
Dr. Schwenkglenks has no relevant financial
relationships to disclose.
Andreas
Matthias
P1-10-06
P1-10-06
P1-11-01
P1-11-01
P1-11-01
P1-11-01
P1-11-01
P1-11-01
P1-11-02
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Health economic evaluation of: Bevacizumab
plus paclitaxel vs. bevacizumab plus
metronomic cyclophosphamide and
capecitabine as first-line therapy in patients
with HER2-negative advanced breast cancer: A
multicenter, randomized phase III trial - SAKK
24/09
Patients' perspectives on using a genomic test
for their breast cancer treatment decisions:
Disparities in information exchange
Patients' perspectives on using a genomic test
for their breast cancer treatment decisions:
Disparities in information exchange
Patients' perspectives on using a genomic test
for their breast cancer treatment decisions:
Disparities in information exchange
Patients' perspectives on using a genomic test
for their breast cancer treatment decisions:
Disparities in information exchange
Patients' perspectives on using a genomic test
for their breast cancer treatment decisions:
Disparities in information exchange
Patients' perspectives on using a genomic test
for their breast cancer treatment decisions:
Disparities in information exchange
Telemedicine: Expanding access to cancer
genetic services to underserved populations
von Moos
Dr. von Moos has no relevant financial
relationships to disclose.
Winterhalder
Dr. Winterhalder has no relevant financial
relationships to disclose.
Armstrong
Dr. Armstrong has no relevant financial
relationships to disclose.
Chanfreau-Coffinier
Dr. Chanfreau-Coffinier has no relevant
financial relationships to disclose.
Ganz
Dr. Ganz has no relevant financial relationships
to disclose.
Jennifer
Haas
Dr. Haas has no relevant financial relationships
to disclose.
Ninez
Ponce
Dr. Ponce has no relevant financial
relationships to disclose.
Michele
Toscano
Angela
Bradbury
Roger
Ralph
Joanne
Catherine
Patricia
Ms. Toscano has no relevant financial
relationships to disclose.
Dr. Bradbury has no relevant financial
relationships to disclose.
P1-11-02
P1-11-02
P1-11-02
P1-11-02
P1-11-02
P1-11-02
P1-11-02
P1-11-02
P1-11-02
P1-11-03
P1-11-03
P1-11-03
P1-11-03
P1-11-03
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Telemedicine: Expanding access to cancer
genetic services to underserved populations
Receipt of Risk Reduction strategies among an
underserved population of BRCA mutation
carriers
Receipt of Risk Reduction strategies among an
underserved population of BRCA mutation
carriers
Receipt of Risk Reduction strategies among an
underserved population of BRCA mutation
carriers
Receipt of Risk Reduction strategies among an
underserved population of BRCA mutation
carriers
Receipt of Risk Reduction strategies among an
underserved population of BRCA mutation
carriers
Amanda
Brandt
Susan
Domchek
Brian
Egleston
Linda
Fleisher
Diana
Harris
Rebbeca
Mueller
Linda
Patrick-Miller
Evelyn
Stevens
Jill
Stopfer
Ms. Brandt has no relevant financial
relationships to disclose.
Dr. Domchek has no relevant financial
relationships to disclose.
Dr. Egleston has no relevant financial
relationships to disclose.
Ms. Fleisher has no relevant financial
relationships to disclose.
Ms. Harris has no relevant financial
relationships to disclose.
Ms. Mueller has no relevant financial
relationships to disclose.
Ms. Patrick-Miller has no relevant financial
relationships to disclose.
Ms. Stevens has no relevant financial
relationships to disclose.
Ms. Stopfer has no relevant financial
relationships to disclose.
Pamela
Ganschow
Dr. Ganschow has no relevant financial
relationships to disclose.
Elizabeth
Marcus
Dr. Marcus has no relevant financial
relationships to disclose.
O'Connell
Ms. O'Connell has no relevant financial
relationships to disclose.
Seelaus
Ms. Seelaus has no relevant financial
relationships to disclose.
Thekkekara
Dr. Thekkekara has no relevant financial
relationships to disclose.
Maria
Christina
Romy
P1-11-04
P1-11-04
P1-11-04
P1-11-04
P1-11-04
P1-11-04
P1-11-04
P1-11-04
P1-11-04
P1-11-05
P1-11-05
P1-11-05
P1-11-05
P1-11-05
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Implementation of cancer risk assessment and
genetic testing in underserved patients
Womens' opinion on when to start screening
mammography and reasons for not undergoing
screening
Womens' opinion on when to start screening
mammography and reasons for not undergoing
screening
Womens' opinion on when to start screening
mammography and reasons for not undergoing
screening
Womens' opinion on when to start screening
mammography and reasons for not undergoing
screening
Womens' opinion on when to start screening
mammography and reasons for not undergoing
screening
Marcia
Bouton
Meredith
Heberer
Ian
Komenaka
Lisa
Madlensky
Maria Elena
Martinez
Jesse
Nodora
Richard
Schwab
Jeffrey
Weitzel
Lisa
Winton
Ms. Bouton has no relevant financial
relationships to disclose.
Ms. Heberer has no relevant financial
relationships to disclose.
Dr. Komenaka has no relevant financial
relationships to disclose.
Ms. Madlensky has no relevant financial
relationships to disclose.
Dr. Martinez has no relevant financial
relationships to disclose.
Dr. Nodora has no relevant financial
relationships to disclose.
Mr. Schwab has no relevant financial
relationships to disclose.
Dr. Weitzel has no relevant financial
relationships to disclose.
Dr. Winton has no relevant financial
relationships to disclose.
Marcia
Bouton
Ms. Bouton has no relevant financial
relationships to disclose.
Meredith
Heberer
Dr. Heberer has no relevant financial
relationships to disclose.
Hsu
Dr. Hsu has no relevant financial relationships
to disclose.
Komenaka
Dr. Komenaka has no relevant financial
relationships to disclose.
Martinez
Dr. Martinez has no relevant financial
relationships to disclose.
Chiu-Hsieh
Ian
Maria Elena
P1-11-05
P1-11-05
P1-11-06
P1-11-06
P1-11-06
P1-11-06
P1-11-06
P1-11-06
P1-11-06
P1-11-07
P1-11-07
Womens' opinion on when to start screening
mammography and reasons for not undergoing
screening
Womens' opinion on when to start screening
mammography and reasons for not undergoing
screening
Mammograms on-the-go: Predictors of repeat
visits to mobile mammography vans in St. Louis,
Missouri
Mammograms on-the-go: Predictors of repeat
visits to mobile mammography vans in St. Louis,
Missouri
Mammograms on-the-go: Predictors of repeat
visits to mobile mammography vans in St. Louis,
Missouri
Mammograms on-the-go: Predictors of repeat
visits to mobile mammography vans in St. Louis,
Missouri
Mammograms on-the-go: Predictors of repeat
visits to mobile mammography vans in St. Louis,
Missouri
Mammograms on-the-go: Predictors of repeat
visits to mobile mammography vans in St. Louis,
Missouri
Mammograms on-the-go: Predictors of repeat
visits to mobile mammography vans in St. Louis,
Missouri
Multivariable analysis of repeat utilization of
mobile mammography units: 10 year analysis of
a comprehensive cancer center
Multivariable analysis of repeat utilization of
mobile mammography units: 10 year analysis of
a comprehensive cancer center
Nodora
Dr. Nodora has no relevant financial
relationships to disclose.
Winton
Dr. Winton has no relevant financial
relationships to disclose.
Abadin
Salmafatima Abadin has no relevant financial
relationships to disclose.
Chang
Dr. Chang has no relevant financial
relationships to disclose.
Drake
Dr. Drake has no relevant financial
relationships to disclose.
Melody
Goodman
Dr. Goodman has no relevant financial
relationships to disclose.
Susan
Kraenzle
Ms. Kraenzle has no relevant financial
relationships to disclose.
Sarah
Lyons
Ms. Lyons has no relevant financial
relationships to disclose.
Steward
Dr. Steward has no relevant financial
relationships to disclose.
Barkley
Dr. Barkley has no relevant financial
relationships to disclose.
Mizuguchi
Dr. Mizguchi has no relevant financial
relationships to disclose.
Jesse
Lisa
Salmafatima
Su-Hsin
Bettina
Lauren
Laura
Sarah
P1-11-07
P1-11-07
P1-11-07
P1-11-07
P1-11-08
P1-11-08
P1-11-08
P1-11-08
P1-11-08
P1-11-09
P1-11-09
P1-11-09
P1-11-09
Multivariable analysis of repeat utilization of
mobile mammography units: 10 year analysis of
a comprehensive cancer center
Multivariable analysis of repeat utilization of
mobile mammography units: 10 year analysis of
a comprehensive cancer center
Multivariable analysis of repeat utilization of
mobile mammography units: 10 year analysis of
a comprehensive cancer center
Multivariable analysis of repeat utilization of
mobile mammography units: 10 year analysis of
a comprehensive cancer center
The impact of social inequalities on breast
cancer mortality in Brazil
The impact of social inequalities on breast
cancer mortality in Brazil
The impact of social inequalities on breast
cancer mortality in Brazil
The impact of social inequalities on breast
cancer mortality in Brazil
The impact of social inequalities on breast
cancer mortality in Brazil
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Jianmin
Shesh
Elizabeth
Pan
Jianmin Pan has no relevant financial
relationships to disclose.
Rai
Dr. Rai has no relevant financial relationships
to disclose.
Riley
Dr. Riley has disclosed that he is a speaker for
Amgen and Genentech.
Lane
Roland
Maria-Paula
Curado
Ruffo
Freitas-Junior
Carolina
Gonzaga
Ana-Luiza
Sousa
Marta
Souza
Dr. Roland has no relevant financial
relationships to disclose.
Dr. Curado has no relevant financial
relationships to disclose.
Dr. Freitas-Junior has no relevant financial
relationships to disclose.
Ms. Gonzaga has no relevant financial
relationships to disclose.
Dr. Sousa has no relevant financial
relationships to disclose.
Dr. Souza has no relevant financial
relationships to disclose.
Ambrisone
Dr. Ambrisone has no relevant financial
relationships to disclose.
Bovberg
Dr. Bovberg has no relevant financial
relationships to disclose.
Hershman
Dr. Hershman has no relevant financial
relationships to disclose.
Hillyer
Ms. Hillyer has no relevant financial
relationships to disclose.
Christine
Dana
Dawn
Grace
P1-11-09
P1-11-09
P1-11-09
P1-11-09
P1-11-09
P1-11-09
P1-11-09
P1-11-09
P1-11-09
P1-11-10
P1-11-10
P1-11-10
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Early discontinuation of adjuvant chemotherapy
in women with early stage breast cancer: The
BQUAL study
Young women with breast cancer: Needs and
experiences
Young women with breast cancer: Needs and
experiences
Young women with breast cancer: Needs and
experiences
Jacobson
Dr. Jacobson has no relevant financial
relationships to disclose.
Kushi
Dr. Kushi has no relevant financial relationships
to disclose.
Lamerato
Dr. Lamerato has no relevant financial
relationships to disclose.
Magai
Dr. Magai has no relevant financial
relationships to disclose.
Mandelblatt
Dr. Mandelblatt has no relevant financial
relationships to disclose.
David
Nathanson
Dr. Nathanson has no relevant financial
relationships to disclose.
Alfred
Neugut
Dr. Neugut has no relevant financial
relationships to disclose.
Jinjoo
Shim
Jinjoo Shim has no relevant financial
relationships to disclose.
Judith
Lawrence
Lois
Carol
Jeanne
Wei Yann
Tsai
Margaret
Forbes
Nicole
Hodgson
Mark
Levine
Dr. Tsai has no relevant financial relationships
to disclose.
Ms. Forbes has no relevant financial
relationships to disclose.
Dr. Hodgson has no relevant financial
relationships to disclose.
Dr. Levine has no relevant financial
relationships to disclose.
P1-11-10
P1-11-10
P1-11-10
P1-11-11
P1-11-11
P1-11-11
P1-11-11
P1-11-12
P1-11-12
P1-11-12
P1-11-12
P1-11-12
P1-11-12
P1-11-12
P1-11-12
Young women with breast cancer: Needs and
experiences
Young women with breast cancer: Needs and
experiences
Young women with breast cancer: Needs and
experiences
Enhancing compliance with national nutrition
recommendations in breast cancer survivors.
Experience in an underprivileged community
Enhancing compliance with national nutrition
recommendations in breast cancer survivors.
Experience in an underprivileged community
Enhancing compliance with national nutrition
recommendations in breast cancer survivors.
Experience in an underprivileged community
Enhancing compliance with national nutrition
recommendations in breast cancer survivors.
Experience in an underprivileged community
Religion-related factors and breast cancer
screening among American Muslims
Religion-related factors and breast cancer
screening among American Muslims
Religion-related factors and breast cancer
screening among American Muslims
Religion-related factors and breast cancer
screening among American Muslims
Religion-related factors and breast cancer
screening among American Muslims
Religion-related factors and breast cancer
screening among American Muslims
Religion-related factors and breast cancer
screening among American Muslims
Religion-related factors and breast cancer
screening among American Muslims
Punam
Rana
Jenna
Ratcliffe
Jonathan
Sussman
Dr. Rana has no relevant financial relationships
to disclose.
Jenna Ratcliffe has no relevant financial
relationships to disclose.
Dr. Sussman has no relevant financial
relationships to disclose.
Bodere
Ms. Bodere has no relevant financial
relationships to disclose.
Bourlier
Delphine Bourlier has no relevant financial
relationships to disclose.
Festa
Ms. Festa has no relevant financial
relationships to disclose.
Chloe
Delphine
Anne
Laurent
Zelek
C
Ajax
Z
Hosseinain
C
Liao
S
Mallick
F
Marfani
S
Murrar
Aasim
Padela
M
Peek
Dr. Zelek has no relevant financial relationships
to disclose.
C. Ajax has no relevant financial relationships
to disclose.
Z Hosseinain has no relevant financial
relationships to disclose.
C Liao has no relevant financial relationships to
disclose.
S Mallick has no relevant financial relationships
to disclose.
F Marfani has no relevant financial
relationships to disclose.
S Murrar has no relevant financial relationships
to disclose.
Dr. Padela has no relevant financial
relationships to disclose.
Dr. Peek has no relevant financial relationships
to disclose.
P1-11-13
P1-11-13
P1-11-13
P1-11-13
P1-11-13
P1-11-14
P1-11-14
P1-11-14
P1-11-14
P1-11-14
P1-11-15
P1-11-15
P1-11-15
An evaluation of mobile mammography
outreach in urban and rural communities
An evaluation of mobile mammography
outreach in urban and rural communities
An evaluation of mobile mammography
outreach in urban and rural communities
An evaluation of mobile mammography
outreach in urban and rural communities
An evaluation of mobile mammography
outreach in urban and rural communities
Evidence-based programs to reduce breast
cancer mortality in Panama City
Evidence-based programs to reduce breast
cancer mortality in Panama City
Evidence-based programs to reduce breast
cancer mortality in Panama City
Evidence-based programs to reduce breast
cancer mortality in Panama City
Evidence-based programs to reduce breast
cancer mortality in Panama City
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Bettina
Drake
Melody
Goodman
Susan
Kraenzle
Sarah
Lyons
Lauren
Steward
Blanca
Benaglio
Anna
Cabanes
Tauane
Cruz
Maria
Roquebert
Becky
Royer
Dr. Drake has no relevant financial
relationships to disclose.
Dr. Goodman has no relevant financial
relationships to disclose.
Ms. Kraenzle has no relevant financial
relationships to disclose.
Ms. Lyons has no relevant financial
relationships to disclose.
Dr. Steward has no relevant financial
relationships to disclose.
Ms. Benaglio has no relevant financial
relationships to disclose.
Dr. Cabanes has no relevant financial
relationships to disclose.
Tauane Cruz has no relevant financial
relationships to disclose.
Ms. Roquebert has no relevant financial
relationships to disclose.
Ms. Royer has no relevant financial
relationships to disclose.
Wendy
Chan
Dr. Chan has no relevant financial relationships
to disclose.
Agnes
Cheung
Ms. Cheung has no relevant financial
relationships to disclose.
Alston
Chiu
Alston Chiu has no relevant financial
relationships to disclose.
P1-11-15
P1-11-15
P1-11-15
P1-11-15
P1-11-15
P1-11-15
P1-11-15
P1-11-15
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Breast cancer prevention awareness and breast
examination attitudes among Hong Kong
women who work in a medical environment - A
pilot study
Kwong
Dr. Kwong has no relevant financial
relationships to disclose.
Lai
Ms. Lai has no relevant financial relationships
to disclose.
To Wai
Leung
Dr. Leung has no relevant financial
relationships to disclose.
Henry
Sze
Dr. Sze has no relevant financial relationships
to disclose.
Janice
Tsang
Dr. Tsang has no relevant financial
relationships to disclose.
Cindy Lai Shan
Wong
Dr. Wong has no relevant financial
relationships to disclose.
Sin Ting
Wong
Sin Ting Wong has no relevant financial
relationships to disclose.
Siu Ting
Yung
Siu Yung has no relevant financial relationships
to disclose.
Dora
Eve
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Valentina
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Bernardo
Aristarco
Valentina Aristarco has no relevant financial
relationships to disclose.
Bonanni
Mr. Bonanni has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Alan
Coates
Dr. Coates has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Marco
Colleoni
Mr. Colleoni has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Richard
Gelber
Dr. Gelber has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Aron
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Kathryn
Goldhirsch
Dr. Goldhirsch has no relevant financial
relationships to disclose.
Gray
Ms. Gray has no relevant financial relationships
to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Harriet
Johansson
Ms. Johansson has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Roswitha
Kammler
Roswitha Kammler has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Debora
Macis
Ms. Macis has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Rudolf
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Olivia
Maibach
Mr. Maibach has no relevant financial
relationships to disclose.
Pagani
Dr. Pagani has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Antonella
Puccio
Antonella Puccio has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Manuela
Rabaglio-Poretti
Manuela Rabaglio-Poretti has no relevant
financial relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Meredith
Regan
Ms. Regan has no relevant financial
relationships to disclose.
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Susanne
P1-12-01
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Giuseppe
P1-12-01
P1-12-02
P1-12-02
CYP19A1 and ESR1 polymorphisms and selected
early-onset side effects during combined
endocrine therapy in the IBCSG TEXT trial for
premenopausal women with hormone receptorpositive (HR+) early breast cancer
Barbara
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Can-ming
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Gen-hong
Roux
Ms. Roux has no relevant financial
relationships to disclose.
Viale
Dr. Viale has no relevant financial relationships
to disclose.
Walley
Ms. Walley has no relevant financial
relationships to disclose.
Chen
Dr. Chen has no relevant financial relationships
to disclose.
Di
Dr. Di has no relevant financial relationships to
disclose.
P1-12-02
P1-12-02
P1-12-02
P1-12-02
P1-12-02
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Hou
Dr. Hou has no relevant financial relationships
to disclose.
Hu
Dr. Hu has no relevant financial relationships to
disclose.
Ya-jie
Ji
Dr. Ji has no relevant financial relationships to
disclose.
Li
Lei
Dr. Lei has no relevant financial relationships to
disclose.
Li
Dr. Li has no relevant financial relationships to
disclose.
Yi-feng
Zhen
Jian-Wei
P1-12-02
P1-12-02
P1-12-02
P1-12-02
P1-12-02
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Liu
Dr. Liu has no relevant financial relationships to
disclose.
Mo
Dr. Mo has no relevant financial relationships
to disclose.
Zhi-Ming
Shao
Dr. Shao has no relevant financial relationships
to disclose.
Zhen-Zhou
Shen
Dr. Shen has no relevant financial relationships
to disclose.
Wu
Dr. Wu has no relevant financial relationships
to disclose.
Guang-yu
Miao
Jiong
P1-12-02
P1-12-03
P1-12-03
P1-12-03
P1-12-03
P1-12-03
P1-12-03
P1-12-03
P1-12-03
Effect of using LHRH analog during
chemotherapy (CT) on premature ovarian
failure and prognosis in premenopausal patients
with early-stage, hormone receptor-positive
breast cancer: The primary analysis of a
randomized controlled phase III trial
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Joint pain and fatigue severity among breast
cancer survivors taking aromatase inhibitors: Is
there a shared inflammatory mechanism?
Yu
Dr. Yu has no relevant financial relationships to
disclose.
Bauml
Dr. Bauml has no relevant financial
relationships to disclose.
Boyer
Dr. Boyer has no relevant financial
relationships to disclose.
Chen
Dr. Chen has no relevant financial relationships
to disclose.
Lu
Chen
Lu Chen has no relevant financial relationships
to disclose.
Angela
DeMichele
Dr. DeMichele has no relevant financial
relationships to disclose.
Michael
Kalos
Dr. Kalos has no relevant financial relationships
to disclose.
Li
Ms. Li has no relevant financial relationships to
disclose.
Mao
Dr. Mao has no relevant financial relationships
to disclose.
Ke-Da
Joshua
Jean
Jinbo
Susan
Jun
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Masashi
Baba
Dr. Baba has no relevant financial relationships
to disclose.
Chiyomi
Egawa
Dr. Egawa has no relevant financial
relationships to disclose.
Hashimoto
Dr. Hashimoto has no relevant financial
relationships to disclose.
Hidaka
Dr. Hidaka has no relevant financial
relationships to disclose.
Ichii
Dr. Ichii has no relevant financial relationships
to disclose.
Kikawa
Dr. Kikawa has no relevant financial
relationships to disclose.
Takashi
Toshiharu
Shigetoshi
Yuichiro
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Masahiro
Kishimoto
Dr. Kishimoto has no relevant financial
relationships to disclose.
Koushiro
Kitatsuji
Dr. Kitatsuji has no relevant financial
relationships to disclose.
Kokufu
Dr. Kokufu has no relevant financial
relationships to disclose.
Konishi
Dr. Konishi has no relevant financial
relationships to disclose.
Konishi
Dr. Konishi has no relevant financial
relationships to disclose.
Kono
Dr. Kono has no relevant financial relationships
to disclose.
Ikuo
Muneharu
Yutaka
Seishi
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Takashi
Matsumoto
Dr. Matsumoto has no relevant financial
relationships to disclose.
Junya
Minohata
Dr. Minohata has no relevant financial
relationships to disclose.
Miya
Dr. Miya has no relevant financial relationships
to disclose.
Miyashita
Dr. Miyashita has no relevant financial
relationships to disclose.
Miyauchi
Dr. Miyauchi has no relevant financial
relationships to disclose.
Miyoshi
Dr. Miyoshi has disclosed that he has received
honoraria from Chugai Pharmaceutical Co.,
Ltd., AstraZeneca K.K., GlaxoSmithKline K.K.
Akihiro
Masaru
Keisuke
Yasuo
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-04
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Hidefumi
Nishikawa
Dr. Nishikawa has no relevant financial
relationships to disclose.
Masayuki
Nishino
Dr. Nishino has no relevant financial
relationships to disclose.
Oh
Dr. Oh has no relevant financial relationships to
disclose.
Okuno
Dr. Okuno has no relevant financial
relationships to disclose.
Sakita
Dr. Sakita has no relevant financial
relationships to disclose.
Sakoda
Dr. Sakoda has no relevant financial
relationships to disclose.
Koushi
Toshitaka
Isao
Yoko
P1-12-04
P1-12-04
P1-12-04
P1-12-04
P1-12-05
P1-12-05
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Factors influencing on discontinuation of
adjuvant anastrozole in postmenopausal
Japanese breast cancer patients: Results from a
prospective multicenter cohort study of patientreported outcomes
Aromatase inhibitor induced musculoskeletal
syndrome (AIMSS) in Australian women with
early breast cancer: An Australia and New
Zealand Breast Cancer Trials Group (ANZBCTG)
survey of members of the Breast Cancer
Network Australia (BCNA)
Aromatase inhibitor induced musculoskeletal
syndrome (AIMSS) in Australian women with
early breast cancer: An Australia and New
Zealand Breast Cancer Trials Group (ANZBCTG)
survey of members of the Breast Cancer
Network Australia (BCNA)
Hirofumi
Suwa
Dr. Suwa has no relevant financial relationships
to disclose.
Shintaro
Takao
Dr. Takao has no relevant financial
relationships to disclose.
Wakita
Dr. Wakita has no relevant financial
relationships to disclose.
Yamagami
Dr. Yamagami has no relevant financial
relationships to disclose.
Jacquie
Chirgwin
Ms. Chirgwin has no relevant financial
relationships to disclose.
John
Forbes
Mr. Forbes has no relevant financial
relationships to disclose.
Kazuyuki
Kazuhiko
P1-12-05
Aromatase inhibitor induced musculoskeletal
syndrome (AIMSS) in Australian women with
early breast cancer: An Australia and New
Zealand Breast Cancer Trials Group (ANZBCTG)
survey of members of the Breast Cancer
Network Australia (BCNA)
Aromatase inhibitor induced musculoskeletal
syndrome (AIMSS) in Australian women with
early breast cancer: An Australia and New
Zealand Breast Cancer Trials Group (ANZBCTG)
survey of members of the Breast Cancer
Network Australia (BCNA)
Aromatase inhibitor induced musculoskeletal
syndrome (AIMSS) in Australian women with
early breast cancer: An Australia and New
Zealand Breast Cancer Trials Group (ANZBCTG)
survey of members of the Breast Cancer
Network Australia (BCNA)
Aromatase inhibitor induced musculoskeletal
syndrome (AIMSS) in Australian women with
early breast cancer: An Australia and New
Zealand Breast Cancer Trials Group (ANZBCTG)
survey of members of the Breast Cancer
Network Australia (BCNA)
Aromatase inhibitor induced musculoskeletal
syndrome (AIMSS) in Australian women with
early breast cancer: An Australia and New
Zealand Breast Cancer Trials Group (ANZBCTG)
survey of members of the Breast Cancer
Network Australia (BCNA)
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Ehtesham
P1-12-05
P1-12-05
P1-12-05
P1-12-05
Grant
Nicca Grant has no relevant financial
relationships to disclose.
Lombard
Ms. Lombard has no relevant financial
relationships to disclose.
Linda
Reaby
Ms. Reaby has no relevant financial
relationships to disclose.
Kathy
Wells
Ms. Wells has no relevant financial
relationships to disclose.
Zdenkowski
Mr. Zdenkowski has no relevant financial
relationships to disclose.
Abdi
Ehtesham Abdi has no relevant financial
relationships to disclose.
Nicca
Janine
Nicholas
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Meritxell
Bellet
Meritxell Bellet has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Jürg
Bernhard
Dr. Bernhard has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Frances
Boyle
Frances Boyle has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Daniel
Budman
Mr. Budman has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Alan
Coates
Dr. Coates has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Susan
Domchek
Dr. Domchek has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Yang
Feng
Yang Feng has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Gini
Fleming
Gini Fleming has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
John
Forbes
Mr. Forbes has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Prudence
Francis
Prudence Francis has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Richard
Gelber
Dr. Gelber has no relevant financial
relationships to disclose.
Karlsson
Per Karlsson has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Paul
Maruff
Mr. Maruff has disclosed that he is a full time
employee of CogState, the company that
provided the cognitive tests used in this study.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Kelly-Anne
Phillips
Ms. Phillips has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Fabio
Puglisi
Mr. Puglisi has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Meredith
Regan
Ms. Regan has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Karin
Ribi
Karin Ribi has no relevant financial
relationships to disclose.
P1-12-06
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Simon
Spazzapan
Mr. Spazzapan has no relevant financial
relationships to disclose.
P1-12-06
P1-12-06
P1-12-07
P1-12-07
P1-12-07
P1-12-07
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Per
Co-SOFT: The cognitive function substudy of the
suppression of ovarian function trial (SOFT)
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Khalil
Zaman
Wonshik
Han
Young Joon
Kang
Jongjin
Kim
Min Kyoon
Kim
Khalil Zaman has no relevant financial
relationships to disclose.
Dr. Han has no relevant financial relationships
to disclose.
Young Joon Kang has no relevant financial
relationships to disclose.
Jongjin Kim has no relevant financial
relationships to disclose.
Min Kyoon Kim has no relevant financial
relationships to disclose.
P1-12-07
P1-12-07
P1-12-07
P1-12-07
P1-12-07
P1-12-07
P1-12-08
P1-12-08
P1-12-08
P1-12-08
P1-12-09
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Characteristics of recurrence after completing
adjuvant tamoxifen therapy for 5 years
Bortezomib enhances the efficacy of fulvestrant
by promoting the aggregation of the ER in the
cytoplasm
Bortezomib enhances the efficacy of fulvestrant
by promoting the aggregation of the ER in the
cytoplasm
Bortezomib enhances the efficacy of fulvestrant
by promoting the aggregation of the ER in the
cytoplasm
Bortezomib enhances the efficacy of fulvestrant
by promoting the aggregation of the ER in the
cytoplasm
Possibility of GnRH agonist plus tamoxifen as an
alternative treatment to AC (adriamycin plus
cyclophosphamide) chemotherapy plus
tamoxifen treatment in premenopausal
hormone responsive HER2 negative breast
cancer patients
Yun-Gyoung
Kim
Eunshin
Lee
Han-Byoel
Lee
Hyeong-Gon
Moon
Dong-Young
Noh
Tae-kyung
Yoo
Yun-Gyoung Kim has no relevant financial
relationships to disclose.
Eunshin Lee has no relevant financial
relationships to disclose.
Han-Byoel Lee has no relevant financial
relationships to disclose.
Hyeong-Gon Moon has no relevant financial
relationships to disclose.
Dr. Noh has no relevant financial relationships
to disclose.
Tae-kyung Yoo has no relevant financial
relationships to disclose.
Adelson
Dr. Adelson has no relevant financial
relationships to disclose.
Doris
Germain
Dr. Germain has no relevant financial
relationships to disclose.
George
Raptis
Dr. Raptis has no relevant financial
relationships to disclose.
Samuel
Waxman
Dr. Waxman has no relevant financial
relationships to disclose.
Ahn
Sei Hyun Ahn has no relevant financial
relationships to disclose.
Kerin
SeiHyun
P1-12-09
P1-12-09
P1-12-09
P1-12-09
P1-12-10
P1-12-10
Possibility of GnRH agonist plus tamoxifen as an
alternative treatment to AC (adriamycin plus
cyclophosphamide) chemotherapy plus
tamoxifen treatment in premenopausal
hormone responsive HER2 negative breast
cancer patients
Possibility of GnRH agonist plus tamoxifen as an
alternative treatment to AC (adriamycin plus
cyclophosphamide) chemotherapy plus
tamoxifen treatment in premenopausal
hormone responsive HER2 negative breast
cancer patients
Possibility of GnRH agonist plus tamoxifen as an
alternative treatment to AC (adriamycin plus
cyclophosphamide) chemotherapy plus
tamoxifen treatment in premenopausal
hormone responsive HER2 negative breast
cancer patients
Possibility of GnRH agonist plus tamoxifen as an
alternative treatment to AC (adriamycin plus
cyclophosphamide) chemotherapy plus
tamoxifen treatment in premenopausal
hormone responsive HER2 negative breast
cancer patients
Tamoxifen treated patients have a better
survival than patients treated with aromatase
inhibitors - A population based registry study in
Sweden
Tamoxifen treated patients have a better
survival than patients treated with aromatase
inhibitors - A population based registry study in
Sweden
Lee
Jong Won Lee has no relevant financial
relationships to disclose.
Park
Heeseung Park has no relevant financial
relationships to disclose.
Guiyun
Sohn
Guiyun Sohn has no relevant financial
relationships to disclose.
Byung Ho
Son
Byung Ho Son has no relevant financial
relationships to disclose.
Per
Broberg
Dr. Broberg has no relevant financial
relationships to disclose.
Rickard
Einefors
Mr. Einefors has no relevant financial
relationships to disclose.
Jong Won
Heeseung
P1-12-10
P1-12-11
P1-12-11
P1-12-11
P1-12-11
P1-12-11
P1-12-11
P1-12-11
Tamoxifen treated patients have a better
survival than patients treated with aromatase
inhibitors - A population based registry study in
Sweden
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
Olsson
Dr. Olsson has no relevant financial
relationships to disclose.
De Grève
Dr. De Grève has no relevant financial
relationships to disclose.
Lore
Decoster
Dr. Decoster has no relevant financial
relationships to disclose.
Christel
Fontaine
Dr. Fontaine has no relevant financial
relationships to disclose.
Jan
Lamote
Dr. Lamote has no relevant financial
relationships to disclose.
Denis
Schallier
Dr. Schallier has no relevant financial
relationships to disclose.
Leen
Vanacker
Dr. Vanacker has no relevant financial
relationships to disclose.
Marian
Vanhoeij
Dr. Vanhoeij has no relevant financial
relationships to disclose.
Håkan
Jacques
P1-12-11
P1-12-12
P1-12-12
P1-12-12
P1-12-12
P1-12-12
P1-12-13
P1-12-13
P1-12-13
P1-12-13
P1-12-13
Prospective study of aromatase inhibitorinduced bone loss and lipid levels in early
hormone sensitive breast cancer treated with AI
during 8 years
The insulin like growth factor axis and
development of tamoxifen resistance in breast
cancer
The insulin like growth factor axis and
development of tamoxifen resistance in breast
cancer
The insulin like growth factor axis and
development of tamoxifen resistance in breast
cancer
The insulin like growth factor axis and
development of tamoxifen resistance in breast
cancer
The insulin like growth factor axis and
development of tamoxifen resistance in breast
cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Verfaillie
Dr. Verfaillie has no relevant financial
relationships to disclose.
James
Beattie
Dr. Beattie has no relevant financial
relationships to disclose.
Reem
El-Gendy
Dr. El-Gendy has no relevant financial
relationships to disclose.
Yousef
Hawsawi
Yousef Hawsawi has no relevant financial
relationships to disclose.
Valerie
Speirs
Dr. Speirs has no relevant financial
relationships to disclose.
Twelves
Dr. Twelves has no relevant financial
relationships to disclose.
Han
Dr. Han has no relevant financial relationships
to disclose.
Kang
Young Joon Kang has no relevant financial
relationships to disclose.
Kim
Jongjin Kim has no relevant financial
relationships to disclose.
Kim
Min Kyoon Kim has no relevant financial
relationships to disclose.
Kim
Tae Ryung Kim has no relevant financial
relationships to disclose.
Guy
Christopher
Wonshik
Young Joon
Jongjin
Min Kyoon
Tae Ryung
P1-12-14
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Factors associated with adherence to adjuvant
endocrine therapy in patients with hormone
receptor positive breast cancer
Retinoic acid sensitizes triple-negative breast
cancer cells to tamoxifen treatment
Retinoic acid sensitizes triple-negative breast
cancer cells to tamoxifen treatment
Retinoic acid sensitizes triple-negative breast
cancer cells to tamoxifen treatment
Retinoic acid sensitizes triple-negative breast
cancer cells to tamoxifen treatment
Retinoic acid sensitizes triple-negative breast
cancer cells to tamoxifen treatment
Retinoic acid sensitizes triple-negative breast
cancer cells to tamoxifen treatment
P1-12-15
Intermittent dosing of aromatase inhibitors (AI)
to improve tolerance in post-menopausal
women
Vincent
P1-12-13
P1-12-13
P1-12-13
P1-12-13
P1-12-13
P1-12-13
P1-12-14
P1-12-14
P1-12-14
P1-12-14
P1-12-14
Yun-Gyoung
Eunshin
Han-Byoel
Hyeong-Gon
Dong Young
Kim
Yun-Gyoung Kim has no relevant financial
relationships to disclose.
Lee
Eunshin Lee has no relevant financial
relationships to disclose.
Lee
Han-Byoel Lee has no relevant financial
relationships to disclose.
Moon
Hyeong-Gon Moon has no relevant financial
relationships to disclose.
Noh
Dr. Noh has no relevant financial relationships
to disclose.
Tae-Kyung
Yoo
Krysta
Coyle
Cheryl
Dean
Diana
Jo
Paola
Marcato
Mohammad
Sultan
Margaret
Thomas
Launay-Vacher
Tae-Kyung Yoo has no relevant financial
relationships to disclose.
Ms. Coyle has no relevant financial
relationships to disclose.
Ms. Dean has no relevant financial
relationships to disclose.
Ms. Jo has no relevant financial relationships to
disclose.
Paola Marcato has no relevant financial
relationships to disclose.
Mr. Sultan has no relevant financial
relationships to disclose.
Ms. Thomas has no relevant financial
relationships to disclose.
Dr. Launay-Vacher has disclosed that he is a
consultant for Roche and Teva. He has also
disclosed that he is a speaker for Leo Pharma
and has a contract with Roche.
P1-12-15
Intermittent dosing of aromatase inhibitors (AI)
to improve tolerance in post-menopausal
women
Jean-Baptiste
Intermittent dosing of aromatase inhibitors (AI)
to improve tolerance in post-menopausal
women
Rémy
P1-12-16
Efficacy of adjuvant tamoxifen in hormone
receptor-positive premenopausal breast cancer
patients according to the body mass index
Sercan
P1-12-16
Efficacy of adjuvant tamoxifen in hormone
receptor-positive premenopausal breast cancer
patients according to the body mass index
Kadri
P1-12-16
Efficacy of adjuvant tamoxifen in hormone
receptor-positive premenopausal breast cancer
patients according to the body mass index
Taner
P1-12-16
Efficacy of adjuvant tamoxifen in hormone
receptor-positive premenopausal breast cancer
patients according to the body mass index
Yavuz
P1-12-16
Efficacy of adjuvant tamoxifen in hormone
receptor-positive premenopausal breast cancer
patients according to the body mass index
Mehmet
Sendur
Dr. Sendur has no relevant financial
relationships to disclose.
P1-12-17
Mature data (> 25 years) on 2 years adjuvant
tamoxifen treatment in premenopausal women
with breast cancer: Time to re-emphasize the
progesterone receptor as predictive factor?
Pär-Ola
Bendahl
Dr. Bendahl has no relevant financial
relationships to disclose.
P1-12-15
Rey
Dr. Rey has disclosed that he is a consultant for
Roche, GSK, Amgen, Leo Pharma, Archimedes
Pharma, Eisai, and Boehringer Ingelheim.
Salmon
Dr. Salmon has disclosed that he is a consultant
for Roche and NanoString.
Aksoy
Dr. Aksoy has no relevant financial
relationships to disclose.
Altundag
Dr. Altundag has no relevant financial
relationships to disclose.
Babacan
Dr. Babacan has no relevant financial
relationships to disclose.
Ozisik
Dr. Ozisik has no relevant financial
relationships to disclose.
P1-12-17
Mature data (> 25 years) on 2 years adjuvant
tamoxifen treatment in premenopausal women
with breast cancer: Time to re-emphasize the
progesterone receptor as predictive factor?
Maria
Ekholm
Dr. Ekholm has no relevant financial
relationships to disclose.
P1-12-17
Mature data (> 25 years) on 2 years adjuvant
tamoxifen treatment in premenopausal women
with breast cancer: Time to re-emphasize the
progesterone receptor as predictive factor?
Mårten
Fernö
Prof. Fernö has no relevant financial
relationships to disclose.
P1-12-17
Mature data (> 25 years) on 2 years adjuvant
tamoxifen treatment in premenopausal women
with breast cancer: Time to re-emphasize the
progesterone receptor as predictive factor?
Bo
Nordenskjöld
Prof. Nordenskjöld has no relevant financial
relationships to disclose.
P1-12-17
Mature data (> 25 years) on 2 years adjuvant
tamoxifen treatment in premenopausal women
with breast cancer: Time to re-emphasize the
progesterone receptor as predictive factor?
Lisa
Rydén
Dr. Rydén has no relevant financial
relationships to disclose.
Stål
Prof. Stål has no relevant financial relationships
to disclose.
Arteaga
Dr. Arteaga has disclosed that he has contracts
with Puma Biotechnology, Symphogen, U3Daichi Sakyo, AstraZeneca, and Novartis.
P1-12-17
P1-13-01
Mature data (> 25 years) on 2 years adjuvant
tamoxifen treatment in premenopausal women
with breast cancer: Time to re-emphasize the
progesterone receptor as predictive factor?
Olle
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Carlos
P1-13-01
P1-13-01
P1-13-01
P1-13-01
P1-13-01
P1-13-01
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Aditya
Bardia
Dr. Bardia has disclosed that he is a consultant
for Seragon Pharmaceuticals.
Jose
Baselga
Dr. Baselga has disclosed that he has
ownership in Seragon Pharmaceuticals.
Chow Maneval
Dr. Chow Maneval has disclosed that she
receives salary from and has ownership in
Seragon Pharmaceuticals.
Dickler
Dr. Dickler has disclosed that she is a
consultant for Merrimack and that she has a
contracts with Seragon Pharmaceuticals,
Novartis, and Genentech.
Hager
Dr. Hager has disclosed that he receives salary
from and has ownership in Seragon
Pharmaceuticals.
Mahmood
Dr. Mahmood has no relevant financial
relationships to disclose.
Edna
Maura
Jeffrey
Umar
P1-13-01
P1-13-01
P1-13-01
P1-13-01
P1-13-01
P1-13-01
P1-13-02
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Phase I study of ARN-810, a novel and potent
oral selective estrogen receptor degrader, in
postmenopausal women with metastatic
estrogen receptor positive (ER+), HER2- breast
cancer
Visceral metastases from hormone receptor
positive breast cancer are as sensitive to
endocrine therapy as non-visceral metastases
H Charles
Manning
Dr. Manning has no relevant financial
relationships to disclose.
Ingrid
Mayer
Dr. Mayer has disclosed that she has a contract
with Novartis.
Rix
Mr. Rix has disclosed that he receives salary
from and has ownership in Seragon
Pharmaceuticals.
Roychowdhury
Dr. Roychowdhury has disclosed that he is a
consultant for and has ownership in Seragon
Pharmaceuticals.
Ulaner
Dr. Ulaner has no relevant financial
relationships to disclose.
Winer
Dr. Winer has disclosed that he has a contract
with Genentech.
Bogaerts
Dr. Bogaerts has no relevant financial
relationships to disclose.
Peter
Debasish
Gary
Eric
Jan
P1-13-02
P1-13-02
P1-13-02
P1-13-02
P1-13-02
P1-13-03
P1-13-03
Visceral metastases from hormone receptor
positive breast cancer are as sensitive to
endocrine therapy as non-visceral metastases
Visceral metastases from hormone receptor
positive breast cancer are as sensitive to
endocrine therapy as non-visceral metastases
Visceral metastases from hormone receptor
positive breast cancer are as sensitive to
endocrine therapy as non-visceral metastases
Visceral metastases from hormone receptor
positive breast cancer are as sensitive to
endocrine therapy as non-visceral metastases
Visceral metastases from hormone receptor
positive breast cancer are as sensitive to
endocrine therapy as non-visceral metastases
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Ian
Christine
Robert
Bradbury
Mr. Bradbury has no relevant financial
relationships to disclose.
Campbell
Ms. Campbell has no relevant financial
relationships to disclose.
Paridaens
Mr. Paridaens has no relevant financial
relationships to disclose.
John
Robertson
Yuri
Rukazenkov
Dr. Robertson has disclosed that he receives
consulting fees for Advisory Boards organised
by AstraZeneca; honoraria for speaking at nonACCME events. He also disclosed that he is an
investigator in AstraZeneca sponsored trials. All
funding related to these research studies has
been paid to academic institution and that he
received travel expenses to make a
presentation on the FALCON study at SABCS in
2013.
Yuri Rukazenkov has disclosed that he is a
salaried employee of AstraZeneca and owns
AstraZeneca stock.
Bardia
Dr. Bardia has no relevant financial
relationships to disclose.
Borger
Dr. Borger has disclosed that he receives
royalty for licensing Snapshot assay to
Bioreference Laboratories (BRL).
Aditya
Darrell
P1-13-03
P1-13-03
P1-13-03
P1-13-03
P1-13-03
P1-13-03
P1-13-03
P1-13-03
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Association of PIK3CA mutation with clinical
response to specific endocrine therapies in
metastatic hormone receptor positive (HR+)
breast cancer
Ellisen
Dr. Ellisen has disclosed that he receives
royalty for licensing Snapshot assay to
Bioreference Laboratories (BRL). He also
disclosed that he is a paid consultant to BRL
which has licensed Snapshot.
Steven
Isakoff
Dr. Isakoff has disclosed that he receives
research support from Genentech.
Dejan
Juric
Dr. Juric has no relevant financial relationships
to disclose.
Douglas
Micalizzi
Dr. Micalizzi has no relevant financial
relationships to disclose.
Beverly
Moy
Dr. Moy has no relevant financial relationships
to disclose.
Andrzej
Niemierko
Dr. Niemierko has no relevant financial
relationships to disclose.
Kerry
Reynolds
Dr. Reynolds has no relevant financial
relationships to disclose.
Vora
Dr. Vora has no relevant financial relationships
to disclose.
Leif
Sadhna
P1-13-04
P1-13-04
P1-13-04
P1-13-04
P1-13-04
P1-13-04
P1-13-04
P1-13-04
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Extermann
Dr. Extermann has disclosed that she has a
contract with GTx research.
Hancock
Mr. Hancock has disclosed he is an employee
of and has stock and stock options in GTx.
Michael
Hassett
Dr. Hassett has no relevant financial
relationships to disclose.
Mary Ann
Johnston
Dr. Johnston has disclosed she is an employee
of and has stock and stock options in GTx.
Nancy
Lin
Dr. Lin has disclosed that she receives research
funding from Synta.
Jane
Liu
Dr. Liu has disclosed that she has a contract
with GTx research.
Beth
Overmoyer
Dr. Overmoyer has no relevant financial
relationships to disclose.
Leroy
Parker
Dr. Parker has no relevant financial
relationships to disclose.
Martine
Michael
P1-13-04
P1-13-04
P1-13-04
P1-13-04
P1-13-04
P1-13-05
P1-13-05
P1-13-05
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Enobosarm for the treatment of metastatic,
estrogen and androgen receptor positive, breast
cancer. Final results of the primary endpoint
and current progression free survival
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Partridge
Dr. Partridge has no relevant financial
relationships to disclose.
Sanz-Altimira
Dr. Sanz-Altimira has disclosed that he has a
contract with GTx research.
Susan
Small
Ms. Small has disclosed she is an employee of
and has stock and stock options in GTx.
Ryan
Taylor
Dr. Taylor has disclosed she is an employee of
and has stock and stock options in GTx.
Eric
Winer
Dr. Winer has no relevant financial
relationships to disclose.
Diana
Crivellari
Ms. Crivellari has no relevant financial
relationships to disclose.
Sara
Gagno
Ms. Gagno has no relevant financial
relationships to disclose.
Giampietro
Gasparini
Giampietro Gasparini has no relevant financial
relationships to disclose.
Ann
Pedro
P1-13-05
P1-13-05
P1-13-05
P1-13-05
P1-13-05
P1-13-06
P1-13-06
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Role of pharmacogenetics in metastatic breast
cancer (MBC) patients treated with exemestane
as first-line hormonal therapy. An Italian
multicentre study
Impact of visceral metastases on treatment
patterns for hormone-receptor-positive
(HR+)/human epidermal growth factor receptor2-negative (HER2-) metastatic breast cancer
(mBC)
Impact of visceral metastases on treatment
patterns for hormone-receptor-positive
(HR+)/human epidermal growth factor receptor2-negative (HER2-) metastatic breast cancer
(mBC)
Mansutti
Mauro Mansutti has no relevant financial
relationships to disclose.
Rossini
Daniele Rossini has no relevant financial
relationships to disclose.
Silvana
Saracchini
Silvana Saracchini has no relevant financial
relationships to disclose.
Donata
Sartori
Donata Sartori has no relevant financial
relationships to disclose.
Zanusso
Chiara Zanusso has no relevant financial
relationships to disclose.
Kageleiry
Mr. Kageleiry has disclosed that he is an
employee of Analysis Group Inc., which
received funding for this research from
Novartis Pharmaceuticals Corporation.
Signorovitch
Dr. Signorovitch has disclosed he is an
employee of Analysis Group Inc., which
received funding for this research from
Novartis Pharmaceuticals Corporation.
Mauro
Daniele
Chiara
Andrew
James
P1-13-06
P1-13-06
P1-13-06
P1-13-06
P1-13-07
P1-13-07
Impact of visceral metastases on treatment
patterns for hormone-receptor-positive
(HR+)/human epidermal growth factor receptor2-negative (HER2-) metastatic breast cancer
(mBC)
Impact of visceral metastases on treatment
patterns for hormone-receptor-positive
(HR+)/human epidermal growth factor receptor2-negative (HER2-) metastatic breast cancer
(mBC)
Impact of visceral metastases on treatment
patterns for hormone-receptor-positive
(HR+)/human epidermal growth factor receptor2-negative (HER2-) metastatic breast cancer
(mBC)
Impact of visceral metastases on treatment
patterns for hormone-receptor-positive
(HR+)/human epidermal growth factor receptor2-negative (HER2-) metastatic breast cancer
(mBC)
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
Elyse
Ruo-Ding
Darren
Jenny
Huifang
Jifeng
Swallow
Ms. Swallow has disclosed she is an employee
of Analysis Group Inc., which received funding
for this research from Novartis
Pharmaceuticals Corporation.
Tan
Dr. Tan has disclosed he is an employee of
Analysis Group Inc., which received funding for
this research from Novartis Pharmaceuticals
Corporation.
Thomason
Mr. Thomason has disclosed he is an employee
of Analysis Group Inc., which received funding
for this research from Novartis
Pharmaceuticals Corporation.
Wang
Dr. Wang has disclosed she is an employee and
stockholder of Novartis Pharmaceuticals
Corporation.
Chen
Huifang Chen has disclosed he is an employee
of AstraZeneca.
Feng
Dr. Feng has no relevant financial relationships
to disclose.
P1-13-07
P1-13-07
P1-13-07
P1-13-07
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
Gu
Kangsheng Gu has no relevant financial
relationships to disclose.
Zefei
Jiang
Dr. Jiang has no relevant financial relationships
to disclose.
Li
Li
Li Li has no relevant financial relationships to
disclose.
Rukazenkov
Yuri Rukazenkov has disclosed that he is an
employee of AstraZeneca.
Kangsheng
Yuri
P1-13-07
P1-13-07
P1-13-07
P1-13-07
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
Shao
Zhimin Shao has no relevant financial
relationships to disclose.
Kunwei
Shen
Kunwei Shen has no relevant financial
relationships to disclose.
Guofang
Sun
Mr. Guofang has disclosed he is an employee
of AstraZeneca.
Tong
Zhongseng Tong has no relevant financial
relationships to disclose.
Zhimin
Zhongseng
P1-13-07
P1-13-07
P1-13-07
P1-13-08
P1-13-08
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
A phase III study of fulvestrant 500 mg versus
250 mg in postmenopausal Chinese women
with advanced breast cancer and disease
progression following failure on prior
antiestrogen or aromatase inhibitor therapy:
Supporting superior clinical benefit for the 500
mg dose
Real-world treatment durations without
chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor
receptor-2-negative (HER2-) metastatic breast
cancer (mBC)
Real-world treatment durations without
chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor
receptor-2-negative (HER2-) metastatic breast
cancer (mBC)
Wang
Xiaojia Wang has no relevant financial
relationships to disclose.
Binghe
Xu
Binghe Xu has no relevant financial
relationships to disclose.
Qingyuan
Zhang
Qingyuan Zhang has no relevant financial
relationships to disclose.
Kageleiry
Mr. Kageleiry has disclosed that he is an
employee of Analysis Group Inc., which
received funding for this research from
Novartis Pharmaceuticals Corporation.
Signorovitch
Dr. Signorovitch has disclosed he is an
employee of Analysis Group Inc., which
received funding for this research from
Novartis Pharmaceuticals Corporation.
Xiaojia
Andrew
James
P1-13-08
P1-13-08
P1-13-08
P1-13-08
P1-14-01
P1-14-01
Real-world treatment durations without
chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor
receptor-2-negative (HER2-) metastatic breast
cancer (mBC)
Real-world treatment durations without
chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor
receptor-2-negative (HER2-) metastatic breast
cancer (mBC)
Real-world treatment durations without
chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor
receptor-2-negative (HER2-) metastatic breast
cancer (mBC)
Real-world treatment durations without
chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor
receptor-2-negative (HER2-) metastatic breast
cancer (mBC)
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
Swallow
Ms. Swallow has disclosed she is an employee
of Analysis Group Inc., which received funding
for this research from Novartis
Pharmaceuticals Corporation.
Tan
Dr. Tan has disclosed he is an employee of
Analysis Group Inc., which received funding for
this research from Novartis Pharmaceuticals
Corporation.
Thomason
Mr. Thomason has disclosed he is an employee
of Analysis Group Inc., which received funding
for this research from Novartis
Pharmaceuticals Corporation.
Wang
Dr. Wang has disclosed she is an employee and
stockholder of Novartis Pharmaceuticals
Corporation.
Hiromitsu
Akabane
Hiromitsu Akabane has no relevant financial
relationships to disclose.
Tomomi
Fujisawa
Tomomii Fujisawa has no relevant financial
relationships to disclose.
Elyse
Ruo-Ding
Darren
Jenny
P1-14-01
P1-14-01
P1-14-01
P1-14-01
P1-14-01
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
Yoshie
Hiroji
Masahiro
Norikazu
Hirofumi
Hasegawa
Dr. Hasegawa has no relevant financial
relationships to disclose.
Iwata
Hiroji Iwata has no relevant financial
relationships to disclose.
Kashiwaba
Massahiro Kashiwaba has no relevant financial
relationships to disclose.
Masuda
Dr. Masuda has disclosed that he is a speaker
for Chugai Pharmacetuical, Eisai, Astra Zeneca,
and Sanofi.
Mukai
Hirofumi Mukai has no relevant financial
relationships to disclose.
P1-14-01
P1-14-01
P1-14-01
P1-14-01
P1-14-01
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
Nakamura
Rikiya Nakamura has no relevant financial
relationships to disclose.
Ohashi
Yasuo Ohashi has disclosed that he is a
consultant for Chugai and Novartis.
Shoichiro
Ohtani
Shoichiro Ohtani has disclosed he is a speaker
for Eisai.
Takehiko
Sakai
Takehiko Sakai has no relevant financial
relationships to disclose.
Taira
Naruto Taira has no relevant financial
relationships to disclose.
Rikiya
Yasuo
Naruto
P1-14-01
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
First report of clinicopathological analysis in
neoadjuvant treatment phase in NEOS: A
randomized study of adjuvant endocrine
therapy with or without chemotherapy for
postmenopausal breast cancer patients who
responded to neoadjuvant letrozole
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Jin-Hee
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Sei-Hyun
P1-14-01
P1-14-01
Tatsuya
Takuhiro
Yutaka
Toyama
Dr. Toyama has no relevant financial
relationships to disclose.
Yamaguchi
Takuhiro Yamaguchi has no relevant financial
relationships to disclose.
Yamamoto
Yutaka Yamamoto has disclosed he receives
research founding: Novartis Pharma.
Ahn
Dr. Ahn has no relevant financial relationships
to disclose.
Ahn
Dr. Ahn has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Gyung-Yub
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Kyung Hae
Gong
Dr. Gong has no relevant financial relationships
to disclose.
Jung
Dr. Jung has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Myoung Joo
Kang
Dr. Kang has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Hak-Hee
Kim
Dr. Kim has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Jeong Eun
Kim
Dr. Kim has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Sung-Bae
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Hee Jin
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Lee
Dr. Lee has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Dae-Hyuk
Moon
Dr. Moon has no relevant financial
relationships to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Ji Hyun
Park
Dr. Park has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Hee Jung
Shin
Dr. Shin has no relevant financial relationships
to disclose.
P1-14-02
Neoadjuvant letrozole and lapatinib is feasible
in Asian postmenopausal women with estrogen
receptor (ER) and human epidermal growth
factor receptor-2 (HER-2) positive breast cancer
[Neo-All-In]: First efficacy and safety report
Byung-Ho
Son
P1-15-01
Association between ischemic cardiac events
and targeting of the internal mammary nodal
region with adjuvant radiation for breast cancer Kent
Griffith
P1-15-01
Association between ischemic cardiac events
and targeting of the internal mammary nodal
region with adjuvant radiation for breast cancer Reshma
Jagsi
Mr. Griffith has no relevant financial
relationships to disclose.
Dr. Jagsi has disclosed that she is an Eviti
(medical advisory board member). She has
also disclosed that she has a contract with
AbbVie (in-kind support of drug and
distribution only for a Phase I trial on which I
am PI; trial itself not industry-funded).
P1-15-01
Association between ischemic cardiac events
and targeting of the internal mammary nodal
region with adjuvant radiation for breast cancer Todd
Koelling
Dr. Koelling has no relevant financial
relationships to disclose.
P1-15-01
Association between ischemic cardiac events
and targeting of the internal mammary nodal
region with adjuvant radiation for breast cancer Adam
Liss
Dr. Liss has no relevant financial relationships
to disclose.
P1-15-01
Association between ischemic cardiac events
and targeting of the internal mammary nodal
region with adjuvant radiation for breast cancer Robin
Marsh
Robin Marsh has no relevant financial
relationships to disclose.
P1-15-01
Association between ischemic cardiac events
and targeting of the internal mammary nodal
region with adjuvant radiation for breast cancer Jean
Moran
Dr. Moran has no relevant financial
relationships to disclose.
Dr. Son has no relevant financial relationships
to disclose.
P1-15-01
P1-15-02
P1-15-02
P1-15-02
P1-15-02
P1-15-02
P1-15-02
P1-15-02
P1-15-02
P1-15-03
P1-15-03
Association between ischemic cardiac events
and targeting of the internal mammary nodal
region with adjuvant radiation for breast cancer
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Utilization of hypofractionated radiation
therapy for early stage breast cancer in women
over 50 years of age
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Pierce
Dr. Pierce has no relevant financial
relationships to disclose.
Gretchen
Ahrendt
Dr. Ahrendt has no relevant financial
relationships to disclose.
Sushil
Beriwal
Dr. Beriwal has no relevant financial
relationships to disclose.
John
Flickinger
Dr. Flickinger has no relevant financial
relationships to disclose.
Dwight
Heron
Dr. Heron has no relevant financial
relationships to disclose.
Kelley
Dr. Kelley has no relevant financial
relationships to disclose.
Lehocky
Mr. Lehocky has no relevant financial
relationships to disclose.
Rajagopalan
Dr. Rajagopalan has no relevant financial
relationships to disclose.
Sukumvanich
Dr. Sukumvanich has no relevant financial
relationships to disclose.
Albarracin
Dr. Albarracin has no relevant financial
relationships to disclose.
Allen
Dr. Allen has no relevant financial relationships
to disclose.
Lori
Joseph
Craig
Malolan
Paniti
Constance
Pamela
P1-15-03
P1-15-03
P1-15-03
P1-15-03
P1-15-03
P1-15-03
P1-15-03
P1-15-04
P1-15-04
P1-15-04
P1-15-04
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
Long term outcomes in patients with phyllodes
tumor of the breast: The UT MD Anderson
experience
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
Brewster
Dr. Brewster has no relevant financial
relationships to disclose.
Guadagnolo
Dr. Guadagnolo has no relevant financial
relationships to disclose.
Hunt
Dr. Hunt has no relevant financial relationships
to disclose.
Porche
Bobbi Porche has no relevant financial
relationships to disclose.
Shaitelman
Dr. Shaitelman has no relevant financial
relationships to disclose.
Welela
Tereffe
Dr. Tereffe has no relevant financial
relationships to disclose.
Wendy
Woodward
Dr. Woodward has no relevant financial
relationships to disclose.
Suzanne
Evans
Ms. Evans has no relevant financial
relationships to disclose.
Gross
Cary Gross has no relevant financial
relationships to disclose.
Haffty
Dr. Haffty has no relevant financial
relationships to disclose.
Mougalian
Dr. Mougalian has no relevant financial
relationships to disclose.
Abenaa
B Ashleigh
Kelly
Bobbi
Simona
Cary
Bruce
Sarah
P1-15-04
P1-15-04
P1-15-04
P1-15-04
P1-15-05
P1-15-05
P1-15-05
P1-15-05
P1-15-05
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
The adoption of hypofractionated whole breast
irradiation for early-stage breast cancer: A
national cancer data base analysis
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Rutter
Mr. Rutter has no relevant financial
relationships to disclose.
Soulos
Ms. Soulos has no relevant financial
relationships to disclose.
Wang
Elyn Wang has no relevant financial
relationships to disclose.
James
Yu
Mr. Yu has no relevant financial relationships
to disclose.
Federica
Cattani
Ms. Cattani has no relevant financial
relationships to disclose.
Veronica
Dell'acqua
Dr. Dell'acqua has no relevant financial
relationships to disclose.
Samantha
Dicuonzo
Dr. Dicuonzo has no relevant financial
relationships to disclose.
Cristiana
Fodor
Ms. Fodor has no relevant financial
relationships to disclose.
Roberta
Lazzari
Dr. Lazzari has no relevant financial
relationships to disclose.
Charles
Pamela
Elyn
P1-15-05
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
Long-term outcome of electron intraoperative
boost and hypofractionated external beam
radiotherapy after breast-conserving surgery in
premenopausal women
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Federica
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Veronica
P1-15-05
P1-15-05
P1-15-05
P1-15-05
P1-15-05
P1-15-05
Leonardi
Dr. Leonardi has no relevant financial
relationships to disclose.
Luini
Dr. Luini has no relevant financial relationships
to disclose.
Anna
Morra
Dr. Morra has no relevant financial
relationships to disclose.
Roberto
Orecchia
Dr. Orecchia has no relevant financial
relationships to disclose.
Floriana
Pansini
Floriana Pansini has no relevant financial
relationships to disclose.
Elena
Rondi
Ms. Rondi has no relevant financial
relationships to disclose.
Santoro
Luigi Santoro has no relevant financial
relationships to disclose.
Cattani
Ms. Cattani has no relevant financial
relationships to disclose.
Dell'acqua
Dr. Dell'acqua has no relevant financial
relationships to disclose.
Maria Cristina
Alberto
Luigi
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Samantha
Dicuonzo
Dr. Dicuonzo has no relevant financial
relationships to disclose.
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Roberta
Lazzari
Dr. Lazzari has no relevant financial
relationships to disclose.
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Maria Cristina
Leonardi
Dr. Leonardi has no relevant financial
relationships to disclose.
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Alberto
Luini
Dr. Luini has no relevant financial relationships
to disclose.
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Patrick
Maisonneuve
Mr. Maisonneuve has no relevant financial
relationships to disclose.
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Mauro
Mastropasqua
Dr. Mastropasqua has no relevant financial
relationships to disclose.
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Anna
Morra
Dr. Morra has no relevant financial
relationships to disclose.
P1-15-06
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Roberto
Orecchia
Dr. Orecchia has no relevant financial
relationships to disclose.
Rotmensz
Ms. Rotmensz has no relevant financial
relationships to disclose.
Bazani
Ms. Bazani has no relevant financial
relationships to disclose.
Cambria
Raffaella Cambria has no relevant financial
relationships to disclose.
P1-15-06
P1-15-07
P1-15-07
Lobular histology and partial breast irradiation:
To what extent is it a cautionary parameter?
Nicole
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Alessia
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Raffaella
P1-15-07
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
Simultaneous integrated boost incorporated
into a hypofractionated regimen using
tomoDirect: Acute toxicity assessment
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Elias
P1-15-07
P1-15-07
P1-15-07
P1-15-07
P1-15-07
P1-15-07
P1-15-07
P1-15-07
Cattani
Ms. Cattani has no relevant financial
relationships to disclose.
Dell'Acqua
Dr. Dell'Acqua has no relevant financial
relationships to disclose.
Dicuonzo
Dr. Dicuonzo has no relevant financial
relationships to disclose.
Lazzari
Dr. Lazzari has no relevant financial
relationships to disclose.
Leonardi
Dr. Leonardi has no relevant financial
relationships to disclose.
Rosa
Luraschi
Ms. Luraschi has no relevant financial
relationships to disclose.
Anna
Morra
Dr. Morra has no relevant financial
relationships to disclose.
Roberto
Orecchia
Dr. Orecchia has no relevant financial
relationships to disclose.
Santoro
Luigi Santoro has no relevant financial
relationships to disclose.
Assaf
Mr. Assaf has no relevant financial
relationships to disclose.
Federica
Veronica
Samantha
Roberta
Maria Cristina
Luigi
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Hakima
Badaoui
Hakima Badaoui has no relevant financial
relationships to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Yazid
Belkacemi
Yazid Belkacemi has no relevant financial
relationships to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Veronique
Bigorie
Veronique Bigorie has no relevant financial
relationships to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Romain
Bosc
Romain Bosc has no relevant financial
relationships to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Ryan
Bouaita
Mr. Bouaita has no relevant financial
relationships to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Elie
Calitchi
Elie Calitchi has no relevant financial
relationships to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Emmanuel
Itti
Mr. Itti has no relevant financial relationships
to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Quiong
Pan
Quiong Pan has no relevant financial
relationships to disclose.
P1-15-08
Tangential fields (TgF) breast radiotherapy (RT):
Prospective evaluation of the dose distribution
in the sentinel lymph node area (SLNa) as
determined intra operatively by clip placement Frederic
Pigneur
Mr. Pigneur has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Yazid
Belkacemi
Yazid Belkacemi has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Julie
Hermans
Ms. Hermans has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Orit
Kaidar-Person
Orit Kaidar-Person has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Ian
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Abraham
Kunkler
Dr. Kunkler has no relevant financial
relationships to disclose.
Kuten
Mr. Kuten has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Mahmut
Ozsahin
Mahmut Ozsahin has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Philippe
Poortmans
Mr. Poortmans has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Nicola
Russell
Ms. Russell has no relevant financial
relationships to disclose.
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Maria-Clara
P1-15-09
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Geertjan
P1-15-09
P1-15-10
P1-15-10
P1-15-10
P1-15-10
P1-15-10
Patterns of practice of regional node irradiation
in the sentinel node biopsy era: Results of the
nodal radiotherapy (NORA) survey. On behalf of
the EORTC Breast Working Party of the
Radiation Oncology Group (ROG)
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Valli
Ms. Valli has no relevant financial relationships
to disclose.
van Tienhoven
Geertjan van Tienhoven has no relevant
financial relationships to disclose.
Helen
Westenberg
Ms. Westenberg has no relevant financial
relationships to disclose.
Rachel
Blitzblau
Dr. Blitzblau has no relevant financial
relationships to disclose.
Rachel
Greenup
Dr. Greenup has no relevant financial
relationships to disclose.
Horton
Dr. Horton has no relevant financial
relationships to disclose.
Houck
Mr. Houck has no relevant financial
relationships to disclose.
Hwang
Dr. Hwang has disclosed that she is on the
advisory committee for Genomic Health Inc.
Janet
Kevin
Eun-Sil
P1-15-10
P1-15-10
P1-15-10
P1-15-11
P1-15-11
P1-15-11
P1-15-11
P1-15-11
P1-15-11
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Low utilization of hypofractionated
radiotherapy for the treatment of early-stage
breast cancer in the US
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Mowery
Dr. Mowery has no relevant financial
relationships to disclose.
Palta
Dr. Palta has no relevant financial relationships
to disclose.
Julie
Sosa
Dr. Sosa has no relevant financial relationships
to disclose.
Deanna
Attai
Dr. Attai has no relevant financial relationships
to disclose.
Ernest
Butler
Mr. Butler has no relevant financial
relationships to disclose.
John
Einck
Dr. Einck has no relevant financial relationships
to disclose.
Steven
Finkelstein
Dr. Finkelstein has no relevant financial
relationships to disclose.
Ben
Han
Dr. Han has no relevant financial relationships
to disclose.
Hong
Dr. Hong has no relevant financial relationships
to disclose.
Yvonne
Manisha
Robert
P1-15-11
P1-15-11
P1-15-11
P1-15-11
P1-15-11
P1-15-11
P1-15-11
P1-15-11
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Lydia
Komarnicky
Robert
Kuske
Dr. Komarnicky has no relevant financial
relationships to disclose.
Dr. Kuske has disclosed that he is on the
Advisory Board of Elekta and Cianna Medical unpaid. He has also disclosed he has minor
stock options in Cianna Medical.
Maureen
Lyden
Ms. Lyden has no relevant financial
relationships to disclose.
Sudha
Mahalingam
Dr. Mahalingam has no relevant financial
relationships to disclose.
Constantine
Mantz
Dr. Mantz has no relevant financial
relationships to disclose.
Nadim
Nasr
Dr. Nasr has no relevant financial relationships
to disclose.
Stephen
Nigh
Dr. Nigh has no relevant financial relationships
to disclose.
Jondavid
Pollock
Dr. Pollock has no relevant financial
relationships to disclose.
P1-15-11
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
Recurrence rates, stratified by age and
histology, for accelerated partial breast
irradiation using strut-based brachytherapy: A
report on 1005 patients
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Bonnie
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Thy Thy
Do
Dr. Do has no relevant financial relationships to
disclose.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Mary
Feng
Dr. Feng has no relevant financial relationships
to disclose.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Erin
Gillespie
Dr. Gillespie has no relevant financial
relationships to disclose.
P1-15-11
P1-15-11
P1-15-11
P1-15-11
Reiff
Dr. Reiff has no relevant financial relationships
to disclose.
Scanderbeg
Dr. Scanderberg has disclosed he is a
consultant for Cianna Medical.
Margaret
Snyder
Ms. Snyder has disclosed she owns Baxter
Healthcare stock
Jon
Strasser
Catheryn
Yashar
Dr. Strasser has no relevant financial
relationships to disclose.
Dr. Yashar has disclosed that he is on the
advisory board of Cianna Medical - unpaid. He
also disclosed he receives honoraria from
Cianna Medical.
DePalma
Ms. DePalma has no relevant financial
relationships to disclose.
Jay
Daniel
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Kent
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Yolanda
Helfrich
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Reshma
Jagsi
Dr. Helfrich has disclosed that he is a
consultant for Galderma.
Dr. Jagsi has disclosed that she has contracts
with NIH, American Cancer Society, Breast
Cancer Research Foundation, and National
Comprehensive Cancer Network. She also
disclosed Provision of drug only from Abbvie
Pharmaceuticals for a Phase I trial (trial itself
investigator-initiated and funded by BCRF not
industry). Eviti Medical Advisory Board. Chair
ROI Research Committee, Chair ASCO Ethics
Committee.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Nirav
Kapadia
Dr. Kapadia has no relevant financial
relationships to disclose.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Adam
Liss
Dr. Liss has no relevant financial relationships
to disclose.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Alexandria
Miller
Alexandria Miller has no relevant financial
relationships to disclose.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Lori
Pierce
Dr. Pierce has no relevant financial
relationships to disclose.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Dean
Shumway
Dr. Shumway has no relevant financial
relationships to disclose.
P1-15-12
Development of a photonumeric scale for acute
radiation dermatitis in breast cancer patients
Eleanor
Walker
Dr. Walker has no relevant financial
relationships to disclose.
Griffith
Mr. Griffith has no relevant financial
relationships to disclose.
P1-15-13
P1-15-13
P1-15-13
P1-15-13
P1-15-13
P1-15-13
P1-15-15
P1-15-15
P1-15-15
P1-15-15
P1-15-15
Short term toxicity of intra-operative
radiotherapy for patients with breast cancer
treated at a single center
Short term toxicity of intra-operative
radiotherapy for patients with breast cancer
treated at a single center
Short term toxicity of intra-operative
radiotherapy for patients with breast cancer
treated at a single center
Short term toxicity of intra-operative
radiotherapy for patients with breast cancer
treated at a single center
Short term toxicity of intra-operative
radiotherapy for patients with breast cancer
treated at a single center
Short term toxicity of intra-operative
radiotherapy for patients with breast cancer
treated at a single center
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Bitterman
Arie Bitterman has no relevant financial
relationships to disclose.
Eitan
Shiloni Eitan has no relevant financial
relationships to disclose.
Leviov
Ms. Leviov has no relevant financial
relationships to disclose.
Shai
Ayelet Shai has no relevant financial
relationships to disclose.
Steiner
Ms. Steiner has no relevant financial
relationships to disclose.
Maoz
Zur
Maoz Zur has no relevant financial
relationships to disclose.
Dustin
Boothe
Dr. Boothe has no relevant financial
relationships to disclose.
KS Clifford
Chao
Dr. Chao has no relevant financial relationships
to disclose.
Ginter
Dr. Ginter has no relevant financial
relationships to disclose.
Hayes
Dr. Hayes has no relevant financial
relationships to disclose.
Nagar
Dr. Nagar has no relevant financial
relationships to disclose.
Arie
Shiloni
Michelle
Ayelet
Mariana
Paula
Mary Katherine
Himanshu
P1-15-15
P1-15-15
P1-15-15
P1-15-15
P1-15-15
P1-15-16
P1-15-16
P1-15-16
P1-15-17
P1-15-17
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
Disease-free survival according to the use of
postmastectomy radiation therapy after
neoadjuvant chemotherapy
The utilization of hypofractionated breast
radiotherapy in the United States between 2003
and 2011
The utilization of hypofractionated breast
radiotherapy in the United States between 2003
and 2011
The utilization of hypofractionated breast
radiotherapy in the United States between 2003
and 2011
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Nori
Dr. Nori has no relevant financial relationships
to disclose.
Shin
Dr. Shin has no relevant financial relationships
to disclose.
Sison
Dr. Sison has no relevant financial relationships
to disclose.
Smith
Dr. Smith has no relevant financial
relationships to disclose.
Vahdat
Dr. Vahdat has no relevant financial
relationships to disclose.
Yasmin
Hasan
Dr. Hasan has no relevant financial
relationships to disclose.
Dezheng
Huo
Dr. Huo has no relevant financial relationships
to disclose.
Katharine
Yao
Dr. Yao has no relevant financial relationships
to disclose.
Ergun
Ahunbay
Dr. Ahunbay has no relevant financial
relationships to disclose.
Bergom
Dr. Bergom has no relevant financial
relationships to disclose.
Dattatreyudu
Sandra
Cristina
Michael
Linda
Carmen
P1-15-17
P1-15-17
P1-15-17
P1-15-17
P1-15-17
P1-15-17
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Adam
Currey
Dr. Currey has no relevant financial
relationships to disclose.
Kristofer
Kainz
Dr. Kainz has no relevant financial relationships
to disclose.
Kelly
Dr. Kelly has no relevant financial relationships
to disclose.
Li
Dr. Li has no relevant financial relationships to
disclose.
Morrow
Dr. Morrow has no relevant financial
relationships to disclose.
Prior
Dr. Prior has no relevant financial relationships
to disclose.
Tracy
X Allen
Natalya
Phillip
P1-15-17
P1-15-17
P1-15-18
P1-15-18
P1-15-18
P1-15-18
P1-15-19
P1-15-19
P1-15-19
P1-15-19
P1-15-19
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Sustained acceptable cosmetic outcomes and
local control following accelerated partial breast
irradiation using CT-guided IMRT in the prone
position: Results from a phase I/II feasibility
study
Evaluation of separation techniques and
dosimetry of the inframammary fold during
whole breast radiation therapy
Evaluation of separation techniques and
dosimetry of the inframammary fold during
whole breast radiation therapy
Evaluation of separation techniques and
dosimetry of the inframammary fold during
whole breast radiation therapy
Evaluation of separation techniques and
dosimetry of the inframammary fold during
whole breast radiation therapy
Effects of statin use on skin toxicity during
breast radiation therapy
Effects of statin use on skin toxicity during
breast radiation therapy
Effects of statin use on skin toxicity during
breast radiation therapy
Effects of statin use on skin toxicity during
breast radiation therapy
Effects of statin use on skin toxicity during
breast radiation therapy
Alonzo
Walker
Dr. Walker has no relevant financial
relationships to disclose.
Julia
White
Dr. White has no relevant financial
relationships to disclose.
Jason
Cheng
Dr. Cheng has no relevant financial
relationships to disclose.
Peter
Guion
Mr. Guion has no relevant financial
relationships to disclose.
Jones
Dr. Jones has no relevant financial relationships
to disclose.
Guy
Aparna
Kesarwala
Christopher
Chen
Marlow
Hernandez
Scott
Lieberman
Leah
Roberts
Elizabeth
Stone
Dr. Kesarwala has no relevant financial
relationships to disclose.
Dr. Chen has no relevant financial relationships
to disclose.
Dr. Hernandez has no relevant financial
relationships to disclose.
Dr. Lieberman has no relevant financial
relationships to disclose.
Ms. Roberts has no relevant financial
relationships to disclose.
Dr. Stone has no relevant financial
relationships to disclose.
P1-15-20
P1-15-20
P1-15-20
P1-15-20
P1-15-20
P1-15-20
P1-15-21
P1-15-21
P1-15-21
P1-15-21
P1-15-21
Prospective study of proton radiotherapy for
treatment of regional lymphatics in breast
cancer
Prospective study of proton radiotherapy for
treatment of regional lymphatics in breast
cancer
Prospective study of proton radiotherapy for
treatment of regional lymphatics in breast
cancer
Prospective study of proton radiotherapy for
treatment of regional lymphatics in breast
cancer
Prospective study of proton radiotherapy for
treatment of regional lymphatics in breast
cancer
Prospective study of proton radiotherapy for
treatment of regional lymphatics in breast
cancer
Safety of eribulin mesylate and concomitant
palliative radiotherapy for metastatic breast
cancer: A single-center experience
Safety of eribulin mesylate and concomitant
palliative radiotherapy for metastatic breast
cancer: A single-center experience
Safety of eribulin mesylate and concomitant
palliative radiotherapy for metastatic breast
cancer: A single-center experience
Safety of eribulin mesylate and concomitant
palliative radiotherapy for metastatic breast
cancer: A single-center experience
Safety of eribulin mesylate and concomitant
palliative radiotherapy for metastatic breast
cancer: A single-center experience
Bradley
Dr. Bradley has no relevant financial
relationships to disclose.
Dagan
Dr. Dagan has no relevant financial
relationships to disclose.
Ho
Dr. Ho has no relevant financial relationships to
disclose.
Li
Dr. Li has no relevant financial relationships to
disclose.
Mendenhall
Dr. Mendenhall has no relevant financial
relationships to disclose.
Christopher
Morris
Mr. Morris has no relevant financial
relationships to disclose.
Carla
De Luca Cardillo
Dr. De Luca Cardillo has no relevant financial
relationships to disclose.
Beatrice
Detti
Dr. Detti has no relevant financial relationships
to disclose.
Di Cataldo
Dr. Di Cataldo has no relevant financial
relationships to disclose.
Livi
Mr. Livi has no relevant financial relationships
to disclose.
Meattini
Dr. Meattini has no relevant financial
relationships to disclose.
Julie
Roi
Meng Wei
Zuofeng
Nancy
Vanessa
Lorenzo
Icro
P1-15-21
Safety of eribulin mesylate and concomitant
palliative radiotherapy for metastatic breast
cancer: A single-center experience
P1-15-22
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Hiromi
P1-15-22
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Yuko
P1-15-22
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Masahiro
P1-15-22
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Jun
P1-15-22
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Yoshio
P1-15-22
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Kazuhiko
P1-15-22
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Hiroshi
Vieri
Scotti
Dr. Scotti has no relevant financial
relationships to disclose.
Fuchikami
Dr. Fuchikami has no relevant financial
relationships to disclose.
Inoue
Dr. Inoue has no relevant financial
relationships to disclose.
Kato
Dr. Kato has no relevant financial relationships
to disclose.
Kubota
Jun Kubota has no relevant financial
relationships to disclose.
Mizuno
Dr. Mizuno has no relevant financial
relationships to disclose.
Sato
Dr. Sato has no relevant financial relationships
to disclose.
Seto
Dr. Seto has no relevant financial relationships
to disclose.
P1-15-22
P1-15-22
P1-15-23
P1-15-23
P1-15-23
P1-15-23
P1-15-23
P1-15-23
P1-15-23
P1-15-23
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Takahiro
Comparison of cardiac dose between
accelerated partial-breast irradiation and wholebreast irradiation in breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Shimo
Takahiro Shimo has no relevant financial
relationships to disclose.
Takeda
Dr. Takeda has no relevant financial
relationships to disclose.
Ahn
Dr. Ahn has no relevant financial relationships
to disclose.
Cho
Dr. Cho has no relevant financial relationships
to disclose.
Choi
Dr. Choi has no relevant financial relationships
to disclose.
Huh
Dr. Huh has no relevant financial relationships
to disclose.
Im
Dr. Im has no relevant financial relationships to
disclose.
Won Ho
Kil
Dr. Kil has no relevant financial relationships to
disclose.
Seok Won
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Jeong Eon
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Naoko
Jin Seok
Eun Yoon
Doo Ho
Seung Jae
Young-Hyuck
P1-15-23
P1-15-23
P1-15-23
P1-15-23
P1-15-24
P1-15-24
P1-15-24
P1-15-24
P1-15-25
P1-15-25
P1-15-25
P1-16-01
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Clinical outcomes according to elective nodal
irradiation and molecular subtypes in high risk
N1 breast cancer patients
Skin toxicities of obese African American breast
cancer patients treated with hypofractionated
radiation therapy
Skin toxicities of obese African American breast
cancer patients treated with hypofractionated
radiation therapy
Skin toxicities of obese African American breast
cancer patients treated with hypofractionated
radiation therapy
Skin toxicities of obese African American breast
cancer patients treated with hypofractionated
radiation therapy
Phase II trial of hypofractionated post
mastectomy radiation
Phase II trial of hypofractionated post
mastectomy radiation
Phase II trial of hypofractionated post
mastectomy radiation
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Nam
Dr. Nam has no relevant financial relationships
to disclose.
Park
Dr. Park has no relevant financial relationships
to disclose.
Park
Dr. Park has no relevant financial relationships
to disclose.
Yu
Dr. Yu has no relevant financial relationships to
disclose.
Amin
Dr. Amin has no relevant financial relationships
to disclose.
Amy
Collins
Ms. Collins has no relevant financial
relationships to disclose.
Gregory
Dyson
Dr. Dyson has no relevant financial
relationships to disclose.
Arun
Paul
Bruce
Haffty
Atif
Khan
Matthew
Poppe
Dr. Paul has no relevant financial relationships
to disclose.
Dr. Haffty has no relevant financial
relationships to disclose.
Dr. Khan has no relevant financial relationships
to disclose.
Dr. Poppe has no relevant financial
relationships to disclose.
Aydogan
Dr. Aydogan has no relevant financial
relationships to disclose.
Seok Jin
Won
Yeon Hee
Jeong Il
Neha
Fatih
P1-16-01
P1-16-01
P1-16-01
P1-16-01
P1-16-01
P1-16-01
P1-16-01
P1-16-02
P1-16-02
P1-16-02
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Effect of margin width on local recurrence in
invasive lobular carcinoma treated with
multimodality therapy
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Barry
Dr. Barry has no relevant financial relationships
to disclose.
Brock
Dr. Brock has no relevant financial
relationships to disclose.
Golshan
Dr. Golshan has no relevant financial
relationships to disclose.
Metzger-Filho
Dr. Metzger-Filho has no relevant financial
relationships to disclose.
Sagara
Dr. Sagara has no relevant financial
relationships to disclose.
Ines
Vaz-Luis
Dr. Vaz Luis has no relevant financial
relationships to disclose.
Eric
Winer
Dr. Winer has no relevant financial
relationships to disclose.
Nicole
Dawson
Dr. Dawson has no relevant financial
relationships to disclose.
Robyn
Dvorak
Ms. Dvorak has no relevant financial
relationships to disclose.
Foster
Dr. Foster has no relevant financial
relationships to disclose.
William
Jane
Mehra
Otto
Yasuaki
Nova
P1-16-02
P1-16-02
P1-16-02
P1-16-02
P1-16-02
P1-16-02
P1-16-02
P1-16-03
P1-16-03
P1-16-03
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Multidisciplinary breast cancer care is
associated with a higher rate of breast
conservation in comparison with nonmultidisciplinary care
Residual disease after breast conservation
surgery: To excise or not to excise?
Residual disease after breast conservation
surgery: To excise or not to excise?
Residual disease after breast conservation
surgery: To excise or not to excise?
Gomez
Dr. Gomez has no relevant financial
relationships to disclose.
Hoyt
Dr. Hoyt has no relevant financial relationships
to disclose.
Sara
Hurvitz
Dr. Hurvitz has no relevant financial
relationships to disclose.
Amy
Kusske
Dr. Kusske has no relevant financial
relationships to disclose.
Susan
McCloskey
Dr. McCloskey has no relevant financial
relationships to disclose.
Charles
Tseng
Dr. Tseng has no relevant financial
relationships to disclose.
Caitlin
Anne
Pin-Chieh
Wang
Susan
Boolbol
Catherine
Campo
Sarah
Cate
Dr. Wang has no relevant financial
relationships to disclose.
Dr. Boolbol has no relevant financial
relationships to disclose.
Dr. Campo has no relevant financial
relationships to disclose.
Dr. Cate has no relevant financial relationships
to disclose.
P1-16-03
P1-16-03
P1-16-03
P1-16-03
P1-16-04
P1-16-04
P1-16-04
P1-16-04
P1-16-04
P1-16-05
P1-16-05
P1-16-05
Residual disease after breast conservation
surgery: To excise or not to excise?
Residual disease after breast conservation
surgery: To excise or not to excise?
Residual disease after breast conservation
surgery: To excise or not to excise?
Residual disease after breast conservation
surgery: To excise or not to excise?
Intraoperative ultrasound-guided breast
conserving surgery for palpable and
nonpalpable breast cancer
Intraoperative ultrasound-guided breast
conserving surgery for palpable and
nonpalpable breast cancer
Intraoperative ultrasound-guided breast
conserving surgery for palpable and
nonpalpable breast cancer
Intraoperative ultrasound-guided breast
conserving surgery for palpable and
nonpalpable breast cancer
Intraoperative ultrasound-guided breast
conserving surgery for palpable and
nonpalpable breast cancer
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Alyssa
Gillego
Priyanka
Mittar
Erika
Reategui
John
Rescigno
Dr. Gillego has no relevant financial
relationships to disclose.
Dr. Mittar has no relevant financial
relationships to disclose.
Dr. Reategui has no relevant financial
relationships to disclose.
Dr. Rescigno has no relevant financial
relationships to disclose.
Bahadir
Dr. Bahadir has no relevant financial
relationships to disclose.
Emre
Dr. Emre has no relevant financial relationships
to disclose.
Karadeniz Cakmak
Dr. Karadeniz Cakmak has no relevant financial
relationships to disclose.
Ozkan
Dr. Ozkan has no relevant financial
relationships to disclose.
Tascilar
Dr. Tascilar has no relevant financial
relationships to disclose.
J
Dixon
Dr. Dixon has no relevant financial
relationships to disclose.
Dhananjay
Kulkarni
Dr. Kulkarni has no relevant financial
relationships to disclose.
Catherine
Kusnick
Dr. Kusnick has disclosed he is a consultant and
owns stock options.
Burak
Ali
Guldeniz
Selcuk
Oge
P1-16-05
P1-16-05
P1-16-05
P1-16-05
P1-16-05
P1-16-05
P1-16-06
P1-16-06
P1-16-06
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Lorna
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Talha
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Intra-operative imaging of surgical margins in
breast conserving surgery using localized tissue
dielectric response
Margin Probe device is able to reduce reexcision rate of breast conserving surgery in
invasive and pre-invasive breast cancer
independent from any patient or tumor related
factors
Margin Probe device is able to reduce reexcision rate of breast conserving surgery in
invasive and pre-invasive breast cancer
independent from any patient or tumor related
factors
Margin Probe device is able to reduce reexcision rate of breast conserving surgery in
invasive and pre-invasive breast cancer
independent from any patient or tumor related
factors
Renshaw
Ms. Renshaw has no relevant financial
relationships to disclose.
Moshe
Sarfaty
Ramaswamy
Sreenivasam
Dr. Saleem has no relevant financial
relationships to disclose.
Dr. Sarfaty has disclosed he is an employee and
receives salary from LS Biopath. He also
disclosed an employee of L S Biopath, he owns
stock and stock options.
Dr. Sreenivasam has disclosed he receives
consulting fees and as a consultant has stock
options.
Jeremy
Thomas
Mr. Thomas has no relevant financial
relationships to disclose.
Oliver
Young
Dr. Young has no relevant financial
relationships to disclose.
Jens
Blohmer
Prof. Blohmer has disclosed he is on an
advisory board.
Julia
de Grahl
Dr. de Grahl has no relevant financial
relationships to disclose.
Gross
Dr. Gross has no relevant financial
relationships to disclose.
Jessica
Saleem
P1-16-06
P1-16-06
P1-16-07
P1-16-07
P1-16-07
P1-16-07
P1-16-07
P1-16-08
P1-16-08
P1-16-08
P1-16-08
Margin Probe device is able to reduce reexcision rate of breast conserving surgery in
invasive and pre-invasive breast cancer
independent from any patient or tumor related
factors
Margin Probe device is able to reduce reexcision rate of breast conserving surgery in
invasive and pre-invasive breast cancer
independent from any patient or tumor related
factors
Translating the concept of intrinsic subtypes
into an oncoplastic cohort of more than 1000
patients-predictors of recurrence and survival
Translating the concept of intrinsic subtypes
into an oncoplastic cohort of more than 1000
patients-predictors of recurrence and survival
Translating the concept of intrinsic subtypes
into an oncoplastic cohort of more than 1000
patients-predictors of recurrence and survival
Translating the concept of intrinsic subtypes
into an oncoplastic cohort of more than 1000
patients-predictors of recurrence and survival
Translating the concept of intrinsic subtypes
into an oncoplastic cohort of more than 1000
patients-predictors of recurrence and survival
Breast contour preserving surgery; a matter of
patient age?
Breast contour preserving surgery; a matter of
patient age?
Breast contour preserving surgery; a matter of
patient age?
Breast contour preserving surgery; a matter of
patient age?
Julia
Tanko
Ms. Tanko has no relevant financial
relationships to disclose.
Ragna
Voelker
Dr. Voelker has no relevant financial
relationships to disclose.
Stephanie
Kellersmann
Ms. Kellersmann has no relevant financial
relationships to disclose.
Peter
Kern
Dr. Kern has no relevant financial relationships
to disclose.
Kimmig
Dr. Kimmig has no relevant financial
relationships to disclose.
Knispel
Ms. Knispel has no relevant financial
relationships to disclose.
Rainer
Sarah
Mahdi
Rezai
Marie-Jeanne
Baas-Vrancken Peeters
Marc
Mureau
Carolien
Smorenburg
Annelotte
van Bommel
Dr. Rezai has no relevant financial relationships
to disclose.
Ms. Baas-Vrancken Peeters has no relevant
financial relationship to disclose.
Mr. Mureau has no relevant financial
relationships to disclose.
Ms. Smorenburg has no relevant financial
relationships to disclose.
Annelotte van Bommel has no relevant
financial relationships to disclose.
P1-16-08
P1-16-08
P1-16-09
P1-16-09
P1-16-09
P1-16-09
P1-16-09
P1-16-09
P1-16-09
P1-16-09
P1-16-09
Breast contour preserving surgery; a matter of
patient age?
Breast contour preserving surgery; a matter of
patient age?
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Thijs
van Dalen
Margriet
van der Heiden - van der Loo
Thijs van Dalen has no relevant financial
relationships to disclose.
Ms. van der Heiden - van der Loo has no
relevant financial relationships to disclose.
Muneer
Ahmed
Muneer Ahmed has no relevant financial
relationships to disclose.
Bauke
Anninga
Bauke Anninga has no relevant financial
relationships to disclose.
Michael
Douek
Dr. Douek has no relevant financial
relationships to disclose.
Sumit
Goyal
Sumit Goyal has no relevant financial
relationships to disclose.
Hamed
Dr. Hamed has no relevant financial
relationships to disclose.
Kothari
Ashutosh Kothari has no relevant financial
relationships to disclose.
Kovacs
Dr. Kovacs has no relevant financial
relationships to disclose.
McWililliams
Ms. McWilliams has no relevant financial
relationships to disclose.
Monnypenny
Mr. Monnypenny has no relevant financial
relationships to disclose.
Hisham
Ashutosh
Tibor
Sarah
Ian
P1-16-09
P1-16-09
P1-16-09
P1-16-09
P1-16-09
P1-16-10
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Magnetic sentinel node and occult lesion
localization in breast cancer: Initial results of the
MagSNOLL trial
Pilot study of a passive non-radioactive
electromagnetic wave technology to localize
non-palpable breast lesions
Pankhurst
Dr. Pankhurst has disclosed that he is the cofounder and sits as a non-executive director on
the Board of Directors of Endomagnetics Ltd
(Cambridge, UK).
Sarah
Pinder
Ms. Pinder has no relevant financial
relationships to disclose.
Anand
Purushotham
Dr. Purushotham has no relevant financial
relationships to disclose.
Julie
Scudder
Ms. Scudder has no relevant financial
relationships to disclose.
Phillippa
Young
Ms. Young has no relevant financial
relationships to disclose.
Cox
Dr. Cox has disclosed that he has provided
consulting to Cianna to assist with
development of the Surgical Guidance System.
He has received between $10,000 and $19,999
in consulting fees over the past 12 mos and
expects to receive between $5,000 and $9,999
over the next 12 mos. He has also disclosed
that he is a member of Cianna's speakers'
bureau. He has received between $5,000 and
$9,999 over the past 12 months and expects to
receive a similar amount over the next 12
months for speaking engagements. He also is
the PI of the current study, which is funded by
the sponsor for a total of $5,000 for data
collection from up to 25 patients enrolled
locally.
Quentin
Charles
P1-16-10
P1-16-10
P1-16-10
P1-16-10
P1-16-10
P2-01-01
P2-01-01
P2-01-01
P2-01-01
Pilot study of a passive non-radioactive
electromagnetic wave technology to localize
non-palpable breast lesions
Pilot study of a passive non-radioactive
electromagnetic wave technology to localize
non-palpable breast lesions
Pilot study of a passive non-radioactive
electromagnetic wave technology to localize
non-palpable breast lesions
Pilot study of a passive non-radioactive
electromagnetic wave technology to localize
non-palpable breast lesions
Pilot study of a passive non-radioactive
electromagnetic wave technology to localize
non-palpable breast lesions
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Michelle
Jeff
Ronald
Steven
Melissa
Severine
Emmanuel
Virginie
Loic
Jung
Ms. Jung has no relevant financial relationships
to disclose.
King
Mr. King has no relevant financial relationships
to disclose.
Prati
Dr. Prati has no relevant financial relationships
to disclose.
Shivers
Dr. Shivers has no relevant financial
relationships to disclose.
Themar-Geck
Dr. Themar-Geck has no relevant financial
relationships to disclose.
Alran
Dr. Alran has no relevant financial relationships
to disclose.
Barranger
Dr. Barranger has no relevant financial
relationships to disclose.
Bordes
Dr. Bordes has no relevant financial
relationships to disclose.
Campion
Dr. Campion has no relevant financial
relationships to disclose.
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Charitansky
Dr. Charitansky has no relevant financial
relationships to disclose.
Chauvet
Dr. Chauvet has no relevant financial
relationships to disclose.
Jean-Marc
Classe
Dr. Classe has no relevant financial
relationships to disclose.
Pascaline
De Blaye
Dr. De Blaye has no relevant financial
relationships to disclose.
Pierre Francois
Dupre
Dr. Dupre has no relevant financial
relationships to disclose.
Christelle
Faure
Dr. Faure has no relevant financial
relationships to disclose.
Gwenael
Ferron
Dr. Ferron has no relevant financial
relationships to disclose.
Pierre
Gimbergues
Dr. Gimbergues has no relevant financial
relationships to disclose.
Helene
Marie Pierre
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
P2-01-01
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Gutowski
Dr. Gutowski has no relevant financial
relationships to disclose.
Houvenaeghel
Dr. Houvenaeghel has no relevant financial
relationships to disclose.
Serge
Lasry
Dr. Lasry has no relevant financial relationships
to disclose.
Celine
Lefebvre
Dr. Lefebvre has no relevant financial
relationships to disclose.
Charlotte
Ngo
Dr. Ngo has no relevant financial relationships
to disclose.
Nicolas
Paillocher
Dr. Paillocher has no relevant financial
relationships to disclose.
Jean Francois
Rodier
Dr. Rodier has no relevant financial
relationships to disclose.
Christine
Tunon de Lara
Dr. Tunon de Lara has no relevant financial
relationships to disclose.
Marian
Gilles
P2-01-01
P2-01-02
P2-01-02
P2-01-02
P2-01-02
P2-01-02
Sentinel node surgery after neoadjuvant
chemotherapy in patient with axillary node
involvement: The French GANEA 2 prospective
multi-institutional trial
Jean Luc
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Gretchen
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Karla
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Judy
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Kelly
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Linda
Veraeghe
Dr. Veraeghe has no relevant financial
relationships to disclose.
Ahrendt
Dr. Ahrendt has no relevant financial
relationships to disclose.
Ballman
Dr. Ballman has no relevant financial
relationships to disclose.
Boughey
Dr. Boughey has no relevant financial
relationships to disclose.
Hunt
Dr. Hunt has no relevant financial relationships
to disclose.
McCall
Ms. McCall has no relevant financial
relationships to disclose.
P2-01-02
P2-01-02
P2-01-02
P2-01-02
P2-01-03
P2-01-03
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Elizabeth
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
William
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Bret
Methods impacting the false negative rate of
sentinel lymph node surgery in patients
presenting with node positive breast cancer (T0T4,N1-2) who receive neoadjuvant
chemotherapy - Results from a prospective trial ACOSOG Z1071 (Alliance)
Lee
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Maureen
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Ayoub
Mittendorf
Dr. Mittendorf has no relevant financial
relationships to disclose.
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
Taback
Dr. Taback has no relevant financial
relationships to disclose.
Wilke
Dr. Wilke has no relevant financial
relationships to disclose.
Aarts
Ms. Aarts has no relevant financial
relationships to disclose.
Charehbili
Ayoub Charehbili has no relevant financial
relationships to disclose.
P2-01-03
P2-01-03
P2-01-03
P2-01-03
P2-01-03
P2-01-03
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Maaike
de Boer
Maaike de Boer has no relevant financial
relationships to disclose.
Judith
Kroep
Dr. Korep has disclosed that she has contracts
with Amgen, Novartis and Sanofi-Aventis.
Liefers
Gerrit-Jan Liefers has no relevant financial
relationships to disclose.
Peer
Petronella Peer has no relevant financial
relationships to disclose.
Tjan-Heijnen
Ms. Tjan-Heijnen has disclosed she has a
contract with Amgen and Sanofi-Aventis.
van de Velde
Mr. van de Velde has disclosed he has a
contract with Pfizer.
Gerrit-Jan
Petronella
Vivianne
Cock
P2-01-03
P2-01-05
P2-01-05
P2-01-05
P2-01-05
P2-01-05
P2-01-05
P2-01-05
Sentinel node procedure before or after
neoadjuvant chemotherapy in clinically node
negative or positive patients; results from 3
phase III studies of the Dutch breast cancer
trialists' group (BOOG)
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Vriens
Birgitte Vriens has no relevant financial
relationships to disclose.
Kimberly
Allison
Dr. Allison has no relevant financial
relationships to disclose.
Nicole
Choy
Dr. Choy has no relevant financial relationships
to disclose.
Debra
Ikeda
Dr. Ikeda has no relevant financial relationships
to disclose.
Jafi
Lipson
Dr. Lipson has no relevant financial
relationships to disclose.
Michael
Ozawa
Dr. Ozawa has no relevant financial
relationships to disclose.
Sunita
Pal
Dr. Pal has no relevant financial relationships
to disclose.
Trinh
Dr. Trinh has no relevant financial relationships
to disclose.
Birgitte
Long
P2-01-05
P2-01-05
P2-01-06
P2-01-06
P2-01-06
P2-01-06
P2-01-06
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
Correlation of percutaneously biopsied axillary
lymph nodes marked with black tattoo ink prior
to neoadjuvant chemotherapy with sentinel
lymph nodes in breast cancer patients
In patients with breast cancer, pre-operative
sentinel node biopsy using intradermal
microbubbles and contrast enhanced
ultrasound predicts volume of axillary
metastases
In patients with breast cancer, pre-operative
sentinel node biopsy using intradermal
microbubbles and contrast enhanced
ultrasound predicts volume of axillary
metastases
In patients with breast cancer, pre-operative
sentinel node biopsy using intradermal
microbubbles and contrast enhanced
ultrasound predicts volume of axillary
metastases
In patients with breast cancer, pre-operative
sentinel node biopsy using intradermal
microbubbles and contrast enhanced
ultrasound predicts volume of axillary
metastases
In patients with breast cancer, pre-operative
sentinel node biopsy using intradermal
microbubbles and contrast enhanced
ultrasound predicts volume of axillary
metastases
Wapnir
Dr. Wapnir has no relevant financial
relationships to disclose.
Amanda
Wheeler
Dr. Wheeler has no relevant financial
relationships to disclose.
Ritchie
Chalmers
Dr. Chalmers has no relevant financial
relationships to disclose.
Cox
Dr. Cox has no relevant financial relationships
to disclose.
Fish
Mr. Fish has no relevant financial relationships
to disclose.
Mills
Ms. Mills has no relevant financial relationships
to disclose.
Sever
Dr. Sever has no relevant financial relationships
to disclose.
Irene
Karina
David
Pippa
Ali
P2-01-06
P2-01-07
P2-01-07
P2-01-07
P2-01-07
P2-01-07
P2-01-07
P2-01-07
In patients with breast cancer, pre-operative
sentinel node biopsy using intradermal
microbubbles and contrast enhanced
ultrasound predicts volume of axillary
metastases
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Weeks
Ms. Weeks has no relevant financial
relationships to disclose.
Futoshi
Akiyama
Futoshi Akiyama has no relevant financial
relationships to disclose.
Rie
Horii
Rie Horii has no relevant financial relationships
to disclose.
Takuji
Iwase
Takuji Iwasa has no relevant financial
relationships to disclose.
Kiyomi
Kimura
Kiyomi Kimura has no relevant financial
relationships to disclose.
Fumiko
Moroo
Fumiko Moroo has no relevant financial
relationships to disclose.
Takehiko
Sakai
Takehiko Sakai has no relevant financial
relationships to disclose.
Sato
Ayaka Sato has no relevant financial
relationships to disclose.
Jennifer
Ayaka
P2-01-07
P2-01-08
P2-01-08
P2-01-08
P2-01-08
P2-01-08
P2-01-08
P2-01-08
P2-01-09
P2-01-09
P2-01-09
P2-01-09
P2-01-10
P2-01-10
Reoperative sentinel lymph node biopsy for
ipsilateral breast tumor recurrence: Impact of
axillary surgery and radiation therapy on
lymphatic drainage patterns
Does axillary lymph node ratio still have a
prognostic value in neoadjuvant setting?
Does axillary lymph node ratio still have a
prognostic value in neoadjuvant setting?
Does axillary lymph node ratio still have a
prognostic value in neoadjuvant setting?
Does axillary lymph node ratio still have a
prognostic value in neoadjuvant setting?
Does axillary lymph node ratio still have a
prognostic value in neoadjuvant setting?
Does axillary lymph node ratio still have a
prognostic value in neoadjuvant setting?
Does axillary lymph node ratio still have a
prognostic value in neoadjuvant setting?
Application of the Z0011 criteria on Dutch
breast cancer patients
Application of the Z0011 criteria on Dutch
breast cancer patients
Application of the Z0011 criteria on Dutch
breast cancer patients
Application of the Z0011 criteria on Dutch
breast cancer patients
Contrast enhanced pre-operative axillary
staging in breast cancer: A systematic review
and meta-analysis
Contrast enhanced pre-operative axillary
staging in breast cancer: A systematic review
and meta-analysis
Masahiko
Tanabe
Jeoung Won
Bae
Seung Pil
Jung
Hoon Yub
Kim
Woo Young
Kim
Hee Yong
Kwak
Hye Yoon
Lee
Jae Bok
Lee
Rudi
Roumen
Vivianne
Tjan-Heijnen
Nicole
Verheuvel
Adri
Voogd
Masahiko Tanabe has no relevant financial
relationships to disclose.
Jeoung Won Bae has no relevant financial
relationships to disclose.
Seung Pil Jung has no relevant financial
relationships to disclose.
Hoon Yub Kim has no relevant financial
relationships to disclose.
Woo Young Kim has no relevant financial
relationships to disclose.
Hee Yong Kwak has no relevant financial
relationships to disclose.
Hye Yoon Lee has no relevant financial
relationships to disclose.
Jae Bok Lee has no relevant financial
relationships to disclose.
Dr. Roumen has no relevant financial
relationships to disclose.
Dr. Tjan-Heijnen has no relevant financial
relationships to disclose.
Dr. Verheuvel has no relevant financial
relationships to disclose.
Dr. Voogd has no relevant financial
relationships to disclose.
Bauke
Anninga
Bauke Anninga has no relevant financial
relationships to disclose.
Michael
Douek
Dr. Douek has no relevant financial
relationships to disclose.
P2-01-10
P2-01-11
P2-01-11
P2-01-11
P2-01-11
P2-01-11
Contrast enhanced pre-operative axillary
staging in breast cancer: A systematic review
and meta-analysis
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
van Hemelrijck
Dr. van Hemelrijck has no relevant financial
relationships to disclose.
Coutant
Dr. Coutant has no relevant financial
relationships to disclose.
Gauthier
D'halluin
Ms. D'halluin has no relevant financial
relationships to disclose.
Virginie
Doridot
Dr. Doridot has no relevant financial
relationships to disclose.
Dupre
Dr. Dupre has no relevant financial
relationships to disclose.
Estevez
Dr. Estevez has no relevant financial
relationships to disclose.
Mieke
Charles
Pierre-François
Pablo
P2-01-11
P2-01-11
P2-01-11
P2-01-11
P2-01-11
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Fritel
Dr. Fritel has no relevant financial relationships
to disclose.
Guillot
Dr. Guillot has no relevant financial
relationships to disclose.
David
Kere
Dr. Kere has no relevant financial relationships
to disclose.
Chafika
Mazouni
Dr. Mazouni has no relevant financial
relationships to disclose.
Meyer
Dr. Meyer has no relevant financial
relationships to disclose.
Xavier
Eugenie
Charles
P2-01-11
P2-01-11
P2-01-11
P2-01-11
P2-01-11
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Pouget
Dr. Pouget has no relevant financial
relationships to disclose.
Rousseau
Dr. Rousseau has no relevant financial
relationships to disclose.
Roman
Rouzier
Dr. Rouzier has no relevant financial
relationships to disclose.
Tabassome
Simon
Dr. Simon has no relevant financial
relationships to disclose.
Uzan
Dr. Uzan has no relevant financial relationships
to disclose.
Nicolas
Alexandra
Catherine
P2-01-11
P2-01-12
P2-01-12
P2-01-12
P2-01-12
P2-01-12
P2-01-12
P2-01-13
P2-01-13
P2-01-13
P2-01-13
P2-01-14
P2-01-14
Prospective evaluation of the reliability of the
combined use of two models to predict nonsentinel lymph node status in breast cancer
patients with metastatic sentinel lymph nodes:
The MSKCC nomogram and the Tenon score PHRC-NOTEGS study
Impact of the ASOCOG Z0011 trial on a multiinstitutional mixed practice setting
Impact of the ASOCOG Z0011 trial on a multiinstitutional mixed practice setting
Impact of the ASOCOG Z0011 trial on a multiinstitutional mixed practice setting
Impact of the ASOCOG Z0011 trial on a multiinstitutional mixed practice setting
Impact of the ASOCOG Z0011 trial on a multiinstitutional mixed practice setting
Impact of the ASOCOG Z0011 trial on a multiinstitutional mixed practice setting
Vascularized lymph node transfer for the
treatment of upper extremity lymphedema in
breast cancer
Vascularized lymph node transfer for the
treatment of upper extremity lymphedema in
breast cancer
Vascularized lymph node transfer for the
treatment of upper extremity lymphedema in
breast cancer
Vascularized lymph node transfer for the
treatment of upper extremity lymphedema in
breast cancer
Pre-operative axillary staging results in overtreatment in some breast cancer patients
Pre-operative axillary staging results in overtreatment in some breast cancer patients
Sonia
Zilberman
Timothy
Fitzgerald
Swapnil
Kachare
Kathyrn
Verbanac
Nasreen
Vohra
Jan
Wong
Emmanuel
Zervos
Dr. Zilberman has no relevant financial
relationships to disclose.
Dr. Fitzgerald has no relevant financial
relationships to disclose.
Dr. Kachare has no relevant financial
relationships to disclose.
Dr. Verbanac has no relevant financial
relationships to disclose.
Dr. Vohra has no relevant financial
relationships to disclose.
Dr. Wong has no relevant financial
relationships to disclose.
Dr. Zervos has no relevant financial
relationships to disclose.
Jeffrey
Feiner
Dr. Feiner has no relevant financial
relationships to disclose.
Richard
Klein
Dr. Klein has no relevant financial relationships
to disclose.
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Kenneth
Kristine
Secrest
Sebastian
Aspinall
Henry
Cain
Ms. Secrest has no relevant financial
relationships to disclose.
Mr. Aspinall has no relevant financial
relationships to disclose.
Dr. Cain has no relevant financial relationships
to disclose.
P2-01-14
P2-01-15
P2-01-15
P2-01-15
P2-01-15
P2-01-16
P2-01-16
P2-01-16
P2-01-16
P2-01-16
P2-01-16
P2-01-16
P2-01-16
P2-01-16
P2-01-16
Pre-operative axillary staging results in overtreatment in some breast cancer patients
Noninvasive assessment of axillary lymph node
metastases in breast cancer using EpCAM
antibody
Noninvasive assessment of axillary lymph node
metastases in breast cancer using EpCAM
antibody
Noninvasive assessment of axillary lymph node
metastases in breast cancer using EpCAM
antibody
Noninvasive assessment of axillary lymph node
metastases in breast cancer using EpCAM
antibody
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Andrew
Pieri
Mr. Pieri has no relevant financial relationships
to disclose.
Jiajia
Guo
Jiajia Guo has no relevant financial
relationships to disclose.
Wang
Shu Wang has no relevant financial
relationships to disclose.
Yang
Houpu Yang has no relevant financial
relationships to disclose.
Shu
Houpu
Liulu
Zhang
Ana
Alvarez
Eduardo
Armanasco
Eugenia
Azar
Gaston
Berman
Gabriel
Bruno
Christian
Gonzalez
Eduardo
Gonzalez
Martin
Ipiña
Dolores
Mansilla
Diana
Montoya
Liulu Zhang has no relevant financial
relationships to disclose.
Ms. Alvarez has no relevant financial
relationships to disclose.
Dr. Armanasco has no relevant financial
relationships to disclose.
Dr. Azar has no relevant financial relationships
to disclose.
Dr. Berman has no relevant financial
relationships to disclose.
Dr. Bruno has no relevant financial
relationships to disclose.
Dr. Gonzalez has no relevant financial
relationships to disclose.
Mr. Gonzalez has no relevant financial
relationships to disclose.
Dr. Ipiña has no relevant financial relationships
to disclose.
Dr. Mansilla has no relevant financial
relationships to disclose.
Dr. Montoya has no relevant financial
relationships to disclose.
P2-01-16
P2-01-16
P2-01-16
P2-01-16
P2-01-17
P2-01-17
P2-01-17
P2-01-17
P2-01-17
P2-01-18
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Role of 18 FDG PET/CT in axillary staging in early
breast cancer
Total tumoral load as a prediction tool of nonsentinel node metastases in patients with early
breast cancer and positive sentinel lymph node
assesed by OSNA
Total tumoral load as a prediction tool of nonsentinel node metastases in patients with early
breast cancer and positive sentinel lymph node
assesed by OSNA
Total tumoral load as a prediction tool of nonsentinel node metastases in patients with early
breast cancer and positive sentinel lymph node
assesed by OSNA
Total tumoral load as a prediction tool of nonsentinel node metastases in patients with early
breast cancer and positive sentinel lymph node
assesed by OSNA
Total tumoral load as a prediction tool of nonsentinel node metastases in patients with early
breast cancer and positive sentinel lymph node
assesed by OSNA
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Cristina
Noblia
Amilcar
Osorio
Patricia
Parma
Carla
Pulero
Dr. Noblia has no relevant financial
relationships to disclose.
Dr. Osorio has no relevant financial
relationships to disclose.
Dr. Parma has no relevant financial
relationships to disclose.
Dr. Pulero has no relevant financial
relationships to disclose.
Sebastian
Diaz-Botero
Dr. Diaz-Botero has no relevant financial
relationships to disclose.
Martin
Espinosa-Bravo
Dr. Espinosa-Bravo has no relevant financial
relationships to disclose.
Francesc
Pérez-Ceresuela
Dr. Pérez-Ceresuela has no relevant financial
relationships to disclose.
Vicente
Peg
Dr. Peg has no relevant financial relationships
to disclose.
Rubio
Dr. Rubio has no relevant financial
relationships to disclose.
Adachi
Dr. Adachi has no relevant financial
relationships to disclose.
Isabel
Yayoi
P2-01-18
P2-01-18
P2-01-18
P2-01-18
P2-01-18
P2-01-18
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Takashi
Fujita
Takashi Fujita has no relevant financial
relationships to disclose.
Masaya
Hattori
Dr. Hattori has no relevant financial
relationships to disclose.
Hisada
Tomoka Hisada has no relevant financial
relationships to disclose.
Ichikawa
Dr. Ichikawa has no relevant financial
relationships to disclose.
Ishiguro
Junko Ishiguro has no relevant financial
relationships to disclose.
Iwata
Hiroji Iwata has no relevant financial
relationships to disclose.
Tomoka
Mari
Junko
Hiroji
P2-01-18
P2-01-18
P2-01-18
P2-01-18
P2-01-19
P2-01-19
P2-01-19
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Preoperative axillary imaging with
ultrasonography: Among the breast cancer
patients with lymph node metastases, can we
identify the patients who may omit axillary
dissection?
Long-term follow-up of the node-negative
breast cancer patients before treatment
evaluated with sentinel node biopsy alone
following neoadjuvant chemotherapy
Long-term follow-up of the node-negative
breast cancer patients before treatment
evaluated with sentinel node biopsy alone
following neoadjuvant chemotherapy
Long-term follow-up of the node-negative
breast cancer patients before treatment
evaluated with sentinel node biopsy alone
following neoadjuvant chemotherapy
Naoto
Kondo
Naoto Kondo has no relevant financial
relationships to disclose.
Haruru
Kotani
Haruru Kotani has no relevant financial
relationships to disclose.
Sawaki
Dr. Sawaki has no relevant financial
relationships to disclose.
Akiyo
Yoshimura
Akiyo Yoshimura has no relevant financial
relationships to disclose.
Makiko
Kamio
Dr. Kamio has no relevant financial
relationships to disclose.
Kumiko
Kato
Dr. Kato has no relevant financial relationships
to disclose.
Hiroko
Nogi
Dr. Nogi has no relevant financial relationships
to disclose.
Masataka
P2-01-19
P2-01-19
P2-01-19
P2-01-20
P2-01-20
P2-01-20
P2-01-20
P2-01-20
Long-term follow-up of the node-negative
breast cancer patients before treatment
evaluated with sentinel node biopsy alone
following neoadjuvant chemotherapy
Long-term follow-up of the node-negative
breast cancer patients before treatment
evaluated with sentinel node biopsy alone
following neoadjuvant chemotherapy
Long-term follow-up of the node-negative
breast cancer patients before treatment
evaluated with sentinel node biopsy alone
following neoadjuvant chemotherapy
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
Takeyama
Dr. Takeyama has no relevant financial
relationships to disclose.
Toriumi
Dr. Toriumi has no relevant financial
relationships to disclose.
Ken
Uchida
Dr. Uchida has no relevant financial
relationships to disclose.
Sana
Ahmed
Dr. Ahmed has no relevant financial
relationships to disclose.
Deedar
Ali
Deedar Ali has no relevant financial
relationships to disclose.
Muhhamed
Chauhan
Mr. Chauhan has no relevant financial
relationships to disclose.
Rajiv
Dave
Rajiv Dave has no relevant financial
relationships to disclose.
Maria
Ghaus
Ms. Ghaus has no relevant financial
relationships to disclose.
Hiroshi
Yasuo
P2-01-20
P2-01-20
P2-01-20
P2-01-20
P2-01-21
P2-01-21
P2-01-21
P2-01-22
P2-01-22
P2-01-22
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
The ratio and size of positive sentinel lymph
nodes predicts the involvement of non-sentinel
lymph nodes following completion axillary
lymph node dissection
Management of the axilla in breast cancer
patients: Do we over treat patients with
preoperative diagnosis of nodal metastasis?
Management of the axilla in breast cancer
patients: Do we over treat patients with
preoperative diagnosis of nodal metastasis?
Management of the axilla in breast cancer
patients: Do we over treat patients with
preoperative diagnosis of nodal metastasis?
Internal mammary sentinel lymph node biopsy
with modified injection technique: High
visualization rate and accurate staging
Internal mammary sentinel lymph node biopsy
with modified injection technique: High
visualization rate and accurate staging
Internal mammary sentinel lymph node biopsy
with modified injection technique: High
visualization rate and accurate staging
Kryjak
Zbigniew Kryjak has no relevant financial
relationships to disclose.
Marriott
Mr. Marriott has no relevant financial
relationships to disclose.
Craig
Sayers
Mr. Sayers has no relevant financial
relationships to disclose.
Shiv
Shapra
Shiv Shapra has no relevant financial
relationships to disclose.
Dunk
Ms. Dunk has no relevant financial
relationships to disclose.
Krupa
Dr. Krupa has no relevant financial
relationships to disclose.
Michalakis
Dr. Michalakis has no relevant financial
relationships to disclose.
Chen
Peng Wei Chen has no relevant financial
relationships to disclose.
Cong
Bin-bin Cong has no relevant financial
relationships to disclose.
Liu
Yan-Bing Liu has no relevant financial
relationships to disclose.
Zbigniew
Joshua
Louisa
Jaroslaw
Ioannis
Peng
Bin-bin
Yan-Bing
P2-01-22
P2-01-22
P2-01-22
P2-01-22
P2-01-23
P2-01-23
P2-01-23
P2-01-23
P2-01-23
Internal mammary sentinel lymph node biopsy
with modified injection technique: High
visualization rate and accurate staging
Internal mammary sentinel lymph node biopsy
with modified injection technique: High
visualization rate and accurate staging
Internal mammary sentinel lymph node biopsy
with modified injection technique: High
visualization rate and accurate staging
Internal mammary sentinel lymph node biopsy
with modified injection technique: High
visualization rate and accurate staging
Validation of diagnostic procedure for
metastatic lymph nodes in breast cancer using a
semi-dry dot-blot method and novel anticytokeratin 18+19 antibodies
Validation of diagnostic procedure for
metastatic lymph nodes in breast cancer using a
semi-dry dot-blot method and novel anticytokeratin 18+19 antibodies
Validation of diagnostic procedure for
metastatic lymph nodes in breast cancer using a
semi-dry dot-blot method and novel anticytokeratin 18+19 antibodies
Validation of diagnostic procedure for
metastatic lymph nodes in breast cancer using a
semi-dry dot-blot method and novel anticytokeratin 18+19 antibodies
Validation of diagnostic procedure for
metastatic lymph nodes in breast cancer using a
semi-dry dot-blot method and novel anticytokeratin 18+19 antibodies
Qiu
Peng-Fei Qiu has no relevant financial
relationships to disclose.
Wang
Yong-Sheng Wang has no relevant financial
relationships to disclose.
Yang
Guo-Ren Yang has no relevant financial
relationships to disclose.
Rong-Rong
Zhao
Rong-Rong Zhao has no relevant financial
relationships to disclose.
Hiroshi
Hirakawa
Dr. Hirakawa has no relevant financial
relationships to disclose.
Takeshi
Nagayasu
Dr. Nagayasu has no relevant financial
relationships to disclose.
Masahiro
Oikawa
Dr. Oikawa has no relevant financial
relationships to disclose.
Ryota
Otsubo
Dr. Otsubo has no relevant financial
relationships to disclose.
Hiroshi
Yano
Dr. Yano has no relevant financial relationships
to disclose.
Peng-Fei
Yong-Sheng
Guo-Ren
P2-01-24
P2-01-24
P2-01-24
P2-01-24
P2-01-24
P2-01-24
P2-01-25
Sentinel lymph node biopsy using intraoperative
indocyanine green fluorescence imaging
navigated with preoperative computed
tomography lymphography for early breast
cancer
Sentinel lymph node biopsy using intraoperative
indocyanine green fluorescence imaging
navigated with preoperative computed
tomography lymphography for early breast
cancer
Sentinel lymph node biopsy using intraoperative
indocyanine green fluorescence imaging
navigated with preoperative computed
tomography lymphography for early breast
cancer
Sentinel lymph node biopsy using intraoperative
indocyanine green fluorescence imaging
navigated with preoperative computed
tomography lymphography for early breast
cancer
Sentinel lymph node biopsy using intraoperative
indocyanine green fluorescence imaging
navigated with preoperative computed
tomography lymphography for early breast
cancer
Sentinel lymph node biopsy using intraoperative
indocyanine green fluorescence imaging
navigated with preoperative computed
tomography lymphography for early breast
cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Hajime
Abe
Dr. Abe has no relevant financial relationships
to disclose.
Masao
Kameyama
Dr. Kameyama has no relevant financial
relationships to disclose.
Kawasaki
Dr. Kawasaki has no relevant financial
relationships to disclose.
Ogawa
Dr. Ogawa has no relevant financial
relationships to disclose.
Yamazaki
Dr. Yamazaki has no relevant financial
relationships to disclose.
Yoneda
Dr. Yoneda has no relevant financial
relationships to disclose.
Ho
Gay Ho has no relevant financial relationships
to disclose.
Masayasu
Masao
Keiichi
Kohri
Gay
P2-01-25
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
Not all sentinel lymph nodes are equal - A
predictive model for axillary burden in early
breast cancer
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-25
P2-01-25
P2-01-25
P2-01-25
P2-01-25
P2-01-25
P2-01-25
Lim
Ms. Lim has no relevant financial relationships
to disclose.
Lim
Ms. Lim has no relevant financial relationships
to disclose.
Loh
Alvona Loh has no relevant financial
relationships to disclose.
Madhukumar
Preetha Madhukumar has no relevant financial
relationships to disclose.
Ong
Dr. Ong has no relevant financial relationships
to disclose.
Yirong
Sim
Dr. Sim has no relevant financial relationships
to disclose.
Shaun
Tan
Shaun Tan has no relevant financial
relationships to disclose.
Veronique
Tan
Ms. Tan has no relevant financial relationships
to disclose.
Bernardin
Dr. Bernardin has no relevant financial
relationships to disclose.
Cindy
Sue Zann
Alvona
Preetha
Kong Wee
Elena
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
Biagioli
Dr. Biagioli has no relevant financial
relationships to disclose.
Bianchi
Dr. Bianchi has no relevant financial
relationships to disclose.
Marcello
Bonavita
Dr. Bonavita has no relevant financial
relationships to disclose.
Chiara
Casiraghi
Dr. Casiraghi has no relevant financial
relationships to disclose.
Cordovana
Dr. Cordovana has no relevant financial
relationships to disclose.
Elena
Filippo
Andrea
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
Croce
Dr. Croce has no relevant financial
relationships to disclose.
Dazzani
Dr. Dazzani has no relevant financial
relationships to disclose.
Gabriella
Farina
Dr. Farina has no relevant financial
relationships to disclose.
Irene
Floriani
Dr. Floriani has no relevant financial
relationships to disclose.
Gerardi
Dr. Gerardi has no relevant financial
relationships to disclose.
Anna Maria
Chiara
Chiara
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
P2-01-26
P2-01-27
P2-01-27
Role of age, menopausal status and biological
tumor characteristics on sentinel lymph node
metastasis in early breast cancer patients with
favorable prognostic features: A retrospective,
mono institutional study on 345 cases
In patients with micrometastatic in sentinel
lymph node biopsies, involvement of the nonsentinel lymph nodes cannot be predicted by
clinicopathological variables
In patients with micrometastatic in sentinel
lymph node biopsies, involvement of the nonsentinel lymph nodes cannot be predicted by
clinicopathological variables
Gherardi
Dr. Gherardi has no relevant financial
relationships to disclose.
La Verde
Dr. La Verde has no relevant financial
relationships to disclose.
Mauro
Lamera
Dr. Lamera has no relevant financial
relationships to disclose.
Claudio
Lunghi
Dr. Lunghi has no relevant financial
relationships to disclose.
Sana
Ahmad
Dr. Ahmad has no relevant financial
relationships to disclose.
Deedar
Ali
Deedar Ali has no relevant financial
relationships to disclose.
Giorgio
Nicla
P2-01-28
In patients with micrometastatic in sentinel
lymph node biopsies, involvement of the nonsentinel lymph nodes cannot be predicted by
clinicopathological variables
In patients with micrometastatic in sentinel
lymph node biopsies, involvement of the nonsentinel lymph nodes cannot be predicted by
clinicopathological variables
In patients with micrometastatic in sentinel
lymph node biopsies, involvement of the nonsentinel lymph nodes cannot be predicted by
clinicopathological variables
In patients with micrometastatic in sentinel
lymph node biopsies, involvement of the nonsentinel lymph nodes cannot be predicted by
clinicopathological variables
In patients with micrometastatic in sentinel
lymph node biopsies, involvement of the nonsentinel lymph nodes cannot be predicted by
clinicopathological variables
Prognosis of metastatic internal mammary
sentinel nodes (IMSN) in breast cancer
Prognosis of metastatic internal mammary
sentinel nodes (IMSN) in breast cancer
Prognosis of metastatic internal mammary
sentinel nodes (IMSN) in breast cancer
P2-01-29
Axillary involvement in lobular breast cancer
Javier
de Santiago
P2-01-29
Axillary involvement in lobular breast cancer
Covadonga
Marti
P2-01-29
Axillary involvement in lobular breast cancer
Jose
Oliver
P2-01-29
Axillary involvement in lobular breast cancer
Ana
Roman
P2-01-27
P2-01-27
P2-01-27
P2-01-27
P2-01-27
P2-01-28
P2-01-28
Chauhan
Mr. Chauhan has no relevant financial
relationships to disclose.
Dave
Rajiv Dave has no relevant financial
relationships to disclose.
Mauria
Ghaus
Ms. Ghaus has no relevant financial
relationships to disclose.
Zbigniew
Kryjak
Zbigniew Kryjak has no relevant financial
relationships to disclose.
Muhammad
Rajiv
Craig
Sayers
Eli
Avisar
Shai
Libson
Eduardo
Perez
Mr. Sayers has no relevant financial
relationships to disclose.
Dr. Avisar has no relevant financial
relationships to disclose.
Dr. Libson has no relevant financial
relationships to disclose.
Dr. Perez has no relevant financial relationships
to disclose.
Dr. de Santiago has no relevant financial
relationships to disclose.
Dr. Marti has no relevant financial relationships
to disclose.
Dr. Oliver has no relevant financial
relationships to disclose.
Dr. Roman has no relevant financial
relationships to disclose.
P2-01-29
Axillary involvement in lobular breast cancer
Jose
Sanchez-Mendez
P2-01-29
Pilar
Zamora
Vlada
Cometova
Dr. Cometova has no relevant financial
relationships to disclose.
Sereda
Idrisova
Sereda Idrisova has no relevant financial
relationships to disclose.
Sergey
Panchenko
Dr. Panchenko has no relevant financial
relationships to disclose.
Valery
Rodionov
Dr. Rodionov has no relevant financial
relationships to disclose.
Rodionova
Ms. Rodionova has no relevant financial
relationships to disclose.
P2-01-30
Axillary involvement in lobular breast cancer
A new nomogram to predict axillary metastasis
in breast cancer patients without axillary
surgery
A new nomogram to predict axillary metastasis
in breast cancer patients without axillary
surgery
A new nomogram to predict axillary metastasis
in breast cancer patients without axillary
surgery
A new nomogram to predict axillary metastasis
in breast cancer patients without axillary
surgery
A new nomogram to predict axillary metastasis
in breast cancer patients without axillary
surgery
A new nomogram to predict axillary metastasis
in breast cancer patients without axillary
surgery
Dr. Sanchez-Mendez has no relevant financial
relationships to disclose.
Dr. Zamora has no relevant financial
relationships to disclose.
Savinov
Yurij Savinov has no relevant financial
relationships to disclose.
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Rajendra
Badwe
Rajendra Badwe has no relevant financial
relationships to disclose.
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Anita
Dhar
Ms. Dhar has no relevant financial relationships
to disclose.
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Rohini
Hawaldar
Rohini Hawaldar has no relevant financial
relationships to disclose.
P2-01-30
P2-01-30
P2-01-30
P2-01-30
P2-01-30
Maria
Yurij
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Nita
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Vani
Nair
Nita Nair has no relevant financial relationships
to disclose.
Parmar
Vani Parmar has no relevant financial
relationships to disclose.
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Amar
Prem
Amar Prem has no relevant financial
relationships to disclose.
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Vaibhav
Sanmali
Vaibhav Sanmali has no relevant financial
relationships to disclose.
P2-01-31
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer Vuthaluru
Seenu
Vuthaluru Seenu has no relevant financial
relationships to disclose.
Srivastava
Dr. Srivastava has no relevant financial
relationships to disclose.
Abe
Eriko Abe has no relevant financial
relationships to disclose.
Hayashi
Dr. Hayashi has no relevant financial
relationships to disclose.
Ohde
Sachiko Ohde has no relevant financial
relationships to disclose.
P2-01-31
P2-01-32
P2-01-32
P2-01-32
Sentinel node mapping with fluorescein and
comparison with methylene blue and
technitium sulphur colloid in early breast cancer
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Anurag
Eriko
Naoki
Sachiko
P2-01-32
P2-01-32
P2-01-32
P2-01-32
P2-01-32
P2-02-01
P2-02-01
P2-02-01
P2-02-01
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Comparison between positive and falsenegative sentinel lymph nodes in breast cancer
patients
Randomised controlled trial of stereotactic 11g
vacuum-assisted or core biopsy for diagnosis
and management of malignant
microcalcification
Randomised controlled trial of stereotactic 11g
vacuum-assisted or core biopsy for diagnosis
and management of malignant
microcalcification
Randomised controlled trial of stereotactic 11g
vacuum-assisted or core biopsy for diagnosis
and management of malignant
microcalcification
Randomised controlled trial of stereotactic 11g
vacuum-assisted or core biopsy for diagnosis
and management of malignant
microcalcification
Toshinao
Koyu
Mieko
Hideko
Yang
Nigel
Sara
Janicke
Anthony
Onoda
Toshinao Onoda has no relevant financial
relationships to disclose.
Suzuki
Koyu Suzuki has no relevant financial
relationships to disclose.
Uno
Meiko Uno has no relevant financial
relationships to disclose.
Yamauchi
Hideko Yamauchi has no relevant financial
relationships to disclose.
Yang
Yang Yang has no relevant financial
relationships to disclose.
Bundred
Dr. Bundred has no relevant financial
relationships to disclose.
Bundred
Dr. Bundred has no relevant financial
relationships to disclose.
Harake
Janicke Harake has no relevant financial
relationships to disclose.
Maxwell
Mr. Maxwell has no relevant financial
relationships to disclose.
P2-02-01
P2-02-01
P2-02-01
P2-02-02
P2-02-02
P2-02-02
P2-02-02
P2-02-02
P2-02-02
P2-02-03
Randomised controlled trial of stereotactic 11g
vacuum-assisted or core biopsy for diagnosis
and management of malignant
microcalcification
Randomised controlled trial of stereotactic 11g
vacuum-assisted or core biopsy for diagnosis
and management of malignant
microcalcification
Randomised controlled trial of stereotactic 11g
vacuum-assisted or core biopsy for diagnosis
and management of malignant
microcalcification
A review of the accuracy of wire localisation
using digital breast tomosynthesis (DBT) in a
prospective series of 81 patients
A review of the accuracy of wire localisation
using digital breast tomosynthesis (DBT) in a
prospective series of 81 patients
A review of the accuracy of wire localisation
using digital breast tomosynthesis (DBT) in a
prospective series of 81 patients
A review of the accuracy of wire localisation
using digital breast tomosynthesis (DBT) in a
prospective series of 81 patients
A review of the accuracy of wire localisation
using digital breast tomosynthesis (DBT) in a
prospective series of 81 patients
A review of the accuracy of wire localisation
using digital breast tomosynthesis (DBT) in a
prospective series of 81 patients
Retrospective analysis of the accuracy of
ultrasound-guided core needle biopsy in the
diagnosis of breast invasive ductal carcinoma:
Experience in Chinese population
Morris
Ms. Morris has no relevant financial
relationships to disclose.
Whiteside
Sigrid Whiteside has no relevant financial
relationships to disclose.
Zhou
Jin Zhou has no relevant financial relationships
to disclose.
Gurung
Amrita Gurung has no relevant financial
relationships to disclose.
Simon
Holt
Mr. Holt has no relevant financial relationships
to disclose.
Anita
Huws
Ms. Huws has no relevant financial
relationships to disclose.
Khaldoun
Nadi
Khaldoun Nadi has no relevant financial
relationships to disclose.
Sharaiha
Yousef Sharaiha has no relevant financial
relationships to disclose.
Williams
Ms. Williams has no relevant financial
relationships to disclose.
Guo
Dr. Guo has no relevant financial relationships
to disclose.
Julie
Sigrid
Jin
Amrita
Yousef
Helen
Yongchuan
P2-02-03
P2-02-03
P2-02-03
P2-03-01
P2-03-01
P2-03-01
P2-03-01
P2-03-01
Retrospective analysis of the accuracy of
ultrasound-guided core needle biopsy in the
diagnosis of breast invasive ductal carcinoma:
Experience in Chinese population
Retrospective analysis of the accuracy of
ultrasound-guided core needle biopsy in the
diagnosis of breast invasive ductal carcinoma:
Experience in Chinese population
Retrospective analysis of the accuracy of
ultrasound-guided core needle biopsy in the
diagnosis of breast invasive ductal carcinoma:
Experience in Chinese population
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Tai
Dr. Tai has no relevant financial relationships
to disclose.
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Zheli
Xu
Dr. Xu has no relevant financial relationships to
disclose.
Jan
Bogaerts
Dr. Bogaerts has no relevant financial
relationships to disclose.
Fatima
Cardoso
Dr. Cardoso has no relevant financial
relationships to disclose.
Martine
Piccart
Dr. Piccart has no relevant financial
relationships to disclose.
Emiel
Rutgers
Dr. Rutgers has no relevant financial
relationships to disclose.
Leen
Slaets
Dr. Slaets has no relevant financial
relationships to disclose.
Guixiang
Wan
P2-03-01
P2-03-01
P2-03-01
P2-03-01
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-03
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Are all small tumors low risk? Characterization
of small invasive node negative breast cancers
(BC) enrolled in the EORTC 10041/BIG 3-04
(MINDACT) trial
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Snoo
Femke Snoo has disclosed he is employed by
Agendia.
Tryfonidis
Dr. Tryfonidis has no relevant financial
relationships to disclose.
Laura
Van't Veer
Dr. Van 't Veer has disclosed she is co- founder
and part time employee of Agendia NV,
Amsterdam, Netherlands.
Giuseppe
Viale
Mahmoud
Abdel-Rasoul
James
Chen
Rachel
Layman
Gustavo
Leone
Maryam
Lustberg
Erin
Macrae
Ewa
Mrozek
Michael
Ostrowski
Susan
Ottman
Femke
Konstantinos
Dr. Viale has no relevant financial relationships
to disclose.
Mahmoud Abdel-Rasoul has no relevant
financial relationships to disclose.
Dr. Chen has no relevant financial relationships
to disclose.
Dr. Layman has no relevant financial
relationships to disclose.
Dr. Leone has no relevant financial
relationships to disclose.
Dr. Lustberg has no relevant financial
relationships to disclose.
Dr. Macrae has no relevant financial
relationships to disclose.
Dr. Mrozek has no relevant financial
relationships to disclose.
Dr. Ostrowski has no relevant financial
relationships to disclose.
Ms. Ottman has no relevant financial
relationships to disclose.
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-03
P2-03-04
P2-03-04
P2-03-04
P2-03-04
P2-03-05
P2-03-05
P2-03-05
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Incidence of actionable genomic alterations in
metastatic breast cancer: A prospective study
Comparative analysis of somatic mutations in
matched primary vs metastatic triple-negative
breast cancers
Comparative analysis of somatic mutations in
matched primary vs metastatic triple-negative
breast cancers
Comparative analysis of somatic mutations in
matched primary vs metastatic triple-negative
breast cancers
Comparative analysis of somatic mutations in
matched primary vs metastatic triple-negative
breast cancers
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
Bhuvaneswari
Ramaswamy
Raquel
Reinbolt
Charles
Shapiro
Cynthia
Timmers
Katlyn
Tolliver
Robert
Wesolowski
Dr. Ramaswamy has no relevant financial
relationships to disclose.
Dr. Reinbolt has no relevant financial
relationships to disclose.
Dr. Shapiro has no relevant financial
relationships to disclose.
Dr. Timmers has no relevant financial
relationships to disclose.
Ms. Tolliver has no relevant financial
relationships to disclose.
Dr. Wesolowski has no relevant financial
relationships to disclose.
Carpten
Mr. Carpten has no relevant financial
relationships to disclose.
Irene
Cherni
Ms. Cherni has no relevant financial
relationships to disclose.
Maren
Levin
Maren Levin has no relevant financial
relationships to disclose.
Joyce
O'Shaughnessy
Dr. O'Shaughnessy has no relevant financial
relationships to disclose.
Bianchini
Giampaolo Bianchini has disclosed he is a
speaker for Genomic Health.
Callari
Maurizio Callari has no relevant financial
relationships to disclose.
Galeota
Ms. Galeota has no relevant financial
relationships to disclose.
John
Giampaolo
Maurizio
Eugenia
P2-03-06
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
The heterogeneous clinical behavior of luminal
breast cancers is associated with different
mutational landscapes
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
P2-03-06
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
P2-03-05
P2-03-05
P2-03-05
P2-03-05
P2-03-05
P2-03-05
P2-03-05
P2-03-06
P2-03-06
P2-03-06
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
Gianni
Dr. Gianni has no relevant financial
relationships to disclose.
Hatzis
Christos Hatzis has no relevant financial
relationships to disclose.
Iwamoto
Takayuki Iwamoto has no relevant financial
relationships to disclose.
Jiang
Tingting Jiang has no relevant financial
relationships to disclose.
Karn
Mr. Karn has no relevant financial relationships
to disclose.
Lajos
Pusztai
Dr. Pusztai has no relevant financial
relationships to disclose.
Milvia
Zambetti
Siraj
Ali
Juliann
Chmielecki
Garrett
Frampton
Maren
Levin
Vincent
Miller
Luca
Christos
Takayuki
Tingting
Thomas
Milvia Zambetti has no relevant financial
relationships to disclose.
Dr. Ali has disclosed he is an employee of and
owns stock in Foundation Medicine.
Dr. Chmielecki has disclosed she is an
employee of and owns stock in Foundation
Medicine.
Dr. Frampton has disclosed he is an employee
of and owns stock in Foundation Medicine.
Maren Levin has no relevant financial
relationships to disclose.
Dr. Miller has disclosed he is an employee of
and owns stock in Foundation Medicine.
P2-03-06
P2-03-06
P2-03-06
P2-03-06
P2-03-06
P2-03-06
P2-03-07
P2-03-07
P2-03-07
P2-03-07
P2-03-07
P2-03-07
P2-03-07
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
FoundationOne profiling of TSC1 and TSC2mutated advanced breast cancers
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deborah
Morosini
Joyce
O'Shaughnessy
Norma
Palma
Gary
Palmer
Jeffrey
Ross
Phil
Stephens
Dr. Morosini has disclosed she is an employee
of and owns stock in Foundation Medicine.
Dr. O'Shaughnessy has no relevant financial
relationships to disclose.
Dr. Palma has disclosed she is an employee of
and holds stock in Foundation Medicine.
Dr. Palmer has disclosed he is an employee of
and owns stock in Foundation Medicine.
Dr. Ross has disclosed he is an employee of and
owns stock in Foundation Medicine.
Dr. Stephens has disclosed he is an employee
of and owns stock in Foundation Medicine.
Lucretia
Alvarez
Dr. Alvarez has no relevant financial
relationships to disclose.
Anderson
Dr. Anderson has no relevant financial
relationships to disclose.
Barrett
Dr. Barrett has no relevant financial
relationships to disclose.
Champion
Dr. Champion has no relevant financial
relationships to disclose.
Evers
Ms. Evers has no relevant financial
relationships to disclose.
Francis
Dr. Francis has no relevant financial
relationships to disclose.
Lenkiewicz
Ms. Lenkiewicz has no relevant financial
relationships to disclose.
Karen
Michael
Mia
Lisa
Princy
Elizabeth
P2-03-07
P2-03-07
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-08
P2-03-09
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Deep clonal profiling identifies distinct
mechanisms of heterogeneity and evolution in
breast cancer
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Mutational landscape of metaplastic breast
carcinomas
Benchmarking mutation function prediction
algorithms using validated cancer driver and
passenger mutations
Ann
McCullough
Dr. McCullough has no relevant financial
relationships to disclose.
Barbara
Pockaj
Edi
Brogi
Maria
De Filippo
Raymond
Lim
Luciano
Martelotto
Rachael
Natrajan
Charlotte
Ng
Larry
Norton
Salvatore
Piscuoglio
Jorge
Reis-Filho
Anne
Vincent-Salomon
Britta
Weigelt
Y Hannah
Wen
Dr. Pockaj has no relevant financial
relationships to disclose.
Dr. Brogi has no relevant financial relationships
to disclose.
Dr. De Filippo has no relevant financial
relationships to disclose.
Mr. Lim has no relevant financial relationships
to disclose.
Dr. Martelotto has no relevant financial
relationships to disclose.
Dr. Natrajan has no relevant financial
relationships to disclose.
Dr. Ng has no relevant financial relationships to
disclose.
Dr. Norton has no relevant financial
relationships to disclose.
Dr. Piscuoglio has no relevant financial
relationships to disclose.
Dr. Reis-Filho has no relevant financial
relationships to disclose.
Dr. Vincent-Salomon has no relevant financial
relationships to disclose.
Dr. Weigelt has no relevant financial
relationships to disclose.
Dr. Wen has no relevant financial relationships
to disclose.
De Filippo
Dr. De Filippo has no relevant financial
relationships to disclose.
Maria
P2-03-09
Benchmarking mutation function prediction
algorithms using validated cancer driver and
passenger mutations
Benchmarking mutation function prediction
algorithms using validated cancer driver and
passenger mutations
Benchmarking mutation function prediction
algorithms using validated cancer driver and
passenger mutations
P2-03-10
Comprehensive somatic SNV and CNV profiling
for triple-negative breast cancer patients by
targeted next-generation sequencing
P2-03-10
Comprehensive somatic SNV and CNV profiling
for triple-negative breast cancer patients by
targeted next-generation sequencing
Min Kyoon
Kim
Dr. Kim has no relevant financial relationships
to disclose.
P2-03-10
Comprehensive somatic SNV and CNV profiling
for triple-negative breast cancer patients by
targeted next-generation sequencing
Byung-Chul
Lee
Dr. Lee has no relevant financial relationships
to disclose.
P2-03-10
Comprehensive somatic SNV and CNV profiling
for triple-negative breast cancer patients by
targeted next-generation sequencing
Dongyoon
Park
Dongyoon Park has no relevant financial
relationships to disclose.
P2-03-10
Comprehensive somatic SNV and CNV profiling
for triple-negative breast cancer patients by
targeted next-generation sequencing
Jungsun
Park
Dr. Park has no relevant financial relationships
to disclose.
P2-03-10
Comprehensive somatic SNV and CNV profiling
for triple-negative breast cancer patients by
targeted next-generation sequencing
Yoo
Dr. Yoo has no relevant financial relationships
to disclose.
P2-03-09
P2-03-09
Ng
Dr. Ng has no relevant financial relationships to
disclose.
Reis-Filho
Dr. Reis-Filho has no relevant financial
relationships to disclose.
Britta
Weigelt
Dr. Weigelt has no relevant financial
relationships to disclose.
Wonshik
Han
Dr. Han has no relevant financial relationships
to disclose.
Charlotte
Jorge
Tae-Kyung
P2-03-10
P2-03-11
P2-03-11
P2-03-11
P2-03-11
P2-03-11
P2-03-11
P2-03-12
P2-03-12
P2-03-12
P2-03-12
Comprehensive somatic SNV and CNV profiling
for triple-negative breast cancer patients by
targeted next-generation sequencing
Interaction between smoking history and gene
expression levels impacts survival of breast
carcinoma patients
Interaction between smoking history and gene
expression levels impacts survival of breast
carcinoma patients
Interaction between smoking history and gene
expression levels impacts survival of breast
carcinoma patients
Interaction between smoking history and gene
expression levels impacts survival of breast
carcinoma patients
Interaction between smoking history and gene
expression levels impacts survival of breast
carcinoma patients
Interaction between smoking history and gene
expression levels impacts survival of breast
carcinoma patients
An academic cancer center's experience in
establishing a breast cancer-focused
multidisciplinary genomic tumor board
An academic cancer center's experience in
establishing a breast cancer-focused
multidisciplinary genomic tumor board
An academic cancer center's experience in
establishing a breast cancer-focused
multidisciplinary genomic tumor board
An academic cancer center's experience in
establishing a breast cancer-focused
multidisciplinary genomic tumor board
Yun
Dr. Yun has no relevant financial relationships
to disclose.
Mohammad
Alatoum
Mr. Alatoum has no relevant financial
relationships to disclose.
Sarah
Andres
Dr. Andres has no relevant financial
relationships to disclose.
Katie
Bickett
Ms. Bickett has no relevant financial
relationships to disclose.
Guy
Brock
Dr. Brock has no relevant financial
relationships to disclose.
Kalbfleisch
Dr. Kalbfleisch has no relevant financial
relationships to disclose.
Wittliff
Dr. Wittliff has no relevant financial
relationships to disclose.
Harris
Dr. Harris has no relevant financial
relationships to disclose.
Marshall
Ms. Marshall has no relevant financial
relationships to disclose.
Maximuk
Mr. Maximuk has no relevant financial
relationships to disclose.
McGowan
Ms. McGowan has no relevant financial
relationships to disclose.
Taegyun
Theodore
James
Lyndsay
Patricia
Steven
Michelle
P2-03-13
An academic cancer center's experience in
establishing a breast cancer-focused
multidisciplinary genomic tumor board
An academic cancer center's experience in
establishing a breast cancer-focused
multidisciplinary genomic tumor board
An academic cancer center's experience in
establishing a breast cancer-focused
multidisciplinary genomic tumor board
Multiple breast cancer risk variants are
associated with differential transcript isoform
expression in tumors
Multiple breast cancer risk variants are
associated with differential transcript isoform
expression in tumors
Multiple breast cancer risk variants are
associated with differential transcript isoform
expression in tumors
Multiple breast cancer risk variants are
associated with differential transcript isoform
expression in tumors
P2-03-14
Long range expression patterns detected by
RNASeq in breast cancer reveal cluster enriched
with triple negative breast cancer
Vartika
Agrawal
P2-03-14
Long range expression patterns detected by
RNASeq in breast cancer reveal cluster enriched
with triple negative breast cancer
Nilanjana
Banerjee
P2-03-14
Long range expression patterns detected by
RNASeq in breast cancer reveal cluster enriched
with triple negative breast cancer
Nevenka
Dimitrova
P2-03-12
P2-03-12
P2-03-12
P2-03-13
P2-03-13
P2-03-13
Ponsaran
Roselle Ponsaran has no relevant financial
relationships to disclose.
Silverman
Dr. Silverman has no relevant financial
relationships to disclose.
Vinayak
Dr. Vinayak has no relevant financial
relationships to disclose.
Caswell
Dr. Caswell has no relevant financial
relationships to disclose.
Hu
Dr. Hu has no relevant financial relationships to
disclose.
Scott
Huntsman
Mr. Huntsman has no relevant financial
relationships to disclose.
Elad
Ziv
Roselle
Paula
Shaveta
Jennifer
Donglei
Dr. Ziv has no relevant financial relationships to
disclose.
Ms. Agrawal has disclosed that she receives
salary and royalties from Philips Research. She
also disclosed that she has a patent with Philips
Research.
Dr. Banerjee has disclosed that she receives
salary and royalties from Philips Research. She
also disclosed that she has a patent with Philips
Research.
Dr. Dimitrova has disclosed that she receives
salary and royalties from Philips Research. She
also disclosed that she has a patent with Philips
Research.
P2-03-14
P2-03-15
P2-03-15
P2-03-15
P2-03-15
P2-03-15
P2-03-15
P2-03-15
Long range expression patterns detected by
RNASeq in breast cancer reveal cluster enriched
with triple negative breast cancer
Re-assessment of 21-gene breast cancer assay
utilization as a quality indicator by the Florida
Initiative for Quality Cancer Care (FIQCC)
Consortium
Re-assessment of 21-gene breast cancer assay
utilization as a quality indicator by the Florida
Initiative for Quality Cancer Care (FIQCC)
Consortium
Re-assessment of 21-gene breast cancer assay
utilization as a quality indicator by the Florida
Initiative for Quality Cancer Care (FIQCC)
Consortium
Re-assessment of 21-gene breast cancer assay
utilization as a quality indicator by the Florida
Initiative for Quality Cancer Care (FIQCC)
Consortium
Re-assessment of 21-gene breast cancer assay
utilization as a quality indicator by the Florida
Initiative for Quality Cancer Care (FIQCC)
Consortium
Re-assessment of 21-gene breast cancer assay
utilization as a quality indicator by the Florida
Initiative for Quality Cancer Care (FIQCC)
Consortium
Re-assessment of 21-gene breast cancer assay
utilization as a quality indicator by the Florida
Initiative for Quality Cancer Care (FIQCC)
Consortium
Mankovich
Mr. Mankovich has disclosed that she receives
salary and royalties from Philips Research. She
also disclosed that she has a patent with Philips
Research.
Fulp
Mr. Fulp has no relevant financial relationships
to disclose.
Jhanelle
Gray
Dr. Gray has disclosed that he receives grant
funding for chart abstracting.
Paul
Jacobsen
Dr. Jacobsen has disclosed he receives grant
funding for chart abstracting.
Christine
Laronga
Dr. Laronga has disclosed that she receives
grant funding for chart abstracting.
Ji-Hyun
Lee
Dr. Lee has disclosed that she receives grant
funding for chart abstracting.
Erin
Siegel
Dr. Siegel has disclosed that she receives grant
funding for chart abstracting.
Weihong
Sun
Dr. Sun has no relevant financial relationships
to disclose.
Alex
William
P2-03-16
Examining 3-dimensional genome architecture
and transcriptional profiles using an optimized
HiC-seq protocol in breast cancer cells
Examining 3-dimensional genome architecture
and transcriptional profiles using an optimized
HiC-seq protocol in breast cancer cells
Examining 3-dimensional genome architecture
and transcriptional profiles using an optimized
HiC-seq protocol in breast cancer cells
Examining 3-dimensional genome architecture
and transcriptional profiles using an optimized
HiC-seq protocol in breast cancer cells
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
John
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Jane
Bayani
Dr. Bayani has no relevant financial
relationships to disclose.
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Paul
Boutros
Dr. Boutros has no relevant financial
relationships to disclose.
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Cheryl
Crozier
Ms. Crozier has no relevant financial
relationships to disclose.
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Clement
Fung
Mr. Fung has no relevant financial relationships
to disclose.
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Esther
Jung
Ms. Jung has no relevant financial relationships
to disclose.
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Julie
Livingstone
Ms. Livingstone has no relevant financial
relationships to disclose.
P2-03-16
P2-03-16
P2-03-16
Amy
Jennifer
Hu
Christian
Brock
Dr. Brock has no relevant financial
relationships to disclose.
Davis
Dr. Davis has no relevant financial relationships
to disclose.
Li
Dr. Li has no relevant financial relationships to
disclose.
Ross
Dr. Ross has no relevant financial relationships
to disclose.
Bartlett
Dr. Bartlett has no relevant financial
relationships to disclose.
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Mary Anne
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Victoria
P2-03-17
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Melanie
P2-03-17
P2-03-18
P2-03-18
P2-03-18
P2-03-18
P2-03-18
Assessing reproducibility of copy number arrays
to assist breast cancer biomarker discovery
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Quintayo
Ms. Quintayo has no relevant financial
relationships to disclose.
Sabine
Dr. Sabine has no relevant financial
relationships to disclose.
Spears
Dr. Spears has no relevant financial
relationships to disclose.
Cindy
Yao
Ms. Yao has no relevant financial relationships
to disclose.
Wonshik Han
Han
Dr. Han has no relevant financial relationships
to disclose.
YoungJoon
Kang
Young Joon Kang has no relevant financial
relationships to disclose.
Jongjin
Kim
Jongjin Kim has no relevant financial
relationships to disclose.
Min Kyoon
Kim
Min Kyoon Kim has no relevant financial
relationships to disclose.
Yun-Gyoung
Kim
Yun-Gyoung Kim has no relevant financial
relationships to disclose.
P2-03-18
P2-03-18
P2-03-18
P2-03-18
P2-03-18
P2-03-18
P2-03-18
P2-03-19
P2-03-19
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of novel amplified genes in primary
breast cancer with copy number and gene
expression analysis of whole exome and
transcriptome sequencing data
Discovery of the genes that underpin the
transition to malignant phenotype of breast
tumors in highly consanguineous region
Discovery of the genes that underpin the
transition to malignant phenotype of breast
tumors in highly consanguineous region
Lee
Eunshin Lee has no relevant financial
relationships to disclose.
Lee
Han-Byoel Lee has no relevant financial
relationships to disclose.
Kyung-Min
Lee
Kyung-Min Lee has no relevant financial
relationships to disclose.
Woosung
Lim
Woosung Lim has no relevant financial
relationships to disclose.
Hyeong-Gon
Moon
Hyeong-Gon Moon has no relevant financial
relationships to disclose.
Dong-Young
Noh
Dr. Noh has no relevant financial relationships
to disclose.
Yoo
Tae-kyung Yoo has no relevant financial
relationships to disclose.
Gupta
Ishita Gupta has no relevant financial
relationships to disclose.
Ouhtit
Dr. Ouhtit has no relevant financial
relationships to disclose.
Eunshin
Han-Byoel
Tae-kyung
Ishita
Allal
P2-03-19
P2-04-01
P2-04-01
P2-04-01
P2-04-01
P2-04-01
P2-04-01
P2-04-01
P2-04-02
P2-04-02
P2-04-02
P2-04-02
Discovery of the genes that underpin the
transition to malignant phenotype of breast
tumors in highly consanguineous region
The signal transduction molecule MAP3K12 is
critical for triple-negative breast cancer cells
The signal transduction molecule MAP3K12 is
critical for triple-negative breast cancer cells
The signal transduction molecule MAP3K12 is
critical for triple-negative breast cancer cells
The signal transduction molecule MAP3K12 is
critical for triple-negative breast cancer cells
The signal transduction molecule MAP3K12 is
critical for triple-negative breast cancer cells
The signal transduction molecule MAP3K12 is
critical for triple-negative breast cancer cells
The signal transduction molecule MAP3K12 is
critical for triple-negative breast cancer cells
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Somya
Shanmuganathan
Powel
Brown
Jamal
Hill
Abhijit
Mazumdar
Gordon
Mills
Graham
Poage
Ivan
Uray
Yun
Zhang
Somya Shanmuganathan has no relevant
financial relationships to disclose.
Dr. Brown has no relevant financial
relationships to disclose.
Mr. Hill has no relevant financial relationships
to disclose.
Abhijit Mazumdar has no relevant financial
relationships to disclose.
Mr. Mills has no relevant financial relationships
to disclose.
Dr. Poage has no relevant financial
relationships to disclose.
Mr. Uray has no relevant financial relationships
to disclose.
Yun Zhang has no relevant financial
relationships to disclose.
Laura
Austin
Dr. Austin has no relevant financial
relationships to disclose.
Tiffany
Avery
Dr. Avery has no relevant financial
relationships to disclose.
Massimo
Cristofanilli
Dr. Cristofanilli has no relevant financial
relationships to disclose.
Hencin
Dr. Hencin has disclosed that he has an
ownership position at Theranostics.
Ron
P2-04-02
P2-04-02
P2-04-02
P2-04-02
P2-04-03
P2-04-03
P2-04-03
P2-04-03
P2-04-03
P2-04-03
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Identifying molecular targets and mechanisms
of treatment resistance in inflammatory breast
cancer (IBC) using reverse-phase protein
microarrays (RPMA)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Rebecca
Kimberly
Juan
Emanuel
Laura
Massimo
Helmy
Paolo
Gangwu
Benjamin
Jaslow
Dr. Jaslow has no relevant financial
relationships to disclose.
Limentani
Dr. Limentani has no relevant financial
relationships to disclose.
Palazzo
Dr. Palazzo has no relevant financial
relationships to disclose.
Petricoin
Dr. Petricoin has disclosed that he has an
ownership position at Theranostics and
leadership and ownership at Perthera.
Austin
Dr. Austin has no relevant financial
relationships to disclose.
Cristofanilli
Dr. Cristofanilli has no relevant financial
relationships to disclose.
Eltoukhy
Dr. Eltoukhy has disclosed that he is CEO, full
time employee and stock owner.
Fortina
Dr. Fortina has no relevant financial
relationships to disclose.
Mei
Gangwu Mei has disclosed that he is a full time
employee and stock owner.
Schiller
Mr. Schiller has disclosed that he is a stock
holder, employee and co-founder.
P2-04-03
P2-04-03
P2-04-03
P2-04-03
P2-04-04
P2-04-04
P2-04-04
P2-04-04
P2-04-04
P2-04-04
P2-04-04
P2-04-04
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Circulating tumor DNA (ctDNA) provides
molecular monitoring for inflammatory breast
cancer (IBC)
Association of mammographic density and
molecular breast cancer subtype
Association of mammographic density and
molecular breast cancer subtype
Association of mammographic density and
molecular breast cancer subtype
Association of mammographic density and
molecular breast cancer subtype
Association of mammographic density and
molecular breast cancer subtype
Association of mammographic density and
molecular breast cancer subtype
Association of mammographic density and
molecular breast cancer subtype
Association of mammographic density and
molecular breast cancer subtype
Dragan
LaiMun
AmirAli
Sebisanovic
Mr. Sebisanovic has disclosed that he is a full
time employee and stock owner.
Siew
Mr. Siew has disclosed he is a full time
employee and stock owner.
Talasaz
Dr. Talasaz has disclosed he is a co-founder, full
time employee and stock owner.
Aubrey
Zapanta
Kristen
Atkins
Wendy
Cohn
Brandy
Edwards
Jennifer
Harvey
Krista
Larson
Wendy
Novicoff
Anneke
Schroen
George
Stukenborg
Ms. Zapanta has disclosed she is a full time
employee and stock owner.
Dr. Atkins has no relevant financial
relationships to disclose.
Dr. Cohn has no relevant financial relationships
to disclose.
Dr. Edwards has no relevant financial
relationships to disclose.
Dr. Harvey has disclosed she does contract
work for Department of Defense. Volpara
Solutions, Ltd. Wellington, New Zealand and
Hologic, Inc. Danbury CT. He also disclosed he
has ownership in Volpara Solutions, Ltd.
Wellington, New Zealand and Hologic, Inc.,
Danbury CT.
Ms. Larsohas no relevant financial relationships
to disclose.
Dr. Novicoff has no relevant financial
relationships to disclose.
Dr. Schroen has no relevant financial
relationships to disclose.
Dr. Stukenborg has no relevant financial
relationships to disclose.
P2-04-05
P2-04-05
P2-04-05
P2-04-05
P2-04-05
P2-04-05
P2-04-05
P2-04-06
P2-04-06
Modeling luminal breast cancer heterogeneity:
Combination therapies to suppress hormone
receptor-negative subpopulations among
receptor-positive ones
Modeling luminal breast cancer heterogeneity:
Combination therapies to suppress hormone
receptor-negative subpopulations among
receptor-positive ones
Modeling luminal breast cancer heterogeneity:
Combination therapies to suppress hormone
receptor-negative subpopulations among
receptor-positive ones
Modeling luminal breast cancer heterogeneity:
Combination therapies to suppress hormone
receptor-negative subpopulations among
receptor-positive ones
Modeling luminal breast cancer heterogeneity:
Combination therapies to suppress hormone
receptor-negative subpopulations among
receptor-positive ones
Modeling luminal breast cancer heterogeneity:
Combination therapies to suppress hormone
receptor-negative subpopulations among
receptor-positive ones
Modeling luminal breast cancer heterogeneity:
Combination therapies to suppress hormone
receptor-negative subpopulations among
receptor-positive ones
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Abdel-Hafiz
Dr. Abdel-Hafiz has no relevant financial
relationships to disclose.
Bliesner
Mr. Bliesner has no relevant financial
relationships to disclose.
James
Haughian
Dr. Haughian has no relevant financial
relationships to disclose.
Kathryn
Horwitz
Dr. Horwitz has no relevant financial
relationships to disclose.
Aaron
Knox
Dr. Knox has no relevant financial relationships
to disclose.
Maurcio
Pinto
Dr. Pinto has no relevant financial relationships
to disclose.
Scaling
Dr. Scaling has no relevant financial
relationships to disclose.
Allred
Dr. Allred has no relevant financial
relationships to disclose.
Dinn
Sean Dinn has no relevant financial
relationships to disclose.
Hany
Brian
Allison
Craig
Sean
P2-04-06
P2-04-06
P2-04-06
P2-04-06
P2-04-06
P2-04-06
P2-04-06
P2-04-06
P2-04-06
P2-04-06
P2-04-07
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Demonstration of immune cell and pathway
heterogeneity in Singapore DCIS samples using
novel hyperplexing method (MultiOmyx®)
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Foo
Mr. Foo has no relevant financial relationships
to disclose.
Gerdes
Mr. Gerdes has no relevant financial
relationships to disclose.
Ginty
Ms. Ginty has no relevant financial
relationships to disclose.
Kaanumalle
Sireesha Kaanumalle has no relevant financial
relationships to disclose.
LaPlante
Ms. LaPlante has no relevant financial
relationships to disclose.
Christina
Lowes
Ms. Lowes has no relevant financial
relationships to disclose.
Elizabeth
McDonough
Ms. McDonough has no relevant financial
relationships to disclose.
Yunxia
Sui
Yunxia Sui has no relevant financial
relationships to disclose.
Tan
Puay-Hoon Tan has no relevant financial
relationships to disclose.
Zhang
Rong Zhang has no relevant financial
relationships to disclose.
Campion
Dr. Campion has no relevant financial
relationships to disclose.
Thomas
Michael
Fiona
Sireesha
Nicole
Puay-Hoon
Rong
Loïc
P2-04-07
P2-04-07
P2-04-07
P2-04-07
P2-04-07
P2-04-07
P2-04-07
P2-04-07
P2-04-07
P2-04-07
P2-04-08
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Gene-expression molecular subtyping of
immunohistochemistry-typed triple-negative
breast cancer tumours
Accuracy of estrogen receptor, progesterone
receptor, HER2 Status and Ki67 labeling index
between core needle and surgical excisional
tumour in 910 patients with breast cancer
Campone
Dr. Campone has no relevant financial
relationships to disclose.
Chassevent
Ms. Chassevent has no relevant financial
relationships to disclose.
Gouraud
Wilfried Gouraud has no relevant financial
relationships to disclose.
Guérin-Charbonnel
Ms. Guérin-Charbonnel has no relevant
financial relationships to disclose.
Guette
Ms. Guette has no relevant financial
relationships to disclose.
Pascal
Jézéquel
Mr. Jézéquel has no relevant financial
relationships to disclose.
Delphine
Loussouarn
Delphine Loussouarn has no relevant financial
relationships to disclose.
Isabelle
Valo
Ms. Valo has no relevant financial relationships
to disclose.
Vanier
Mr. Vanier has no relevant financial
relationships to disclose.
Verrièle
Ms. Verrièle has no relevant financial
relationships to disclose.
Itami
Dr. Itami has no relevant financial relationships
to disclose.
Mario
Agnès
Wilfried
Catherine
Catherine
Antoine
Véronique
Makiko
P2-04-08
P2-04-08
P2-04-08
P2-04-08
P2-04-10
P2-04-10
P2-04-10
Accuracy of estrogen receptor, progesterone
receptor, HER2 Status and Ki67 labeling index
between core needle and surgical excisional
tumour in 910 patients with breast cancer
Accuracy of estrogen receptor, progesterone
receptor, HER2 Status and Ki67 labeling index
between core needle and surgical excisional
tumour in 910 patients with breast cancer
Accuracy of estrogen receptor, progesterone
receptor, HER2 Status and Ki67 labeling index
between core needle and surgical excisional
tumour in 910 patients with breast cancer
Accuracy of estrogen receptor, progesterone
receptor, HER2 Status and Ki67 labeling index
between core needle and surgical excisional
tumour in 910 patients with breast cancer
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Itookubo
Dr. Itookubo has no relevant financial
relationships to disclose.
Nakagawa
Dr. Nakagawa has no relevant financial
relationships to disclose.
Rikiya
Nakamura
Dr. Nakamura has no relevant financial
relationships to disclose.
Naohito
Yamamoto
Dr. Yamamoto has no relevant financial
relationships to disclose.
Dennis
Eslie Dennis has disclosed that she is a full time
employee of and has stock of Ventana Medical
Systems, Inc.
Hayashi
Yuji Hayashi has no relevant financial
relationships to disclose.
Horiguchi
Jun Horiguchi has no relevant financial
relationships to disclose.
Yoshiyuki
Ayako
Eslie
Yuji
Jun
P2-04-10
P2-04-10
P2-04-10
P2-04-10
P2-04-10
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Inoue
Kenichi Inoue has no relevant financial
relationships to disclose.
Kurosumi
Masafumi Kurosumi has no relevant financial
relationships to disclose.
Sasagu
Kurozumi
Sasagu Kurozumi has no relevant financial
relationships to disclose.
Hiroshi
Matsumoto
Hiroshi Matsumoto has no relevant financial
relationships to disclose.
Nagai
Shigenori Nagai has no relevant financial
relationships to disclose.
Kenichi
Masafumi
Shigenori
P2-04-10
P2-04-10
P2-04-10
P2-04-10
P2-04-10
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
Hiroaki
Hanako
Mary
Jim
Izumi
Nitta
Hiroaki Nitta has disclosed that he is a full time
employee of and has ownership in Ventana
Medical Systems, Inc.
Oba
Hanako Oba has no relevant financial
relationships to disclose.
Padilla
Ms. Padilla has disclosed that she is a full time
employee of and owns stock of Ventana
Medical Systems, Inc.
Ranger-Moore
Mr. Ranger-Moore has disclosed he is a full
time employee of and has stock of Ventana
Medical Systems, Inc.
Takeyoshi
Izumi Takeyoshi has no relevant financial
relationships to disclose.
P2-04-11
Utility of simultaneous HER2 protein and gene
assessment for the evaluation of discrepancy
and intratumoral heterogeneity of HER2 status
and the prediction of prognosis in invasive
breast cancer using the gene-protein assay
(GPA)
HER2/Neu genetic heterogeneity analysis in
breast carcinoma
HER2/Neu genetic heterogeneity analysis in
breast carcinoma
HER2/Neu genetic heterogeneity analysis in
breast carcinoma
HER2/Neu genetic heterogeneity analysis in
breast carcinoma
HER2/Neu genetic heterogeneity analysis in
breast carcinoma
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Ashwag
Albukhari
Ashwag Albukhari has no relevant financial
relationships to disclose.
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Francesca
Buffa
Dr. Buffa has no relevant financial relationships
to disclose.
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Hani
Choudhry
Hani Choudhry has no relevant financial
relationships to disclose.
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Syed
Haider
Dr. Haider has no relevant financial
relationships to disclose.
P2-04-10
P2-04-11
P2-04-11
P2-04-11
P2-04-11
Katsunori
Tozuka
Zhongzhong
Chen
Yuan
Sheng
Kainan
Wu
Yanmei
Wu
Yue
Yu
Katsunori Tozuka has no relevant financial
relationships to disclose.
Zhongzhong Chen has no relevant financial
relationships to disclose.
Dr. Sheng has no relevant financial
relationships to disclose.
Kainan Wu has no relevant financial
relationships to disclose.
Yanmei Wu has no relevant financial
relationships to disclose.
Yue Yu has no relevant financial relationships
to disclose.
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Adrian
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
David
Harris
Dr. Harris has no relevant financial
relationships to disclose.
Mole
Dr. Mole has no relevant financial relationships
to disclose.
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Ioannis
Ragousis
Dr. Ragousis has no relevant financial
relationships to disclose.
P2-05-01
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Peter
Ratcliffe
Dr. Ratcliffe has no relevant financial
relationships to disclose.
Schodel
Dr. Schodel has no relevant financial
relationships to disclose.
Bergh
Dr. Bergh has no relevant financial
relationships to disclose.
Bjöhle
Dr. Bjöhle has no relevant financial
relationships to disclose.
P2-05-01
P2-05-02
P2-05-02
The non-coding transcriptome of hypoxic breast
cancer: Novel insights of clinical relevant long
non-coding RNA in hypoxia signalling
Johannes
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Jonas
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Judith
P2-05-02
P2-05-02
P2-05-02
P2-05-02
P2-05-02
P2-05-02
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Jan
Frisell
Thomas
Hatschek
Dr. Frisell has no relevant financial
relationships to disclose.
Dr. Hatschek has disclosed that he receives
speakers honoraria from Roche. He also
disclosed that he receives, as PI, research
grants to support the PROMIX trial, Roche and
Sanofi-Aventis.
Hedenfalk
Ms. Hedenfalk has no relevant financial
relationships to disclose.
Johansson
Dr. Johansson has no relevant financial
relationships to disclose.
Lekberg
Dr. Lekberg has no relevant financial
relationships to disclose.
Loman
Dr. Loman has disclosed that he receives
speakers honoraria from Roche.
Ingrid
Ida
Tobias
Niklas
P2-05-02
P2-05-02
P2-05-03
P2-05-03
P2-05-03
P2-05-03
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Preliminary translational results from PROMIX, a
phase II trial of preoperative chemotherapy
with the addition of bevacizumab in large
operable and locally advanced HER2-negative
breast cancer
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Lisa
Rydén
Dr. Rydén has no relevant financial
relationships to disclose.
Anna
von Wachenfeldt
Dr. von Wachenfeldt has no relevant financial
relationships to disclose.
Atkins
Dr. Atkins has no relevant financial
relationships to disclose.
Falchook
Dr. Falchook has no relevant financial
relationships to disclose.
Fu
Dr. Fu has no relevant financial relationships to
disclose.
Hong
Dr. Hong has no relevant financial relationships
to disclose.
Johnique
Gerald
Siqing
David
P2-05-03
P2-05-03
P2-05-03
P2-05-03
P2-05-03
P2-05-03
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Filip
Janku
Dr. Janku has no relevant financial
relationships to disclose.
Razelle
Kurzrock
Dr. Kurzrock has no relevant financial
relationships to disclose.
Meric-Bernstam
Dr. Meric-Bernstam has no relevant financial
relationships to disclose.
Miller
Dr. Miller has disclosed he receives salary from
Foundation Medicine.
Moulder
Dr. Moulder has no relevant financial
relationships to disclose.
Naing
Dr. Naing has no relevant financial
relationships to disclose.
Funda
Vince
Stacy
Aung
P2-05-03
P2-05-03
P2-05-03
P2-05-03
P2-05-03
P2-05-03
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Sarina
Philip
Apostolia
Vincente
Jennifer
Roman
Piha-Paul
Dr. Piha-Paul has no relevant financial
relationships to disclose.
Stephens
Dr. Stephens has disclosed he receives salary
from and has ownership in Foundation
Medicine.
Tsimberidou
Dr. Tsimberidou has no relevant financial
relationships to disclose.
Valero
Dr. Valero has no relevant financial
relationships to disclose.
Wheler
Dr. Wheler has no relevant financial
relationships to disclose.
Yelensky
Dr. Yelensky has disclosed he receives salary
from and has ownership in Foundation
Medicine.
P2-05-03
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-04
P2-05-05
P2-05-05
Anastrozole and everolimus in hormone
receptor-positive metastatic breast cancer:
Safety profile, activity and associations of
molecular alterations in the PI3K/AKT/mTOR
pathway
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
Gene expression associated with poor prognosis
of young TNBC patients
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
Ralph
Zinner
Sven
Becker
Giampaolo
Bianchini
Balazs
Györffy
Christos
Hatzis
Uwe
Holtrich
Thomas
Karn
Cornelia
Liedtke
Volkmar
Müller
Lajos
Pusztai
Achim
Rody
Marcus
Schmidt
Dr. Zinner has no relevant financial
relationships to disclose.
Mr. Becker has no relevant financial
relationships to disclose.
Giampaolo Bianchini has no relevant financial
relationships to disclose.
Dr. Györffy has no relevant financial
relationships to disclose.
Christos Hatzis has no relevant financial
relationships to disclose.
Uwe Holtrich has no relevant financial
relationships to disclose.
Mr. Karn has no relevant financial relationships
to disclose.
Cornelia Liedtke has no relevant financial
relationships to disclose.
Dr. Müller has no relevant financial
relationships to disclose.
Dr. Pusztai has no relevant financial
relationships to disclose.
Achim Rody has no relevant financial
relationships to disclose.
Dr. Schmidt has no relevant financial
relationships to disclose.
Bartlett
Dr. Bartlett has no relevant financial
relationships to disclose.
Levine
Dr. Levine has no relevant financial
relationships to disclose.
John
Mark
P2-05-05
P2-05-05
P2-05-05
P2-05-05
P2-05-05
P2-05-05
P2-05-05
P2-05-06
P2-05-06
P2-05-06
P2-05-06
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
A four gene signature predicts anthracycline
benefit: Evidence from the BR9601 and MA5
breast cancer trials
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Lyttle
Ms. Lyttle has no relevant financial
relationships to disclose.
Munro
Ms. Munro has no relevant financial
relationships to disclose.
Pritchard
Dr. Pritchard has no relevant financial
relationships to disclose.
Shepherd
Dr. Shepherd has no relevant financial
relationships to disclose.
Spears
Dr. Spears has no relevant financial
relationships to disclose.
Christopher
Twelves
Dr. Twelves has no relevant financial
relationships to disclose.
Fouad
Yousif
Fouad Yousif has no relevant financial
relationships to disclose.
François
Bertucci
Dr. Bertucci has no relevant financial
relationships to disclose.
Bieche
Dr. Bieche has no relevant financial
relationships to disclose.
de la Grange
Dr. de la Grange has no relevant financial
relationships to disclose.
Gentien
Mr. Gentien has no relevant financial
relationships to disclose.
Nicola
Alison
Kathleen
Lois
Melanie
Ivan
Pierre
David
P2-05-06
P2-05-06
P2-05-06
P2-05-06
P2-05-06
P2-05-07
P2-05-07
P2-05-07
P2-05-07
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Identification of specific gene signatures and
alternative splice variants using exon array in
Inflammatory breast Cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Marie
Florence
Sophie
Sophie
Steven
Wonshik
Je-Gun
Young Joon
Jisun
Le Cann
Dr. Le Cann has no relevant financial
relationships to disclose.
Lerebours
Dr. Lerebours has no relevant financial
relationships to disclose.
Rondeau
Dr. Rondeau has no relevant financial
relationships to disclose.
Vacher
Ms. Vacher has no relevant financial
relationships to disclose.
Van Laere
Dr. Van Laere has no relevant financial
relationships to disclose.
Han
Dr. Han has no relevant financial relationships
to disclose.
Joung
Dr. Joung has no relevant financial
relationships to disclose.
Kang
Dr. Kang has no relevant financial relationships
to disclose.
Kim
Dr. Kim has no relevant financial relationships
to disclose.
P2-05-07
P2-05-07
P2-05-07
P2-05-07
P2-05-07
P2-05-07
P2-05-07
P2-05-07
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Yun-Gyoung
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Eunshin
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Hae-ock
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Han-Byoel
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Kyung-Min
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Hyeong-Gon
Moon
Dr. Moon has no relevant financial
relationships to disclose.
Jongjin
Min Kyoon
P2-05-07
P2-05-07
P2-05-07
P2-05-07
P2-05-07
P2-05-08
P2-05-08
P2-05-08
P2-05-08
P2-05-08
P2-05-08
P2-05-08
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
Feasibility and sensitivity of fine-needle
aspiration biopsies for the detection of somatic
mutations using next-generation sequencing in
breast cancer
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
Noh
Dr. Noh has no relevant financial relationships
to disclose.
Park
Dr. Park has no relevant financial relationships
to disclose.
Woong-Yang
Park
Dr. Park has no relevant financial relationships
to disclose.
Han Suk
Ryu
Dr. Ryu has no relevant financial relationships
to disclose.
Dong-Young
In-Ae
Tae-Kyung
Yoo
Martin
Abba
C Marcelo
Aldaz
Marcos
Estecio
Ting
Gong
Jaeho
Lee
Yue
Lu
Aysegul
Sahin
Dr. Yoo has no relevant financial relationships
to disclose.
Dr. Abba has no relevant financial relationships
to disclose.
Dr. Aldaz has no relevant financial relationships
to disclose.
Dr. Estecio has no relevant financial
relationships to disclose.
Dr. Gong has no relevant financial relationships
to disclose.
Dr. Lee has no relevant financial relationships
to disclose.
Dr. Lu has no relevant financial relationships to
disclose.
Dr. Sahin has no relevant financial relationships
to disclose.
P2-05-09
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
The molecular landscape of breast ductal
carcinoma in situ (DCIS)
Functional mapping of the oncogenic kinome
activity of triple-negative breast cancer cells
Functional mapping of the oncogenic kinome
activity of triple-negative breast cancer cells
Functional mapping of the oncogenic kinome
activity of triple-negative breast cancer cells
Functional mapping of the oncogenic kinome
activity of triple-negative breast cancer cells
Functional mapping of the oncogenic kinome
activity of triple-negative breast cancer cells
Functional mapping of the oncogenic kinome
activity of triple-negative breast cancer cells
Functional mapping of the oncogenic kinome
activity of triple-negative breast cancer cells
P2-05-10
Explore the differences and relationships
between normal and ADH, DCIS and IDC tissues
in breast based on Raman spectroscopy
Ye
P2-05-10
Explore the differences and relationships
between normal and ADH, DCIS and IDC tissues
in breast based on Raman spectroscopy
Zhimin
P2-05-10
Explore the differences and relationships
between normal and ADH, DCIS and IDC tissues
in breast based on Raman spectroscopy
Bing
P2-05-10
Explore the differences and relationships
between normal and ADH, DCIS and IDC tissues
in breast based on Raman spectroscopy
Lijia
P2-05-08
P2-05-08
P2-05-09
P2-05-09
P2-05-09
P2-05-09
P2-05-09
P2-05-09
Jianjun
Shen
Yoko
Takata
Jean-Philippe
Coppe
Marij
Hartog
Pei Rong Evelyn
Lee
Miki
Mori
Bo
Pan
Qiang
Sun
Laura
van 't Veer
Dr. Shen has no relevant financial relationships
to disclose.
Yoko Takata has no relevant financial
relationships to disclose.
Dr. Coppe has no relevant financial
relationships to disclose.
Marij Hartog has no relevant financial
relationships to disclose.
Ms. Lee has no relevant financial relationships
to disclose.
Dr. Mori has no relevant financial relationships
to disclose.
Dr. Pan has no relevant financial relationships
to disclose.
Dr. Sun has no relevant financial relationships
to disclose.
Dr. van 't Veer has no relevant financial
relationships to disclose.
Du
Dr. Du has no relevant financial relationships to
disclose.
Fan
Prof. Fan has no relevant financial relationships
to disclose.
Han
Prof. Han has no relevant financial
relationships to disclose.
Liang
Lijia Liang has no relevant financial
relationships to disclose.
P2-05-10
Explore the differences and relationships
between normal and ADH, DCIS and IDC tissues
in breast based on Raman spectroscopy
Weiqing
P2-05-10
Explore the differences and relationships
between normal and ADH, DCIS and IDC tissues
in breast based on Raman spectroscopy
Haipeng
P2-05-10
P2-05-11
P2-05-11
P2-05-11
P2-05-11
P2-05-11
Explore the differences and relationships
between normal and ADH, DCIS and IDC tissues
in breast based on Raman spectroscopy
Genetic profiling of breast cancer confirms a
pivotal role of EGFR pathway in the
development of acquired resistance to
tamoxifen
Genetic profiling of breast cancer confirms a
pivotal role of EGFR pathway in the
development of acquired resistance to
tamoxifen
Genetic profiling of breast cancer confirms a
pivotal role of EGFR pathway in the
development of acquired resistance to
tamoxifen
Genetic profiling of breast cancer confirms a
pivotal role of EGFR pathway in the
development of acquired resistance to
tamoxifen
Genetic profiling of breast cancer confirms a
pivotal role of EGFR pathway in the
development of acquired resistance to
tamoxifen
Xu
Prof. Xu has no relevant financial relationships
to disclose.
Zhang
Dr. Zhang has no relevant financial
relationships to disclose.
Chao
Zheng
Dr. Zheng has no relevant financial
relationships to disclose.
Nasr
Allahloubi
Dr. Allahloubi has no relevant financial
relationships to disclose.
Abeer
Bahnasy
Dr. Bahnasy has no relevant financial
relationships to disclose.
Rabab
Gaafar
Dr. Gaafar has no relevant financial
relationships to disclose.
Ibrahim
Malash
Dr. Malash has no relevant financial
relationships to disclose.
Osman
Mansour
Dr. Mansour has no relevant financial
relationships to disclose.
P2-05-11
P2-05-12
P2-05-12
P2-05-12
P2-05-12
P2-05-12
P2-05-12
P2-05-12
P2-05-12
P2-05-13
Genetic profiling of breast cancer confirms a
pivotal role of EGFR pathway in the
development of acquired resistance to
tamoxifen
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Signatures of endocrine resistance in the
tamoxifen and exemestane adjuvant
multinational trial (TEAM)-UK cohort
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Shaarawy
Dr. Shaarawy has no relevant financial
relationships to disclose.
John
Bartlett
Dr. Bartlett has no relevant financial
relationships to disclose.
Jane
Bayani
Dr. Bayani has no relevant financial
relationships to disclose.
Paul
Boutros
Dr. Boutros has no relevant financial
relationships to disclose.
Cassandra
Brookes
Ms. Brookes has no relevant financial
relationships to disclose.
Haider
Dr. Haider has no relevant financial
relationships to disclose.
Quintayo
Ms. Quintayo has no relevant financial
relationships to disclose.
Rea
Dr. Rea has no relevant financial relationships
to disclose.
Cindy
Yao
Ms. Yao has no relevant financial relationships
to disclose.
Fiona
Bane
Ms. Bane has no relevant financial
relationships to disclose.
Sabry
Syed
Mary Anne
Daniel
P2-05-13
P2-05-13
P2-05-13
P2-05-13
P2-05-13
P2-05-13
P2-05-13
P2-05-13
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Transcriptomic profiling of patient sequential
tumours provides cutting edge view of global
metastatic expression changes following
endocrine therapy
Bolger
Dr. Bolger has no relevant financial
relationships to disclose.
Byrne
Dr. Byrne has no relevant financial
relationships to disclose.
Ailis
Fagan
Dr. Fagan has no relevant financial
relationships to disclose.
Arnold
Hill
Mr. Hill has no relevant financial relationships
to disclose.
Jean
McBryan
Dr. McBryan has no relevant financial
relationships to disclose.
Damian
McCartan
Dr. McCartan has no relevant financial
relationships to disclose.
Marie
McIlroy
Ms. McIlroy has no relevant financial
relationships to disclose.
Leonie
Young
Leonie Young has no relevant financial
relationships to disclose.
Jarlath
Christopher
P2-05-14
P2-05-14
P2-05-14
P2-05-14
P2-05-14
P2-05-14
P2-05-14
P2-05-14
P2-05-14
P2-05-14
P2-05-14
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
Carlson
Ms. Carlson has no relevant financial
relationships to disclose.
Cyr
Ms. Cyr has no relevant financial relationships
to disclose.
De
Dr. De has no relevant financial relationships to
disclose.
Dey
Dr. Dey has no relevant financial relationships
to disclose.
King
Ms. King has no relevant financial relationships
to disclose.
Jessica
Klein
Ms. Klein has no relevant financial relationships
to disclose.
Amy
Krie
Brian
Leyland-Jones
Dr. Krie has no relevant financial relationships
to disclose.
Dr. Leyland-Jones has disclosed that he is a
consultant for Roche and Genentech. He has
also disclosed that he is a speaker for
Genentech.
Small
Ms. Small has no relevant financial
relationships to disclose.
Sun
Dr. Sun has no relevant financial relationships
to disclose.
Williams
Dr. Williams has no relevant financial
relationships to disclose.
Jennifer
Brigitte
Pradip
Nandini
Michelle
Misty
Yuliang
Casey
P2-05-14
P2-05-14
P2-05-14
P2-05-15
P2-05-15
P2-05-15
P2-05-15
P2-05-15
P2-05-15
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
New treatment options for metastatic breast
cancer revealed by reverse-phase protein
microarray and genomic profiling
Exploring type II microcalcifications in benign,
premalignant and malignant breast lesions by
shell-isolated nanoparticle-enhanced Raman
spectroscopy (SHINERS)
Exploring type II microcalcifications in benign,
premalignant and malignant breast lesions by
shell-isolated nanoparticle-enhanced Raman
spectroscopy (SHINERS)
Exploring type II microcalcifications in benign,
premalignant and malignant breast lesions by
shell-isolated nanoparticle-enhanced Raman
spectroscopy (SHINERS)
Exploring type II microcalcifications in benign,
premalignant and malignant breast lesions by
shell-isolated nanoparticle-enhanced Raman
spectroscopy (SHINERS)
Exploring type II microcalcifications in benign,
premalignant and malignant breast lesions by
shell-isolated nanoparticle-enhanced Raman
spectroscopy (SHINERS)
Exploring type II microcalcifications in benign,
premalignant and malignant breast lesions by
shell-isolated nanoparticle-enhanced Raman
spectroscopy (SHINERS)
Williams
Ms. Williams has no relevant financial
relationships to disclose.
Willis
Dr. Willis has no relevant financial relationships
to disclose.
Brandon
Young
Mr. Young has no relevant financial
relationships to disclose.
Ye
Du
Dr. Du has no relevant financial relationships to
disclose.
Zhimin
Fan
Prof. Fan has no relevant financial relationships
to disclose.
Bing
Han
Prof. Han has no relevant financial
relationships to disclose.
Lijia
Liang
Lijia Liang has no relevant financial
relationships to disclose.
Weiqing
Xu
Prof. Xu has no relevant financial relationships
to disclose.
Zhang
Dr. Zhang has no relevant financial
relationships to disclose.
Kirstin
Scooter
Haipeng
P2-05-15
P2-05-16
P2-05-16
P2-05-16
P2-05-16
P2-05-16
P2-05-16
P2-05-16
P2-05-16
P2-05-16
P2-05-16
Exploring type II microcalcifications in benign,
premalignant and malignant breast lesions by
shell-isolated nanoparticle-enhanced Raman
spectroscopy (SHINERS)
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Zheng
Dr. Zheng has no relevant financial
relationships to disclose.
Stephen
Allpress
Dr. Allpress has no relevant financial
relationships to disclose.
Cherie
Blenkiron
Dr. Blenkiron has no relevant financial
relationships to disclose.
Reuben
Broom
Dr. Broom has no relevant financial
relationships to disclose.
Anna
Brown
Ms. Brown has no relevant financial
relationships to disclose.
Gale
Dr. Gale has no relevant financial relationships
to disclose.
Harman
Dr. Harman has no relevant financial
relationships to disclose.
Lasham
Dr. Lasham has no relevant financial
relationships to disclose.
Print
Dr. Print has no relevant financial relationships
to disclose.
Rice
Dr. Rice has no relevant financial relationships
to disclose.
Shin
Dr. Shin has no relevant financial relationships
to disclose.
Chao
Katherine
Richard
Annette
Cristin
Sam
Peter
P2-05-16
P2-06-01
P2-06-01
P2-06-01
P2-06-01
P2-06-01
P2-06-01
P2-06-01
P2-06-01
P2-06-01
P2-06-01
Gene expression in synchronous primary,
axillary nodal and disseminated breast cancer
cells
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Whineray Kelly
Dr. Whineray Kelly has no relevant financial
relationships to disclose.
Alvarado
Mr. Alvarado has no relevant financial
relationships to disclose.
Egelhoff
Dr. Egelhoff has no relevant financial
relationships to disclose.
Hale
Dr. Hale has no relevant financial relationships
to disclose.
Hitomi
Dr. Hitomi has no relevant financial
relationships to disclose.
Awad
Jarrar
Mr. Jarrar has no relevant financial
relationships to disclose.
Justin
Lathia
Dr. Lathia has no relevant financial
relationships to disclose.
Baltin
Otvos
Dr. Otvos has no relevant financial
relationships to disclose.
Reizes
Dr. Reizes has no relevant financial
relationships to disclose.
Rich
Dr. Rich has no relevant financial relationships
to disclose.
Sinyuk
Mr. Sinyuk has no relevant financial
relationships to disclose.
Erica
Alvaro
Thomas
James
Masahiro
Ofer
Jeremy
Maksim
P2-06-01
P2-06-01
P2-06-01
P2-06-01
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Development of a fluorescent reporter system
to delineate self-renewing cells in triple
negative breast cancer
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Stoltz
Mr. Stoltz has no relevant financial
relationships to disclose.
Thiagarajan
Dr. Thiagarajan has no relevant financial
relationships to disclose.
Thomas
Mr. Thomas has no relevant financial
relationships to disclose.
Zheng
Dr. Zheng has no relevant financial
relationships to disclose.
Absar
Mr. Absar has no relevant financial
relationships to disclose.
Denis
Alfarez
Mr. Alfarez has no relevant financial
relationships to disclose.
Anne
Armstrong
Ms. Armstrong has no relevant financial
relationships to disclose.
Maria
Bramley
Ms. Bramley has no relevant financial
relationships to disclose.
Chatterjee
Sumohan Chatterjee has no relevant financial
relationships to disclose.
Clarke
Dr. Clarke has no relevant financial
relationships to disclose.
Eyre
Ms. Eyre has no relevant financial relationships
to disclose.
Kevin
Praveena
Dustin
Qiao
Mohamed
Sumohan
Robert
Rachel
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-02
P2-06-03
P2-06-03
P2-06-03
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Breast cancer stem-like cell activity correlates
with tumour progression to metastasis but not
with clinical or tumour characteristics
Prostaglandin E receptor EP4 is a therapeutic
target in breast cancer stem cells
Prostaglandin E receptor EP4 is a therapeutic
target in breast cancer stem cells
Prostaglandin E receptor EP4 is a therapeutic
target in breast cancer stem cells
Gandhi
Ashu Gandhi has no relevant financial
relationships to disclose.
Howell
Dr. Howell has no relevant financial
relationships to disclose.
Kirwan
Dr. Kirwan has no relevant financial
relationships to disclose.
Saad
Zahida Saad has no relevant financial
relationships to disclose.
Santiago-Gomez
Ms. Santiago-Gomez has no relevant financial
relationships to disclose.
Fran
Shaw
Fran Shaw has no relevant financial
relationships to disclose.
Bruno
Simoes
Mr. Simoes has no relevant financial
relationships to disclose.
Katherine
Spence
Ms. Spence has no relevant financial
relationships to disclose.
Ashu
Sacha
Cliona
Zahida
Angelica
Andrew
Wardley
Amy
Fulton
Tyler
Kochel
Namita
Kundu
Mr. Wardley has no relevant financial
relationships to disclose.
Dr. Fulton has no relevant financial
relationships to disclose.
Mr. Kochel has no relevant financial
relationships to disclose.
Dr. Kundu has no relevant financial
relationships to disclose.
P2-06-03
Prostaglandin E receptor EP4 is a therapeutic
target in breast cancer stem cells
Prostaglandin E receptor EP4 is a therapeutic
target in breast cancer stem cells
P2-06-04
Proteosome inhibitor bortezomib inhibits NFκB
and effectively overcomes cancer stem cell
escape triggered by Wnt inhibitor therapy in
FOXC1+ basal-Like/claudin-low breast cancer
Tor
P2-06-04
Proteosome inhibitor bortezomib inhibits NFκB
and effectively overcomes cancer stem cell
escape triggered by Wnt inhibitor therapy in
FOXC1+ basal-Like/claudin-low breast cancer
Bomy
Kim
P2-06-04
Proteosome inhibitor bortezomib inhibits NFκB
and effectively overcomes cancer stem cell
escape triggered by Wnt inhibitor therapy in
FOXC1+ basal-Like/claudin-low breast cancer
Partha
Ray
Bomy Kim has no relevant financial
relationships to disclose.
Dr. Ray has disclosed that she is a named
inventor, patents related to FOXC1. She also
disclosed that she is on the Scientific Advisory
Board for Oracle Biosciences and has Stock
Ownership in Oracle Biosciences.
P2-06-04
Proteosome inhibitor bortezomib inhibits NFκB
and effectively overcomes cancer stem cell
escape triggered by Wnt inhibitor therapy in
FOXC1+ basal-Like/claudin-low breast cancer
Tania
Ray
Dr. Ray has disclosed that she receives salary
from and has stock ownership in Oracle
Biosciences.
Tsai
Dr. Tsai has no relevant financial relationships
to disclose.
Benedetti
Giovanni Benedetti has no relevant financial
relationships to disclose.
P2-06-03
P2-06-04
P2-06-05
Xinrong
Ma
Jocelyn
Reader
Dr. Ma has no relevant financial relationships
to disclose.
Dr. Reader has no relevant financial
relationships to disclose.
Jensen
Dr. Jensen has disclosed that he is a consultant
for Oracle Biosciences.
Proteosome inhibitor bortezomib inhibits NFκB
and effectively overcomes cancer stem cell
escape triggered by Wnt inhibitor therapy in
FOXC1+ basal-Like/claudin-low breast cancer
Connie
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Giovanni
P2-06-05
P2-06-05
P2-06-05
P2-06-05
P2-06-05
P2-06-05
P2-06-05
P2-06-05
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Biscotti
Tommasina Biscotti has no relevant financial
relationships to disclose.
Ciccioli
Giancarlo Ciccioli has no relevant financial
relationships to disclose.
Paolo
Decembrini
Mr. Decembrini has no relevant financial
relationships to disclose.
Mauro
Finicelli
Mauro Finicelli has no relevant financial
relationships to disclose.
Umberto
Galderisi
Mr. Galderisi has no relevant financial
relationships to disclose.
Antonio
Giordano
Dr. Giordano has no relevant financial
relationships to disclose.
Luciano
Latini
Mr. Latini has no relevant financial
relationships to disclose.
Andrea
Marcellusi
Ms. Marcellusi has no relevant financial
relationships to disclose.
Tommasina
Giancarlo
P2-06-05
P2-06-05
P2-06-05
P2-06-05
P2-06-06
P2-06-06
P2-06-06
P2-06-06
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Expression of the pluripotency transcription
factor SOX2 in primary breast cancers (BCs):
Correlation with clinicopathological features
(CPfs) and recurrence
Mammospheres derived from circulating
epithelial tumor cells are an indicator for
presence of metastasis in patient with breast
cancer
Mammospheres derived from circulating
epithelial tumor cells are an indicator for
presence of metastasis in patient with breast
cancer
Mammospheres derived from circulating
epithelial tumor cells are an indicator for
presence of metastasis in patient with breast
cancer
Mammospheres derived from circulating
epithelial tumor cells are an indicator for
presence of metastasis in patient with breast
cancer
Mariani
Paola Mariani has no relevant financial
relationships to disclose.
Pistilli
Ms. Pistilli has no relevant financial
relationships to disclose.
Alfredo
Santinelli
Mr. Santinelli has no relevant financial
relationships to disclose.
Tiziana
Squillaro
Tiziana Squillaro has no relevant financial
relationships to disclose.
Katharina
Pachmann
Dr. Pachmann has no relevant financial
relationships to disclose.
Ulrich
Pachmann
Dr. Pachmann has no relevant financial
relationships to disclose.
Monika
Pizon
Dr. Pizon has no relevant financial relationships
to disclose.
Dorothea
Zimon
Ms. Zimon has no relevant financial
relationships to disclose.
Paola
Barbara
P2-06-07
P2-06-07
P2-06-07
P2-06-07
P2-06-07
P2-06-07
P2-06-08
P2-06-08
P2-06-08
P2-06-08
P2-06-09
StemScreen®, an innovative platform
technology for the identification of novel cancer
stem cell-directed compounds
StemScreen®, an innovative platform
technology for the identification of novel cancer
stem cell-directed compounds
StemScreen®, an innovative platform
technology for the identification of novel cancer
stem cell-directed compounds
StemScreen®, an innovative platform
technology for the identification of novel cancer
stem cell-directed compounds
StemScreen®, an innovative platform
technology for the identification of novel cancer
stem cell-directed compounds
StemScreen®, an innovative platform
technology for the identification of novel cancer
stem cell-directed compounds
SIRT1 inhibitors significantly reduce cancer stem
cells and block epithelial mesenchymal
transformation in breast cancer cells
SIRT1 inhibitors significantly reduce cancer stem
cells and block epithelial mesenchymal
transformation in breast cancer cells
SIRT1 inhibitors significantly reduce cancer stem
cells and block epithelial mesenchymal
transformation in breast cancer cells
SIRT1 inhibitors significantly reduce cancer stem
cells and block epithelial mesenchymal
transformation in breast cancer cells
Inflammation promotes stem-like
characteristics and increases stemness of breast
epithelial cells
Christopher
Brooks
Janice
Chen
Mr. Brooks has disclosed that he receives
salary from and has ownership in Stemline
Therapeutics, Inc..
Ms. Chen has disclosed that she receives salary
from and has ownership in Stemline
Therapeutics, Inc..
Glicksman
Ms. Glicksman has disclosed that she is a
consultant for Stemline Therapeutics, Inc.
Karan
Mr. Karan has disclosed that he has a contract
with Stemline Therapeutics, Inc.
Marcie
Charles
Hai
Li
Eric
Rowinsky
Hai Li has disclosed that he has a contract with
Stemline Therapeutics, Inc.
Dr. Rowinsky has disclosed that he receives
salary from and has ownership in Stemline
Therapeutics, Inc..
Robert
Brown
Dr. Brown has no relevant financial
relationships to disclose.
Baoxiang
Guan
Baoxiang Guan has no relevant financial
relationships to disclose.
Li
Dr. Li has no relevant financial relationships to
disclose.
Zhang
Dr. Zhang has no relevant financial
relationships to disclose.
Arnold
Dr. Arnold has no relevant financial
relationships to disclose.
Min
Songlin
Kimberly
P2-06-09
P2-06-09
P2-06-09
P2-06-12
P2-06-12
P2-06-12
P2-06-12
P2-06-13
P2-06-14
P2-06-14
P2-06-14
Inflammation promotes stem-like
characteristics and increases stemness of breast
epithelial cells
Inflammation promotes stem-like
characteristics and increases stemness of breast
epithelial cells
Inflammation promotes stem-like
characteristics and increases stemness of breast
epithelial cells
The expression of aldehyde dehydrogenase1 in
cytoplasm or stroma of breast cancer is
associated with clinical prognosis
The expression of aldehyde dehydrogenase1 in
cytoplasm or stroma of breast cancer is
associated with clinical prognosis
The expression of aldehyde dehydrogenase1 in
cytoplasm or stroma of breast cancer is
associated with clinical prognosis
The expression of aldehyde dehydrogenase1 in
cytoplasm or stroma of breast cancer is
associated with clinical prognosis
Flynn
Dr. Flynn has no relevant financial relationships
to disclose.
Opdenaker
Dr. Opdenaker has no relevant financial
relationships to disclose.
Sims-Mourtada
Dr. Sims-Mourtada has no relevant financial
relationships to disclose.
Dong
Dr. Dong has no relevant financial relationships
to disclose.
Fan
Dr. Fan has no relevant financial relationships
to disclose.
Xin
Guan
Xin Guan has no relevant financial relationships
to disclose.
Aiping
Shi
Dr. Shi has no relevant financial relationships
to disclose.
Gotoh
Dr. Gotoh has no relevant financial
relationships to disclose.
Imawari
Yoshimi Imawari has no relevant financial
relationships to disclose.
Kamio
Dr. Kamio has no relevant financial
relationships to disclose.
Kato
Dr. Kato has no relevant financial relationships
to disclose.
Daniel
Lynn
Jennifer
Yi
Zhimin
Maintenance of stemness of breast cancer stemlike cells by FRS2beta, a feedback inhibitor for
HER, during mammary tumorigenesis
Noriko
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Yoshimi
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Makiko
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Kumiko
P2-06-14
P2-06-14
P2-06-14
P2-06-14
P2-06-14
P2-06-14
P2-06-15
P2-06-16
P2-06-16
P2-06-16
P2-06-16
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Clinical relevance and biological properties of
oligometastatic breast cancer in lung;
prognostic impact of CD44+/CD24-/low cells
Post transcriptionally regulating LMO2, a highly
expressed gene in breast cancer stem cells, to
study its invasive and metastatic properties in
breast cancer
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
Kobayashi
Tadashi Kobayashi has no relevant financial
relationships to disclose.
Mimoto
Rei Mimoto has no relevant financial
relationships to disclose.
Nogi
Dr. Nogi has no relevant financial relationships
to disclose.
Hiroshi
Takeyama
Dr. Takeyama has no relevant financial
relationships to disclose.
Yasuo
Toriumi
Dr. Toriumi has no relevant financial
relationships to disclose.
Ken
Uchida
Mr. Uchida has no relevant financial
relationships to disclose.
Mesa
Lazaro Mesa has no relevant financial
relationships to disclose.
Endo
Dr. Endo has no relevant financial relationships
to disclose.
Ichikawa
Dr. Ichikawa has no relevant financial
relationships to disclose.
Takashi
Ishikawa
Dr. Ishikawa has no relevant financial
relationships to disclose.
Kumiko
Kida
Dr. Kida has no relevant financial relationships
to disclose.
Tadashi
Rei
Hiroko
Lazaro
Itaru
Yasushi
P2-06-16
P2-06-16
P2-06-16
P2-06-16
P2-07-01
P2-07-01
P2-07-01
P2-07-01
P2-07-01
P2-07-01
P2-07-01
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
The impact of ALDH1 on chemo-resistance and
prognosis according to intrinsic subtype in
breast cancers
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
Narui
Dr. Narui has no relevant financial relationships
to disclose.
Sugae
Dr. Sugae has no relevant financial
relationships to disclose.
Tanabe
Dr. Tanabe has no relevant financial
relationships to disclose.
Yamada
Dr. Yamada has no relevant financial
relationships to disclose.
Claessen
Mr. Claessen has no relevant financial
relationships to disclose.
Catherine
Del Vecchio
Ms. Del Vecchio has no relevant financial
relationships to disclose.
Yuxiong
Feng
Yuxiong Feng has no relevant financial
relationships to disclose.
Piyush
Gupta
Piyush Gupta has no relevant financial
relationships to disclose.
Jin
Mr. Jin has no relevant financial relationships
to disclose.
Ploegh
Hidde Ploegh has no relevant financial
relationships to disclose.
Proia
Ms. Proia has no relevant financial
relationships to disclose.
Kazutaka
Sadataka
Mikiko
Akimitsu
Jasper
Dexter
Hidde
Theresa
P2-07-01
P2-07-01
P2-07-01
P2-07-01
P2-07-02
P2-07-02
P2-07-02
P2-07-02
P2-07-02
P2-07-03
P2-07-03
P2-07-03
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
EMT activates PERK-eIF2α signaling and
sensitizes cells to perturbations in endoplasmic
reticulum function
IGF1R/FAK crosstalk is essential for epithelial-tomesenchymal transition (EMT), migration, and
invasion of TNBC cells
IGF1R/FAK crosstalk is essential for epithelial-tomesenchymal transition (EMT), migration, and
invasion of TNBC cells
IGF1R/FAK crosstalk is essential for epithelial-tomesenchymal transition (EMT), migration, and
invasion of TNBC cells
IGF1R/FAK crosstalk is essential for epithelial-tomesenchymal transition (EMT), migration, and
invasion of TNBC cells
IGF1R/FAK crosstalk is essential for epithelial-tomesenchymal transition (EMT), migration, and
invasion of TNBC cells
Pax-5 regulates EMT and MET in breast cancer
through FAK1 regulation
Pax-5 regulates EMT and MET in breast cancer
through FAK1 regulation
Pax-5 regulates EMT and MET in breast cancer
through FAK1 regulation
Reinhardt
Forenc Reinhardt has no relevant financial
relationships to disclose.
Sanduja
Sandhya Sanduja has no relevant financial
relationships to disclose.
Sokol
Mr. Sokol has no relevant financial
relationships to disclose.
Wang
Qiu Wang has no relevant financial
relationships to disclose.
Liu
Tongrui Liu has no relevant financial
relationships to disclose.
Tanisha
McGlothen
Dr. McGlothen has no relevant financial
relationships to disclose.
Ruth
O'Regan
Dr. O'Regan has no relevant financial
relationships to disclose.
Elaine
Oberlick
Ms. Oberlick has no relevant financial
relationships to disclose.
Ferenc
Sandhya
Ethan
Qiu
Tongrui
LaTonia
Taliaferro-Smith
Annie-Pier
Beauregard
Sami
Benzina
Roxann
Guérrette
Dr. Taliaferro-Smith has no relevant financial
relationships to disclose.
Ms. Beauregard has no relevant financial
relationships to disclose.
Dr. Benzina has no relevant financial
relationships to disclose.
Ms. Guérirette has no relevant financial
relationships to disclose.
P2-07-03
P2-07-03
P2-07-03
P2-07-04
P2-07-04
P2-07-04
P2-07-04
P2-07-04
P2-07-04
P2-07-04
P2-07-05
Pax-5 regulates EMT and MET in breast cancer
through FAK1 regulation
Pax-5 regulates EMT and MET in breast cancer
through FAK1 regulation
Pax-5 regulates EMT and MET in breast cancer
through FAK1 regulation
Treatment of metastatic breast cancer using
two nanoparticles combined with siRNA
targeting Twist1 to inhibit EMT
Treatment of metastatic breast cancer using
two nanoparticles combined with siRNA
targeting Twist1 to inhibit EMT
Treatment of metastatic breast cancer using
two nanoparticles combined with siRNA
targeting Twist1 to inhibit EMT
Treatment of metastatic breast cancer using
two nanoparticles combined with siRNA
targeting Twist1 to inhibit EMT
Treatment of metastatic breast cancer using
two nanoparticles combined with siRNA
targeting Twist1 to inhibit EMT
Treatment of metastatic breast cancer using
two nanoparticles combined with siRNA
targeting Twist1 to inhibit EMT
Treatment of metastatic breast cancer using
two nanoparticles combined with siRNA
targeting Twist1 to inhibit EMT
A potential role for Janus protein tyrosine
kinases in the regulation of epithelialmesenchymal transition in a model of epidermal
growth factor induced breast cancer epithelialmesenchymal transition
Stéphanie
Jean
Pierre
O'Brien
Gilles
Robichaud
Ms. Jean has no relevant financial relationships
to disclose.
Mr. O'Brien has no relevant financial
relationships to disclose.
Dr. Robichaud has no relevant financial
relationships to disclose.
Finlay
Dr. Finlay has no relevant financial
relationships to disclose.
Glackin
Dr. Glackin has no relevant financial
relationships to disclose.
Lowe
Ms. Lowe has no relevant financial
relationships to disclose.
Ling
Peng
Dr. Peng has no relevant financial relationships
to disclose.
Cai
Roberts
Cai Roberts has no relevant financial
relationships to disclose.
Fuyuhiko
Tamanoi
Dr. Tamanoi has no relevant financial
relationships to disclose.
Jeff
Zink
Dr. Zink has no relevant financial relationships
to disclose.
Iman
Azimi
Iman Azimi has no relevant financial
relationships to disclose.
James
Carlotta
Gina
P2-07-05
P2-07-05
P2-07-05
P2-07-05
P2-07-05
P2-07-05
P2-07-06
A potential role for Janus protein tyrosine
kinases in the regulation of epithelialmesenchymal transition in a model of epidermal
growth factor induced breast cancer epithelialmesenchymal transition
A potential role for Janus protein tyrosine
kinases in the regulation of epithelialmesenchymal transition in a model of epidermal
growth factor induced breast cancer epithelialmesenchymal transition
A potential role for Janus protein tyrosine
kinases in the regulation of epithelialmesenchymal transition in a model of epidermal
growth factor induced breast cancer epithelialmesenchymal transition
A potential role for Janus protein tyrosine
kinases in the regulation of epithelialmesenchymal transition in a model of epidermal
growth factor induced breast cancer epithelialmesenchymal transition
A potential role for Janus protein tyrosine
kinases in the regulation of epithelialmesenchymal transition in a model of epidermal
growth factor induced breast cancer epithelialmesenchymal transition
A potential role for Janus protein tyrosine
kinases in the regulation of epithelialmesenchymal transition in a model of epidermal
growth factor induced breast cancer epithelialmesenchymal transition
Niclosamid overcomes epithelial-mesenchymal
transition of lapatinib resistance through
inhibiting Src activation in HER2 positive breast
cancer
Andrew
Brooks
Mr. Brooks has no relevant financial
relationships to disclose.
Felicity
Davis
Ms. Davis has no relevant financial
relationships to disclose.
Monteith
Mr. Monteith has no relevant financial
relationships to disclose.
Roberts-Thomson
Ms. Roberts-Thomson has no relevant financial
relationships to disclose.
Stewart
Teneale Stewart has no relevant financial
relationships to disclose.
Thompson
Mr. Thompson has no relevant financial
relationships to disclose.
Chen
Dr. Chen has no relevant financial relationships
to disclose.
Gregory
Sarah
Teneale
Erik
Xiaosong
P2-07-06
P2-07-06
P2-07-06
P2-07-07
P2-07-07
P2-07-07
P2-07-07
P2-07-07
P2-07-07
P2-07-08
Niclosamid overcomes epithelial-mesenchymal
transition of lapatinib resistance through
inhibiting Src activation in HER2 positive breast
cancer
Niclosamid overcomes epithelial-mesenchymal
transition of lapatinib resistance through
inhibiting Src activation in HER2 positive breast
cancer
Niclosamid overcomes epithelial-mesenchymal
transition of lapatinib resistance through
inhibiting Src activation in HER2 positive breast
cancer
Prostaglandin E receptor 2 (EP2) regulates
breast cancer stem-cell like property and
promotes epithelial-mesenchymal transition
Prostaglandin E receptor 2 (EP2) regulates
breast cancer stem-cell like property and
promotes epithelial-mesenchymal transition
Prostaglandin E receptor 2 (EP2) regulates
breast cancer stem-cell like property and
promotes epithelial-mesenchymal transition
Prostaglandin E receptor 2 (EP2) regulates
breast cancer stem-cell like property and
promotes epithelial-mesenchymal transition
Prostaglandin E receptor 2 (EP2) regulates
breast cancer stem-cell like property and
promotes epithelial-mesenchymal transition
Prostaglandin E receptor 2 (EP2) regulates
breast cancer stem-cell like property and
promotes epithelial-mesenchymal transition
Interaction of mesenchymal stem cell with
breast cancer lineage cells and evaluation of
their biological behavior
Liu
Junjun Liu has no relevant financial
relationships to disclose.
Mao
Yan Mao has no relevant financial relationships
to disclose.
Shen
Kunwei Shen has no relevant financial
relationships to disclose.
Chen
Mr. Chen has no relevant financial
relationships to disclose.
Isabella
Cheuk
Ms. Cheuk has no relevant financial
relationships to disclose.
John
Ho
Mr. Ho has no relevant financial relationships
to disclose.
Ava
Kwong
Ava Kwong has no relevant financial
relationships to disclose.
Shin
Ms. Shin has no relevant financial relationships
to disclose.
Siu
Man Siu has no relevant financial relationships
to disclose.
Abraham da Silveira
Willian Abraham da Silveira has no relevant
financial relationships to disclose.
Junjun
Yan
Kunwei
Jiawei
Vivian
Man
Willian
P2-07-08
P2-07-08
P2-07-08
P2-07-08
P2-08-01
P2-08-01
P2-08-01
P2-08-01
P2-08-01
P2-08-01
P2-08-01
P2-08-01
P2-08-02
P2-08-02
Interaction of mesenchymal stem cell with
breast cancer lineage cells and evaluation of
their biological behavior
Interaction of mesenchymal stem cell with
breast cancer lineage cells and evaluation of
their biological behavior
Interaction of mesenchymal stem cell with
breast cancer lineage cells and evaluation of
their biological behavior
Interaction of mesenchymal stem cell with
breast cancer lineage cells and evaluation of
their biological behavior
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity in breast carcinogenesis. A new
paradigm
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Daniel
Fernanda
Heriton Marcelo
Guimaraes Tiezzi
Prof. Guimaraes Tiezzi has no relevant financial
relationships to disclose.
Marques Rey
Fernanda Marques Rey has no relevant
financial relationships to disclose.
Ribeiro Antonio
Mr. Ribeiro Antonio has no relevant financial
relationships to disclose.
Renata
Sicchieri
Dhananjay
Chitale
Félix
Fernández Madrid
Leonard
Lipovich
Marie-Claire
Maroun
Lisa
Polin
Azadeh
Stark
Larry
Tait
Richard
Zarbo
Renata Sicchieri has no relevant financial
relationships to disclose.
Dr. Chitale has no relevant financial
relationships to disclose.
Dr. Fernández Madrid has no relevant financial
relationships to disclose.
Mr. Lipovich has no relevant financial
relationships to disclose.
Dr. Maroun has no relevant financial
relationships to disclose.
Ms. Polin has no relevant financial
relationships to disclose.
Azadeh Stark has no relevant financial
relationships to disclose.
Mr. Tait has no relevant financial relationships
to disclose.
Mr. Zarbo has no relevant financial
relationships to disclose.
Abrams
Ms. Abrams has no relevant financial
relationships to disclose.
Chen
Wei Chen has no relevant financial
relationships to disclose.
Judith
Wei
P2-08-02
P2-08-02
P2-08-02
P2-08-02
P2-08-02
P2-08-02
P2-08-02
P2-08-03
P2-08-03
P2-08-03
P2-09-01
P2-09-01
P2-09-01
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
Autoimmunity to centrosomal and proteasome
proteins in breast cancer. A link to chromosome
instability?
The association between primary breast cancer
and thyroid cancer: A meta-analysis
The association between primary breast cancer
and thyroid cancer: A meta-analysis
The association between primary breast cancer
and thyroid cancer: A meta-analysis
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
Chitale
Dr. Chitale has no relevant financial
relationships to disclose.
Fernández Madrid
Dr. Fernández Madrid has no relevant financial
relationships to disclose.
Maroun
Ms. Maroun has no relevant financial
relationships to disclose.
Olivero
Ofelia Olivero has no relevant financial
relationships to disclose.
Peebles
Ms. Peebles has no relevant financial
relationships to disclose.
Azadeh
Stark
Azadeh Stark has no relevant financial
relationships to disclose.
Larry
Tait
Senarath
Edirimanne
Guy
Eslick
Kyle
Joseph
Alison
Butt
Elly
Cohen
Susan
Colen
Dhanajay
Félix
Marie-Claire
Ofelia
Carol
Mr. Tait has no relevant financial relationships
to disclose.
Senarath Edirimanne has no relevant financial
relationships to disclose.
Mr. Eslick has no relevant financial
relationships to disclose.
Mr. Joseph has no relevant financial
relationships to disclose.
Dr. Butt has no relevant financial relationships
to disclose.
Dr. Cohen has no relevant financial
relationships to disclose.
Ms. Colen has no relevant financial
relationships to disclose.
P2-09-01
P2-09-01
P2-09-01
P2-09-01
P2-09-01
P2-09-01
P2-09-01
P2-09-02
P2-09-02
P2-09-02
P2-09-02
P2-09-02
P2-09-03
P2-09-03
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
MBC alliance: Coordinating metastatic research
from lab bench to clinical trials
ICRP analysis: Environmental influences in
breast cancer
ICRP analysis: Environmental influences in
breast cancer
ICRP analysis: Environmental influences in
breast cancer
ICRP analysis: Environmental influences in
breast cancer
ICRP analysis: Environmental influences in
breast cancer
Got patient advocates? The value of patient
advocate participation in a large research study
to develop personalized risk-based breast
cancer screening strategies
Got patient advocates? The value of patient
advocate participation in a large research study
to develop personalized risk-based breast
cancer screening strategies
Lynne
Davies
Samantha
Finstad
Marc
Hurlbert
Ginny
Mason
Musa
Mayer
Katherine
McKenzie
Stephanie
Reffey
Lynne
Davies
Samantha
Finstad
Marc
Hurlbert
Senaida
Poole
Kari
Wojtanik
Dr. Davies has no relevant financial
relationships to disclose.
Dr. Finstad has no relevant financial
relationships to disclose.
Dr. Hurlbert has no relevant financial
relationships to disclose.
Ms. Mason has no relevant financial
relationships to disclose.
Musa Mayer has no relevant financial
relationships to disclose.
Dr. McKenzie has no relevant financial
relationships to disclose.
Dr. Reffey has no relevant financial
relationships to disclose.
Dr. Davies has no relevant financial
relationships to disclose.
Dr. Finstad has no relevant financial
relationships to disclose.
Dr. Hurlbert has no relevant financial
relationships to disclose.
Dr. Poole has no relevant financial
relationships to disclose.
Dr. Wojtanik has no relevant financial
relationships to disclose.
Carolyn
Achenbach
Ms. Achenbach has no relevant financial
relationships to disclose.
Vernal
Branch
Vernal Branch has no relevant financial
relationships to disclose.
P2-09-03
P2-09-03
P2-09-03
P2-09-03
P2-09-03
P2-09-04
P2-09-04
P2-09-04
Got patient advocates? The value of patient
advocate participation in a large research study
to develop personalized risk-based breast
cancer screening strategies
Wendy
Got patient advocates? The value of patient
advocate participation in a large research study
to develop personalized risk-based breast
cancer screening strategies
Got patient advocates? The value of patient
advocate participation in a large research study
to develop personalized risk-based breast
cancer screening strategies
Got patient advocates? The value of patient
advocate participation in a large research study
to develop personalized risk-based breast
cancer screening strategies
Got patient advocates? The value of patient
advocate participation in a large research study
to develop personalized risk-based breast
cancer screening strategies
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Harvey
Dr. Cohn has no relevant financial relationships
to disclose.
Dr. Harvey has disclosed that she has contracts
with Volpara Solutions, Ltd, Wellington, NZ;
Hologic, Inc., Danbury CT; VuComp, Inc, Dallas,
TX- Research agreements and has ownership in
Volpara Solutions, Ltd, Wellington, NZshareholder; Hologic, Inc., Danbury CTShareholder.
Knaus
Dr. Knaus has no relevant financial
relationships to disclose.
Ross
Ms. Ross has no relevant financial relationships
to disclose.
Yaffe
Dr. Yaffe has disclosed he is a shareholder of
Volpara Solutions, Ltd., Wellington, NZ.
Cynthia
Chauhan
Ms. Chauhan has no relevant financial
relationships to disclose.
Wayland
Eppard
Mr. Eppard has no relevant financial
relationships to disclose.
Debra
Gearhart
Ms. Gearhart has no relevant financial
relationships to disclose.
Jennifer
William
Kathleen
Martin
Cohn
P2-09-04
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
Measurements of advocate participation in and
contributions to the Mayo Clinic breast cancer
SPORE
P2-09-05
ICRP analysis: Obesity research in breast cancer Rhonda
Aizenberg
P2-09-05
ICRP analysis: Obesity research in breast cancer Lynne
Davies
P2-09-05
ICRP analysis: Obesity research in breast cancer Susan
Higginbotham
P2-09-05
ICRP analysis: Obesity research in breast cancer
onlineDeCISion.org : An interactive web-based
clinical decision aid for DCIS treatment
onlineDeCISion.org : An interactive web-based
clinical decision aid for DCIS treatment
onlineDeCISion.org : An interactive web-based
clinical decision aid for DCIS treatment
onlineDeCISion.org : An interactive web-based
clinical decision aid for DCIS treatment
Kari
Wojtanik
Michael
Fordis
Elissa
Ozanne
Rinaa
Punglia
Katharine
Schneider
P2-09-04
P2-09-04
P2-09-04
P2-09-04
P2-09-04
P2-10-01
P2-10-01
P2-10-01
P2-10-01
Lawanna
James
Ruth
Linda
Mary
Mary
Holmes
Lawanna Holmes has no relevant financial
relationships to disclose.
Ingle
Dr. Ingle has no relevant financial relationships
to disclose.
Kraft
Ms. Kraft has no relevant financial relationships
to disclose.
Miller
Ms. Miller has no relevant financial
relationships to disclose.
Sitta
Ms. Sitta has no relevant financial relationships
to disclose.
Smith
Ms. Smith has no relevant financial
relationships to disclose.
Dr. Aizenberg has no relevant financial
relationships to disclose.
Dr. Davies has no relevant financial
relationships to disclose.
Dr. Higginbotham has no relevant financial
relationships to disclose.
Dr. Wojtanik has no relevant financial
relationships to disclose.
Dr. Fordis has no relevant financial
relationships to disclose.
Dr. Ozanne has no relevant financial
relationships to disclose.
Dr. Punglia has no relevant financial
relationships to disclose.
Ms. Schneider has no relevant financial
relationships to disclose.
P2-10-01
onlineDeCISion.org : An interactive web-based
clinical decision aid for DCIS treatment
onlineDeCISion.org : An interactive web-based
clinical decision aid for DCIS treatment
onlineDeCISion.org : An interactive web-based
clinical decision aid for DCIS treatment
P2-10-02
Treatment adverse effect registration. A PC
based electronic patient - hospital
communication portal that allows registration
of adverse effects of chemotherapy and returns
advice and recommandations for action
Helle
P2-10-02
Treatment adverse effect registration. A PC
based electronic patient - hospital
communication portal that allows registration
of adverse effects of chemotherapy and returns
advice and recommandations for action
Jakob
P2-10-01
P2-10-01
P2-10-02
P2-10-03
P2-10-03
P2-10-03
Treatment adverse effect registration. A PC
based electronic patient - hospital
communication portal that allows registration
of adverse effects of chemotherapy and returns
advice and recommandations for action
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Deborah
Schrag
Djøra
Soeteman
Natasha
Stout
Dr. Schrag has no relevant financial
relationships to disclose.
Dr. Soeteman has no relevant financial
relationships to disclose.
Dr. Stout has no relevant financial relationships
to disclose.
Christensen
Ms. Christensen has no relevant financial
relationships to disclose.
Due
Mr. Due has no relevant financial relationships
to disclose.
Vestlev
Dr. Vestlev has no relevant financial
relationships to disclose.
Borges
Dr. Borges has no relevant financial
relationships to disclose.
Come
Dr. Come has no relevant financial
relationships to disclose.
Gelber
Ms. Gelber has no relevant financial
relationships to disclose.
Peter Michael
Virginia
Steven
Shari
P2-10-03
P2-10-03
P2-10-03
P2-10-03
P2-10-03
P2-10-03
P2-10-03
P2-10-03
P2-10-04
P2-10-04
P2-10-04
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Decision-making surrounding adjuvant
chemotherapy in young women with early stage
breast cancer
Characterizing the metastatic breast cancer
patient experience around preparing for a
treatment decision
Characterizing the metastatic breast cancer
patient experience around preparing for a
treatment decision
Characterizing the metastatic breast cancer
patient experience around preparing for a
treatment decision
Lin
Dr. Lin has no relevant financial relationships to
disclose.
Morgan
Mr. Morgan has no relevant financial
relationships to disclose.
Partridge
Dr. Partridge has no relevant financial
relationships to disclose.
Rosenberg
Shoshana Rosenberg has no relevant financial
relationships to disclose.
Ruddy
Dr. Ruddy has no relevant financial
relationships to disclose.
Lidia
Schapira
Dr. Schapira has no relevant financial
relationships to disclose.
Karen
Sepucha
Dr. Sepucha has no relevant financial
relationships to disclose.
Rulla
Tamimi
Rulla Tamimi has no relevant financial
relationships to disclose.
Buzaglo
Dr. Buzaglo has no relevant financial
relationships to disclose.
Golant
Dr. Golant has no relevant financial
relationships to disclose.
Harvey
Ms. Harvey has no relevant financial
relationships to disclose.
Nancy
Evan
Ann
Shoshana
Kathryn
Joanne
Mitch
Allison
P2-10-04
P2-10-04
P2-10-05
P2-10-05
P2-10-05
P2-10-05
P2-10-05
P2-10-05
P2-10-05
P2-10-05
P2-10-05
Characterizing the metastatic breast cancer
patient experience around preparing for a
treatment decision
Characterizing the metastatic breast cancer
patient experience around preparing for a
treatment decision
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
Miller
Dr. Miller has no relevant financial
relationships to disclose.
Morris
Ms. Morris has no relevant financial
relationships to disclose.
Bauerfeind
Dr. Bauerfeind has no relevant financial
relationships to disclose.
Drewes
Ms. Drewes has no relevant financial
relationships to disclose.
Goldmann-Posch
Ms. Goldmann-Posch has no relevant financial
relationships to disclose.
Renate
Haidinger
Renate Haidinger has no relevant financial
relationships to disclose.
Nadia
Harbeck
Dr. Harbeck has no relevant financial
relationships to disclose.
Thomas
Kirkovits
Mr. Kirkovits has no relevant financial
relationships to disclose.
Paradies
Kerstin Paradies has no relevant financial
relationships to disclose.
Schiltz
Mr. Schiltz has no relevant financial
relationships to disclose.
Schinkoethe
Prof. Schinkoethe has no relevant financial
relationships to disclose.
Melissa
Anne
Ingo
Caroline
Ursula
Kerstin
Daniel
Timo
P2-10-05
P2-10-06
P2-10-06
P2-10-06
P2-10-06
P2-10-07
P2-10-07
P2-10-07
P2-10-07
P2-10-08
P2-10-08
P2-10-08
eHealth in modern breast cancer treatment:
New possibilities in communication between
patients, doctors and nursing staff
Group visits to provide gynecologic care for
women affected by breast cancer
Group visits to provide gynecologic care for
women affected by breast cancer
Group visits to provide gynecologic care for
women affected by breast cancer
Group visits to provide gynecologic care for
women affected by breast cancer
Patient experience of the introduction of an
enhanced recovery programme for breast
cancer surgery
Patient experience of the introduction of an
enhanced recovery programme for breast
cancer surgery
Patient experience of the introduction of an
enhanced recovery programme for breast
cancer surgery
Patient experience of the introduction of an
enhanced recovery programme for breast
cancer surgery
Understanding potential gaps in treatment
discussions between caregivers/patients with
advanced breast cancer and oncologists
Understanding potential gaps in treatment
discussions between caregivers/patients with
advanced breast cancer and oncologists
Understanding potential gaps in treatment
discussions between caregivers/patients with
advanced breast cancer and oncologists
Rachel
Wuerstlein
Mindy
Goldman
Sally
Greenwald
Tami
Rowen
Sarah
Watson
Dr. Wuerstlein has no relevant financial
relationships to disclose.
Dr. Goldman has no relevant financial
relationships to disclose.
Dr. Greenwald has no relevant financial
relationships to disclose.
Dr. Rowen has no relevant financial
relationships to disclose.
Ms. Watson has no relevant financial
relationships to disclose.
Lannigan
Dr. Lannigan has no relevant financial
relationships to disclose.
Macey
Alistair Macey has no relevant financial
relationships to disclose.
McGIvern
Ms. McGlvern has no relevant financial
relationships to disclose.
Murray
Dr. Murray has no relevant financial
relationships to disclose.
Alison
Alistair
Jayne
Juliette
Helen
Coons
Stephen
Jones
Ms. Coons has disclosed she receives other
financial assistance from Novartis.
Mr. Jones has disclosed he is on the speakers'
bureau and is a consultant for Novartis. He
also disclosed he receives other financial
support from Novartis.
Mayer
Musa Mayer has no relevant financial
relationships to disclose.
Musa
P2-10-08
Understanding potential gaps in treatment
discussions between caregivers/patients with
advanced breast cancer and oncologists
P2-11-01
Treatment of metastatic breast cancer patients
by community health practitioners: Practice
pattern and competence assessments
Sara
P2-11-01
Treatment of metastatic breast cancer patients
by community health practitioners: Practice
pattern and competence assessments
Maureen
P2-11-01
P2-11-02
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
Treatment of metastatic breast cancer patients
by community health practitioners: Practice
pattern and competence assessments
Managing breast and ovarian cancer risk: A
novel approach to teaching residents
comprehensive risk reduction and management
strategies
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Deana
Alison
Deborah
Bart
Agnes
Marc
John
Marc
Percassi
Ms. Percassi has no relevant financial
relationships to disclose.
Fagerlie
Dr. Fagerlie has no relevant financial
relationships to disclose.
Haas
Dr. Haas has no relevant financial relationships
to disclose.
Heintz
Ms. Heintz has no relevant financial
relationships to disclose.
Lindner
Dr. Lindner has no relevant financial
relationships to disclose.
de Vries
Mr. de Vries has no relevant financial
relationships to disclose.
Jager
Dr. Jager has no relevant financial relationships
to disclose.
Lobbes
Mr. Lobbes has no relevant financial
relationships to disclose.
Maduro
Mr. Maduro has no relevant financial
relationships to disclose.
Mureau
Mr. Mureau has no relevant financial
relationships to disclose.
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-03
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Pijnappel
Dr. Pijnappel has no relevant financial
relationships to disclose.
Richel
Ms. Richel has no relevant financial
relationships to disclose.
Rutgers
Dr. Rutgers has no relevant financial
relationships to disclose.
Schepens
Maike Schepens has no relevant financial
relationships to disclose.
Schrieks
Marga Schrieks has no relevant financial
relationships to disclose.
Sabine
Siesling
Sabine Siesling has no relevant financial
relationships to disclose.
Carolien
Smorenburg
Ms. Smorenburg has no relevant financial
relationships to disclose.
Henk
Struikmans
Henk Struikmans has no relevant financial
relationships to disclose.
Tjan-Heijnen
Dr. Tjan-Heijnen has no relevant financial
relationships to disclose.
van Bommel
Annelotte van Bommel has no relevant
financial relationships to disclose.
van Dalen
Thijs van Dalen has no relevant financial
relationships to disclose.
Ruud
Carol
Emiel
Maike
Marga
Vivianne
Annelotte
Thijs
P2-11-03
P2-11-03
P2-11-03
P2-11-03
P2-11-04
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Multidisciplinary breast cancer care registry and
quality control system in the Netherlands: The
NABON breast cancer audit
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
P2-11-04
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
P2-11-04
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
P2-11-04
Margriet
Marie-Jeanne
Pieter
van der Heiden-van der Loo
Ms. van der Heiden - van der Loo has no
relevant financial relationships to disclose.
Vrancken Peeters
Ms. Vrancken Peeters has no relevant financial
relationships to disclose.
Westenend
Mr. Westenend has no relevant financial
relationships to disclose.
Michel
Wouters
Arin
Ahlum Hanson
Carey
Anders
Catherine
Creme Henry
Hayley
Dinerman
Michel Wouters has no relevant financial
relationships to disclose.
Arin Ahlum Hanson has disclosed that Living
Beyond Breast Cancer received funding from
Genentech and Celgene to conduct the
research under review in this abstract.
Dr. Anders has disclosed he has contracts with
Sanofi/Bipar, Novartis, GERON, to-BBB, and
Merrimack. He also disclosed that he is an
advisor (uncompensated) for Lilly,
Sanofi/Bipar, Novartis, GERON, to-BBB, and
Merrimack.
Ms. Creme Henry has disclosed Living Beyond
Breast Cancer received funding from
Genentech and Celgene to conduct the
research under review in this abstract.
Ms. Dinerman has disclosed the organization
she represents, Triple Negative Breast Cancer
Foundation, received unrestricted funding
from Celgene and Genentech in the past year.
These companies also provided funding to
Living Beyond Breast Cancer for the research
under review.
P2-11-04
P2-11-04
P2-11-04
P2-11-04
P2-11-04
P2-12-01
P2-12-01
P2-12-01
P2-12-01
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
Education and information preferences for
women with triple-negative breast cancer:
Should personal or medical demographic
variables impact program tailoring?
Improving completeness of client-level data
collection in the Avon Breast Health Outreach
Program through electronic tablet technology
Improving completeness of client-level data
collection in the Avon Breast Health Outreach
Program through electronic tablet technology
Improving completeness of client-level data
collection in the Avon Breast Health Outreach
Program through electronic tablet technology
Improving completeness of client-level data
collection in the Avon Breast Health Outreach
Program through electronic tablet technology
Susan
Domchek
Janine
Guglielmino
Dr. Domchek has no relevant financial
relationships to disclose.
Ms. Guglielmino has disclosed that Living
Beyond Breast Cancer received funding from
Genentech and Celgene to conduct the
research under review in this abstract.
Hope
Rugo
Dr. Rugo has disclosed that she has a contract
with uc Regents from Genentech.
Jocelyn
Sendecki
Ms. Sendecki has no relevant financial
relationships to disclose.
Swiger
Ms. Swiger has no relevant financial
relationships to disclose.
Aliaga
Mr. Aliaga has no relevant financial
relationships to disclose.
Kathryn
Gates-Ferris
Ms. Gates-Ferris has no relevant financial
relationships to disclose.
Marc
Hurlbert
Dr. Hurlbert has no relevant financial
relationships to disclose.
Kelly
Opdyke
Kelly Opdyke has no relevant financial
relationships to disclose.
Kathleen
Marvin
P2-12-01
P2-12-02
P2-12-02
P2-12-02
P2-12-02
P2-12-02
P2-12-03
P2-12-03
P2-12-03
P2-12-03
Improving completeness of client-level data
collection in the Avon Breast Health Outreach
Program through electronic tablet technology
Perceptions about cancer clinical trials among
metastatic breast cancer patients: Findings from
a patient powered registry
Perceptions about cancer clinical trials among
metastatic breast cancer patients: Findings from
a patient powered registry
Perceptions about cancer clinical trials among
metastatic breast cancer patients: Findings from
a patient powered registry
Perceptions about cancer clinical trials among
metastatic breast cancer patients: Findings from
a patient powered registry
Perceptions about cancer clinical trials among
metastatic breast cancer patients: Findings from
a patient powered registry
The financial costs of metastatic breast cancer
and the decisions patients make to cope with
costs: Findings from the Cancer Experience
Registry
The financial costs of metastatic breast cancer
and the decisions patients make to cope with
costs: Findings from the Cancer Experience
Registry
The financial costs of metastatic breast cancer
and the decisions patients make to cope with
costs: Findings from the Cancer Experience
Registry
The financial costs of metastatic breast cancer
and the decisions patients make to cope with
costs: Findings from the Cancer Experience
Registry
Lindsay
Joanne
Mitch
Allison
Melissa
Anne
Joanne
Mitch
Allison
Melissa
Senter
Ms. Senter has no relevant financial
relationships to disclose.
Buzaglo
Dr. Buzaglo has no relevant financial
relationships to disclose.
Golant
Dr. Golant has no relevant financial
relationships to disclose.
Harvey
Ms. Harvey has no relevant financial
relationships to disclose.
Miller
Dr. Miller has no relevant financial
relationships to disclose.
Morris
Ms. Morris has no relevant financial
relationships to disclose.
Buzaglo
Dr. Buzaglo has no relevant financial
relationships to disclose.
Golant
Dr. Golant has no relevant financial
relationships to disclose.
Harvey
Ms. Harvey has no relevant financial
relationships to disclose.
Miller
Dr. Miller has no relevant financial
relationships to disclose.
P2-12-04
The financial costs of metastatic breast cancer
and the decisions patients make to cope with
costs: Findings from the Cancer Experience
Registry
The curriculum for recovery,' a five week
educational and experiential support group for
breast cancer survivorship recovery
The curriculum for recovery,' a five week
educational and experiential support group for
breast cancer survivorship recovery
The curriculum for recovery,' a five week
educational and experiential support group for
breast cancer survivorship recovery
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Paolo
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Marina
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Federica
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Diego
P2-12-03
P2-12-04
P2-12-04
Morris
Ms. Morris has no relevant financial
relationships to disclose.
Robert
Fisher
Dr. Fisher has no relevant financial
relationships to disclose.
Anh
Lai-O'Connell
Anh Lai-O'Connell has no relevant financial
relationships to disclose.
Marianne
Stenhouse
Ms. Stenhouse has no relevant financial
relationships to disclose.
Bidoli
Paolo Bidoli has no relevant financial
relationships to disclose.
Cazzaniga
Dr. Cazzaniga has no relevant financial
relationships to disclose.
Cicchiello
Dr. Cicchiello has no relevant financial
relationships to disclose.
Cortinovis
Dr. Cortinovis has no relevant financial
relationships to disclose.
Anne
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Alessandra
Crippa
Dr. Crippa has no relevant financial
relationships to disclose.
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Francesca
Gallina
Dr. Gallina has no relevant financial
relationships to disclose.
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Francesca
Riva
Dr. Riva has no relevant financial relationships
to disclose.
P2-12-05
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Marco
Tagliabue
Dr. Tagliabue has no relevant financial
relationships to disclose.
Valentini
Dr. Valentini has no relevant financial
relationships to disclose.
Kulkarni
Dr. Kulkarni has no relevant financial
relationships to disclose.
Rabbit
Ms. Rabbit has no relevant financial
relationships to disclose.
Van Haitsma
Dr. van Haitsma has no relevant financial
relationships to disclose.
P2-12-05
P2-12-06
P2-12-06
P2-12-06
Psychological status of early breast cancer (EBC)
patients (pts) after surgery and before the
starting of aromatase Inhibitors (AIs). Results of
a single-institution, prospective study
Sources of information and influence on
decisions regarding contralateral prophylactic
mastectomy: A prospective study
Sources of information and influence on
decisions regarding contralateral prophylactic
mastectomy: A prospective study
Sources of information and influence on
decisions regarding contralateral prophylactic
mastectomy: A prospective study
Annalisa
Swati
Sarah
Martha
P2-12-06
P2-12-06
P2-12-07
P2-12-07
P2-12-07
P2-12-07
P2-12-07
P2-12-07
P2-12-07
Sources of information and influence on
decisions regarding contralateral prophylactic
mastectomy: A prospective study
Sources of information and influence on
decisions regarding contralateral prophylactic
mastectomy: A prospective study
The association between exercise behavior and
patient-reported outcomes in women with early
breast cancer receiving locoregional radiation
therapy
The association between exercise behavior and
patient-reported outcomes in women with early
breast cancer receiving locoregional radiation
therapy
The association between exercise behavior and
patient-reported outcomes in women with early
breast cancer receiving locoregional radiation
therapy
The association between exercise behavior and
patient-reported outcomes in women with early
breast cancer receiving locoregional radiation
therapy
The association between exercise behavior and
patient-reported outcomes in women with early
breast cancer receiving locoregional radiation
therapy
The association between exercise behavior and
patient-reported outcomes in women with early
breast cancer receiving locoregional radiation
therapy
The association between exercise behavior and
patient-reported outcomes in women with early
breast cancer receiving locoregional radiation
therapy
Wroblewski
Ms. Wroblewski has no relevant financial
relationships to disclose.
Kathy
Yao
Dr. Yao has no relevant financial relationships
to disclose.
Ritu
Arya
Ritu Arya has no relevant financial relationships
to disclose.
Blitzblau
Dr. Blitzblau has no relevant financial
relationships to disclose.
Broadwater
Ms. Broadwater has no relevant financial
relationships to disclose.
Horton
Dr. Horton has no relevant financial
relationships to disclose.
Jones
Dr. Jones has no relevant financial relationships
to disclose.
Massa
Ms. Massa has no relevant financial
relationships to disclose.
Palta
Dr. Palta has no relevant financial relationships
to disclose.
Kristen
Rachel
Gloria
Janet
Lee
Lisa
Manisha
P2-12-08
P2-12-08
P2-12-08
P2-12-08
P2-12-08
P2-12-08
P2-12-08
P2-12-08
P2-12-09
P2-12-09
P2-12-09
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Chemotherapy-induced fatigue and
mitochondrial function in early stage breast
cancer
Psycho-oncological intervention in breast cancer
patients - A quantitative analysis of tumor
associated fatigue treatment
Psycho-oncological intervention in breast cancer
patients - A quantitative analysis of tumor
associated fatigue treatment
Psycho-oncological intervention in breast cancer
patients - A quantitative analysis of tumor
associated fatigue treatment
Chitambar
Dr. Chitambar has no relevant financial
relationships to disclose.
Dranka
Mr. Dranka has no relevant financial
relationships to disclose.
Herath
Dr. Herath has no relevant financial
relationships to disclose.
Hoffmann
Dr. Hoffmann has no relevant financial
relationships to disclose.
Kalyanaraman
Dr. Kalyanaraman has no relevant financial
relationships to disclose.
George
Lessmann
Mr. Lessmann has no relevant financial
relationships to disclose.
Donna
McAllister
Ms. McAllister has no relevant financial
relationships to disclose.
Namrata
Peswani
Dr. Peswani has no relevant financial
relationships to disclose.
Eichler
Dr. Eichler has no relevant financial
relationships to disclose.
Multhaupt
Pia Multhaupt has no relevant financial
relationships to disclose.
Multhaupt
Ms. Multhaupt has no relevant financial
relationships to disclose.
Christopher
Brian
Kanchana
Raymond
Balaraman
Christian
Pia
Sibylle
P2-12-09
P2-12-09
P2-12-10
P2-12-10
P2-12-10
P2-12-11
P2-12-11
P2-12-11
P2-12-11
P2-12-11
P2-12-11
P2-12-11
Psycho-oncological intervention in breast cancer
patients - A quantitative analysis of tumor
associated fatigue treatment
Psycho-oncological intervention in breast cancer
patients - A quantitative analysis of tumor
associated fatigue treatment
Examining diagnostic and therapeutic delays
using patient reported outcomes
Examining diagnostic and therapeutic delays
using patient reported outcomes
Examining diagnostic and therapeutic delays
using patient reported outcomes
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Mathias
Warm
Mr. Warm has no relevant financial
relationships to disclose.
Friedrich
Wolff
Kimlin
Ashing
Odicie
Fielder-Kimbrough
Mayra
Serrano
Mr. Wolff has no relevant financial
relationships to disclose.
Dr. Ashing has no relevant financial
relationships to disclose.
Dr. Fielder-Kimbrough has no relevant financial
relationships to disclose.
Mayra Serrano has no relevant financial
relationships to disclose.
Adair
Dr. Adair has no relevant financial relationships
to disclose.
Gary
Burton
Dr. Burton has no relevant financial
relationships to disclose.
Sanjay
Juneja
Dr. Juneja has no relevant financial
relationships to disclose.
Kimberly
Nguyen
Ms. Nguyen has no relevant financial
relationships to disclose.
Panati
Dr. Panati has no relevant financial
relationships to disclose.
Shahid
Dr. Shahid has no relevant financial
relationships to disclose.
Shi
Dr. Shi has no relevant financial relationships
to disclose.
Lauren
Swetha
Kamran
Runhua
P2-12-11
P2-12-12
P2-12-12
P2-12-12
P2-12-12
P2-12-12
P2-12-12
P2-12-13
P2-12-13
P2-12-13
P2-12-13
P2-12-13
P2-12-13
Socioeconomic factors and the use of
complimentary and alternative therapies in
patients with early stage breast cancer
Breast cancer in young women: Fertility
preservation as a component of treatment
planning and discussion
Breast cancer in young women: Fertility
preservation as a component of treatment
planning and discussion
Breast cancer in young women: Fertility
preservation as a component of treatment
planning and discussion
Breast cancer in young women: Fertility
preservation as a component of treatment
planning and discussion
Breast cancer in young women: Fertility
preservation as a component of treatment
planning and discussion
Breast cancer in young women: Fertility
preservation as a component of treatment
planning and discussion
Knowledge and Information seeking about
personalized breast cancer therapy
Knowledge and Information seeking about
personalized breast cancer therapy
Knowledge and Information seeking about
personalized breast cancer therapy
Knowledge and Information seeking about
personalized breast cancer therapy
Knowledge and Information seeking about
personalized breast cancer therapy
Knowledge and Information seeking about
personalized breast cancer therapy
Watson
Dr. Watson has no relevant financial
relationships to disclose.
Almeida Santos
Ms. Almeida Santos has no relevant financial
relationships to disclose.
Brito
Ms. Brito has no relevant financial relationships
to disclose.
Melo
Ms. Melo has no relevant financial
relationships to disclose.
Moreira
Mr. Moreira has no relevant financial
relationships to disclose.
Hugo
Nunes
Mr. Nunes has no relevant financial
relationships to disclose.
Fátima
Vaz
Elmer
Bernstam
Allison
Burton-Chase
Bryan
Fellman
Shelley
Hovick
Yisheng
Li
Funda
Meric-Bernstam
Kaylin
Ana Teresa
Margarida
Cláudia
António
Dr. Vaz has no relevant financial relationships
to disclose.
Dr. Bernstam has no relevant financial
relationships to disclose.
Dr. Burton-Chase has no relevant financial
relationships to disclose.
Mr. Fellman has no relevant financial
relationships to disclose.
Dr. Hovick has no relevant financial
relationships to disclose.
Dr. Li has no relevant financial relationships to
disclose.
Dr. Meric-Bernstam has no relevant financial
relationships to disclose.
P2-12-13
P2-12-13
P2-12-13
P2-12-14
P2-12-14
P2-12-14
P2-12-14
P2-12-14
P2-12-15
P2-12-15
P2-12-15
P2-12-15
Knowledge and Information seeking about
personalized breast cancer therapy
Knowledge and Information seeking about
personalized breast cancer therapy
Knowledge and Information seeking about
personalized breast cancer therapy
The effect of low intensity exercise for mental
status and quality of life of Japanese early
breast cancer patients
The effect of low intensity exercise for mental
status and quality of life of Japanese early
breast cancer patients
The effect of low intensity exercise for mental
status and quality of life of Japanese early
breast cancer patients
The effect of low intensity exercise for mental
status and quality of life of Japanese early
breast cancer patients
The effect of low intensity exercise for mental
status and quality of life of Japanese early
breast cancer patients
Perception of women after undergoing
microbiopsy following a positive breast cander
screening
Perception of women after undergoing
microbiopsy following a positive breast cander
screening
Perception of women after undergoing
microbiopsy following a positive breast cander
screening
Perception of women after undergoing
microbiopsy following a positive breast cander
screening
Susan
Peterson
Deevakar
Rogith
Rafeek
Yusuf
Ms. Peterson has no relevant financial
relationships to disclose.
Deevakar Rogith has no relevant financial
relationships to disclose.
Dr. Yusuf has no relevant financial relationships
to disclose.
Kamio
Dr. Kamio has no relevant financial
relationships to disclose.
Kawase
Kazumi Kawase has no relevant financial
relationships to disclose.
Nogi
Dr. Nogi has no relevant financial relationships
to disclose.
Hiroshi
Takeyama
Dr. Takeyama has no relevant financial
relationships to disclose.
Ken
Uchida
Mr. Uchida has no relevant financial
relationships to disclose.
Mireille
Aimont
Mireille Aimont has no relevant financial
relationships to disclose.
Beauloye
Mr. Beauloye has no relevant financial
relationships to disclose.
Carly
Birgit Carly has no relevant financial
relationships to disclose.
Liebens
Fabienne Liebens has no relevant financial
relationships to disclose.
Makiko
Kazumi
Hiroko
Nicolas
Birgit
Fabienne
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
Alba
Dr. Alba has no relevant financial relationships
to disclose.
Kadri
Altundag
Kadri Altundag has no relevant financial
relationships to disclose.
Jose
Bines
Jose Bines has no relevant financial
relationships to disclose.
Bozcuk
Hakan Bozcuk has no relevant financial
relationships to disclose.
Emilio
Hakan
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
Chmielowska
Ewa Chmielowska has no relevant financial
relationships to disclose.
Saverio
Cinieri
Saverio Cigler has no relevant financial
relationships to disclose.
Paulo
Cortes
Dr. Cortes has disclosed he receives consulting
fees from Roche.
de Ducla
Ms. de Ducla has disclosed that she receives
salary from and has ownership in Roche.
Ewa
Sabine
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
Doval
Dinesh Doval has no relevant financial
relationships to disclose.
Lesley
Fallowfield
Ms. Fallowfield has disclosed that she is a
consultant and speaker for Roche.
Ulrich
Freudensprung
Mr. Freudensprung has disclosed that he is
receives salary from Roche.
Gligorov
Mr. Gligorov has disclosed that he is a
consultant and speaker for Roche.
Dinesh
Joseph
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
Gupta
Sudeep Gupta has no relevant financial
relationships to disclose.
Vineet
Gupta
Vineet Gupta has no relevant financial
relationships to disclose.
Guillermo
Lopez Vivanco
Guillermo Lopez Vivanco has no relevant
financial relationships to disclose.
Montcuquet
Mr. Montcuquet has no relevant financial
relationships to disclose.
Sudeep
Philippe
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
P2-12-16
P2-13-01
Exploratory post hoc analyses of patientreported outcomes (PROs) in the IMELDA
randomized phase III trial: Maintenance
bevacizumab (BEV) ± capecitabine (CAP) after
initial first-line BEV plus docetaxel (DOC) for
HER2-negative metastatic breast cancer (mBC)
Stage-related risk categorization and influence
of free margins on survival in triple negative
early breast cancer - a population-based study
of 2037 TNBC patients with adjuvant
chemotherapy
Mustacchi
Mr. Mustacchi has disclosed that he is a
consultant for Roche, Celgene, and Eisai.
Alfred
Namour
Mr. Namour has no relevant financial
relationships to disclose.
Jean-Yves
Pierga
Dr. Pierga has disclosed that he is a consultant
for and has a contract with Roche and Janssen.
Wang
Xiaojia Wang has no relevant financial
relationships to disclose.
Flach
Ms. Flach has no relevant financial
relationships to disclose.
Giorgio
Xiaojia
Annika
P2-13-01
P2-13-01
P2-13-01
P2-13-01
P2-13-01
P2-13-01
P2-13-02
P2-13-02
Stage-related risk categorization and influence
of free margins on survival in triple negative
early breast cancer - a population-based study
of 2037 TNBC patients with adjuvant
chemotherapy
Stage-related risk categorization and influence
of free margins on survival in triple negative
early breast cancer - a population-based study
of 2037 TNBC patients with adjuvant
chemotherapy
Stage-related risk categorization and influence
of free margins on survival in triple negative
early breast cancer - a population-based study
of 2037 TNBC patients with adjuvant
chemotherapy
Stage-related risk categorization and influence
of free margins on survival in triple negative
early breast cancer - a population-based study
of 2037 TNBC patients with adjuvant
chemotherapy
Stage-related risk categorization and influence
of free margins on survival in triple negative
early breast cancer - a population-based study
of 2037 TNBC patients with adjuvant
chemotherapy
Stage-related risk categorization and influence
of free margins on survival in triple negative
early breast cancer - a population-based study
of 2037 TNBC patients with adjuvant
chemotherapy
Nipple sparing mastectomy in patients with
BRCA1 and BRCA2 mutations
Nipple sparing mastectomy in patients with
BRCA1 and BRCA2 mutations
Peter
Kern
Dr. Kern has no relevant financial relationships
to disclose.
Rainer
Kimmig
Dr. Kimmig has no relevant financial
relationships to disclose.
Pütter
Dr. Pütter has no relevant financial
relationships to disclose.
Pavlidou
Ms. Pavlidou has no relevant financial
relationships to disclose.
Rezai
Dr. Rezai has no relevant financial relationships
to disclose.
Carolin
Sofia
Mahdi
Gunter
von Minckwitz
Deborah
Capko
Anne
Eaton
Dr. von Minckwitz has no relevant financial
relationships to disclose.
Dr. Capko has no relevant financial
relationships to disclose.
Ms. Eaton has no relevant financial
relationships to disclose.
P2-13-02
Nipple sparing mastectomy in patients with
BRCA1 and BRCA2 mutations
Nipple sparing mastectomy in patients with
BRCA1 and BRCA2 mutations
Nipple sparing mastectomy in patients with
BRCA1 and BRCA2 mutations
Nipple sparing mastectomy in patients with
BRCA1 and BRCA2 mutations
Nipple sparing mastectomy in patients with
BRCA1 and BRCA2 mutations
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Angel
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Stephen
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Michael
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Melissa
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Nancy
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Beverly
P2-13-02
P2-13-02
P2-13-02
P2-13-02
Aidan
Manning
Andrea
Pusic
Virgilio
Sacchini
Michelle
Stempel
Caitlin
Wood
Dr. Manning has no relevant financial
relationships to disclose.
Dr. Pusic has no relevant financial relationships
to disclose.
Dr. Sacchini has no relevant financial
relationships to disclose.
Ms. Stempel has no relevant financial
relationships to disclose.
Caitlin Wood has no relevant financial
relationships to disclose.
Cronin
Angel Cronin has no relevant financial
relationships to disclose.
Edge
Mr. Edge has no relevant financial relationships
to disclose.
Hassett
Dr. Hassett has no relevant financial
relationships to disclose.
Hughes
Ms. Hughes has no relevant financial
relationships to disclose.
Lin
Dr. Lin has no relevant financial relationships to
disclose.
Moy
Dr. Moy has no relevant financial relationships
to disclose.
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Hope
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Richard
P2-13-03
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
Ines
P2-13-03
P2-13-04
P2-13-04
P2-13-04
P2-13-04
Variation in the use of mastectomy (MAST) in
women with small node negative breast cancer
(BC) treated at US academic institutions
The role of preoperative MRI in negative
margins after breast conserving surgery in
patients with invasive breast cancer or purely
DCIS
The role of preoperative MRI in negative
margins after breast conserving surgery in
patients with invasive breast cancer or purely
DCIS
The role of preoperative MRI in negative
margins after breast conserving surgery in
patients with invasive breast cancer or purely
DCIS
The role of preoperative MRI in negative
margins after breast conserving surgery in
patients with invasive breast cancer or purely
DCIS
Rugo
Dr. Rugo has no relevant financial relationships
to disclose.
Theriault
Dr. Theriault has no relevant financial
relationships to disclose.
Vaz Luis
Dr. Vaz Luis has no relevant financial
relationships to disclose.
Winer
Dr. Winer has no relevant financial
relationships to disclose.
Linetta
Koppert
Ms. Koppert has no relevant financial
relationships to disclose.
Inge-Marie
Obdeijn
Ms. Obdeijn has no relevant financial
relationships to disclose.
Cornelis
Verhoef
Cornelis Verhoef has no relevant financial
relationships to disclose.
Adri
Voogd
Dr. Voogd has no relevant financial
relationships to disclose.
Eric
P2-13-04
P2-13-05
P2-13-05
P2-13-05
P2-13-05
P2-13-05
P2-13-05
P2-13-05
P2-13-05
P2-13-06
P2-13-06
The role of preoperative MRI in negative
margins after breast conserving surgery in
patients with invasive breast cancer or purely
DCIS
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Radioguided occult lesion localization (ROLL). A
12-year single institution experience of 942
ROLL excisions
Flat epithelial atypia on core biopsy and
upgrade to cancer: A systematic review and
meta-analysis
Flat epithelial atypia on core biopsy and
upgrade to cancer: A systematic review and
meta-analysis
Vos
Ms. Vos has no relevant financial relationships
to disclose.
Iain
Brown
Mr. Brown has no relevant financial
relationships to disclose.
Donna
Christensen
Ms. Christensen has no relevant financial
relationships to disclose.
Philip
Drew
Mr. Drew has no relevant financial
relationships to disclose.
Mohsen
El-Gammal
Mohsen El-Gammal has no relevant financial
relationships to disclose.
Hawkins
Mr. Hawkins has no relevant financial
relationships to disclose.
Paterson
Alistair Paterson has no relevant financial
relationships to disclose.
Stepp
Ms. Stepp has no relevant financial
relationships to disclose.
Widdison
Ms. Widdison has no relevant financial
relationships to disclose.
Degnim
Dr. Degnim has no relevant financial
relationships to disclose.
Farrell
Ms. Farrell has no relevant financial
relationships to disclose.
Elvira
Simon
Alistair
Kirsten
Sue
Amy
Ann
P2-13-06
P2-13-06
P2-13-07
P2-13-07
P2-13-07
P2-13-07
P2-13-07
P2-13-07
P2-13-07
P2-13-08
P2-13-08
P2-13-08
P2-13-08
Flat epithelial atypia on core biopsy and
upgrade to cancer: A systematic review and
meta-analysis
Flat epithelial atypia on core biopsy and
upgrade to cancer: A systematic review and
meta-analysis
Prophylactic mastectomy in young women with
breast cancer
Prophylactic mastectomy in young women with
breast cancer
Prophylactic mastectomy in young women with
breast cancer
Prophylactic mastectomy in young women with
breast cancer
Prophylactic mastectomy in young women with
breast cancer
Prophylactic mastectomy in young women with
breast cancer
Prophylactic mastectomy in young women with
breast cancer
Initial experience with an ambulatory extended
recovery program for patients undergoing
mastectomy
Initial experience with an ambulatory extended
recovery program for patients undergoing
mastectomy
Initial experience with an ambulatory extended
recovery program for patients undergoing
mastectomy
Initial experience with an ambulatory extended
recovery program for patients undergoing
mastectomy
Anatoliy
Rudin
Dr. Rudin has no relevant financial
relationships to disclose.
Hoskin
Tanya
Christel
Helwig
Alex
Kiss
Nim
Li
Rodica
Mandel
Cristiane
Metran Nascente
Ellen
Warner
Frances
Wright
Hoskin Tanya has no relevant financial
relationships to disclose.
Christel Helwig has no relevant financial
relationships to disclose.
Dr. Kiss has no relevant financial relationships
to disclose.
Nim Li has no relevant financial relationships to
disclose.
Rodica Mandel has no relevant financial
relationships to disclose.
Dr. Metran Nascente has no relevant financial
relationships to disclose.
Ms. Warnars has no relevant financial
relationships to disclose.
Dr. Wright has no relevant financial
relationships to disclose.
Cassella
Ms. Cassella has no relevant financial
relationships to disclose.
Aidan
Manning
Dr. Manning has no relevant financial
relationships to disclose.
Lisa
Sclafani
Dr. Sclafani has no relevant financial
relationships to disclose.
Beverly
Tseng-Reyes
Ms. Tseng-Reyes has no relevant financial
relationships to disclose.
Danielle
P2-13-09
Initial experience with an ambulatory extended
recovery program for patients undergoing
mastectomy
Implication of breast-conserving therapy in the
subtype era of breast cancer
Implication of breast-conserving therapy in the
subtype era of breast cancer
Implication of breast-conserving therapy in the
subtype era of breast cancer
Implication of breast-conserving therapy in the
subtype era of breast cancer
Implication of breast-conserving therapy in the
subtype era of breast cancer
Implication of breast-conserving therapy in the
subtype era of breast cancer
P2-13-10
Assessment of diagnostic and therapeutic value
of ductoscopy biopsy in single intraductal
papillary lesion compared with open surgery
Yiqi
P2-13-10
Assessment of diagnostic and therapeutic value
of ductoscopy biopsy in single intraductal
papillary lesion compared with open surgery
Qiang
P2-13-10
Assessment of diagnostic and therapeutic value
of ductoscopy biopsy in single intraductal
papillary lesion compared with open surgery
Deli
P2-13-10
Assessment of diagnostic and therapeutic value
of ductoscopy biopsy in single intraductal
papillary lesion compared with open surgery
Wanying
P2-13-08
P2-13-09
P2-13-09
P2-13-09
P2-13-09
P2-13-09
Stacy
Ugras
Jee Ye
Kim
Sanghwa
Kim
Seung Il
Kim
Hyung Seok
Park
Seho
Park
Jegyu
Ryu
Dr. Ugras has no relevant financial
relationships to disclose.
Dr. Kim has no relevant financial relationships
to disclose.
Dr. Kim has no relevant financial relationships
to disclose.
Dr. Kim has no relevant financial relationships
to disclose.
Dr. Park has no relevant financial relationships
to disclose.
Dr. Park has no relevant financial relationships
to disclose.
Dr. Ryu has no relevant financial relationships
to disclose.
Gu
Dr. Gu has no relevant financial relationships to
disclose.
Li
Dr. Li has no relevant financial relationships to
disclose.
Xing
Dr. Xing has no relevant financial relationships
to disclose.
Xing
Dr. Xing has no relevant financial relationships
to disclose.
P2-13-11
Assessment of diagnostic and therapeutic value
of ductoscopy biopsy in single intraductal
papillary lesion compared with open surgery
Multimodality perioperative analgesia with
paravertebral nerve block and gabapentin
reduces narcotic use and hospital length of stay
in mastectomy patients
Multimodality perioperative analgesia with
paravertebral nerve block and gabapentin
reduces narcotic use and hospital length of stay
in mastectomy patients
Multimodality perioperative analgesia with
paravertebral nerve block and gabapentin
reduces narcotic use and hospital length of stay
in mastectomy patients
Multimodality perioperative analgesia with
paravertebral nerve block and gabapentin
reduces narcotic use and hospital length of stay
in mastectomy patients
Multimodality perioperative analgesia with
paravertebral nerve block and gabapentin
reduces narcotic use and hospital length of stay
in mastectomy patients
P2-13-12
Does the implementation of an enhanced
recovery programme impact on post- operative
outcomes in populations with significant
comorbidity and social deprivation?
Alison
P2-13-12
Does the implementation of an enhanced
recovery programme impact on post- operative
outcomes in populations with significant
comorbidity and social deprivation?
Juliette
P2-13-10
P2-13-11
P2-13-11
P2-13-11
P2-13-11
Xu
Dr. Xu has no relevant financial relationships to
disclose.
Bishop
Dr. Bishop has no relevant financial
relationships to disclose.
Theresa
Bowling
Dr. Bowling has no relevant financial
relationships to disclose.
Zandra
Cheng
Dr. Cheng has no relevant financial
relationships to disclose.
Vlad
Frenk
Dr. Frenk has no relevant financial relationships
to disclose.
Helen
Pass
Dr. Pass has no relevant financial relationships
to disclose.
Lannigan
Ms. Lannigan has no relevant financial
relationships to disclose.
Murray
Ms. Murray has no relevant financial
relationships to disclose.
Zheli
Jennifer
P2-13-12
P2-13-12
P2-13-13
P2-13-13
P2-13-13
P2-13-13
P2-13-13
P2-13-14
P2-13-14
P2-13-14
P2-13-14
P2-13-14
P2-13-14
P2-13-14
Does the implementation of an enhanced
recovery programme impact on post- operative
outcomes in populations with significant
comorbidity and social deprivation?
Adrian
Does the implementation of an enhanced
recovery programme impact on post- operative
outcomes in populations with significant
comorbidity and social deprivation?
Predictors of bilateral mastectomy in breast
cancer patients
Predictors of bilateral mastectomy in breast
cancer patients
Predictors of bilateral mastectomy in breast
cancer patients
Predictors of bilateral mastectomy in breast
cancer patients
Predictors of bilateral mastectomy in breast
cancer patients
Does therapeutic mammoplasty reduce
mastectomy rates?
Does therapeutic mammoplasty reduce
mastectomy rates?
Does therapeutic mammoplasty reduce
mastectomy rates?
Does therapeutic mammoplasty reduce
mastectomy rates?
Does therapeutic mammoplasty reduce
mastectomy rates?
Does therapeutic mammoplasty reduce
mastectomy rates?
Does therapeutic mammoplasty reduce
mastectomy rates?
Wong
Ee Von
Woon
Michelle
Dewing
Yun
Fu
Chang
Helena
Apple
Sophia
Zhigang
Zhuang
Julie
Doughty
Alison
Lannigan
James
Mansell
Juliette
Murray
Jennifer
Pollard
Laszlo
Romics
Sheila
Stallard
Mr. Wong has no relevant financial
relationships to disclose.
Ee Von Woon has no relevant financial
relationships to disclose.
Dr. Dewing has no relevant financial
relationships to disclose.
Dr. Fu has no relevant financial relationships to
disclose.
Dr. Helena has no relevant financial
relationships to disclose.
Dr. Sophia has no relevant financial
relationships to disclose.
Dr. Zhuang has no relevant financial
relationships to disclose.
Ms. Doughty has no relevant financial
relationships to disclose.
Ms. Lannigan has no relevant financial
relationships to disclose.
Mr. Mansell has no relevant financial
relationships to disclose.
Ms. Murray has no relevant financial
relationships to disclose.
Ms. Pollard has no relevant financial
relationships to disclose.
Laszlo Romics has no relevant financial
relationships to disclose.
Ms. Stallard has no relevant financial
relationships to disclose.
P2-13-14
P2-13-14
P2-13-16
P2-13-16
P2-13-16
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
Does therapeutic mammoplasty reduce
mastectomy rates?
Does therapeutic mammoplasty reduce
mastectomy rates?
Intraoperative ultrasound guided wire
bracketing of nonpalpable breast lesions for
excision
Intraoperative ultrasound guided wire
bracketing of nonpalpable breast lesions for
excision
Intraoperative ultrasound guided wire
bracketing of nonpalpable breast lesions for
excision
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Christopher
Wilson
Pang
Wong
Mr. Wilson has no relevant financial
relationships to disclose.
Pang Wong has no relevant financial
relationships to disclose.
Rachel
Novella
Ms. Novella has no relevant financial
relationships to disclose.
David
Rock
Dr. Rock has no relevant financial relationships
to disclose.
Aimee
Stewart
Aimee Stewart has no relevant financial
relationships to disclose.
Encarna
Adrover
Dr. Adrover has no relevant financial
relationships to disclose.
Emilio
Alba
Dr. Alba has no relevant financial relationships
to disclose.
Raquel
Andrés
Dr. Andrés has no relevant financial
relationships to disclose.
Norberto
Batista
Dr. Batista has no relevant financial
relationships to disclose.
Calvo
Dr. Calvo has no relevant financial relationships
to disclose.
Lourdes
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Carrasco
Dr. Carrasco has no relevant financial
relationships to disclose.
Escudero
Mr. Escudero has no relevant financial
relationships to disclose.
Antonio
Fernández
Dr. Fernández has no relevant financial
relationships to disclose.
ángel
Guerrero
Dr. Guerrero has no relevant financial
relationships to disclose.
Carlos
Jara
Dr. Jara has no relevant financial relationships
to disclose.
Sara
López-Tarruella
Dr. López-Tarruella has no relevant financial
relationships to disclose.
José Manuel
López-Vega
Dr. López-Vega has no relevant financial
relationships to disclose.
Juan
Lao
Dr. Lao has no relevant financial relationships
to disclose.
Eva
María José
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-17
P2-13-18
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Impact on survival of primary tumor resection in
women with de novo metastatic breast cancer.
The GEICAM Alamo I-III breast cancer registry
(1990-2001)
Oncologic outcome of 2,217 patients with
breast cancer after negative sentinel lymph
node biopsy without axillary lymph node
dissection
Llombart
Dr. Llombart has no relevant financial
relationships to disclose.
Lluch
Dr. Lluch has no relevant financial relationships
to disclose.
Miguel
Martín
Dr. Martín has no relevant financial
relationships to disclose.
Purificación
Martínez del Prado
Dr. Martínez del Prado has no relevant
financial relationships to disclose.
Marina
Pollán
Dr. Pollán has no relevant financial
relationships to disclose.
Ignacio
Porras
Dr. Porras has no relevant financial
relationships to disclose.
Ana
Santaballa
Dr. Santaballa has no relevant financial
relationships to disclose.
Sung Gwe
Ahn
Dr. Ahn has no relevant financial relationships
to disclose.
Antonio
Ana
P2-13-18
P2-13-18
P2-13-18
P2-13-18
P2-13-19
P2-13-19
P2-13-20
P2-13-20
P2-13-20
Oncologic outcome of 2,217 patients with
breast cancer after negative sentinel lymph
node biopsy without axillary lymph node
dissection
Oncologic outcome of 2,217 patients with
breast cancer after negative sentinel lymph
node biopsy without axillary lymph node
dissection
Oncologic outcome of 2,217 patients with
breast cancer after negative sentinel lymph
node biopsy without axillary lymph node
dissection
Oncologic outcome of 2,217 patients with
breast cancer after negative sentinel lymph
node biopsy without axillary lymph node
dissection
Papillary breast lesions: Association with
malignancy and upgrade rates on surgical
excision
Papillary breast lesions: Association with
malignancy and upgrade rates on surgical
excision
Randomized clinical trial comparing 2octylcyanoacrylate versus intradermic suture
with nylon: Similar cosmetic results with
different safety profile
Randomized clinical trial comparing 2octylcyanoacrylate versus intradermic suture
with nylon: Similar cosmetic results with
different safety profile
Randomized clinical trial comparing 2octylcyanoacrylate versus intradermic suture
with nylon: Similar cosmetic results with
different safety profile
Jeong
Dr. Jeong has no relevant financial
relationships to disclose.
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Seung Ah
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Jong Tae
Park
Dr. Park has no relevant financial relationships
to disclose.
Farha
Dr. Farha has no relevant financial relationships
to disclose.
Mursleen
Asma Mursleen has no relevant financial
relationships to disclose.
Becker
Thiago Becker has no relevant financial
relationships to disclose.
Freitas-Junior
Dr. Freitas-Junior has no relevant financial
relationships to disclose.
Paulinelli
Dr. Paulinelli has no relevant financial
relationships to disclose.
Joon
Hak Min
Maen
Asma
Thiago
Ruffo
Regis
P2-13-20
P2-13-21
P2-13-21
P2-13-21
P2-13-21
P2-13-21
P2-13-21
P2-13-21
P2-13-22
P2-13-22
P2-13-22
P2-13-22
Randomized clinical trial comparing 2octylcyanoacrylate versus intradermic suture
with nylon: Similar cosmetic results with
different safety profile
Multiple radioactive seed localization in breast
conserving surgery for multifocal or extensive
DCIS
Multiple radioactive seed localization in breast
conserving surgery for multifocal or extensive
DCIS
Multiple radioactive seed localization in breast
conserving surgery for multifocal or extensive
DCIS
Multiple radioactive seed localization in breast
conserving surgery for multifocal or extensive
DCIS
Multiple radioactive seed localization in breast
conserving surgery for multifocal or extensive
DCIS
Multiple radioactive seed localization in breast
conserving surgery for multifocal or extensive
DCIS
Multiple radioactive seed localization in breast
conserving surgery for multifocal or extensive
DCIS
Treatment of benign breast tumor with
ultrasound-guided radiofrequency ablation
Treatment of benign breast tumor with
ultrasound-guided radiofrequency ablation
Treatment of benign breast tumor with
ultrasound-guided radiofrequency ablation
Treatment of benign breast tumor with
ultrasound-guided radiofrequency ablation
Rahal
Dr. Rahal has no relevant financial relationships
to disclose.
Emilie
Groen
Dr. Groen has no relevant financial
relationships to disclose.
Natasja
Janssen
Natasja Janssen has no relevant financial
relationships to disclose.
Claudette
Loo
Dr. Loo has no relevant financial relationships
to disclose.
Hester
Oldenburg
Dr. Oldenburg has no relevant financial
relationships to disclose.
van den Berg
Dr. van den Berg has no relevant financial
relationships to disclose.
van la Parra
Dr. van la Parra has no relevant financial
relationships to disclose.
Rosemar
Marieke
Raquel
Marie-Jeanne
Vrancken-Peeters
Xinyu
Feng
Yanxi
Liu
Denghua
Sun
Guang
Sun
Dr. Vrancken-Peeters has no relevant financial
relationships to disclose.
Xinyu Feng has no relevant financial
relationships to disclose.
Yanxi Liu has no relevant financial relationships
to disclose.
Denghua Sun has no relevant financial
relationships to disclose.
Dr. Sun has no relevant financial relationships
to disclose.
P2-13-22
Treatment of benign breast tumor with
ultrasound-guided radiofrequency ablation
P2-13-23
The oncologic safety of nipple-areolar complex
skin sparing mastectomy compared with skin
sparing mastectomy: 8 years follow up results
P2-13-23
The oncologic safety of nipple-areolar complex
skin sparing mastectomy compared with skin
sparing mastectomy: 8 years follow up results
P2-13-23
The oncologic safety of nipple-areolar complex
skin sparing mastectomy compared with skin
sparing mastectomy: 8 years follow up results
P2-13-23
The oncologic safety of nipple-areolar complex
skin sparing mastectomy compared with skin
sparing mastectomy: 8 years follow up results
P2-13-23
The oncologic safety of nipple-areolar complex
skin sparing mastectomy compared with skin
sparing mastectomy: 8 years follow up results
P2-13-23
P2-13-24
P2-13-24
P2-13-24
P2-13-24
The oncologic safety of nipple-areolar complex
skin sparing mastectomy compared with skin
sparing mastectomy: 8 years follow up results
DCIS in low resource settings: The black swan of
breast health care?
DCIS in low resource settings: The black swan of
breast health care?
DCIS in low resource settings: The black swan of
breast health care?
DCIS in low resource settings: The black swan of
breast health care?
Xu
Dr. Xu has no relevant financial relationships to
disclose.
Young Kyung
Bae
Dr. Bae has no relevant financial relationships
to disclose.
Jung Eun
Choi
Dr. Choi has no relevant financial relationships
to disclose.
Kang
Dr. Kang has no relevant financial relationships
to disclose.
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Park
Dr. Park has no relevant financial relationships
to disclose.
Zheli
Su Hwan
Soo Jung
Jeong Yeong
Kyung Jun
Yeu
Lydia
Cairncross
Miriam
Mutebi
Eugenio
Panieri
Hannah
Simonds
Dr. Yeu has no relevant financial relationships
to disclose.
Ms. Caincross has no relevant financial
relationships to disclose.
Ms. Mutebi has no relevant financial
relationships to disclose.
Eugenio Panieri has no relevant financial
relationships to disclose.
Ms. Simonds has no relevant financial
relationships to disclose.
P2-13-25
P2-13-25
P2-13-25
P2-13-25
P2-13-25
P2-13-25
Cytology and histopathology evaluation of subnipple tissue during intraoperative and
postoperative time to predict neoplastic
involvement of the nipple in patients with
breast carcinoma
Cytology and histopathology evaluation of subnipple tissue during intraoperative and
postoperative time to predict neoplastic
involvement of the nipple in patients with
breast carcinoma
Cytology and histopathology evaluation of subnipple tissue during intraoperative and
postoperative time to predict neoplastic
involvement of the nipple in patients with
breast carcinoma
Cytology and histopathology evaluation of subnipple tissue during intraoperative and
postoperative time to predict neoplastic
involvement of the nipple in patients with
breast carcinoma
Cytology and histopathology evaluation of subnipple tissue during intraoperative and
postoperative time to predict neoplastic
involvement of the nipple in patients with
breast carcinoma
Cytology and histopathology evaluation of subnipple tissue during intraoperative and
postoperative time to predict neoplastic
involvement of the nipple in patients with
breast carcinoma
Giuliano
Duarte
Dr. Duarte has no relevant financial
relationships to disclose.
Luciana
Moreira
Dr. Moreira has no relevant financial
relationships to disclose.
Oliveira
Dr. Oliveira has no relevant financial
relationships to disclose.
Thomazin
Dr. Thomazin has no relevant financial
relationships to disclose.
Tocchet
Dr. Tocchet has no relevant financial
relationships to disclose.
Torresan
Dr. Torresan has no relevant financial
relationships to disclose.
André
Maria Virginia
Fernado
Renato
P2-13-25
P2-13-26
P2-13-26
P2-13-26
P2-13-26
P2-13-26
P2-13-26
P2-13-27
Cytology and histopathology evaluation of subnipple tissue during intraoperative and
postoperative time to predict neoplastic
involvement of the nipple in patients with
breast carcinoma
Trend in primary tumor resection and disease
specific survival in patients with metastatic
breast cancer: A SEER database analysis (19882011)
Trend in primary tumor resection and disease
specific survival in patients with metastatic
breast cancer: A SEER database analysis (19882011)
Trend in primary tumor resection and disease
specific survival in patients with metastatic
breast cancer: A SEER database analysis (19882011)
Trend in primary tumor resection and disease
specific survival in patients with metastatic
breast cancer: A SEER database analysis (19882011)
Trend in primary tumor resection and disease
specific survival in patients with metastatic
breast cancer: A SEER database analysis (19882011)
Trend in primary tumor resection and disease
specific survival in patients with metastatic
breast cancer: A SEER database analysis (19882011)
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Worschech
Ms. Worschech has no relevant financial
relationships to disclose.
Timothy
Fitzgerald
Dr. Fitzgerald has no relevant financial
relationships to disclose.
Swapnil
Kachare
Dr. Kachare has no relevant financial
relationships to disclose.
Mahvish
Muzaffar
Dr. Muzaffar has no relevant financial
relationships to disclose.
Kathryn
Verbanac
Dr. Verbanac has no relevant financial
relationships to disclose.
Nasreen
Vohra
Dr. Vohra has no relevant financial
relationships to disclose.
Jan
Wong
Dr. Wong has no relevant financial
relationships to disclose.
Chalasani
Dr. Chalasani has no relevant financial
relationships to disclose.
Adriana
Pavani
P2-13-27
P2-13-27
P2-13-27
P2-13-27
P2-13-27
P2-13-27
P2-13-27
P2-13-27
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Nipple sparing mastectomy: Risks of wound
complication in the setting of neo-adjuvant or
adjuvant chemotherapy and/or radiation
therapy
Gonzalez
Dr. Gonzalez has no relevant financial
relationships to disclose.
Hurst
Dr. Hurst has no relevant financial relationships
to disclose.
Ethan
Larson
Dr. Larson has no relevant financial
relationships to disclose.
Michele
Ley
Dr. Ley has disclosed that she is a consultant
and speaker for Genentech.
Robert
Livingston
Dr. Livingston has no relevant financial
relationships to disclose.
Selyne
Samuel
Dr. Samuel has no relevant financial
relationships to disclose.
Rebecca
Viscusi
Dr. Viscusi has no relevant financial
relationships to disclose.
Amy
Waer
Dr. Waer has no relevant financial relationships
to disclose.
Victor
Craig
P2-13-28
P2-13-28
P2-13-28
P2-13-28
P2-13-29
P2-13-29
P2-13-29
P2-13-29
P2-13-29
P2-13-29
P2-13-29
Flap fixation reduces seroma in patients
undergoing mastectomy: A significant
implication for clinical practice
Flap fixation reduces seroma in patients
undergoing mastectomy: A significant
implication for clinical practice
Flap fixation reduces seroma in patients
undergoing mastectomy: A significant
implication for clinical practice
Flap fixation reduces seroma in patients
undergoing mastectomy: A significant
implication for clinical practice
External dosimetry and in vivo measurements
improve surgical comprehension of
intraoperative radiotherapy using Intrabeam™
External dosimetry and in vivo measurements
improve surgical comprehension of
intraoperative radiotherapy using Intrabeam™
External dosimetry and in vivo measurements
improve surgical comprehension of
intraoperative radiotherapy using Intrabeam™
External dosimetry and in vivo measurements
improve surgical comprehension of
intraoperative radiotherapy using Intrabeam™
External dosimetry and in vivo measurements
improve surgical comprehension of
intraoperative radiotherapy using Intrabeam™
External dosimetry and in vivo measurements
improve surgical comprehension of
intraoperative radiotherapy using Intrabeam™
External dosimetry and in vivo measurements
improve surgical comprehension of
intraoperative radiotherapy using Intrabeam™
Beckers
Dr. Beckers has no relevant financial
relationships to disclose.
Snoeijs
Dr. Snoeijs has no relevant financial
relationships to disclose.
Van Bastelaar
Dr. Van Bastelaar has no relevant financial
relationships to disclose.
Vissers
Dr. Vissers has no relevant financial
relationships to disclose.
Bert
Dr. Bert has no relevant financial relationships
to disclose.
Nicolas
Boussion
Dr. Boussion has no relevant financial
relationships to disclose.
Dounia
Bouzid
Dounia Bouzid has no relevant financial
relationships to disclose.
Pierre-Francois
Dupré
Dr. Dupré has no relevant financial
relationships to disclose.
Miglierini
Dr. Miglierini has no relevant financial
relationships to disclose.
Pradier
Dr. Pradier has no relevant financial
relationships to disclose.
Visvikis
Mr. Visvikis has no relevant financial
relationships to disclose.
Arianne
Maarten
James
Yvonne
Julien
Petra
Olivier
Dimitris
P2-14-01
P2-14-01
P2-14-01
P2-14-01
P2-14-01
P2-14-01
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Michael
Alvarado
Dr. Alvarado has no relevant financial
relationships to disclose.
Laura
Esserman
Dr. Esserman has no relevant financial
relationships to disclose.
Ewing
Dr. Ewing has no relevant financial
relationships to disclose.
Foster
Dr. Foster has no relevant financial
relationships to disclose.
Fowble
Dr. Fowble has no relevant financial
relationships to disclose.
Lentz
Dr. Lentz has no relevant financial relationships
to disclose.
Cheryl
Robert
Barbara
Rachel
P2-14-01
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Hani
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Frederick
Immediate implant-based breast reconstruction
following total skin-sparing mastectomy:
Defining the risk of preoperative and
postoperative radiation therapy on surgical
outcomes
Anne
P2-14-02
Complications of breast reconstruction in a
provincial population of breast cancer survivors Cheryl
Alexander
Ms. Alexander has no relevant financial
relationships to disclose.
P2-14-02
Complications of breast reconstruction in a
provincial population of breast cancer survivors Mary
Lesperance
Dr. Lesperance has no relevant financial
relationships to disclose.
P2-14-02
Complications of breast reconstruction in a
provincial population of breast cancer survivors Ling
Lu
Ling Lu has no relevant financial relationships
to disclose.
P2-14-02
Complications of breast reconstruction in a
provincial population of breast cancer survivors Mary
McBride
Ms. McBride has no relevant financial
relationships to disclose.
P2-14-02
Complications of breast reconstruction in a
provincial population of breast cancer survivors Chris
Taylor
Dr. Taylor has no relevant financial
relationships to disclose.
P2-14-02
Complications of breast reconstruction in a
provincial population of breast cancer survivors Scott
Tyldesley
Dr. Tyldesley has no relevant financial
relationships to disclose.
P2-14-01
P2-14-01
Sbitany
Dr. Sbitany has disclosed that he is a consultant
for and on the Speaker's Bureau for Lifecell.
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Warren Peled
Dr. Warren Peled has no relevant financial
relationships to disclose.
P2-14-02
P2-14-03
P2-14-04
P2-14-04
P2-14-04
P2-14-04
P2-14-04
P2-14-06
P2-14-06
P2-14-06
P2-14-06
P2-14-06
P2-14-07
Complications of breast reconstruction in a
provincial population of breast cancer survivors
Mastectomy without drains: Flap adhesion and
closure of dead space using TissuGlu® vs
standard wound closure (SWC) - a parallel
cohort comparison
Is the combination of fat grafts and platelet rich
plasma effective and safe? An experimental
study in rats
Is the combination of fat grafts and platelet rich
plasma effective and safe? An experimental
study in rats
Is the combination of fat grafts and platelet rich
plasma effective and safe? An experimental
study in rats
Is the combination of fat grafts and platelet rich
plasma effective and safe? An experimental
study in rats
Is the combination of fat grafts and platelet rich
plasma effective and safe? An experimental
study in rats
Prediction of local recurrence following
mastectomy
Prediction of local recurrence following
mastectomy
Prediction of local recurrence following
mastectomy
Prediction of local recurrence following
mastectomy
Prediction of local recurrence following
mastectomy
A systematic review of the clinical evidence of
the regarding PIP breast implants
Wai
Dr. Wai has no relevant financial relationships
to disclose.
Stefan
Paepke
Dr. Paepke has no relevant financial
relationships to disclose.
Alexandre
Blumenschein
Alexandre Blumenschein has no relevant
financial relationships to disclose.
Maria-Auxiliadora
Cysneiros
Dr. Cysneiros has no relevant financial
relationships to disclose.
Ruffo
Freitas-Junior
Dr. Freitas-Junior has no relevant financial
relationships to disclose.
Moreira
Dr. Moreira has no relevant financial
relationships to disclose.
Elaine
Marise
Roseana
Pereira
Sarah
Al-Himdani
Nigel
Bundred
Julie
Morris
Kian
Tan
Simon
Timbrell
Abdul
Kasem
Ms. Pereira has no relevant financial
relationships to disclose.
Ms. Al-Himdani has no relevant financial
relationships to disclose.
Dr. Bundred has no relevant financial
relationships to disclose.
Ms. Morris has no relevant financial
relationships to disclose.
Kian Tan has no relevant financial relationships
to disclose.
Mr. Timbrell has no relevant financial
relationships to disclose.
Dr. Kasem has no relevant financial
relationships to disclose.
P2-14-07
P2-14-07
P2-14-08
P2-14-08
P2-14-08
P2-14-08
P2-14-09
P2-14-09
P2-14-09
P2-14-09
P2-14-09
P2-14-10
P2-14-10
A systematic review of the clinical evidence of
the regarding PIP breast implants
A systematic review of the clinical evidence of
the regarding PIP breast implants
Immediate breast reconstruction with
anatomical implants following mastectomy: The
Radiation perspective
Immediate breast reconstruction with
anatomical implants following mastectomy: The
Radiation perspective
Immediate breast reconstruction with
anatomical implants following mastectomy: The
Radiation perspective
Immediate breast reconstruction with
anatomical implants following mastectomy: The
Radiation perspective
Variation in UK reconstructive practice in the
face of post-mastectomy radiotherapy
Variation in UK reconstructive practice in the
face of post-mastectomy radiotherapy
Variation in UK reconstructive practice in the
face of post-mastectomy radiotherapy
Variation in UK reconstructive practice in the
face of post-mastectomy radiotherapy
Variation in UK reconstructive practice in the
face of post-mastectomy radiotherapy
Technical results and complication rates after
nipple-sparing mastectomy and direct-toimplant breast reconstruction using porcine
acellular dermal matrix for implant coverage
Technical results and complication rates after
nipple-sparing mastectomy and direct-toimplant breast reconstruction using porcine
acellular dermal matrix for implant coverage
Kefah
Mokbel
Umar
Wazir
Kefah Mokbel has no relevant financial
relationships to disclose.
Umar Wazir has no relevant financial
relationships to disclose.
Merav
Ben-David
Dr. Ben-David has no relevant financial
relationships to disclose.
Ilana
Gelernter
Ilana Gelernter has no relevant financial
relationships to disclose.
Hila
Granot
Hila Granot has no relevant financial
relationships to disclose.
Michael
Scheflan
Nigel
Bundred
Paula
Duxbury
Ashu
Gandhi
James
Harvey
Cliona
Kirwan
Dr. Scheflan has disclosed that he is a
consultant.
Dr. Bundred has no relevant financial
relationships to disclose.
Ms. Duxbury has no relevant financial
relationships to disclose.
Dr. Gandhi has no relevant financial
relationships to disclose.
Dr. Harvey has no relevant financial
relationships to disclose.
Dr. Kirwan has no relevant financial
relationships to disclose.
Peintinger
Dr. Peintinger has no relevant financial
relationships to disclose.
Reitsamer
Dr. Reitsamer has no relevant financial
relationships to disclose.
Florentia
Roland
P2-14-11
P2-14-11
P2-14-11
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
Antibiotic prophylaxis in prosthesis-based
mammoplasty: A systematic review
Antibiotic prophylaxis in prosthesis-based
mammoplasty: A systematic review
Antibiotic prophylaxis in prosthesis-based
mammoplasty: A systematic review
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Naisi
Huang
Mengying
Liu
Jiong
Wu
Naisi Huang has no relevant financial
relationships to disclose.
Mengying Liu has no relevant financial
relationships to disclose.
Jiong Wu has no relevant financial relationships
to disclose.
James
Allison
Dr. Allison has disclosed he receives royalties
from and has a patent with Bristol-Myers
Squibb.
Brian
Blum
Mr. Blum has no relevant financial
relationships to disclose.
Edi
Brogi
Dr. Brogi has no relevant financial relationships
to disclose.
Comen
Dr. Come has no relevant financial
relationships to disclose.
Comstock
Dr. Comstock has no relevant financial
relationships to disclose.
Elizabeth
Christopher
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Zhiwan
Dong
Dr. Dong has no relevant financial relationships
to disclose.
Ryan
Emerson
Dr. Emerson has disclosed he receives salary
and owns stock in Adaptive Biotechnologies.
Ginsberg
Arielle Ginsberg has no relevant financial
relationships to disclose.
Hudis
Dr. Hudis has no relevant financial relationships
to disclose.
Kotin
Dr. Kotin has no relevant financial relationships
to disclose.
Maybody
Dr. Maybody has no relevant financial
relationships to disclose.
Arielle
Clifford
Alan
Majid
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Heather
McArthur
Dr. McArthur has disclosed that she is a
consultant for Celgene and receives research
funds from Bristol-Myers Squibb.
Elizabeth
Morris
Dr. Morris has no relevant financial
relationships to disclose.
Morrow
Dr. Morrow has no relevant financial
relationships to disclose.
Mu
Dr. Mu has no relevant financial relationships
to disclose.
Neville
Deirdre Neville has no relevant financial
relationships to disclose.
Norton
Dr. Norton has no relevant financial
relationships to disclose.
Monica
Zhenyu
Deirdre
Larry
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
David
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Sujata
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
David
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Harlan
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Virgilio
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Stephen
Page
Dr. Page has no relevant financial relationships
to disclose.
Patil
Dr. Patil has no relevant financial relationships
to disclose.
Robins
Mr. Redmond has no relevant financial
relationships to disclose.
Dr. Robins has disclosed he has a patent with
Adaptive Biotechnologies. He also disclosed
that he consults for Adaptive Biotechnologies,
Janssen Pharmaceuticals, and Bristol-Myers
Squibb. He also has ownership in Adaptive
Biotechnologies.
Sacchini
Dr. Sacchini has no relevant financial
relationships to disclose.
Solomon
Dr. Solomon has disclosed he is a consultant
for General Electric, JNJ, Covidien, and
AngioDynamics. He also disclosed that he is
the Director of Devicor.
Redmond
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-01
P2-15-02
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
Integrated immunologic assessment of tumor
infiltrating lymphocytes (TILs) and peripheral
blood to assess synergy of cryoablation (cryo)
plus ipilimumab (ipi) in early stage breast cancer
(ESBC) patients (pts)
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
Janice
Jedd
Phillip
Jianda
Chunjun
Mark
Sung
Dr. Sung has no relevant financial relationships
to disclose.
Wolchok
Dr. Wolchok has disclosed that he is a
consultant for Bristol-Myers Squibb. He also
disclosed that he receives research funding,
Bristol-Myers Squibb.
Wong
Dr. Wong has no relevant financial
relationships to disclose.
Yuan
Dr. Yuan has disclosed that he has a patent
with Adaptive Biotechnologies and receives
research funds from Bristol-Myers Squibb.
Zhao
Chunjun Zhao has no relevant financial
relationships to disclose.
Ahn
Dr. Ahn has disclosed that he is an employee of
Galena Biopharma, Inc.
P2-15-02
P2-15-02
P2-15-02
P2-15-02
P2-15-02
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
Alieva
Dr. Alieva has no relevant financial
relationships to disclose.
Brunt
Dr. Brunt has no relevant financial relationships
to disclose.
Lacey
Chance
Ms. Chance has disclosed that she is an
employee of Galena Biopharma, Inc.
Gavin
Choy
Dr. Choy has disclosed that he is an employee
of Galena Biopharma, Inc.
Hamm
Dr. Hamm has no relevant financial
relationships to disclose.
Svitiana
Murray
Adamm
P2-15-02
P2-15-02
P2-15-02
P2-15-02
P2-15-02
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
Kumar
Dr. Kumar has no relevant financial
relationships to disclose.
Litwiniuk
Dr. Litwiniuk has no relevant financial
relationships to disclose.
John
Mackey
Dr. Mackey has disclosed that he is a
consultant for Roche, Pfizer, and Lilly.
Michelle
Melisko
Dr. Melisko has no relevant financial
relationships to disclose.
Mittendorf
Dr. Mittendorf has no relevant financial
relationships to disclose.
Sonia
Maria
Elizabeth
P2-15-02
P2-15-02
P2-15-02
P2-15-02
P2-15-03
P2-15-03
P2-15-03
P2-15-03
P2-15-03
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
HER2 discordant results in local vs. central
testing in the phase 3 nelipepimut-S trial and
implementation of Leica Bond Oracle HER2
Immunohistochemistry (IHC) System for low
and intermediate levels (1+, 2+) of HER2 protein
expression as a companion diagnostic
A Phase Ib Study of an adjuvant GM-CSFSecreting Breast Cancer Vaccine
A Phase Ib Study of an adjuvant GM-CSFSecreting Breast Cancer Vaccine
A Phase Ib Study of an adjuvant GM-CSFSecreting Breast Cancer Vaccine
A Phase Ib Study of an adjuvant GM-CSFSecreting Breast Cancer Vaccine
A Phase Ib Study of an adjuvant GM-CSFSecreting Breast Cancer Vaccine
Petrakova
Dr. Petrakova has no relevant financial
relationships to disclose.
Rugo
Dr. Rugo has no relevant financial relationships
to disclose.
Sufia
Safina
Dr. Safina has no relevant financial
relationships to disclose.
Michael
Schenker
Karen
Anderson
Christine
Canning
Glenn
Dranoff
Beth
Overmoyer
Jennifer
Savoie
Katarina
Hope
Dr. Schenker has no relevant financial
relationships to disclose.
Dr. Anderson has no relevant financial
relationships to disclose.
Ms. Canning has no relevant financial
relationships to disclose.
Mr. Dranoff has no relevant financial
relationships to disclose.
Dr. Overmoyer has no relevant financial
relationships to disclose.
Ms. Savoie has no relevant financial
relationships to disclose.
P2-15-03
P2-15-03
P2-15-04
P2-15-04
P2-15-04
P2-15-04
P2-15-04
P2-15-04
P2-15-04
P2-15-04
P2-15-04
P2-15-04
A Phase Ib Study of an adjuvant GM-CSFSecreting Breast Cancer Vaccine
A Phase Ib Study of an adjuvant GM-CSFSecreting Breast Cancer Vaccine
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
A phase 1/2 study of Ad.p53 DC vaccine with
indoximod immunotherapy in metastatic breast
cancer
Garrick
Wallstrom
Eric
Winer
Dr. Wallstrom has no relevant financial
relationships to disclose.
Dr. Winer has no relevant financial
relationships to disclose.
Scott
Antonia
Dr. Antonia has no relevant financial
relationships to disclose.
Hyo
Han
Dr. Han has no relevant financial relationships
to disclose.
Roohi
Ismail-Khan
Gene
Kennedy
Dr. Islmail-Khan has no relevant financial
relationships to disclose.
Dr. Kennedy has disclosed that he receives a
salary from and has ownership in NewLink
Genetics.
Link
Dr. Link has disclosed that he receives a salary
from and has ownership in NewLink Genetics.
Minton
Dr. Minton has no relevant financial
relationships to disclose.
Soliman
Dr. Soliman has disclosed that he is a
consultant and speaker for Celgene.
Streicher
Dr. Streicher has no relevant financial
relationships to disclose.
Charles
Susan
Hatem
Howard
Daniel
Sullivan
Nicholas
Vahanian
Dr. Sullivan has no relevant financial
relationships to disclose.
Dr. Vahanian has disclosed that he receives a
salary from and has ownership in NewLink
Genetics.
P2-16-01
P2-16-01
P2-16-01
P2-16-01
P2-16-01
P2-16-01
P2-16-01
P2-16-01
P2-16-01
P2-16-02
P2-16-02
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Discovery of fully human monoclonal antibodies
as therapeutic candidates for the treatment of
HER2-negative breast cancer
Bi-specific antibodies targeting signaling
pathway crosstalk are a new breast cancer
immunotherapeutic strategy
Bi-specific antibodies targeting signaling
pathway crosstalk are a new breast cancer
immunotherapeutic strategy
Algate
Mr. Algate has no relevant financial
relationships to disclose.
Bonavia
Aurelio Bonavia has no relevant financial
relationships to disclose.
Boozer
Ms. Boozer has no relevant financial
relationships to disclose.
Branum
Mr. Branum has no relevant financial
relationships to disclose.
Chan-Hui
Po-Ying Chan-Hui has no relevant financial
relationships to disclose.
Alison
Fitch
Ms. Fitch has no relevant financial relationships
to disclose.
Brad
Greenfield
Mr. Greenfield has no relevant financial
relationships to disclose.
Claire
Sutherland
Ms. Sutherland has no relevant financial
relationships to disclose.
Swiderek
Ms. Swiderek has no relevant financial
relationships to disclose.
Carmody
Dr. Carmody has no relevant financial
relationships to disclose.
Chagar
Dr. Chagar has no relevant financial
relationships to disclose.
Paul
Aurelio
Christy
Mark
Po-Ying
Kristine
Lisa
Sarabjit
P2-16-02
P2-16-02
P2-16-02
P2-16-02
P2-16-02
P2-16-03
P2-16-03
P2-16-03
P2-16-03
P2-16-03
P2-16-03
P2-16-03
P2-16-03
Bi-specific antibodies targeting signaling
pathway crosstalk are a new breast cancer
immunotherapeutic strategy
Bi-specific antibodies targeting signaling
pathway crosstalk are a new breast cancer
immunotherapeutic strategy
Bi-specific antibodies targeting signaling
pathway crosstalk are a new breast cancer
immunotherapeutic strategy
Bi-specific antibodies targeting signaling
pathway crosstalk are a new breast cancer
immunotherapeutic strategy
Bi-specific antibodies targeting signaling
pathway crosstalk are a new breast cancer
immunotherapeutic strategy
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
C-Met is a potential therapeutic target for
antibody-drug conjugates in breast cancer
Yanwen
Gunnar
Barbara
Yanliang
Fu
Dr. Fu has no relevant financial relationships to
disclose.
Kaufmann
Dr. Kaufmann has no relevant financial
relationships to disclose.
Swanson
Dr. Swanson has no relevant financial
relationships to disclose.
Zhang
Dr. Zhang has no relevant financial
relationships to disclose.
Heyue
Zhou
Gary
Chen
Yanwen
Fu
Edwige
Gros
Kimberly
Johnson
Bryan
Jones
Gunnar
Kaufmann
Alice
Lee
David
Miao
Dr. Zhou has no relevant financial relationships
to disclose.
Dr. Chen has no relevant financial relationships
to disclose.
Dr. Fu has no relevant financial relationships to
disclose.
Dr. Gros has no relevant financial relationships
to disclose.
Ms. Johnson has no relevant financial
relationships to disclose.
Dr. Jones has no relevant financial relationships
to disclose.
Dr. Kaufmann has no relevant financial
relationships to disclose.
Ms. Lee has no relevant financial relationships
to disclose.
Dr. Miao has no relevant financial relationships
to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Emilio
Alba
Dr. Alba has no relevant financial relationships
to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Kadri
Altundag
Kadri Altundag has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Jose
Bines
Jose Bines has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Hakan
Bozcuk
Hakan Bozcuk has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Ewa
Chmielowska
Ewa Chmielowska has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Saverio
Cinieri
Saverio Cigler has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Paulo
Cortes
Dr. Cortes has disclosed he receives consulting
fees from Roche.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Romulo
Costa
Romulo Costa has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Sabine
de Ducla
Ms. de Ducla has disclosed that she receives
salary from and has ownership in Roche.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Dinesh
Doval
Dinesh Doval has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Ulrich
Freudensprung
Mr. Freudensprung has disclosed that he is
receives salary from Roche.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Rabab
Gaafar
Rabab Gaafar has disclosed that he is a
consultant for Lilly, Novartis, AstraZeneca, and
Pfizer and has contracts with Roche, BI, and
Parexel.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Joseph
Gligorov
Mr. Gligorov has disclosed that he is a
consultant and speaker for Roche.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Sudeep
Gupta
Sudeep Gupta has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Vineet
Gupta
Vineet Gupta has no relevant financial
relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Guillermo
Lopez Vivanco
Guillermo Lopez Vivanco has no relevant
financial relationships to disclose.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Giorgio
Mustacchi
Mr. Mustacchi has disclosed that he is a
consultant for Roche, Celgene, and Eisai.
P2-17-01
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC) Jean-Yves
Pierga
Dr. Pierga has disclosed that he is a consultant
for and has a contract with Roche and Janssen.
P2-17-01
P2-17-02
P2-17-02
P2-17-02
P2-17-02
P2-17-02
P2-17-02
P2-17-02
Overall survival (OS) in the IMELDA randomized
phase III trial of maintenance bevacizumab
(BEV) with or without capecitabine (CAP) for
HER2-negative metastatic breast cancer (mBC)
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
Wang
Xiaojia Wang has no relevant financial
relationships to disclose.
Jun
Cao
Dr. Cao has no relevant financial relationships
to disclose.
Xichun
Hu
Ms. Hu has no relevant financial relationships
to disclose.
Ting
Li
Ting Li has no relevant financial relationships to
disclose.
Fangfang
Lv
Fangfang Lv has no relevant financial
relationships to disclose.
Chen
Ni
Chen Ni has no relevant financial relationships
to disclose.
Si
Sun
Si Sun has no relevant financial relationships to
disclose.
Wang
Biyun Wang has no relevant financial
relationships to disclose.
Xiaojia
Biyun
P2-17-02
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
A phase II study of bevacizumab in combination
with modified FOLFOX6 in heavily pretreated
patients with HER2-negative metastatic breast
cancer
P2-18-02
Characteristics and outcome of breast cancer
patients enrolled in cancer therapy evaluation
program (CTEP) sponsored phase I clinical trials Pamela
Harris
Dr. Harris has no relevant financial
relationships to disclose.
P2-18-02
Characteristics and outcome of breast cancer
patients enrolled in cancer therapy evaluation
program (CTEP) sponsored phase I clinical trials Filipa
Lynce
Dr. Lynce has no relevant financial
relationships to disclose.
P2-17-02
P2-17-02
P2-17-02
P2-17-02
P2-17-02
Wang
Leiping Wang has no relevant financial
relationships to disclose.
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Zhenhua
Wu
Zhenhua Wu has no relevant financial
relationships to disclose.
Jie
Xie
Jie Xie has no relevant financial relationships to
disclose.
Jian
Zhang
Jian Zhang has no relevant financial
relationships to disclose.
Sheng
Zhang
Sheng Zhang has no relevant financial
relationships to disclose.
Leiping
Zhonghua
P2-18-02
Characteristics and outcome of breast cancer
patients enrolled in cancer therapy evaluation
program (CTEP) sponsored phase I clinical trials Larry
Rubinstein
Dr. Rubinstein has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Martine
Berliere
Dr. Berliere has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Laurence
Delle Vigne
Dr. Delle Vigne has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Marie-Agnes
Docquier
Dr. Docquier has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment François
Duhoux
Dr. Duhoux has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Lafita
Fellah
Dr. Fellah has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Aurore
Lafosse
Dr. Lafosse has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Sarah
Lamerant
Dr. Lamerant has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Isabelle
Leconte
Dr. Leconte has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Philippe
Piette
Dr. Piette has no relevant financial
relationships to disclose.
P2-18-03
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment Fabienne
Roelants
Dr. Roelants has no relevant financial
relationships to disclose.
P2-18-03
P2-18-04
P2-18-04
P2-18-04
P2-18-04
P2-18-04
P2-18-04
P2-18-04
P2-18-04
P2-18-04
P2-18-04
Potential benefits of hypnosis sedation on
different modalities of breast cancer treatment
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Watremez
Dr. Watremez has no relevant financial
relationships to disclose.
Chen
Dr. Chen has no relevant financial relationships
to disclose.
Di
Dr. Di has no relevant financial relationships to
disclose.
Hou
Dr. Hou has no relevant financial relationships
to disclose.
Hu
Dr. Hu has no relevant financial relationships to
disclose.
Hong
Ling
Dr. Ling has no relevant financial relationships
to disclose.
Guangyu
Liu
Dr. Liu has no relevant financial relationships to
disclose.
Zhebin
Liu
Dr. Liu has no relevant financial relationships to
disclose.
Ma
Dr. Ma has no relevant financial relationships
to disclose.
Shao
Dr. Shao has no relevant financial relationships
to disclose.
Shen
Dr. Shen has no relevant financial relationships
to disclose.
Christine
Canmin
Genhong
Yifeng
Zhen
Fangjing
Zhimin
Zhenzhou
P2-18-04
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
Differential prognosis of pulmonary
lumpectomy in patients with a history of
curative breast cancer
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Mora
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Reinaldo
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Federico
Colo
Dr. Colo has no relevant financial relationships
to disclose.
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Victoria
Costanzo
Dr. Costanzo has no relevant financial
relationships to disclose.
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Veronica
Fabiano
Dr. Fabiano has no relevant financial
relationships to disclose.
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Jose
Loza
Dr. Loza has no relevant financial relationships
to disclose.
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Martin
Loza
Dr. Loza has no relevant financial relationships
to disclose.
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Mercedes
Maino
Dr. Maino has no relevant financial
relationships to disclose.
P2-18-04
P2-18-04
Yihua
Jiong
Keda
Sun
Dr. Sun has no relevant financial relationships
to disclose.
Wu
Dr. Wu has no relevant financial relationships
to disclose.
Yu
Dr. Yu has no relevant financial relationships to
disclose.
Amat
Dr. Amat has no relevant financial relationships
to disclose.
Chacon
Dr. Chacon has no relevant financial
relationships to disclose.
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Daniel
P2-18-05
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Jorge
P2-18-06
Isolated loco-regional recurrence in the breast:
Re-quadrantectomy and systemic treatment
Adrian
Low dose capecitabine is effective and relatively
nontoxic in breast cancer treatment
John
P3-01-01
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Amrita
Mysler
Dr. Mysler has no relevant financial
relationships to disclose.
Nadal
Dr. Nadal has no relevant financial
relationships to disclose.
Carpenter
Dr. Nervo has no relevant financial
relationships to disclose.
Dr. Carpenter has no relevant financial
relationships to disclose.
Gurung
Amrita Gurung has no relevant financial
relationships to disclose.
P3-01-01
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Simon
Holt
Mr. Holt has no relevant financial relationships
to disclose.
P3-01-01
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Anita
Huws
Ms. Huws has no relevant financial
relationships to disclose.
P2-18-05
Nervo
P3-01-01
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Ali
Moalla
Ali Moalla has no relevant financial
relationships to disclose.
P3-01-01
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Khaldoun
Nadi
Khaldoun Nadi has no relevant financial
relationships to disclose.
P3-01-01
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Yousef
Sharaiha
Yousef Sharaiha has no relevant financial
relationships to disclose.
P3-01-01
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Daniel
Thomas
Mr. Thomas has no relevant financial
relationships to disclose.
P3-01-01
P3-01-02
P3-01-02
P3-01-02
P3-01-02
P3-01-02
P3-01-02
Can synthetic 2D mammography be used to
select patients in whom there is no need to
review the digital breast tomosynthesis from
which they were constructed? A review of 1871
consecutive mammogram sets of patients
presenting symptomatically or for follow up
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Helen
Yasufumi
Elham
Shotaro
Masako
Toshiyuki
Tsuyoshi
Williams
Ms. Williams has no relevant financial
relationships to disclose.
Asao
Dr. Asao has disclosed he receives salary from
and has ownership in Canon Inc.
Fakhrejahani
Dr. Fakhrejahani has no relevant financial
relationships to disclose.
Kanao
Dr. Kanao has no relevant financial
relationships to disclose.
Kataoka
Dr. Kataoka has no relevant financial
relationships to disclose.
Kitai
Dr. Kitai has no relevant financial relationships
to disclose.
Shiina
Dr. Shiina has no relevant financial
relationships to disclose.
P3-01-02
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
Clinical, anatomical and histological
characteristics of breast lesions visualized by
photoacoustic mammography; first clinical
study in CK project
P3-01-03
Are more frequent early follow up mammogram
protocols necessary after breast conserving
surgery and radiation therapy?
Manjeet
Chadha
Manjeet Chadha has no relevant financial
relationships to disclose.
P3-01-03
Are more frequent early follow up mammogram
protocols necessary after breast conserving
surgery and radiation therapy?
Tamara
Fulop
Ms. Fulop has no relevant financial
relationships to disclose.
P3-01-03
Are more frequent early follow up mammogram
protocols necessary after breast conserving
surgery and radiation therapy?
Chavi
Kaufman
Chavi Kaufman has no relevant financial
relationships to disclose.
P3-01-03
Are more frequent early follow up mammogram
protocols necessary after breast conserving
surgery and radiation therapy?
David
Lucido
Mr. Lucido has no relevant financial
relationships to disclose.
P3-01-02
P3-01-02
P3-01-02
Takada
Dr. Takada has no relevant financial
relationships to disclose.
Toi
Dr. Toi has no relevant financial relationships
to disclose.
Masae
Torii
Dr. Torii has no relevant financial relationships
to disclose.
Iku
Yamaga
Dr. Yamaga has no relevant financial
relationships to disclose.
Masahiro
Masakazu
P3-01-03
P3-01-04
P3-01-04
P3-01-04
P3-01-04
P3-01-04
P3-01-04
P3-02-01
P3-02-01
P3-02-01
P3-02-01
P3-02-01
Are more frequent early follow up mammogram
protocols necessary after breast conserving
surgery and radiation therapy?
Mammographic changes after oncoplastic
reduction mammoplasty
Mammographic changes after oncoplastic
reduction mammoplasty
Mammographic changes after oncoplastic
reduction mammoplasty
Mammographic changes after oncoplastic
reduction mammoplasty
Mammographic changes after oncoplastic
reduction mammoplasty
Mammographic changes after oncoplastic
reduction mammoplasty
The aggregate number of false-positive recalls
and biopsies performed under different breast
cancer screening strategies in the US
The aggregate number of false-positive recalls
and biopsies performed under different breast
cancer screening strategies in the US
The aggregate number of false-positive recalls
and biopsies performed under different breast
cancer screening strategies in the US
The aggregate number of false-positive recalls
and biopsies performed under different breast
cancer screening strategies in the US
The aggregate number of false-positive recalls
and biopsies performed under different breast
cancer screening strategies in the US
Suzan
Naam
Laura
Esserman
Robert
Foster
Merisa
Piper
Elissa
Price
Hani
Sbitany
Anne
Warren Peled
Ms. Naam has no relevant financial
relationships to disclose.
Dr. Esserman has no relevant financial
relationships to disclose.
Dr. Foster has no relevant financial
relationships to disclose.
Dr. Piper has no relevant financial relationships
to disclose.
Dr. Price has no relevant financial relationships
to disclose.
Dr. Sbitany has disclosed that he is a consultant
for and on the Speaker's Bureau for Lifecell
Corporation.
Dr. Warren Peled has no relevant financial
relationships to disclose.
Eklund
Dr. Eklundi has no relevant financial
relationships to disclose.
Esserman
Dr. Esserman has no relevant financial
relationships to disclose.
Cristina
O'Donoghue
Dr. O'Donoghue has no relevant financial
relationships to disclose.
Elissa
Ozanne
Dr. Ozanne has no relevant financial
relationships to disclose.
Carlie
Thompson
Dr. Thompson has no relevant financial
relationships to disclose.
Martin
Laura
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Lawrence
Bassett
R
Brenner
Bruce
Daniel
Dr. Bassett has no relevant financial
relationships to disclose.
Dr. Brenner has disclosed that he is on the
scientific advisory board and options holder in
Gamma Medica, is a consultant and passive
shareholder in Hologic, Inc. and is a central
reviewer for Allergan silicone breast MRI postapproval studies.
Dr. Daniel has disclosed that he receives
Research grant from GE Healthcare that
includes work on Breast MRI.
Durbin
Dr. Durbin has no relevant financial
relationships to disclose.
Stephen
Feig
Dr. Feig has no relevant financial relationships
to disclose.
Linda
Garcia
Ms. Garcia has no relevant financial
relationships to disclose.
Jonathan
Hargreaves
Dr. Hargreaves has no relevant financial
relationships to disclose.
Ikeda
Dr. Ikeda has no relevant financial relationships
to disclose.
Joe
Dr. Joe has disclosed that she receives
UpToDate author royalties.
Kurian
Dr. Kurian has no relevant financial
relationships to disclose.
Meg
Debra
Bonnie
Allison
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
P3-02-02
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Leung
Dr. Leung has disclosed that she is on the
Hologic, Inc. Scientific Advisory Board
(Interventional Division). She also disclosed
that she is on the Hologic, Inc. Speakers
Bureau.
Lindfors
Dr. Lindfors has no relevant financial
relationships to disclose.
Lipson
Dr. Lipson has no relevant financial
relationships to disclose.
Liu
Dr. Liu has no relevant financial relationships to
disclose.
Love
Dr. Love has no relevant financial relationships
to disclose.
Miyake
Dr. Miyake has no relevant financial
relationships to disclose.
Nayak
Dr. Nayak has no relevant financial
relationships to disclose.
Haydee
Ojeda-Fournier
Dr. Ojeda-Fournier has no relevant financial
relationships to disclose.
Elissa
Price
Dr. Price has no relevant financial relationships
to disclose.
Lauren
Ryan
Ms. Ryan has no relevant financial relationships
to disclose.
Jessica
Karen
Jafi
Yueyi
Elyse
Kanae
Lina
P3-02-02
P3-02-02
P3-02-02
P3-02-03
P3-02-03
P3-02-03
P3-02-03
P3-02-03
P3-02-03
P3-02-03
P3-02-03
P3-02-03
P3-02-03
P3-02-04
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Impact of breast density notification laws on
radiology practices: A survey of 110 radiology
facilities
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
Breast cancer screening by women from BRCA1
& BRCA2 mutation positive families
The contribution of the national health system
to mammographic screening in Brazil
Edward
William
Sickles
Dr. Sickles has no relevant financial
relationships to disclose.
Thomas
Dr. Thomas has no relevant financial
relationships to disclose.
Donna
Walgenbach
Michael
Friedlander
John
Hopper
kConFab Investigators
Sue-Anne
McLachlan
Roger
Milne
Kelly-Anne
Phillips
Sandra
Picken
Charmaine
Smith
Prue
Weideman
Melanie
Wuttke
Rosangela
Correa
Ms. Walgenbach has no relevant financial
relationships to disclose.
Mr. Friedlander has no relevant financial
relationships to disclose.
Mr. Hopper has no relevant financial
relationships to disclose.
kConFab Investigators have no relevant
financial relationships to disclose.
Ms. McLachlan has no relevant financial
relationships to disclose.
Mr. Milne has no relevant financial
relationships to disclose.
Ms. Phillips has no relevant financial
relationships to disclose.
Ms. Picken has no relevant financial
relationships to disclose.
Ms. Smith has no relevant financial
relationships to disclose.
Prue Weideman has no relevant financial
relationships to disclose.
Ms. Wuttke has no relevant financial
relationships to disclose.
Dr. Correa has no relevant financial
relationships to disclose.
P3-02-04
P3-02-04
P3-02-04
P3-02-04
P3-02-05
P3-02-05
P3-02-05
P3-03-01
P3-03-01
P3-03-01
P3-03-01
P3-03-01
P3-03-01
The contribution of the national health system
to mammographic screening in Brazil
The contribution of the national health system
to mammographic screening in Brazil
The contribution of the national health system
to mammographic screening in Brazil
The contribution of the national health system
to mammographic screening in Brazil
Qatar experience of Standard risk breast cancer
screening program (BCSP)
Qatar experience of Standard risk breast cancer
screening program (BCSP)
Qatar experience of Standard risk breast cancer
screening program (BCSP)
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Ruffo
Freitas-Junior
João-Emilio
Peixoto
Rosemar
Rahal
Danielle
Rodrigues
Reena
Alassam
Hekmat
Bugrein
Salha
Bujassoum
Dr. Freitas-Junior has no relevant financial
relationships to disclose.
Dr. Peixoto has no relevant financial
relationships to disclose.
Dr. Rahal has no relevant financial relationships
to disclose.
Ms. Rodrigues has no relevant financial
relationships to disclose.
Dr. Alassam has no relevant financial
relationships to disclose.
Hekmat Bugrein has no relevant financial
relationships to disclose.
Salha Bujassoum has no relevant financial
relationships to disclose.
Hashimoto
Jun Hashimoto has no relevant financial
relationships to disclose.
Imai
Hirohisa Imai has no relevant financial
relationships to disclose.
Kazama
Toshiki Kazama has no relevant financial
relationships to disclose.
Jun
Koizumi
Jun Koizumi has no relevant financial
relationships to disclose.
Toru
Morioka
Toru Morioka has no relevant financial
relationships to disclose.
Naoki
Niikura
Naoki Niikura has no relevant financial
relationships to disclose.
Jun
Yutaka
Toshiki
P3-03-01
P3-03-01
P3-03-01
P3-03-01
P3-03-01
P3-03-01
P3-03-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Diagnostic performance of PET/CT and bone
scintigraphy in breast cancer patients with
suspected bone metastasis
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Ogiya
Rin Ogiya has no relevant financial
relationships to disclose.
Okamura
Takuho Okamura has no relevant financial
relationships to disclose.
Oshitanai
Dr. Oshitanai has no relevant financial
relationships to disclose.
Saito
Yuki Saito has no relevant financial
relationships to disclose.
Terao
Mayako Terao has no relevant financial
relationships to disclose.
Yutaka
Tokuda
Yutaka Tokuda has no relevant financial
relationships to disclose.
Banri
Tuda
Banri Tuda has no relevant financial
relationships to disclose.
Kimberly
Blackwell
Dr. Blackwell has no relevant financial
relationships to disclose.
Carey
Dr. Carey has no relevant financial
relationships to disclose.
Forero
Andres Forero has no relevant financial
relationships to disclose.
Giri
Dr. Giri has no relevant financial relationships
to disclose.
Rin
Takuho
Risa
Yuki
Mayako
Lisa
Andres
Dilip
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-01
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Gucalp
Dr. Gucalp has no relevant financial
relationships to disclose.
Hudis
Dr. Hudis has no relevant financial relationships
to disclose.
Ingle
Dr. Ingle has no relevant financial relationships
to disclose.
Isakoff
Dr. Isakoff has no relevant financial
relationships to disclose.
Liu
Dr. Liu has no relevant financial relationships to
disclose.
Lisle
Mose
Lisle Mose has no relevant financial
relationships to disclose.
Lisle
Nabell
Lisle Nabell has no relevant financial
relationships to disclose.
Joel
Parker
Mr. Parker has disclosed that he is a consultant
for Nanostring.
Polkinghorn
Mr. Polkinghorn has no relevant financial
relationships to disclose.
Rugo
Dr. Rugo has no relevant financial relationships
to disclose.
Sawyers
Mr. Sawyers has no relevant financial
relationships to disclose.
Ayca
Clifford
James
Steven
Minetta
William
Hope
Charles
P3-04-01
P3-04-01
P3-04-01
P3-04-01
P3-04-02
P3-04-02
P3-04-02
P3-04-02
P3-04-02
P3-04-03
P3-04-03
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Whole transcriptome analysis of AR+ ER/PRmetastatic breast cancers treated with
bicalutamide on TBCRC011
Multiple subtypes of triple negative breast
cancer are dependent on androgen receptor
Multiple subtypes of triple negative breast
cancer are dependent on androgen receptor
Multiple subtypes of triple negative breast
cancer are dependent on androgen receptor
Multiple subtypes of triple negative breast
cancer are dependent on androgen receptor
Multiple subtypes of triple negative breast
cancer are dependent on androgen receptor
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Matthew
Soloway
Mr. Soloway has no relevant financial
relationships to disclose.
Dr. Tolaney has no relevant financial
relationships to disclose.
Ms. Traina has disclosed she is a consultant for
Eisai, Halozyme, Genentech, and Celgene. She
also disclosed she has contracts with
AstraZeneca, eisai, medivation, and janssen.
Sara
Tolaney
Tiffany
Traina
Agnes
Viale
Valerie
Barton
Nicholas
D'Amato
Michael
Gordon
Britta
Jacobsen
Jennifer
Richer
Ms. Viale has no relevant financial relationships
to disclose.
Ms. Barton has no relevant financial
relationships to disclose.
Dr. D'Amato has no relevant financial
relationships to disclose.
Mr. Gordon has no relevant financial
relationships to disclose.
Dr. Jacobsen has no relevant financial
relationships to disclose.
Dr. Richer has no relevant financial
relationships to disclose.
Arteaga
Dr. Arteaga has no relevant financial
relationships to disclose.
Balko
Dr. Balko has no relevant financial relationships
to disclose.
Carlos
Justin
P3-04-03
P3-04-03
P3-04-03
P3-04-03
P3-04-03
P3-04-03
P3-04-03
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Joshua
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Xi
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Henry
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Kimberly
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Brian
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Gordon
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
Christopher
Bauer
Mr. Bauer has disclosed that he receives patent
licensing royalties from Insight Genetics Inc.
Markers of triple-negative breast cancer and
uses thereof, #WO 2013075059 A1.
Chen
Xi Chen has disclosed he receives Insight
Genetics Inc. patent licensing royalties. He has
a patent for markers of triple-negative breast
cancer and uses thereof #WO 2013075059 A1.
Gomez
Mr. Gomez has no relevant financial
relationships to disclose.
Johnson
Ms. Johnson has no relevant financial
relationships to disclose.
Lehmann
Mr. Lehmann has disclosed that he receives
Insight Genetics Inc. patent licensing royalties.
Markers of triple-negative breast cancer and
uses thereof: #WO 2013075059 A1
Mills
Mr. Mills has no relevant financial relationships
to disclose.
Pendleton
Mr. Pendleton has no relevant financial
relationships to disclose.
P3-04-03
P3-04-03
P3-04-03
P3-04-03
P3-04-04
P3-04-04
P3-04-04
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
PIK3CA mutations in androgen receptor-positive
triple negative breast cancer confer sensitivity
to the combination of PI3K and androgen
receptor inhibitors
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
Pietenpol
Ms. Pietenpol has disclosed Insight Genetics
Inc pays patent licensing royalties. Markers of
triple-negative breast cancer and uses thereof:
#WO 2013075059 A1.
Sanders
Ms. Sanders has no relevant financial
relationships to disclose.
Johanna
Schafer
Ms. Schafer has no relevant financial
relationships to disclose.
Luojia
Tang
Luojia Tang has no relevant financial
relationships to disclose.
Floris
Guiseppe
Floris Guiseppe has no relevant financial
relationships to disclose.
Hans
Wildiers Hans has no relevant financial
relationships to disclose.
Ignace
Vergote Ignace has no relevant financial
relationships to disclose.
Jennifer
Melinda
Wildiers
Vergote
P3-04-04
P3-04-04
P3-04-04
P3-04-04
P3-04-04
P3-04-04
P3-04-05
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
The prognostic effect of a negative
progesterone receptor (PgR) by
immunohistochemistry (IHC) in luminal HER-2
negative breast cancer (BC) by age at diagnosis:
10 years follow-up study
Invasive lobular carcinoma cell lines utilize
WNT4 signaling to mediate estrogen-induced
growth
Annouschka
Laenen
Annouschka Laenen has no relevant financial
relationships to disclose.
Christiaens
Marie-Rose
Christiaens Marie-Rose has no relevant
financial relationships to disclose.
Olbrecht
Siel Olbrecht has no relevant financial
relationships to disclose.
Patrick
Neven Patrick has no relevant financial
relationships to disclose.
Remmerie
Chantal Remmerie has no relevant financial
relationships to disclose.
Van Asten
Ms. Van Asten has no relevant financial
relationships to disclose.
Alexander
Dr. Alexander has no relevant financial
relationships to disclose.
Siel
Neven
Chantal
Kathleen
Caroline
P3-04-05
Invasive lobular carcinoma cell lines utilize
WNT4 signaling to mediate estrogen-induced
growth
Invasive lobular carcinoma cell lines utilize
WNT4 signaling to mediate estrogen-induced
growth
Invasive lobular carcinoma cell lines utilize
WNT4 signaling to mediate estrogen-induced
growth
P3-04-06
Inhibiting androgen receptor nuclear
localization decreases estrogen receptor (ER)
activity and tumor growth in ER+ breast cancer Beatrice
P3-04-06
Inhibiting androgen receptor nuclear
localization decreases estrogen receptor (ER)
activity and tumor growth in ER+ breast cancer Dawn
Cochrane
Dr. Cochrane has no relevant financial
relationships to disclose.
P3-04-06
Inhibiting androgen receptor nuclear
localization decreases estrogen receptor (ER)
activity and tumor growth in ER+ breast cancer Nicholas
D'Amato
Dr. D'Amato has no relevant financial
relationships to disclose.
P3-04-06
Inhibiting androgen receptor nuclear
localization decreases estrogen receptor (ER)
activity and tumor growth in ER+ breast cancer Anthony
Elias
Dr. Elias has no relevant financial relationships
to disclose.
P3-04-06
Inhibiting androgen receptor nuclear
localization decreases estrogen receptor (ER)
activity and tumor growth in ER+ breast cancer Britta
Jacobsen
Dr. Jacobsen has no relevant financial
relationships to disclose.
P3-04-06
Inhibiting androgen receptor nuclear
localization decreases estrogen receptor (ER)
activity and tumor growth in ER+ breast cancer Jennifer
Richer
Dr. Richer has no relevant financial
relationships to disclose.
P3-04-05
P3-04-05
Amir
Steffi
Matthew
Bahreini
Amir Bahreini has no relevant financial
relationships to disclose.
Oesterreich
Dr. Oesterreich has no relevant financial
relationships to disclose.
Sikora
Dr. Sikora has no relevant financial
relationships to disclose.
Babbs
Ms. Babbs has no relevant financial
relationships to disclose.
P3-04-06
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-07
P3-04-09
P3-04-09
Inhibiting androgen receptor nuclear
localization decreases estrogen receptor (ER)
activity and tumor growth in ER+ breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Androgen receptor expression in triple negative
breast cancer
Discordance with estrogen receptor alpha
status estimated by immunohistochemical and
immunofluorescent method associated with
flowcytometry in breast cancer tissue
Discordance with estrogen receptor alpha
status estimated by immunohistochemical and
immunofluorescent method associated with
flowcytometry in breast cancer tissue
Nicole
Spoelstra
Hannah
Gilmore
Lyndsay
Harris
Peter
Hsu
Stephanie
Kim
Robert
Lindner
Kristy
Miskimen
Aditi
Palkar
Cheryl
Thompson
Vinay
Varadan
Shaveta
Vinayak
Nicole
Williams
Ms. Spoelstra has no relevant financial
relationships to disclose.
Dr. Gilmore has no relevant financial
relationships to disclose.
Dr. Harris has no relevant financial
relationships to disclose.
Dr. Hsu has no relevant financial relationships
to disclose.
Dr. Kim has no relevant financial relationships
to disclose.
Mr. Lindner has no relevant financial
relationships to disclose.
Dr. Miskimen has no relevant financial
relationships to disclose.
Aditi Palkar has no relevant financial
relationships to disclose.
Dr. Thompson has no relevant financial
relationships to disclose.
Dr. Varadan has no relevant financial
relationships to disclose.
Dr. Vinayak has no relevant financial
relationships to disclose.
Dr. Williams has no relevant financial
relationships to disclose.
Bogush
Dr. Bogush has no relevant financial
relationships to disclose.
Dudko
Dr. Dudko has no relevant financial
relationships to disclose.
Tatiana
Evgeniy
P3-04-09
P3-04-09
P3-04-09
P3-04-09
P3-04-09
P3-04-10
P3-04-10
P3-04-10
Discordance with estrogen receptor alpha
status estimated by immunohistochemical and
immunofluorescent method associated with
flowcytometry in breast cancer tissue
Discordance with estrogen receptor alpha
status estimated by immunohistochemical and
immunofluorescent method associated with
flowcytometry in breast cancer tissue
Discordance with estrogen receptor alpha
status estimated by immunohistochemical and
immunofluorescent method associated with
flowcytometry in breast cancer tissue
Discordance with estrogen receptor alpha
status estimated by immunohistochemical and
immunofluorescent method associated with
flowcytometry in breast cancer tissue
Discordance with estrogen receptor alpha
status estimated by immunohistochemical and
immunofluorescent method associated with
flowcytometry in breast cancer tissue
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Elena
Dr. Elena has no relevant financial relationships
to disclose.
Elena
Dr. Elena has no relevant financial relationships
to disclose.
Vorotnikov
Igor
Dr. Igor has no relevant financial relationships
to disclose.
Davidov
Michael
Dr. Michael has no relevant financial
relationships to disclose.
Maria
Rodionova
Ms. Rodionova has no relevant financial
relationships to disclose.
Mi Ran
Choi
Dr. Choi has no relevant financial relationships
to disclose.
Susan
Clare
Dr. Clare has no relevant financial relationships
to disclose.
Akash
Gupa
Dr. Gupa has no relevant financial relationships
to disclose.
Bogush
Shestakova
P3-04-10
P3-04-10
P3-04-10
P3-04-10
P3-04-10
P3-04-11
P3-04-11
P3-04-11
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Progesterone receptor (PR) blockade by
antiprogestin, CDB4124 in hormone receptor
positive breast cancer cells leads to significant
inhibition of G2/M cell cycle genes
Thyroid hormone up-regulates estrogenic and
pro-carcinogenic signaling, inducing a basaloid
and more motile phenotype in only steroid
receptor positive breast cancer cells
Thyroid hormone up-regulates estrogenic and
pro-carcinogenic signaling, inducing a basaloid
and more motile phenotype in only steroid
receptor positive breast cancer cells
Thyroid hormone up-regulates estrogenic and
pro-carcinogenic signaling, inducing a basaloid
and more motile phenotype in only steroid
receptor positive breast cancer cells
Ivancic
Mr. Ivancic has no relevant financial
relationships to disclose.
Khan
Dr. Khan has no relevant financial relationships
to disclose.
J
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Oukseub
Lee
Dr. Lee has no relevant financial relationships
to disclose.
Jun
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Susan
Edgerton
Ms. Edgerton has no relevant financial
relationships to disclose.
Zeying
Fan
Zeying Fan has no relevant financial
relationships to disclose.
Ann
Thor
Dr. Thor has no relevant financial relationships
to disclose.
David
Seema
P3-04-11
P3-04-12
P3-04-12
P3-04-12
P3-04-12
P3-04-13
P3-04-13
P3-04-13
P3-04-13
P3-04-13
Thyroid hormone up-regulates estrogenic and
pro-carcinogenic signaling, inducing a basaloid
and more motile phenotype in only steroid
receptor positive breast cancer cells
Pathological and molecular effects of lack of PR
expression in ER positive breast tumors
Pathological and molecular effects of lack of PR
expression in ER positive breast tumors
Pathological and molecular effects of lack of PR
expression in ER positive breast tumors
Pathological and molecular effects of lack of PR
expression in ER positive breast tumors
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Reema
Wahdan-Alaswad
Rachel
Ellsworth
Matthew
Hueman
Craig
Shriver
Allyson
Valente
Dr. Wahdan-Alaswad has no relevant financial
relationships to disclose.
Dr. Ellsworth has no relevant financial
relationships to disclose.
Dr. Hueman has no relevant financial
relationships to disclose.
Dr. Shriver has no relevant financial
relationships to disclose.
Ms. Valente has no relevant financial
relationships to disclose.
Mauro
Cenciarini
Dr. Cenciarini has no relevant financial
relationships to disclose.
Leandro
Cerchietti
Dr. Cerchietti has no relevant financial
relationships to disclose.
Patricia
Elizalde
Dr. Elizalde has no relevant financial
relationships to disclose.
Gloria
Inurrigarro
Dr. Inurrigarro has no relevant financial
relationships to disclose.
Franco
Izzo
Franco Izzo has no relevant financial
relationships to disclose.
P3-04-13
P3-04-13
P3-04-13
P3-04-13
P3-04-14
P3-04-14
P3-04-14
P3-04-14
P3-04-15
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Progesterone receptor activation
downregulates GATA3 by transcriptional
repression and increased protein turnover
promoting breast tumor growth
Prognostic impact of Her2 and hormone
receptor expression in inflammatory breast
cancer: A SEER database analysis
Prognostic impact of Her2 and hormone
receptor expression in inflammatory breast
cancer: A SEER database analysis
Prognostic impact of Her2 and hormone
receptor expression in inflammatory breast
cancer: A SEER database analysis
Prognostic impact of Her2 and hormone
receptor expression in inflammatory breast
cancer: A SEER database analysis
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Mercogliano
Ms. Mercogliano has no relevant financial
relationships to disclose.
Proietti
Dr. Proietti has no relevant financial
relationships to disclose.
Roxana
Schillaci
Dr. Schillaci has no relevant financial
relationships to disclose.
Leandro
Venturutti
Leandro Venturutti has no relevant financial
relationships to disclose.
Affan
Ms. Affan has no relevant financial
relationships to disclose.
Iruku
Dr. Iruku has no relevant financial relationships
to disclose.
Mohan
Dr. Mohan has no relevant financial
relationships to disclose.
Ravakhah
Dr. Ravakhah has no relevant financial
relationships to disclose.
Fujiwara
Dr. Fujiwara has no relevant financial
relationships to disclose.
Florencia
Cecilia
Anna Maria
Kali Praveena
Babu
Keyvan
Saori
P3-04-15
P3-04-15
P3-04-15
P3-04-15
P3-04-15
P3-04-15
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Mitsuhiro
Hayashi
Dr. Hayashi has no relevant financial
relationships to disclose.
Hirotaka
Iwase
Dr. Iwasa has no relevant financial
relationships to disclose.
Omoto
Dr. Omoto has no relevant financial
relationships to disclose.
Sueta
Dr. Sueta has no relevant financial
relationships to disclose.
Takeshita
Dr. Takeshita has no relevant financial
relationships to disclose.
Yamamoto
Dr. Yamamoto has no relevant financial
relationships to disclose.
Yoko
Aiko
Takashi
Yutaka
P3-04-15
P3-04-16
P3-04-16
P3-04-16
P3-04-16
P3-04-17
P3-04-17
P3-04-17
P3-04-17
P3-04-17
Ethinylestradiol treatment downregulates ER
and upregulates PgR; Immunohistochemical
analysis in postmenopausal breast cancer
tissues after prior long-term estrogendeprivation therapy
Estrogen receptor β agonists reduce breast
cancer tumor growth in syngeneic mouse
models
Estrogen receptor β agonists reduce breast
cancer tumor growth in syngeneic mouse
models
Estrogen receptor β agonists reduce breast
cancer tumor growth in syngeneic mouse
models
Estrogen receptor β agonists reduce breast
cancer tumor growth in syngeneic mouse
models
Triple negative breast carcinomas clinical and
pathology associated with androgen receptor
expression
Triple negative breast carcinomas clinical and
pathology associated with androgen receptor
expression
Triple negative breast carcinomas clinical and
pathology associated with androgen receptor
expression
Triple negative breast carcinomas clinical and
pathology associated with androgen receptor
expression
Triple negative breast carcinomas clinical and
pathology associated with androgen receptor
expression
Yamamoto-Ibusuki
Dr. Yamamoto-Ibusuki has no relevant financial
relationships to disclose.
Krishnegowda
Dr. Krishnegowda has no relevant financial
relationships to disclose.
Samayoa
Ms. Samayoa has no relevant financial
relationships to disclose.
Tekmal
Dr. Tekmal has no relevant financial
relationships to disclose.
Vadlamudi
Dr. Vadlamudi has no relevant financial
relationships to disclose.
Graudenz
Dr. Graudenz has no relevant financial
relationships to disclose.
Jacques
Sídia Jacques has no relevant financial
relationships to disclose.
João
Maximiliano
João Maximiliano has no relevant financial
relationships to disclose.
Mirian
Pedron
Mirian Pedron has no relevant financial
relationships to disclose.
Diego
Uchça
Mr. Uchôa has no relevant financial
relationships to disclose.
Mutsuko
Naveen
Cathy
Rajeshwar
Ratna
Marcia
Sídia
P3-05-01
P3-05-01
P3-05-01
P3-05-01
P3-05-01
P3-05-01
P3-05-01
P3-05-01
P3-05-01
P3-05-01
P3-05-01
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Development for clinical utility of a validated
predictive test of clinical response to aromatase
inhibitors
Arthur
Ms. Arthur has no relevant financial
relationships to disclose.
Dixon
Dr. Dixon has no relevant financial
relationships to disclose.
Dowsett
Dr. Dowsett has no relevant financial
relationships to disclose.
Dunbier
Dr. Dunbier has no relevant financial
relationships to disclose.
Heerlyn
Ms. Heerlyn has no relevant financial
relationships to disclose.
Lorna
Renshaw
Ms. Renshaw has no relevant financial
relationships to disclose.
Andrew
Sims
Dr. Sims has no relevant financial relationships
to disclose.
Jeremy
Thomas
Mr. Thomas has no relevant financial
relationships to disclose.
Thornton
Phoebe Thornton has no relevant financial
relationships to disclose.
Turnbull
Dr. Turnbull has no relevant financial
relationships to disclose.
Webber
Ms. Webber has no relevant financial
relationships to disclose.
Laura
J Michael
Mitch
Anita
Charlotte
Phoebe
Arran
Victoria
P3-05-02
P3-05-02
P3-05-02
P3-05-02
P3-05-02
P3-05-02
P3-05-02
P3-05-02
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Bolger
Dr. Bolger has no relevant financial
relationships to disclose.
Byrne
Dr. Byrne has no relevant financial
relationships to disclose.
Ailis
Fagan
Dr. Fagan has no relevant financial
relationships to disclose.
Arnold
Hill
Mr. Hill has no relevant financial relationships
to disclose.
Damian
McCartan
Dr. McCartan has no relevant financial
relationships to disclose.
Marie
McIlroy
Dr. McIlroy has no relevant financial
relationships to disclose.
Peadar
O'Gaora
Dr. O'Gaora has no relevant financial
relationships to disclose.
Damir
Vareslija
Dr. Vareslija has no relevant financial
relationships to disclose.
Jarlath
Christopher
P3-05-02
P3-05-03
P3-05-03
P3-05-03
P3-05-03
P3-05-03
P3-05-03
P3-05-03
P3-05-03
P3-05-04
Global characterisation of the SRC-1
transcriptome and rational drug design results
in the identification of a novel peptide targeting
ADAM22 in endocrine resistance
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
Reversal of endocrine therapy resistance with
inhibitors of AKT, mTOR, or MEK as single
agents or in combination
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
Young
Leonie Young has no relevant financial
relationships to disclose.
Xiaoyong
Fu
Xiaoyong Fu has no relevant financial
relationships to disclose.
Teresa
Klinowska
Ms. Klinowska has disclosed she is an
employee and shareholder in AstraZeneca.
Tamika
Mitchell
Tamika Mitchell has no relevant financial
relationships to disclose.
Gladys
Morrison
Ms. Morrison has no relevant financial
relationships to disclose.
Leonie
Agostina
Nardone
C Kent
Osborne
Dr. Nardone has no relevant financial
relationships to disclose.
Dr. Osborne has disclosed he is a consultant for
AstraZeneca, GSK, Genentech, Novartis, Pfizer,
and Nanostring.
Schiff
Dr. Schiff has disclosed that she is a consultant
for AstraZeneca.
Martin
Shea
Mr. Shea has no relevant financial relationships
to disclose.
Barry
Davies
Dr. Davies has disclosed that he receives salary
as an employee of AstraZeneca.
Rachel
P3-05-04
P3-05-04
P3-05-04
P3-05-04
P3-05-04
P3-05-04
P3-05-04
P3-05-04
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
Dowsett
Dr. Dowsett has disclosed that he received an
academic award from AstraZeneca.
Gao
Qiong Gao has no relevant financial
relationships to disclose.
Stephanie
Guest
Ms. Guest has no relevant financial
relationships to disclose.
Stephen
Johnston
Dr. Johnston has disclosed that he received an
academic award from AstraZeneca.
Lesley-Ann
Martin
Dr. Martín has disclosed that she has received
an academic award AstraZeneca.
Sunil
Pancholi
Dr. Pancholi has no relevant financial
relationships to disclose.
Aradhana
Rani
Dr. Rani has no relevant financial relationships
to disclose.
Ricardo
Ribas
Dr. Ribas has no relevant financial relationships
to disclose.
Mitch
Qiong
P3-05-04
P3-05-06
P3-05-06
P3-05-06
P3-05-06
P3-05-06
P3-05-06
P3-05-06
AKT antagonist AZD5363 targets estrogen
receptor (ER) function in endocrine resistant
breast cancer (BC) and synergises with
fulvestrant in vivo
A nude mouse model of diet-induced-obesity to
study the mechanisms of resistance to
aromatase inhibitor letrozole in MCF-7Ca
xenografts
A nude mouse model of diet-induced-obesity to
study the mechanisms of resistance to
aromatase inhibitor letrozole in MCF-7Ca
xenografts
A nude mouse model of diet-induced-obesity to
study the mechanisms of resistance to
aromatase inhibitor letrozole in MCF-7Ca
xenografts
A nude mouse model of diet-induced-obesity to
study the mechanisms of resistance to
aromatase inhibitor letrozole in MCF-7Ca
xenografts
A nude mouse model of diet-induced-obesity to
study the mechanisms of resistance to
aromatase inhibitor letrozole in MCF-7Ca
xenografts
A nude mouse model of diet-induced-obesity to
study the mechanisms of resistance to
aromatase inhibitor letrozole in MCF-7Ca
xenografts
A nude mouse model of diet-induced-obesity to
study the mechanisms of resistance to
aromatase inhibitor letrozole in MCF-7Ca
xenografts
Simigdala
Dr. Simigdala has no relevant financial
relationships to disclose.
Brodie
Dr. Brodie has no relevant financial
relationships to disclose.
Saranya
Chumsri
Dr. Chumsri has no relevant financial
relationships to disclose.
Olga
Goloubeva
Dr. Goloubeva has no relevant financial
relationships to disclose.
Gauri
Sabnis
Dr. Sabnis has no relevant financial
relationships to disclose.
Amanda
Schech
Dr. Schech has no relevant financial
relationships to disclose.
Preeti
Shah
Dr. Shah has no relevant financial relationships
to disclose.
Stephen
Yu
Mr. Yu has no relevant financial relationships
to disclose.
Nikiana
Angela
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Sarat
Chandarlapaty
Dr. Chandarlapaty has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Sean
Fanning
Dr. Fanning has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Geoffrey
Greene
Dr. Greene has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
John
Katzenellenbogen
Dr. Katzenellenbogen has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Christopher
Mayne
Dr. Mayne has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Kendall
Nettles
Dr. Nettles has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Jason
Nowak
Mr. Nowak has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Srinivas
Panchamukhi
Srinivas Panchamukhi has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Abhishek
Sharma
Dr. Sharma has no relevant financial
relationships to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Yang
Shen
Dr. Shen has no relevant financial relationships
to disclose.
P3-05-07
Determining the role of somatic ERα mutations
in acquired hormone (or SERM) resistance
Weiyi
Toy
Dr. Toy has no relevant financial relationships
to disclose.
P3-05-08
P3-05-08
P3-05-08
P3-05-08
P3-05-10
P3-05-10
P3-05-10
Effect of a novel selective progesterone
receptor modulator EC312 for menopausal
hormone therapy (MHT) in comparison with
Bazedoxifene in vitro
Walter
Effect of a novel selective progesterone
receptor modulator EC312 for menopausal
hormone therapy (MHT) in comparison with
Bazedoxifene in vitro
Hareesh
Effect of a novel selective progesterone
receptor modulator EC312 for menopausal
hormone therapy (MHT) in comparison with
Bazedoxifene in vitro
Klaus
Effect of a novel selective progesterone
receptor modulator EC312 for menopausal
hormone therapy (MHT) in comparison with
Bazedoxifene in vitro
Bindu
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Melanie
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Chelain
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Jeffery
Elger
Dr. Elger has disclosed that he is an employee
of Evestra, Inc.
Nair
Dr. Nair has disclosed that he is an employee of
Evestra, Inc.
Nickisch
Dr. Nickisch has disclosed that he is an
employee of Evestra, Inc.
Santhamma
Dr. Santhamma has disclosed that he is an
employee of Evestra, Inc.
Girondo
Ms. Girondo has no relevant financial
relationships to disclose.
Goodman
Chelain Goodman has no relevant financial
relationships to disclose.
Hooke
Mr. Hooke has no relevant financial
relationships to disclose.
P3-05-10
P3-05-10
P3-05-10
P3-05-10
P3-05-10
P3-05-10
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Terry
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Albert
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Chengbao
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Edith
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Amy
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Hallgeir
Hyslop
Terry Hyslop has no relevant financial
relationships to disclose.
Kovatich
Mr. Kovatich has no relevant financial
relationships to disclose.
Liu
Chengbao Liu has no relevant financial
relationships to disclose.
Mitchell
Ms. Mitchell has no relevant financial
relationships to disclose.
Peck
Ms. Peck has no relevant financial relationships
to disclose.
Rui
Dr. Rui has no relevant financial relationships
to disclose.
P3-05-11
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Takahiro
Glucocorticoid and aldosterone mimic progestininduction of a therapy-resistant cytokeratin-5
positive cell population in estrogen receptorpositive breast cancer through a Bcl6dependent mechanism
Craig
Glutamine metabolism promotes survival
through the unfolded protein response in
endocrine resistant breast cancer
Robert
P3-05-11
Glutamine metabolism promotes survival
through the unfolded protein response in
endocrine resistant breast cancer
P3-05-10
P3-05-10
P3-05-11
P3-05-12
P3-05-12
P3-05-12
Glutamine metabolism promotes survival
through the unfolded protein response in
endocrine resistant breast cancer
Circulating oxysterol metabolites as potential
new surrogate markers for hormonotherapy in
patients with hormone receptor-positive breast
cancer? A pilot study
Circulating oxysterol metabolites as potential
new surrogate markers for hormonotherapy in
patients with hormone receptor-positive breast
cancer? A pilot study
Circulating oxysterol metabolites as potential
new surrogate markers for hormonotherapy in
patients with hormone receptor-positive breast
cancer? A pilot study
Sato
Shriver
Clarke
Takahiro Sato has no relevant financial
relationships to disclose.
Dr. Shriver has no relevant financial
relationships to disclose.
Dr. Clarke has disclosed that he received other
financial support for Anti-glutaminase CB-839
from Calithera Biosciences.
Susan
Demo
Ayeasha
Shajahan-Haq
Dr. Demo has disclosed that she receives
salary, royalties, has a patent, does consulting,
and has ownership in Calithera Biosciences.
Dr. Shajahan-Haq has disclosed that she
receives reimbursement of travel expenses to
SABCS 2014 and anti-glutaminase CB-839 from
Calithera Biosciences.
Florence
Dalenc
Dr. Dalenc has no relevant financial
relationships to disclose.
Thomas
Filleron
Dr. Filleron has no relevant financial
relationships to disclose.
Iuliano
Dr. Iuliano has no relevant financial
relationships to disclose.
Luggi
P3-05-12
P3-05-12
P3-05-12
P3-05-12
P3-05-13
P3-05-13
P3-05-13
P3-05-13
Circulating oxysterol metabolites as potential
new surrogate markers for hormonotherapy in
patients with hormone receptor-positive breast
cancer? A pilot study
Circulating oxysterol metabolites as potential
new surrogate markers for hormonotherapy in
patients with hormone receptor-positive breast
cancer? A pilot study
Circulating oxysterol metabolites as potential
new surrogate markers for hormonotherapy in
patients with hormone receptor-positive breast
cancer? A pilot study
Circulating oxysterol metabolites as potential
new surrogate markers for hormonotherapy in
patients with hormone receptor-positive breast
cancer? A pilot study
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Poirot
Dr. Poirot has no relevant financial
relationships to disclose.
Roché
Dr. Roché has no relevant financial
relationships to disclose.
Sandrine
Silvente-Poirot
Dr. Silvente-Poirot has no relevant financial
relationships to disclose.
Maud
Voisin
Maud Voisin has no relevant financial
relationships to disclose.
Gary
Chamness
Dr. Chamness has no relevant financial
relationships to disclose.
Chad
Creighton
Dr. Creighton has no relevant financial
relationships to disclose.
Dean
Edwards
Mr. Edwards has no relevant financial
relationships to disclose.
Xiaoyong
Fu
Xiaoyong Fu has no relevant financial
relationships to disclose.
Marc
Henri
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Giuliano
Mr. Giuliano has no relevant financial
relationships to disclose.
Gray
Dr. Gray has no relevant financial relationships
to disclose.
Carolina
Gutierrez
Dr. Gutierrez has no relevant financial
relationships to disclose.
Maria
Hahn
Ms. Hahn has no relevant financial
relationships to disclose.
Laura
Heiser
Ms. Heiser has no relevant financial
relationships to disclose.
Sabrina
Herrera
Dr. Herrera has no relevant financial
relationships to disclose.
Susan
Hilsenbeck
Dr. Hilsenbeck has no relevant financial
relationships to disclose.
Huizhong
Hu
Huizhong Hu has no relevant financial
relationships to disclose.
Mario
Joe
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
P3-05-13
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Jung
Sung Yun Jung has no relevant financial
relationships to disclose.
Nanda
Sarmistha Nanda has no relevant financial
relationships to disclose.
C Kent
Osborne
Dr. Osborne has no relevant financial
relationships to disclose.
Lanfang
Qin
Lanfang Qin has no relevant financial
relationships to disclose.
Rachel
Schiff
Dr. Schiff has no relevant financial relationships
to disclose.
Chad
Shaw
Mr. Shaw has no relevant financial
relationships to disclose.
Martin
Shea
Mr. Shea has no relevant financial relationships
to disclose.
Nicholas
Wang
Mr. Wang has no relevant financial
relationships to disclose.
Sung Yun
Sarmistha
P3-05-13
P3-05-14
P3-05-14
P3-05-14
P3-05-14
P3-05-15
P3-05-15
P3-05-15
P3-05-15
P3-05-15
Overexpression of insulin receptor substrate 4
can mediate acquired resistance to lapatinibcontaining regimens in HER2+ breast cancer
cells
Modeling chemoendocrine therapy for
ER+/p53wt luminal breast cancer
Modeling chemoendocrine therapy for
ER+/p53wt luminal breast cancer
Modeling chemoendocrine therapy for
ER+/p53wt luminal breast cancer
Modeling chemoendocrine therapy for
ER+/p53wt luminal breast cancer
Divergent activation of AKT1 and AKT2 isoforms
downstream of PI3K mutation impacts response
of breast cancer cells to estradiol and PI3K
inhibitors
Divergent activation of AKT1 and AKT2 isoforms
downstream of PI3K mutation impacts response
of breast cancer cells to estradiol and PI3K
inhibitors
Divergent activation of AKT1 and AKT2 isoforms
downstream of PI3K mutation impacts response
of breast cancer cells to estradiol and PI3K
inhibitors
Divergent activation of AKT1 and AKT2 isoforms
downstream of PI3K mutation impacts response
of breast cancer cells to estradiol and PI3K
inhibitors
Divergent activation of AKT1 and AKT2 isoforms
downstream of PI3K mutation impacts response
of breast cancer cells to estradiol and PI3K
inhibitors
Xiaowei
Xu
Shiliang
Cao
Elgene
Lim
Brown
Myles
Bailey
Shannon
Xiaowei Xu has no relevant financial
relationships to disclose.
Shiliang Cao has no relevant financial
relationships to disclose.
Dr. Lim has no relevant financial relationships
to disclose.
Dr. Myles has no relevant financial
relationships to disclose.
Dr. Shannon has no relevant financial
relationships to disclose.
Sunil
Badve
Dr. Badve has no relevant financial
relationships to disclose.
Poornima
Bhat-Nakshatri
Poornima Bhat-Nakshatri has no relevant
financial relationships to disclose.
Chirayu
Goswami
Chirayu Goswami has no relevant financial
relationships to disclose.
Mathieu
Lupien
Dr. Lupien has no relevant financial
relationships to disclose.
Luca
Magnani
Dr. Magnani has no relevant financial
relationships to disclose.
P3-05-15
P3-05-16
P3-05-16
P3-05-16
P3-05-16
P3-05-16
P3-05-16
Divergent activation of AKT1 and AKT2 isoforms
downstream of PI3K mutation impacts response
of breast cancer cells to estradiol and PI3K
inhibitors
The effect of HER-2/neu inhibition on
prolonging clinical benefit with fulvestrant
treatment for metastatic estrogen receptor
positive breast cancer patients treated with
trastuzumab
The effect of HER-2/neu inhibition on
prolonging clinical benefit with fulvestrant
treatment for metastatic estrogen receptor
positive breast cancer patients treated with
trastuzumab
The effect of HER-2/neu inhibition on
prolonging clinical benefit with fulvestrant
treatment for metastatic estrogen receptor
positive breast cancer patients treated with
trastuzumab
The effect of HER-2/neu inhibition on
prolonging clinical benefit with fulvestrant
treatment for metastatic estrogen receptor
positive breast cancer patients treated with
trastuzumab
The effect of HER-2/neu inhibition on
prolonging clinical benefit with fulvestrant
treatment for metastatic estrogen receptor
positive breast cancer patients treated with
trastuzumab
The effect of HER-2/neu inhibition on
prolonging clinical benefit with fulvestrant
treatment for metastatic estrogen receptor
positive breast cancer patients treated with
trastuzumab
Nakshatri
Dr. Nakshatri has no relevant financial
relationships to disclose.
Charif
Dr. Charif has no relevant financial
relationships to disclose.
Kennedy
Ms. Kennedy has no relevant financial
relationships to disclose.
Shugufta
Khan
Dr. Khan has no relevant financial relationships
to disclose.
Harriet
Kumar
Ms. Kumar has no relevant financial
relationships to disclose.
Elyse
Lower
Dr. Lower has no relevant financial
relationships to disclose.
Radhakrishnan
Dr. Radhakrishnan has no relevant financial
relationships to disclose.
Harikrishna
Mahmoud
Diane
Neetu
P3-05-16
P3-05-17
P3-05-17
P3-05-18
P3-05-18
P3-05-18
P3-05-18
P3-05-19
P3-05-19
P3-05-19
P3-05-19
P3-05-19
The effect of HER-2/neu inhibition on
prolonging clinical benefit with fulvestrant
treatment for metastatic estrogen receptor
positive breast cancer patients treated with
trastuzumab
Haddow's paradox revisited: Anti-estrogen
withdrawal induces ER-driven apoptosis in antiestrogen-resistant cells
Haddow's paradox revisited: Anti-estrogen
withdrawal induces ER-driven apoptosis in antiestrogen-resistant cells
RNA-seq reveals lncRNAs associated with
hormonal influences and endocrine therapy
RNA-seq reveals lncRNAs associated with
hormonal influences and endocrine therapy
RNA-seq reveals lncRNAs associated with
hormonal influences and endocrine therapy
RNA-seq reveals lncRNAs associated with
hormonal influences and endocrine therapy
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
Xiaoting
Sarah
Zhang
Dr. Zhang has no relevant financial
relationships to disclose.
Hosford
Ms. Hosford has no relevant financial
relationships to disclose.
Todd
Miller
Nilanjana
Banerjee
Patrick
Cheung
Nevenka
Dimitrova
Wim
Verhaegh
Dr. Miller has no relevant financial
relationships to disclose.
Nilanjana Banerjee has no relevant financial
relationships to disclose.
Mr. Cheung has no relevant financial
relationships to disclose.
Nevenka Dimitrova has no relevant financial
relationships to disclose.
Wim Verhaegh has no relevant financial
relationships to disclose.
Barrow
Ms. Barrow has no relevant financial
relationships to disclose.
Dutkowski
Ms. Dutkowski has no relevant financial
relationships to disclose.
Fiegl
Dr. Fiegl has no relevant financial relationships
to disclose.
Denise
Carol
Heidi
Pauline
Finlay
Julia
Gee
Ms. Finlay has no relevant financial
relationships to disclose.
Dr. Gee has disclosed that she is in receipt of
research funding for aspects of my group's
research from AstraZeneca.
P3-05-19
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
A new cell panel to study oestrogen receptor
loss in acquired endocrine resistant breast
cancer
P3-05-20
P3-05-19
P3-05-19
P3-05-19
P3-05-19
P3-05-19
Lindy
Susan
Richard
Mei Yee
Huw
Goddard
Lindy Goddard has no relevant financial
relationships to disclose.
Kyme
Ms. Kyme has no relevant financial
relationships to disclose.
McClelland
Mr. McClelland has no relevant financial
relationships to disclose.
Meng
Mei Yee Meng has no relevant financial
relationships to disclose.
Mottram
Huw Mottram has no relevant financial
relationships to disclose.
Neelamraju
Dr. Parson has no relevant financial
relationships to disclose.
Dr. Badve has no relevant financial
relationships to disclose.
Dr. Gokmen-Polar has no relevant financial
relationships to disclose.
Chirayu Goswami has no relevant financial
relationships to disclose.
Dr. Janga has no relevant financial relationships
to disclose.
Dr. Nakshatri has no relevant financial
relationships to disclose.
Yaseswini Neelamraju has no relevant financial
relationships to disclose.
Ali
Azlena Ali has no relevant financial
relationships to disclose.
Walther
Parson
ESRP1 adds sp(l)ice to endocrine resistance
Sunil
Badve
P3-05-20
ESRP1 adds sp(l)ice to endocrine resistance
Yesim
Gokmen-Polar
P3-05-20
ESRP1 adds sp(l)ice to endocrine resistance
Chirayu Pankaj
Goswami
P3-05-20
ESRP1 adds sp(l)ice to endocrine resistance
Sarath Chandra
Janga
P3-05-20
ESRP1 adds sp(l)ice to endocrine resistance
Harikrishna
Nakshatri
P3-05-20
ESRP1 adds sp(l)ice to endocrine resistance
Yaseswini
Investigation into the oncogenic potential of the
androgen receptor in aromatase inhibitor
resistant breast cancer
Azlena
P3-05-21
P3-05-21
P3-05-21
P3-05-21
P3-05-21
P3-05-22
P3-05-22
P3-05-22
P3-05-22
P3-05-22
P3-05-22
P3-05-22
Investigation into the oncogenic potential of the
androgen receptor in aromatase inhibitor
resistant breast cancer
Investigation into the oncogenic potential of the
androgen receptor in aromatase inhibitor
resistant breast cancer
Investigation into the oncogenic potential of the
androgen receptor in aromatase inhibitor
resistant breast cancer
Investigation into the oncogenic potential of the
androgen receptor in aromatase inhibitor
resistant breast cancer
PI3K pathway as a novel target in androgendriven aromatase inhibitor resistant breast
cancer
PI3K pathway as a novel target in androgendriven aromatase inhibitor resistant breast
cancer
PI3K pathway as a novel target in androgendriven aromatase inhibitor resistant breast
cancer
PI3K pathway as a novel target in androgendriven aromatase inhibitor resistant breast
cancer
PI3K pathway as a novel target in androgendriven aromatase inhibitor resistant breast
cancer
PI3K pathway as a novel target in androgendriven aromatase inhibitor resistant breast
cancer
PI3K pathway as a novel target in androgendriven aromatase inhibitor resistant breast
cancer
Creevey
Dr. Creevey has no relevant financial
relationships to disclose.
Hill
Mr. Hill has no relevant financial relationships
to disclose.
McIlroy
Dr. McIlroy has no relevant financial
relationships to disclose.
Young
Dr. Young has no relevant financial
relationships to disclose.
Ali
Azlena Ali has no relevant financial
relationships to disclose.
Fiona
Bane
Ms. Bane has no relevant financial
relationships to disclose.
Laura
Creevey
Dr. Creevey has no relevant financial
relationships to disclose.
Arnold
Hill
Mr. Hill has no relevant financial relationships
to disclose.
Marzuki
Wan Afif Marzuki has no relevant financial
relationships to disclose.
McIlroy
Ms. McIlroy has no relevant financial
relationships to disclose.
Young
Leonie Young has no relevant financial
relationships to disclose.
Laura
Arnold
Marie
Leonie
Azlena
Wan Afif
Marie
Leonie
P3-05-23
P3-05-23
P3-05-23
P3-05-23
P3-05-23
P3-05-23
P3-05-23
P3-05-23
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Novel, non-uterotrophic, selective estrogen
mimics cause regression of tamoxifen-resistant
breast cancer in 2D and 3D cultures and in
mouse xenograft models
Liang
Xiao Liang has no relevant financial
relationships to disclose.
Molloy
Dr. Molloy has no relevant financial
relationships to disclose.
Hitisha
Patel
Hitisha Patel has no relevant financial
relationships to disclose.
Gregory
Thatcher
Dr. Thatcher has no relevant financial
relationships to disclose.
Debra
Tonetti
Dr. Tonetti has no relevant financial
relationships to disclose.
Yue-ting
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Rui
Xiong
Rui Xiong has no relevant financial
relationships to disclose.
Jiong
Zhao
Dr. Zhao has no relevant financial relationships
to disclose.
Xiao
Mary Ellen
P3-05-24
Adaptation to AI therapy in breast cancer can
induce dynamic alterations in ER activity
resulting in estrogen independent metastatic
tumours
Adaptation to AI therapy in breast cancer can
induce dynamic alterations in ER activity
resulting in estrogen independent metastatic
tumours
Adaptation to AI therapy in breast cancer can
induce dynamic alterations in ER activity
resulting in estrogen independent metastatic
tumours
Adaptation to AI therapy in breast cancer can
induce dynamic alterations in ER activity
resulting in estrogen independent metastatic
tumours
Adaptation to AI therapy in breast cancer can
induce dynamic alterations in ER activity
resulting in estrogen independent metastatic
tumours
Adaptation to AI therapy in breast cancer can
induce dynamic alterations in ER activity
resulting in estrogen independent metastatic
tumours
Adaptation to AI therapy in breast cancer can
induce dynamic alterations in ER activity
resulting in estrogen independent metastatic
tumours
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Itaru
P3-05-24
P3-05-24
P3-05-24
P3-05-24
P3-05-24
P3-05-24
Fagan
Dr. Fagan has no relevant financial
relationships to disclose.
Hao
Dr. Hao has no relevant financial relationships
to disclose.
Arnold
Hill
Dr. Hill has no relevant financial relationships
to disclose.
Jean
McBryan
Dr. McBryan has no relevant financial
relationships to disclose.
Aisling
Redmond
Dr. Redmond has no relevant financial
relationships to disclose.
Damir
Vareslija
Dr. Vareslija has no relevant financial
relationships to disclose.
Young
Dr. Young has no relevant financial
relationships to disclose.
Endo
Dr. Endo has no relevant financial relationships
to disclose.
Ailis
Yuan
Leonie
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Natsu
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Toru
Fujiki
Natsu Fujiki has no relevant financial
relationships to disclose.
Hanamura
Dr. Hanamura has no relevant financial
relationships to disclose.
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Shin-ichi
Hayashi
Dr. Hayashi has disclosed that he has contracts
with AstraZeneca and Novartis.
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Takashi
Ishikawa
Dr. Ishikawa has no relevant financial
relationships to disclose.
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Mariko
Kimura
Dr. Kimura has no relevant financial
relationships to disclose.
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Toshifumi
Niwa
Dr. Niwa has no relevant financial relationships
to disclose.
P3-05-25
Efficacy of everolimus on multiple mechanisms
of AI-resistance in vitro and xenograft, and
characterization of their everolimus-resistance Yuri
Yamaguchi
Dr. Yamaguchi has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Peter
Barrett-Lee
Dr. Barrett-Lee has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Judith
Bliss
Dr. Bliss has no relevant financial relationships
to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Jack
Cuzick
Dr. Cuzick has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Mitch
Dowsett
Dr. Dowsett has disclosed that he is in receipt
of grant funding from AstraZeneca.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Ian
Ellis
Dr. Ellis has no relevant financial relationships
to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Julia
Gee
Dr. Gee has disclosed that she In receipt of
grant funding from AstraZeneca.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Adrian
Harris
Dr. Harris has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Stephen
Hiscox
Dr. Hiscox has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Eleftheria
Kalaizak
Dr. Kalaizak has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Robert
Nicholson
Dr. Nicholson has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Ivana
Sestak
Dr. Sestak has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Ivana
Sestak
Dr. Sestak has no relevant financial
relationships to disclose.
P3-06-01
Nuclear β-catenin negativity predicts for late
relapse in ER+, tamoxifen-treated breast cancer Chris
Smith
Chris Smith has no relevant financial
relationships to disclose.
P3-06-02
P3-06-02
P3-06-02
P3-06-02
P3-06-02
P3-06-02
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Urania
Dafni
Dr. Dafni has no relevant financial relationships
to disclose.
Pradip
De
Dr. De has no relevant financial relationships to
disclose.
Dey
Dr. Dey has no relevant financial relationships
to disclose.
Dowsett
Dr. Dowsett has no relevant financial
relationships to disclose.
Leyland-Jones
Dr. Leyland-Jones has no relevant financial
relationships to disclose.
Long
Mr. Long has no relevant financial relationships
to disclose.
Nandini
Mitch
Brian
Bradley
P3-06-02
P3-06-02
P3-06-02
P3-06-02
P3-06-02
P3-06-03
P3-06-03
P3-06-03
P3-06-03
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Exploratory analysis of single gene predictive
biomarkers in TransHERA DASL cohort reveals
that C8A mRNA expression is prognostic of
outcome and predictive of benefit of
trastuzumab
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Varvara
Polydoropoulou
Varvara Polydoropoulou has no relevant
financial relationships to disclose.
Zoi
Tsourti
Dr. Tsourti has no relevant financial
relationships to disclose.
Williams
Dr. Williams has no relevant financial
relationships to disclose.
Willis
Dr. Willis has no relevant financial relationships
to disclose.
Casey
Scooter
Brandon
Young
Petri
Bono
Ahmed
Chenna
Weidong
Huang
Heikki
Joensuu
Mr. Young has no relevant financial
relationships to disclose.
Dr. Bono has no relevant financial relationships
to disclose.
Ahmed Chenna has disclosed he is an
employee of and has ownership in LabCorp.
Weidong Huang has disclosed he is an
employee of and has ownership in LabCorp.
Heikki Joensuu has no relevant financial
relationships to disclose.
P3-06-03
P3-06-03
P3-06-03
P3-06-03
P3-06-03
P3-06-03
P3-06-04
P3-06-04
P3-06-04
P3-06-04
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
Quantitative p95HER2 and HER2 correlations
with outcome in the FinHer trial
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
Pirkko-Liisa
Kellokumpu-Lehtinen
Yolanda
Lie
Jeff
Sperinde
Aki
Vehtari
Jodi
Weidler
John
Winslow
Dr. Kellokumpu-Lehtinen has no relevant
financial relationships to disclose.
Ms. Lie has disclosed she is an employee of
LabCorp.
Mr. Sperinde has disclosed he is an employee
of and has ownership in LabCorp.
Aki Vehtari has no relevant financial
relationships to disclose.
Ms. Weidler has disclosed she is an employee
of LabCorp.
Mr. Winslow has disclosed he is an employee
of LabCorp.
Decker
Mr. Decker has no relevant financial
relationships to disclose.
Distelrath
Ms. Distelrath has no relevant financial
relationships to disclose.
Fasching
Mr. Fasching has disclosed he is a consultant
for Novartis and is on the Speakers' Bureau for
Pfizer, Roche, Novartis, and Genomic Health.
He also disclosed he receives Grant/Research
Support from Novartis and Amgen.
Grischke
Ms. Grischke has no relevant financial
relationships to disclose.
Thomas
Andrea
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
Peter
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
Eva-Maria
P3-06-04
P3-06-04
P3-06-04
P3-06-04
P3-06-04
P3-06-04
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
Peyman
Hadji
Hadji Peyman has disclosed that he is on
Novartis Advisory Boards.
Wolfgang
Janni
Mr. Janni has disclosed that he is on Novartis
Advisory Boards.
Kreuzeder
Ms. Kreuzeder disclosed that she is an
employee of Novartis.
Kurbacher
Mr. Kurbacher has no relevant financial
relationships to disclose.
Lüftner
Ms. Lüftner has disclosed that she is a
consultant for and has a contract with
Novartis.
Lux
Mr. Lux has disclosed that he is on Novartis
Advisory Boards.
Julia
Christian
Diana
Micheal
P3-06-04
P3-06-04
P3-06-04
P3-06-04
P3-06-04
P3-06-04
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
Frederik
Marmé
Mr. Marmé has no relevant financial
relationships to disclose.
Christoph
Mundhenke
Dr. Mundhenke has no relevant financial
relationships to disclose.
Muth
Mr. Muth disclosed that he is an employee of
Novartis.
Neumeister
Romy Neumeister has no relevant financial
relationships to disclose.
Schneeweiss
Andreas Schneeweiss has no relevant financial
relationships to disclose.
Stoetzer
Mr. Stoetzer has no relevant financial
relationships to disclose.
Mathias
Romy
Andreas
Oliver
P3-06-04
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
Hans
4EVER: The impact of mTOR inhibition on bone
health in postmenopausal women with
hormone receptor positive (HR+) advanced
breast cancer treated with everolimus (EVE) in
combination with exemestane (EXE)
Claudia
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Don
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Lamorna
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Meredith
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Anneleen
P3-06-04
Tesch
Mr. Tesch has disclosed he is on an Advisory
Board, is a principal investigator and receives
honoraria from Novartis.
Weiss
Ms. Weiss disclosed that she is an employee of
Novartis.
Berry
Mr. Berry has disclosed he is co-owner of Berry
Consultant, LLC. Berry Consultants designs
adaptive clinical trials for many pharmaceutical
and medical device companies and NIH
cooperative groups.
Brown-Swigart
Lamorna Brown-Swigart has no relevant
financial relationships to disclose.
Buxton
Ms. Buxton has no relevant financial
relationships to disclose.
Daemen
Ms. Daemen has disclosed she is an employee
of Genentech.
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Angela
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Laura
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Susan
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Joe
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Laura
DeMichele
Dr. DeMichele has no relevant financial
relationships to disclose.
Esserman
Dr. Esserman has no relevant financial
relationships to disclose.
Flynn
Ms. Flynn has no relevant financial
relationships to disclose.
Gray
Dr. Gray has disclosed that he is a consultant
for New Leaf Ventures (consultant/advisory),
Susan G Komen for the Cure
(consultant/advisory), Kroma TiD
(consultant/advisory).
Heiser
Ms. Heiser has no relevant financial
relationships to disclose.
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Gillian
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Nola
Hirst
Ms. Hirst has no relevant financial relationships
to disclose.
Hylton
Dr. Hylton has no relevant financial
relationships to disclose.
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
I-SPY 2 TRIAL Investigators
I-SPY 2 TRIAL Investigators have no relevant
financial relationships to disclose.
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Olufunmilayo
Olopade
Olufunmilayo Olopade has no relevant financial
relationships to disclose.
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Melissa
Paoloni
Ms. Paoloni has no relevant financial
relationships to disclose.
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Hope
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Ashish
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Fraser
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Laura
P3-06-05
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Denise
Rugo
Dr. Rugo has no relevant financial relationships
to disclose.
Sanil
Ashish Sanil has disclosed he is an employee of
Berry Consultants, LLC and his wife is an
employed by Genentech.
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
van 't Veer
Dr. van 't Veer has disclosed that she is a parttime employee of Agendia Inc. She also
disclosed that she is a stockholder and cofounder of Agendia Inc.
Wolf
Ms. Wolf has no relevant financial relationships
to disclose.
P3-06-05
P3-06-05
P3-06-06
P3-06-06
P3-06-06
P3-06-06
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Christina
Evaluation of an in vitro derived signature of
olaparib response (PARPi-7) as a predictive
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy in high-risk
breast cancer: Results from the I-SPY 2 TRIAL
Prediction of benefit from endocrine therapy in
ER+ early stage breast cancer: Correlative
studies of the breast cancer index
HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
expression in the randomized Stockholm trial
Prediction of benefit from endocrine therapy in
ER+ early stage breast cancer: Correlative
studies of the breast cancer index
HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
expression in the randomized Stockholm trial
Prediction of benefit from endocrine therapy in
ER+ early stage breast cancer: Correlative
studies of the breast cancer index
HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
expression in the randomized Stockholm trial
Prediction of benefit from endocrine therapy in
ER+ early stage breast cancer: Correlative
studies of the breast cancer index
HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
expression in the randomized Stockholm trial
Doug
Tommy
Piiha-Lotta
Catherine
Brock
Yau
Ms. Yau has no relevant financial relationships
to disclose.
Yee
Dr. Yee has no relevant financial relationships
to disclose.
Fornander
Dr. Fornander has no relevant financial
relationships to disclose.
Jerevall Jannok
Dr. Jerevall Jannok has no relevant financial
relationships to disclose.
Schnabel
Dr. Schnabel has disclosed she receives salary
from and has ownership in bioTheranostics,
Inc.
Schroeder
Dr. Schroeder has disclosed he receives salary
from and has ownership in bioTheranostics,
Inc.
P3-06-06
P3-06-06
P3-06-06
P3-06-07
P3-06-07
P3-06-07
P3-06-07
Prediction of benefit from endocrine therapy in
ER+ early stage breast cancer: Correlative
studies of the breast cancer index
HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
expression in the randomized Stockholm trial
Prediction of benefit from endocrine therapy in
ER+ early stage breast cancer: Correlative
studies of the breast cancer index
HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
expression in the randomized Stockholm trial
Prediction of benefit from endocrine therapy in
ER+ early stage breast cancer: Correlative
studies of the breast cancer index
HoxB13/IL17BR (H/I) ratio, ER, PR, and HER2
expression in the randomized Stockholm trial
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Dennis
Sgroi
Dr. Sgroi has no relevant financial relationships
to disclose.
Olle
Stal
Dr. Stal has no relevant financial relationships
to disclose.
Zhang
Dr. Zhang has disclosed he receives salary from
and has ownership in bioTheranostics, Inc.
Andre
Dr. Andre has no relevant financial
relationships to disclose.
Bachelot
Mr. Bachelot has disclosed he is a consultant
for Roche and Novartis.
Yi
Fabrice
Thomas
Jacques
Bonneterre
Mario
Campone
Dr. Bonneterre has no relevant financial
relationships to disclose.
Mr. Campone has disclosed he receives
consulting fees from Novartis and Servier. He
has also disclosed he has contracts with Roche
and Novartis.
P3-06-07
P3-06-07
P3-06-07
P3-06-07
P3-06-07
P3-06-07
P3-06-07
P3-06-07
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
Dieras
Ms. Dieras has disclosed she is a consultant for
Roche.
Jimenez
Ms. Jiminez has no relevant financial
relationships to disclose.
Agnès
Leroux
Ms. Leroux has no relevant financial
relationships to disclose.
Maeva
Lion
Maeva Lion has no relevant financial
relationships to disclose.
Delphine
Loussouarn
Delphine Loussouarn has no relevant financial
relationships to disclose.
Jean-Louis
Merlin
Mr. Merlin has disclosed that he is a consultant
for Roche and Novartis.
Maria
Rios
Ms. Rios has no relevant financial relationships
to disclose.
Isabelle
Treilleux
Dr. Treilleux has no relevant financial
relationships to disclose.
Véronique
Marta
P3-06-07
Alterations of intratumoral signalling in breast
cancer patients receiving pre-operative
trastuzumab alone or combined with
everolimus
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Eva
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Javier
Wong
Ms. Wong has no relevant financial
relationships to disclose.
Ciruelos
Ms. Ciruelos has no relevant financial
relationships to disclose.
Cortes
Dr. Cortes has disclosed he receives consulting
fees from Roche and Celgene. He also
disclosed that he receives speaker fees from
Roche, Celgene, Novartis, and Eisai.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Sabine
de Ducla
Ms. de Ducla has disclosed that she receives
salary from and has ownership in Roche.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Andrea
Fontana
Ms. Fontana has no relevant financial
relationships to disclose.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Ulrich
Freudensprung
Mr. Freudensprung has disclosed that he is
receives salary from Roche.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Joseph
Gligorov
Mr. Gligorov has disclosed that he is a
consultant and speaker for Roche.
Jennifer
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
István
Lang
István Lang has no relevant financial
relationships to disclose.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Norbert
Marschner
Mr. Marschner has no relevant financial
relationships to disclose.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Mikkel
Oestergaard
Mikkel Oestergaard has disclosed he receives
salary from and has ownership in Roche.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Fabio
Puglisi
Mr. Puglisi has disclosed that he is a consultant
for Roche.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Gilles
Romieu
Dr. Romieu has no relevant financial
relationships to disclose.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Corinne
Veyret
Corinne Veyret has no relevant financial
relationships to disclose.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Cristian
Villanueva
Cristian Villanueva has no relevant financial
relationships to disclose.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Gunter
von Minckwitz
Mr. von Minckwitz has disclosed he is a
consultant for and has a contract with Roche.
P3-06-08
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Eduard
Vrdoljak
Mr. Vrdoljak has disclosed he is a consultant
for Roche, Pfizer, Novartis, GSK, and BI. He
also disclosed he is a speaker for Roche, Pfizer,
Novartis, and BI.
Zielinski
Dr. Zielinski has disclosed that he is a
consultant and speaker for Roche.
Berends
Dr. Berends has no relevant financial
relationships to disclose.
Bos
Dr. Bos has no relevant financial relationships
to disclose.
P3-06-08
P3-06-09
P3-06-09
Plasma (p) biomarker results from the TANIA
trial evaluating continued or reintroduced
bevacizumab (BEV) after 1st-line BEV for HER2negative metastatic breast cancer (mBC)
Christoph
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Johan
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Monique
P3-06-09
P3-06-09
P3-06-09
P3-06-09
P3-06-09
P3-06-09
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Epie
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Hans
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Steffen
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Marien
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Joep
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Aafke
Boven
Dr. Boven has disclosed he receives research
grants from Roche and Novartis.
Braun
Dr. Braun has no relevant financial
relationships to disclose.
de Groot
Steffen de Groot has no relevant financial
relationships to disclose.
den Boer
Dr. den Boer has no relevant financial
relationships to disclose.
Douma
Dr. Douma has no relevant financial
relationships to disclose.
Honkoop
Dr. Honkoop has no relevant financial
relationships to disclose.
P3-06-09
P3-06-09
P3-06-09
P3-06-09
P3-06-09
P3-06-09
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Agnes
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Frank
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Judith
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Siu
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Sabine
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Maartje
Jager
Dr. Jager has no relevant financial relationships
to disclose.
Jeurissen
Dr. Jerurissen has no relevant financial
relationships to disclose.
Kroep
Dr. Kroep has no relevant financial
relationships to disclose.
Linn
Dr. Lam has disclosed he has unrestricted
educational grants from Roche.
Dr. Linn has disclosed that he is an advisory
board member for Cergentis, Novartis, Roche,
and Sanofi. He also disclosed that he received
research support funding from Amgen,
AstraZeneca, Roche, and Sanofi.
Los
Dr. Los has no relevant financial relationships
to disclose.
Lam
P3-06-09
P3-06-09
P3-06-09
P3-06-09
P3-06-09
P3-06-09
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Jetske
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Nienke
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Johanneke
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Carolien
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Bea
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Joan
Meerum Terwogt
Dr. Meerum Terwogt has no relevant financial
relationships to disclose.
Nota
Nienke Nota has no relevant financial
relationships to disclose.
Portielje
Dr. Portielje has no relevant financial
relationships to disclose.
Smorenburg
Dr. Smorenburg has no relevant financial
relationships to disclose.
Tanis
Dr. Tanis has no relevant financial relationships
to disclose.
van den Bosch
Dr. van den Bosch has no relevant financial
relationships to disclose.
P3-06-09
P3-06-09
P3-06-09
P3-06-10
P3-06-10
P3-06-10
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Ankie
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Johanna
Plasma biomarker analysis in patients with HER2negative locally recurrent or metastatic breast
cancer (LR/MBC) treated with first-line
bevacizumab (A) and paclitaxel (T) without or
with capecitabine (X)
Harm
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Zielinski
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Vrbanec
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Messinger
van der Velden
Dr. van der Velden has no relevant financial
relationships to disclose.
van Riel
Dr. van Riel has no relevant financial
relationships to disclose.
van Tinteren
Dr. van Tinteren has no relevant financial
relationships to disclose.
Christoph
Dr. Christoph has disclosed that he is on the
Advisory Board for Roche.
Damir
Dr. Damir has no relevant financial
relationships to disclose.
Diethelm
Messinger Diethelm has no relevant financial
relationships to disclose.
P3-06-10
P3-06-10
P3-06-10
P3-06-10
P3-06-10
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Inbar
Dr. Inbar has no relevant financial relationships
to disclose.
Istvan
Dr. Istvan has no relevant financial
relationships to disclose.
Anghel
Rodica
Dr. Rodica has no relevant financial
relationships to disclose.
Stemmer
Salomon
Dr. Salomon has no relevant financial
relationships to disclose.
Semir
Dr. Semir has no relevant financial
relationships to disclose.
Moshe
Lang
Beslija
P3-06-10
P3-06-10
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-11
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Hand-foot-syndrome (HFS) is a strong predictor
for OS and PFS in HER2-negative metastatic
breast cancer (mBC) treated with first-line
capecitabine (CAP) + bevacizumab (BEV):
Results of a subanalysis of the randomized
phase III CECOG TURANDOT trial
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Thomas
Dr. Thomas has no relevant financial
relationships to disclose.
Kahan
Zsuzsanna
Dr. Zsuzsanna has no relevant financial
relationships to disclose.
William
Barry
Dr. Barry has no relevant financial relationships
to disclose.
Nicolai
Birkbak
Dr. Birkbak has disclosed he receives patent
licensing fees from Myriad Genetics, Inc.
Judy
Garber
Dr. Garber has no relevant financial
relationships to disclose.
April
Greene-Collozi
Ms. Greene-Collozi has no relevant financial
relationships to disclose.
Alexander
Gutin
Dr. Gutin has disclosed he is an employee of
Myriad Genetic Laboratories, Inc.
Brodowicz
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-11
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Hartman
Dr. Hartman has disclosed she is an employee
of Myriad Genetic Laboratories, Inc.
Iglehart
Dr. Iglehart has no relevant financial
relationships to disclose.
Steven
Isakoff
Dr. Isakoff has no relevant financial
relationships to disclose.
Joshua
Jones
Dr. Jones has disclosed he is an employee of
Myriad Genetic Laboratories, Inc.
Erica
Mayer
Dr. Mayer has no relevant financial
relationships to disclose.
Julia
Reid
Ms. Reid has disclosed she is an employee of
Myriad Genetic Laboratories, Inc.
Andrea
Richardson
Dr. Richardson has disclosed she receives
patent licensing fees from Myriad Genetics,
Inc.
Paula
Ryan
Dr. Ryan has no relevant financial relationships
to disclose.
Anne-Renee
J Dirk
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-11
P3-06-12
P3-06-12
P3-06-12
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Homologous recombination deficiency (HRD)
assay predicts response to cisplatin neoadjuvant
chemotherapy in patients with triple negative
breast cancer
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Silver
Dr. Silver has disclosed he has received patent
licensing fees from Myriad Genetics, Inc.
Szallasi
Dr. Szallasi has disclosed he receives patent
licensing fees from Myriad Genetics, Inc.
Kirsten
Timms
Dr. Timms has disclosed she is an employee of
Myriad Genetic Laboratories, Inc.
Nadine
Tung
Dr. Tung has no relevant financial relationships
to disclose.
Zhigang
Wang
Dr. Wang has disclosed he receives patent
licensing fees from Myriad Genetics, Inc.
Eric
Winer
Dr. Winer has no relevant financial
relationships to disclose.
Brase
Ms. Brase has disclosed she is an employee of
Sividon Diagnostics, Cologne.
Daniel
Zoltan
Jan
Silvia
Darb-Esfahani
Carsten
Denkert
Ms. Darb-Esfahani has no relevant financial
relationships to disclose.
Dr. Denkert has disclosed that he is cofounder
and shareholder of Sividon Diagnostics,
Cologne.
P3-06-12
P3-06-12
P3-06-12
P3-06-12
P3-06-12
P3-06-12
P3-06-12
P3-06-12
P3-06-12
P3-06-12
P3-06-12
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Engels
Knut Engels has no relevant financial
relationships to disclose.
Fend
Falko Fend has no relevant financial
relationships to disclose.
Gade
Mr. Gade has no relevant financial
relationships to disclose.
Hilfrich
Dr. Hilfrich has no relevant financial
relationships to disclose.
Holzhausen
Mr. Holzhausen has no relevant financial
relationships to disclose.
Jens
Huober
Jens Huober has no relevant financial
relationships to disclose.
Kristin
Krappmann
Ralf
Kronenwett
Ms. Krappmann has disclosed she is an
employee of Sividon Diagnostics, Cologne.
Mr. Kronenwett has disclosed he is an
employee and major stock shareholder of
Sividon Diagnostics, Cologne.
Loibl
Dr. Loibl has no relevant financial relationships
to disclose.
Mehta
Keyur Mehta has no relevant financial
relationships to disclose.
Pfitzner
Dr. Pfitzner has no relevant financial
relationships to disclose.
Knut
Falko
Stephan
Joern
Hans Juergen
Sibylle
Keyur
Berit Maria
P3-06-12
P3-06-12
P3-06-12
P3-06-13
P3-06-13
P3-06-13
P3-06-13
P3-06-13
P3-06-13
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Predicting residual risk of recurrence after
neoadjuvant chemotherapy- a retrospective
analysis of EndoPredict® in the GeparTrio trial
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Schem
Dr. Schem has no relevant financial
relationships to disclose.
Thomssen
Dr. Thomssen has no relevant financial
relationships to disclose.
Gunter
von Minckwitz
Dr. von Minckwitz has no relevant financial
relationships to disclose.
Ingo
Bauerfeind
Dr. Bauerfeind has no relevant financial
relationships to disclose.
Christian
Christoph
Alexander
Crispin
Nina
Ditsch
Franz
Edler von Koch
Holger
Fischer
Ilona
Funke
Mr. Crispin has disclosed that he has a contract
with SpheroTech GmbH.
Dr. Ditsch has disclosed that she receives
royalties from Myriad Genetics. She also
disclosed that she is a consultant for
AstraZenec.
Mr. Edler von Koch has no relevant financial
relationships to disclose.
Mr. Fischer has disclosed he receives royalties
from Roche. He also disclosed he is a
consultant for Roche. He has contracts with
German Breast Group and Women's
Healthcare Study Group.
Ms. Funke has disclosed that she receives
salary from, has a patent with, is a consultant
for, has a contract with and has ownership in
SpheroTec GmbH.
P3-06-13
P3-06-13
P3-06-13
P3-06-13
P3-06-13
P3-06-14
P3-06-14
P3-06-14
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Prospective cohort study using the breast
cancer spheroid model as a predictor for
response to neoadjuvant therapy - The
SpheroNEO study
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Kathrin
Halfter
Tanja
Hauzenberger
Hans-Christian
Kolberg
Ms. Halfter has disclosed that she receives
salary from SpheroTec GmbH.
Tanja Hauzenberger has no relevant financial
relationships to disclose.
Mr. Kolberg has disclosed that he is a
consultant for Novartis. He has also disclosed
that he has contracts with Novartis and
Amgen.
Barbara
Mayer
Gunter
von Minckwitz
Dr. Mayer has disclosed that she receives
salary from, has a patent with and has
ownership in SpheroTec GmbH.
Mr. von Minckwitz has disclosed he receives
salary from and has ownership in German
Breast Group Research GmbH. He also
disclosed he is a consultant for SpheroTec
GmbH; a speaker for Amgen, Astra Zeneca and
Roche and does contract work for Pfizer, GSK,
Sanofi-Aventis, Amgen, Roche, Novartis,
Celgene, Teva and Boehringer-Ingelheim.
Ali
Dr. Ali has no relevant financial relationships to
disclose.
Suhail
Nicholas
Bade
Walter
Carney
Mr. Bade has disclosed that he is a R&D
Systems, Inc. salaried employee.
Dr. Carney has disclosed that he is a salaried
employee of Nuclea
Biotechnologies/Oncogene Science - CSO.
P3-06-14
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
P3-06-14
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Allan
Lipton
P3-06-14
Serum activin A and response to the aromatase
inhibibitor (AI) letrozole versus tamoxifen in
metastatic breast cancer
Jaqueline
Rogerio
P3-06-14
P3-06-14
P3-06-14
P3-06-14
P3-06-14
P3-06-14
P3-06-14
Hilary
Chaudri-Ross
David
Chen
Ms. Chaudri-Ross has disclosed that she is a
Novartis salaried employee.
Dr. Chen has disclosed that he is a salaried
employee of Novartis Pharma and a Novartis
stock holder.
Garg
Dr. Garg has no relevant financial relationships
to disclose.
Hall
Mr. Hall has disclosed that he is a Novartis
salaried employee and a Novartis stock holder.
Hofsess
Mr. Hofsess has disclosed that he is a Novartis
salaried employee and a Novartis stock holder.
Meghan
Jensen
Meghan Jensen has no relevant financial
relationships to disclose.
Ashley
Kang
Ms. Kang has no relevant financial relationships
to disclose.
Kim
Leitzel
Ashwani
Raymond
Scott
Kim Leitzel has no relevant financial
relationships to disclose.
Dr. Lipton has disclosed that he is on a
speakers bureau. He also disclosed he is a
Novartis laboratory research grants PI and
receives other financial support for expert
testimony.
Dr. Rogerio has disclosed he is a full-time
employee of Novartis Pharmaceutical Corp.,
East Hanover, NJ. He has also disclosed he
owns Novartis stock and Novartis stock
options.
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Berry
Mr. Berry has disclosed he is co-owner of Berry
Consultant, LLC. Berry Consultants designs
adaptive clinical trials for many pharmaceutical
and medical device companies and NIH
cooperative groups.
Lamorna
Brown-Swigart
Lamorna Brown-Swigart has no relevant
financial relationships to disclose.
Meredith
Buxton
Ms. Buxton has no relevant financial
relationships to disclose.
Angela
DeMichele
Dr. DeMichele has no relevant financial
relationships to disclose.
Laura
Esserman
Dr. Esserman has no relevant financial
relationships to disclose.
Susan
Flynn
Ms. Flynn has no relevant financial
relationships to disclose.
Rosa
Gallagher
Ms. Gallagher has no relevant financial
relationships to disclose.
Hirst
Ms. Hirst has no relevant financial relationships
to disclose.
Donald
Gillian
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
P3-06-15
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Hylton
Dr. Hylton has no relevant financial
relationships to disclose.
I-SPY 2 TRIAL Investigators
I-SPY 2 TRIAL Investigators have no relevant
financial relationships to disclose.
Minetta
Liu
Dr. Liu has no relevant financial relationships to
disclose.
Melissa
Paoloni
Ms. Paoloni has no relevant financial
relationships to disclose.
John
Park
Mr. Park has no relevant financial relationships
to disclose.
Emanuel
Petricoin III
Nola
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Ashish
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
William
Sanil
Dr. Petricoin has disclosed that he has
ownership in Theranostics Health, LLC.
Ashish Sanil has disclosed he is employed by
Berry Consultants, LLC. Berry Consultants
designs adaptive clinical trials for many
pharmaceutical and medical device companies
and NIH cooperative groups.
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
P3-06-15
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
Evaluation of HER family protein signaling
network as a predictive biomarker for pCR for
breast cancer patients treated with neratinib in
the I-SPY 2 trial
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Carol
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Carol
P3-06-15
P3-06-15
P3-06-15
P3-06-15
van't Veer
Dr. van't Veer has no relevant financial
relationships to disclose.
Wolf
Ms. Wolf has no relevant financial relationships
to disclose.
Julia
Wulfkuhle
Dr. Wulfkuhle has disclosed she has ownership
in Theranostics Health.
Christina
Yau
Ms. Yau has no relevant financial relationships
to disclose.
Yee
Dr. Yee has disclosed he is a consultant for
Genentech, Symphogen, and Boehringer
Ingelheim.
Connor
Dr. Connor has no relevant financial
relationships to disclose.
Fabian
Dr. Fabian has no relevant financial
relationships to disclose.
Laura
Denise
Douglas
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Andrew
Godwin
Dr. Godwin has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Roy
Jensen
Dr. Jensen has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Qamar
Khan
Dr. Khan has no relevant financial relationships
to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Bruce
Kimler
Dr. Kimler has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Jennifer
Klemp
Dr. Klemp has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Joshua
Mammen
Dr. Mammen has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Marilee
McGinness
Dr. McGinness has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Benjamin
Powers
Dr. Powers has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Priyanka
Sharma
Dr. Sharma has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Jamie
Wagner
Dr. Wagner has no relevant financial
relationships to disclose.
P3-06-16
Thrombocytopenia is associated with
pathological complete response to neoadjuvant
carboplatin/docetaxel chemotherapy in BRCA
wild type triple negative breast cancer
Claire
Ward
Ms. Ward has no relevant financial
relationships to disclose.
P3-06-17
Multiplatform molecular profiling of BC reveals
significant differences in actionable targets from
matched female breast carcinomas
Zoran
Gatalica
Dr. Gatalica has disclosed that he receives
salary and has ownership interest.
P3-06-17
Multiplatform molecular profiling of BC reveals
significant differences in actionable targets from
matched female breast carcinomas
Sherri
Millis
Dr. Millis has disclosed that she receives salary.
P3-06-17
P3-06-17
P3-06-18
P3-06-18
P3-06-18
P3-06-18
P3-06-18
Multiplatform molecular profiling of BC reveals
significant differences in actionable targets from
matched female breast carcinomas
Joyce
Multiplatform molecular profiling of BC reveals
significant differences in actionable targets from
matched female breast carcinomas
The structural hotspot mutation at amino acid
282 in the TP53 gene is overrepresented in
residual disease of patients with invasive breast
cancer following neoadjuvant chemotherapy
with DNA damaging agents
The structural hotspot mutation at amino acid
282 in the TP53 gene is overrepresented in
residual disease of patients with invasive breast
cancer following neoadjuvant chemotherapy
with DNA damaging agents
The structural hotspot mutation at amino acid
282 in the TP53 gene is overrepresented in
residual disease of patients with invasive breast
cancer following neoadjuvant chemotherapy
with DNA damaging agents
The structural hotspot mutation at amino acid
282 in the TP53 gene is overrepresented in
residual disease of patients with invasive breast
cancer following neoadjuvant chemotherapy
with DNA damaging agents
The structural hotspot mutation at amino acid
282 in the TP53 gene is overrepresented in
residual disease of patients with invasive breast
cancer following neoadjuvant chemotherapy
with DNA damaging agents
O'Shaughnessy
Dr. O'Shaughnessy has no relevant financial
relationships to disclose.
Joanne
Xiu
Dr. Xiu has disclosed that she receives salary.
Melissa
Bondy
Dr. Bondy has no relevant financial
relationships to disclose.
Brewster
Dr. Brewster has no relevant financial
relationships to disclose.
Gutierrez
Dr. Gutierrez has no relevant financial
relationships to disclose.
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
Thompson
Dr. Thompson has no relevant financial
relationships to disclose.
Abenaa
Carolina
William
Patricia
P3-06-19
P3-06-19
P3-06-19
P3-06-19
P3-06-19
P3-06-19
P3-06-19
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Richard
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Sara
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Alan
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Laura
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Marcia
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Nola
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Alex
Brumbaugh
Mr. Anderson has disclosed he receives salary
from Symmetric Computing. He also disclosed
he is a consultant for and has a contract with
BIOARRAY Therapeutics Inc. He has ownership
in Symmetric Computing and BIOARRAY
Therapeutics Inc.
Ms. Brumbaugh has disclosed she receives
salary from Ceres Analytics. She receives
royalties from and has ownership in BIOARRAY
Therapeutics Inc. Ms. Brumbaugh has also
disclosed she has a patent with BIOARRAY
Therapeutics Inc. and is a consultant for
BIOARRAY Therapeutics Inc.
Derr
Mr. Derr has disclosed he receives royalties
from, has a patent with, consults for and has
ownership in BIOARRAY Therapeutics Inc.
Anderson
Fournier
Dr. Esserman has no relevant financial
relationships to disclose.
Dr. Fournier has disclosed she receives salary
and royalties from and has ownership in
BIOARRAY Therapeutics Inc. She also disclosed
she has a patent with BIOARRAY Therapeutics
Inc.
Hylton
Dr. Hylton has no relevant financial
relationships to disclose.
Margulis
Dr. Margulis has disclosed that he is a
consultant for and has ownership in BIOARRAY
Therapeutics Inc.
Esserman
P3-06-19
P3-06-19
P3-06-20
P3-06-20
P3-06-20
P3-06-20
P3-06-20
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
Gene expression profiles accompanying
phenotypic changes during non-malignant
breast epithelial cells acini formation to explain
MRI phenotypes
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
Reid
Mr. Reid has disclosed he receives salary from
BIOARRAY Therapeutics Inc. He also disclosed
he is a consultant for BIOARRAY Therapeutics
Inc.
W Fraser
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
Jin Seok
Ahn
Dr. Ahn has no relevant financial relationships
to disclose.
Cho
Dr. Cho has no relevant financial relationships
to disclose.
Do
In-Gu Do has no relevant financial relationships
to disclose.
Im
Dr. Im has no relevant financial relationships to
disclose.
Jung
Hae Hyun Jung has no relevant financial
relationships to disclose.
Kevin
Eun Yoon
In-Gu
Young-Hyuck
Hae Hyun
P3-06-20
P3-06-20
P3-06-20
P3-06-20
P3-06-20
P3-06-20
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
Sin-Ho
Jung
Sin-Ho Jung has no relevant financial
relationships to disclose.
Won Ho
Kil
Dr. Kil has no relevant financial relationships to
disclose.
Kim
Dr. Kim has no relevant financial relationships
to disclose.
Lee
Jeong Eon Lee has no relevant financial
relationships to disclose.
Nam
Seok Jin Nam has no relevant financial
relationships to disclose.
Park
Yeon Hee Park has no relevant financial
relationships to disclose.
Seok Won
Jeong Eon
Seok Jin
Yeon Hee
P3-06-20
P3-06-21
P3-06-21
P3-06-21
P3-06-21
P3-06-21
P3-06-21
P3-06-21
P3-06-21
P3-06-21
A seven-gene signature can predict distant
recurrence in patients with triple-negative
breast cancers (TNBCs) who receive adjuvant
chemotherapy following curative surgery of the
primary breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Sohn
Insuk Sohn has no relevant financial
relationships to disclose.
Bernards
Dr. Bernards has no relevant financial
relationships to disclose.
Besselink
Ms. Besselink has no relevant financial
relationships to disclose.
Hoogstraat
Marlous Hoogstraat has no relevant financial
relationships to disclose.
Koudijs
Dr. Koudijs has no relevant financial
relationships to disclose.
Lips
Dr. Lips has no relevant financial relationships
to disclose.
Michaut
Dr. Michaut has no relevant financial
relationships to disclose.
Lennart
Mulder
Lennart Mulder has no relevant financial
relationships to disclose.
Petra
Nederlof
Dr. Nederlof has no relevant financial
relationships to disclose.
Sjoerd
Rodenhuis
Dr. Rodenhuis has no relevant financial
relationships to disclose.
Insuk
Rene
Nicolle
Marlous
Marco
Esther
Magali
P3-06-21
P3-06-21
P3-06-21
P3-06-22
P3-06-22
P3-06-22
P3-06-22
P3-06-22
P3-06-22
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Next generation sequencing to find predictors
for chemotherapy response in triple negative
breast cancer
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Voest
Dr. Voest has no relevant financial
relationships to disclose.
Wesseling
Dr. Wesseling has no relevant financial
relationships to disclose.
Lodewyk
Wessels
Dr. Wessels has no relevant financial
relationships to disclose.
Lina
Asmar
Dr. Asmar has no relevant financial
relationships to disclose.
Sasha
Badbanchi
Dr. Badbanchi has no relevant financial
relationships to disclose.
Stephan
Brock
Dr. Brock has no relevant financial
relationships to disclose.
Francesca
Diella
Dr. Diella has no relevant financial relationships
to disclose.
Anja
Doerks
Dr. Doerks has no relevant financial
relationships to disclose.
Gunn
Dr. Gunn has no relevant financial relationships
to disclose.
Emile
Jelle
Shelly
P3-06-22
P3-06-22
P3-06-22
P3-06-22
P3-06-22
P3-06-22
P3-06-23
P3-06-23
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Identification of ERBB2 gene variants in HER2
positive disease associated with trastuzumab
response in an adjuvant trastuzumab
chemotherapy trial
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Hartenfeller
Dr. Hartenfeller has no relevant financial
relationships to disclose.
Jackson
Dr. Jackson has no relevant financial
relationships to disclose.
Steve
Jones
Dr. Jones has no relevant financial relationships
to disclose.
Martin
Stein
Dr. Stein has no relevant financial relationships
to disclose.
Yunfei
Wang
Dr. Wang has no relevant financial
relationships to disclose.
Alexander
Zien
Dr. Zien has no relevant financial relationships
to disclose.
Massimo
Ambroggi
Dr. Ambroggi has no relevant financial
relationships to disclose.
Ardizzoni
Ms. Ardizzoni has no relevant financial
relationships to disclose.
Markus
David
Andrea
P3-06-23
P3-06-23
P3-06-23
P3-06-23
P3-06-23
P3-06-23
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Giancarlo
Bisagni
Giancarlo Bisagni has no relevant financial
relationships to disclose.
Daniela
Boggiani
Ms. Boggiani has no relevant financial
relationships to disclose.
Bortesi
Ms. Bortesi has no relevant financial
relationships to disclose.
Cagossi
Ms. Cagossi has no relevant financial
relationships to disclose.
Conte
Dr. Conte has disclosed that he is a consultant
for PierFranco Conte, GlaxoSmithKline, and
Roche.
Dieci
Ms. Dieci has no relevant financial relationships
to disclose.
Beatrice
Katia
Pierfranco
Maria
P3-06-23
P3-06-23
P3-06-23
P3-06-23
P3-06-23
P3-06-23
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Antonio
Frassoldati
Mr. Frassoldati has no relevant financial
relationships to disclose.
Daniele
Generali
Ms. Generali has no relevant financial
relationships to disclose.
Gianni
Dr. Gianni has no relevant financial
relationships to disclose.
Guarneri
Dr. Guarneri has no relevant financial
relationships to disclose.
Musolino
Dr. Musolino has no relevant financial
relationships to disclose.
Naldi
Ms. Naldi has no relevant financial
relationships to disclose.
Lorenzo
Valentina
Antonino
Nadia
P3-06-23
P3-06-23
P3-06-23
P3-06-24
P3-06-24
P3-06-24
P3-06-24
P3-06-24
P3-06-24
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Immunoglobulin G fragment C receptor
polymorphisms and clinical efficacy of
preoperative chemotherapy plus trastuzumab
and lapatinib in patients with HER2-positive
operable breast cancer
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
Federico
Piacentini
Federico Piacentini has no relevant financial
relationships to disclose.
Samanta
Sarti
Dr. Sarti has no relevant financial relationships
to disclose.
Sgargi
Mr. Sgargi has no relevant financial
relationships to disclose.
MM
Abu-khalaf
Dr. Abu-Khalaf has no relevant financial
relationships to disclose.
VV
Bossuyt
Dr. Bossuyt has no relevant financial
relationships to disclose.
LN
Harris
Dr. Harris has no relevant financial
relationships to disclose.
Krop
Dr. Krop has no relevant financial relationships
to disclose.
Miskimen
Dr. Miskimen has no relevant financial
relationships to disclose.
Vadodkar
Dr. Vadodkar has no relevant financial
relationships to disclose.
Paolo
I
Kristy
Aditi Shirish
P3-06-24
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
Vinay
Brief exposure to trastuzumab prior to
preoperative chemotherapy confirms predictors
of response to treatment
E
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Kathy
Albain
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Don
Berry
Dr. Albain has no relevant financial
relationships to disclose.
Mr. Berry has disclosed he is co-owner of Berry
Consultant, LLC. Berry Consultants designs
adaptive clinical trials for many pharmaceutical
and medical device companies and NIH
cooperative groups.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Judy
Boughey
Dr. Boughey has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Lamorna
Brown-Swigart
Lamorna Brown-Swigart has no relevant
financial relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Meredith
Buxton
Ms. Buxton has no relevant financial
relationships to disclose.
P3-06-24
Varadan
Dr. Varadan has no relevant financial
relationships to disclose.
Winer
Dr. Winer has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Jo
Chien
Jo Chien has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Steven
Chui
Mr. Chui has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Angela
DeMichele
Dr. DeMichele has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Kirsten
Edmiston
Ms. Edmiston has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Anthony
Elias
Dr. Elias has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Laura
Esserman
Dr. Esserman has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Susan
Flynn
Ms. Flynn has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Barbara
Haley
Dr. Haley has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Gillian
Hirst
Ms. Hirst has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Nola
Hylton
Dr. Hylton has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Claudine
Isaacs
Dr. Isaacs has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Hank
Kaplan
Mr. Kaplan has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Qamar
Khan
Dr. Khan has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Stacey
Moulder
Stacey Moulder has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Donald
Northfelt
Dr. Northfelt has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Olufunmilayo
Olopade
Olufunmilayo Olopade has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Melissa
Paoloni
Ms. Paoloni has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Hope
Rugo
Dr. Rugo has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Ashish
Sanil
Ashish Sanil has disclosed he is an employee of
Berry Consultants, LLC and his wife is an
employee of Genentech. He also disclosed he
is consulting with a number of the
pharmaceutical companies involved
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Toncred
Styblo
Toncred Styblo has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Fraser
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Debu
Tripathy
Dr. Tripathy has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Laura
van 't Veer
Dr. van 't Veer has disclosed that she is a parttime employee of Agendia Inc. She also
disclosed that she is a stockholder and cofounder of Agendia Inc.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Rebecca
Viscuzi
Ms. Viscuzi has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Anne
Wallace
Ms. Wallace has no relevant financial
relationships to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Denise
Wolf
Ms. Wolf has no relevant financial relationships
to disclose.
P3-06-25
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Christina
Yau
Ms. Yau has no relevant financial relationships
to disclose.
Yee
Dr. Yee has no relevant financial relationships
to disclose.
Carvajal-Hausdorf
Dr. Carvajal-Hausdorf has no relevant financial
relationships to disclose.
George
Fountzilas
Dr. Fountzilas has no relevant financial
relationships to disclose.
Konstantine
Kalogeras
Dr. Kalogeras has no relevant financial
relationships to disclose.
Vassiliki
Kotoula
Dr. Kotoula has no relevant financial
relationships to disclose.
P3-06-25
P3-06-26
P3-06-26
P3-06-26
P3-06-26
MammaPrint High1/High2 risk class as a
biomarker of response to veliparib/carboplatin
plus standard neoadjuvant therapy for breast
cancer in the I-SPY 2 TRIAL
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
Doug
Daniel
P3-06-26
P3-06-26
P3-06-26
P3-06-26
P3-06-27
P3-06-27
P3-06-27
P3-06-27
P3-06-27
P3-06-27
P3-06-27
P3-06-27
P3-06-27
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
Amanda
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
Lajos
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
Measurement of domain-specific HER2 (ERBB2)
expression classifies benefit from Trastuzumab
in breast cancer
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
BRCAness is important to identify TNBC subtype
resistant to taxanes
David
Psyrri
Dr. Psyrri has no relevant financial
relationships to disclose.
Pusztai
Dr. Pusztai has no relevant financial
relationships to disclose.
Rimm
Dr. Rimm has disclosed that he is a consultant
for Genoptix Medical Laboratories and
Advanced Cell Diagnostics, Inc and received a
Genoptix/Novartis Research Grant.
Kurt
Schalper
Itaru
Endo
Yasushi
Ichikawa
Takashi
Ishikawa
Kumiko
Kida
Kazutaka
Narui
Mari
Oba
Kazuhiro
Shimada
Sadatoshi
Sugae
Mikiko
Tanabe
Dr. Schalper has no relevant financial
relationships to disclose.
Dr. Endo has no relevant financial relationships
to disclose.
Dr. Ichikawa has no relevant financial
relationships to disclose.
Dr. Ishikawa has no relevant financial
relationships to disclose.
Dr. Kida has no relevant financial relationships
to disclose.
Dr. Narui has no relevant financial relationships
to disclose.
Dr. Oba has no relevant financial relationships
to disclose.
Dr. Shimada has no relevant financial
relationships to disclose.
Dr. Sugae has no relevant financial
relationships to disclose.
Dr. Tanabe has no relevant financial
relationships to disclose.
P3-06-28
P3-06-28
P3-06-28
P3-06-28
P3-06-28
P3-06-28
P3-06-28
P3-06-28
P3-06-29
P3-06-29
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
Alterations in HER2 status and outcome
following neoadjuvant chemotherapy in HER2positive breast cancer (BC)
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
Chen
Dr. Chen has no relevant financial relationships
to disclose.
Chua
Mr. Chua has no relevant financial
relationships to disclose.
Grenert
Dr. Grenert has no relevant financial
relationships to disclose.
Hou
Jie Hou has no relevant financial relationships
to disclose.
Krings
Dr. Krings has no relevant financial
relationships to disclose.
Dianna
Ng
Dr. Ng has no relevant financial relationships to
disclose.
Kristie
White
Dr. White has no relevant financial
relationships to disclose.
Christina
Yau
Dr. Yau has no relevant financial relationships
to disclose.
Kathy
Albain
Dr. Albain has no relevant financial
relationships to disclose.
Don
Berry
Mr. Berry has disclosed he is co-owner of Berry
Consultant, LLC.
Yunn-Yi
Anthony
James
Jie
Gregor
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
Boughey
Dr. Boughey has no relevant financial
relationships to disclose.
Brown-Swigart
Lamorna Brown-Swigart has no relevant
financial relationships to disclose.
Meredith
Buxton
Ms. Buxton has no relevant financial
relationships to disclose.
Jo
Chien
Jo Chien has no relevant financial relationships
to disclose.
Steven
Chiu
Mr. Chiu has no relevant financial relationships
to disclose.
Angela
DeMichele
Dr. DeMichele has no relevant financial
relationships to disclose.
Kirsten
Edmiston
Ms. Edmiston has no relevant financial
relationships to disclose.
Anthony
Elias
Dr. Elias has no relevant financial relationships
to disclose.
Judy
Lamorna
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
Esserman
Dr. Esserman has no relevant financial
relationships to disclose.
Flynn
Ms. Flynn has no relevant financial
relationships to disclose.
Barbara
Haley
Dr. Haley has no relevant financial relationships
to disclose.
Gillian
Hirst
Ms. Hirst has no relevant financial relationships
to disclose.
Nola
Hylton
Dr. Hylton has no relevant financial
relationships to disclose.
Claudine
Isaacs
Dr. Isaacs has no relevant financial
relationships to disclose.
Hank
Kaplan
Mr. Kaplan has no relevant financial
relationships to disclose.
Minetta
Liu
Dr. Liu has no relevant financial relationships to
disclose.
Laura
Susan
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
Moulder
Stacey Moulder has no relevant financial
relationships to disclose.
Nanda
Ms. Nanda has no relevant financial
relationships to disclose.
Donald
Northfelt
Dr. Northfelt has no relevant financial
relationships to disclose.
Melissa
Paoloni
Ms. Paoloni has no relevant financial
relationships to disclose.
Stacey
Rita
John
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
Ashish
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
Toncred
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
W Fraser
Sanil
Mr. Park has no relevant financial relationships
to disclose.
Ashish Sanil has disclosed he is an employee of
Berry Consultants, LLC and his wife is an
employee of Genentech/Roche. He also
disclosed he is consulting with a number of the
pharmaceutical companies involved
Styblo
Toncred Styblo has no relevant financial
relationships to disclose.
Symmans
Dr. Symmans has no relevant financial
relationships to disclose.
Park
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-29
P3-06-31
P3-06-31
P3-06-31
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
MammaPrint High1/High2 risk class as a
biomarker of response to neratinib plus
standard neoadjuvant therapy for breast cancer
in the I-SPY 2 TRIAL
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Debu
Tripathy
Laura
van 't Veer
Dr. Tripathy has no relevant financial
relationships to disclose.
Dr. van 't Veer has disclosed that she is a parttime employee of Agendia Inc. She also
disclosed that she is a stockholder and cofounder of Agendia Inc.
Rebecca
Viscusi
Ms. Viscusi has no relevant financial
relationships to disclose.
Anne
Wallace
Ms. Wallace has no relevant financial
relationships to disclose.
Denise
Wolf
Ms. Wolf has no relevant financial relationships
to disclose.
Christina
Yau
Ms. Yau has no relevant financial relationships
to disclose.
Doug
Yee
Daniel
Ciznadija
Angela
Davies
Hanna
Irie
Dr. Yee has no relevant financial relationships
to disclose.
Dr. Ciznadija has disclosed that he receives
salary and has stock options.
Dr. Davies has disclosed she receives salary and
has stock options.
Dr. Irie has no relevant financial relationships
to disclose.
P3-06-31
P3-06-31
P3-06-31
P3-06-31
P3-06-31
P3-06-32
P3-06-32
P3-06-32
P3-06-32
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Patient-derived xenografts accurately predict
patient response in breast cancer patients
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Amanda
Katz
Keren
Paz
Elisa
Port
Justin
Stebbing
Lisa
Stow
Dr. Katz has disclosed that she receives salary
and has stock options.
Dr. Paz has disclosed he receives salary and has
stock options.
Dr. Port has no relevant financial relationships
to disclose.
Dr. Stebbing has no relevant financial
relationships to disclose.
Dr. Stow has disclosed that she receives salary
and has stock options.
Abramson
Dr. Abramson has no relevant financial
relationships to disclose.
Estrada
Dr. Estrada has no relevant financial
relationships to disclose.
Giltnane
Dr. Giltnane has no relevant financial
relationships to disclose.
Mayer
Dr. Mayer has no relevant financial
relationships to disclose.
Vandana
Monica
Jena
Ingrid
P3-06-32
P3-06-32
P3-06-32
P3-06-32
P3-06-32
P3-06-32
P3-06-33
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Genetic heterogeneity for Her2 accounts for a
significant percentage of breast cancers
changing Her2 status following implementation
of the 2013 CAP/ASCO HER2 reporting
guidelines
Comparison of pathologic response evaluation
systems after neoadjuvant chemotherapy
among different molecular subtypes of breast
cancers
Julie
Means
Dr. Means has no relevant financial
relationships to disclose.
Ingrid
Meszoely
Dr. Meszoely has no relevant financial
relationships to disclose.
Rexer
Dr. Rexer has no relevant financial
relationships to disclose.
Sanders
Dr. Sanders has no relevant financial
relationships to disclose.
Wheeler
Dr. Wheeler has no relevant financial
relationships to disclose.
Yenamandra
Dr. Yenamandra has no relevant financial
relationships to disclose.
Gong
Gyungyub Gong has no relevant financial
relationships to disclose.
Brent
Melinda
Ferrin
Ashwini
Gyungyub
P3-06-33
P3-06-33
P3-06-33
P3-06-34
P3-06-34
P3-06-34
P3-06-34
P3-06-34
P3-06-34
P3-06-34
Comparison of pathologic response evaluation
systems after neoadjuvant chemotherapy
among different molecular subtypes of breast
cancers
Comparison of pathologic response evaluation
systems after neoadjuvant chemotherapy
among different molecular subtypes of breast
cancers
Comparison of pathologic response evaluation
systems after neoadjuvant chemotherapy
among different molecular subtypes of breast
cancers
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Lee
Hee Jin Lee has no relevant financial
relationships to disclose.
Park
In Ah Park has no relevant financial
relationships to disclose.
Song
In Hye Song has no relevant financial
relationships to disclose.
Fujimura
Takashi Fujimura has no relevant financial
relationships to disclose.
Sachio
Fushida
Sachio Fushida has no relevant financial
relationships to disclose.
Hironori
Hayashi
Hironori Hayashi has no relevant financial
relationships to disclose.
Masafumi
Inokuchi
Masafumi Inokuchi has no relevant financial
relationships to disclose.
Ishikawa
Satoko Ishikawa has no relevant financial
relationships to disclose.
Kitagawa
Hirohisa Kitagawa has no relevant financial
relationships to disclose.
Miyashita
Dr. Miyashita has no relevant financial
relationships to disclose.
Hee Jin
In Ah
In Hye
Takashi
Satoko
Hirohisa
Tomoharu
P3-06-34
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
Platelet predominant breast cancer is a new
predictor for pathological complete response to
neoadjuvant chemotherapy
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
Laura
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
David
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
J
Dixon
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
Cynthia
Loman
P3-06-34
P3-06-34
P3-06-34
P3-06-34
P3-06-34
Hisatoshi
Itasu
Tetsuo
Katsunobu
Hidehiro
Hiroyuki
Nakagawara
Hisatoshi Nakagawara has no relevant financial
relationships to disclose.
Ninomiya
Itasu Ninomiya has no relevant financial
relationships to disclose.
Ohta
Tetsuo Ohta has no relevant financial
relationships to disclose.
Oyama
Katsunobu Oyama has no relevant financial
relationships to disclose.
Tajima
Hidehiro Tajima has no relevant financial
relationships to disclose.
Takamura
Hiroyuki Takamura has no relevant financial
relationships to disclose.
Arthur
Ms. Arthur has no relevant financial
relationships to disclose.
Cameron
Dr. Cameron has no relevant financial
relationships to disclose.
Dr. Dixon has no relevant financial
relationships to disclose.
Ms. Loman has disclosed she is an employee of
Genomic Health Inc and receives a salary and
owns stock and stock options in Genomic
Health Inc.
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
Juliette
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
Lorna
Renshaw
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
Megan
Rothney
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
Amy
Sing
Ms. Renshaw has no relevant financial
relationships to disclose.
Dr. Rothney has disclosed she is an employee
of Genomic Health Inc and receives a salary
and owns stock and stock options in Genomic
Health Inc.
Dr. Sing has disclosed she is an employee of
Genomic Health Inc and receives a salary and
owns stock and stock options in Genomic
Health Inc.
P3-06-35
Association of estrogen receptor (ER) levels and
prediction of antiproliferative effect of hormone
therapy (HT) in lower ER-expressing tumors
Jeremy
Thomas
Mr. Thom

¿Cómo Se Dice en Español?

ECIBC National Contacts

2014 Summer Seminar in Breast Imaging Saturday, July 19, 2014

Scorecard - Kirtlington Golf Club

For personal use only

Nutritional Supplements Human milk fortifier Lactodex – HMF (2G

MD Anderson Represented at The 4 International IBC Conference

Digital Mamography - Union General Hospital

View PDF - ijournals

Axillary adenopathy as presenting characteristic of